id	sid	tid	token	lemma	pos
cord-324810-92fosk3c	1	1	key	key	NN
cord-324810-92fosk3c	1	2	:	:	:
cord-324810-92fosk3c	2	1	cord-324810	cord-324810	JJ
cord-324810-92fosk3c	2	2	-	-	HYPH
cord-324810-92fosk3c	2	3	92fosk3c	92fosk3c	CD
cord-324810-92fosk3c	2	4	authors	author	NNS
cord-324810-92fosk3c	2	5	:	:	:
cord-324810-92fosk3c	2	6	Sharma	Sharma	NNP
cord-324810-92fosk3c	2	7	,	,	,
cord-324810-92fosk3c	2	8	Sat	Sat	NNP
cord-324810-92fosk3c	2	9	;	;	:
cord-324810-92fosk3c	2	10	Anthonisen	Anthonisen	NNP
cord-324810-92fosk3c	2	11	,	,	,
cord-324810-92fosk3c	2	12	Nicholas	Nicholas	NNP
cord-324810-92fosk3c	2	13	title	title	NN
cord-324810-92fosk3c	2	14	:	:	:
cord-324810-92fosk3c	2	15	Role	role	NN
cord-324810-92fosk3c	2	16	of	of	IN
cord-324810-92fosk3c	2	17	Antimicrobial	Antimicrobial	NNP
cord-324810-92fosk3c	2	18	Agents	Agents	NNPS
cord-324810-92fosk3c	2	19	in	in	IN
cord-324810-92fosk3c	2	20	the	the	DT
cord-324810-92fosk3c	2	21	Management	Management	NNP
cord-324810-92fosk3c	2	22	of	of	IN
cord-324810-92fosk3c	2	23	Exacerbations	Exacerbations	NNPS
cord-324810-92fosk3c	2	24	of	of	IN
cord-324810-92fosk3c	2	25	COPD	COPD	NNP
cord-324810-92fosk3c	2	26	date	date	NN
cord-324810-92fosk3c	2	27	:	:	:
cord-324810-92fosk3c	2	28	2012	2012	CD
cord-324810-92fosk3c	2	29	-	-	SYM
cord-324810-92fosk3c	2	30	08	08	CD
cord-324810-92fosk3c	2	31	-	-	HYPH
cord-324810-92fosk3c	2	32	23	23	CD
cord-324810-92fosk3c	2	33	journal	journal	NN
cord-324810-92fosk3c	2	34	:	:	:
cord-324810-92fosk3c	3	1	Treat	treat	VB
cord-324810-92fosk3c	3	2	Respir	Respir	NNP
cord-324810-92fosk3c	3	3	Med	Med	NNP
cord-324810-92fosk3c	3	4	DOI	doi	NN
cord-324810-92fosk3c	3	5	:	:	:
cord-324810-92fosk3c	3	6	10.2165/00151829	10.2165/00151829	CD
cord-324810-92fosk3c	3	7	-	-	HYPH
cord-324810-92fosk3c	3	8	200504030	200504030	CD
cord-324810-92fosk3c	3	9	-	-	HYPH
cord-324810-92fosk3c	3	10	00001	00001	CD
cord-324810-92fosk3c	4	1	sha	sha	NNP
cord-324810-92fosk3c	4	2	:	:	:
cord-324810-92fosk3c	4	3	4a46f62620d8446cbca1961358ecb328a2d5bfde	4a46f62620d8446cbca1961358ecb328a2d5bfde	CD
cord-324810-92fosk3c	4	4	doc_id	doc_id	CD
cord-324810-92fosk3c	4	5	:	:	:
cord-324810-92fosk3c	4	6	324810	324810	CD
cord-324810-92fosk3c	4	7	cord_uid	cord_uid	NNS
cord-324810-92fosk3c	4	8	:	:	:
cord-324810-92fosk3c	5	1	92fosk3c	92fosk3c	CD
cord-324810-92fosk3c	5	2	Acute	acute	JJ
cord-324810-92fosk3c	5	3	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	5	4	of	of	IN
cord-324810-92fosk3c	5	5	chronic	chronic	JJ
cord-324810-92fosk3c	5	6	obstructive	obstructive	JJ
cord-324810-92fosk3c	5	7	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	5	8	disease	disease	NN
cord-324810-92fosk3c	5	9	(	(	-LRB-
cord-324810-92fosk3c	5	10	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	5	11	)	)	-RRB-
cord-324810-92fosk3c	5	12	are	be	VBP
cord-324810-92fosk3c	5	13	a	a	DT
cord-324810-92fosk3c	5	14	common	common	JJ
cord-324810-92fosk3c	5	15	occurrence	occurrence	NN
cord-324810-92fosk3c	5	16	and	and	CC
cord-324810-92fosk3c	5	17	characterize	characterize	VB
cord-324810-92fosk3c	5	18	the	the	DT
cord-324810-92fosk3c	5	19	natural	natural	JJ
cord-324810-92fosk3c	5	20	history	history	NN
cord-324810-92fosk3c	5	21	of	of	IN
cord-324810-92fosk3c	5	22	the	the	DT
cord-324810-92fosk3c	5	23	disease	disease	NN
cord-324810-92fosk3c	5	24	.	.	.
cord-324810-92fosk3c	6	1	Over	over	IN
cord-324810-92fosk3c	6	2	the	the	DT
cord-324810-92fosk3c	6	3	past	past	JJ
cord-324810-92fosk3c	6	4	decade	decade	NN
cord-324810-92fosk3c	6	5	,	,	,
cord-324810-92fosk3c	6	6	new	new	JJ
cord-324810-92fosk3c	6	7	knowledge	knowledge	NN
cord-324810-92fosk3c	6	8	has	have	VBZ
cord-324810-92fosk3c	6	9	substantially	substantially	RB
cord-324810-92fosk3c	6	10	enhanced	enhance	VBN
cord-324810-92fosk3c	6	11	our	-PRON-	PRP$
cord-324810-92fosk3c	6	12	understanding	understanding	NN
cord-324810-92fosk3c	6	13	of	of	IN
cord-324810-92fosk3c	6	14	the	the	DT
cord-324810-92fosk3c	6	15	pathogenesis	pathogenesis	NN
cord-324810-92fosk3c	6	16	,	,	,
cord-324810-92fosk3c	6	17	outcome	outcome	NN
cord-324810-92fosk3c	6	18	and	and	CC
cord-324810-92fosk3c	6	19	natural	natural	JJ
cord-324810-92fosk3c	6	20	history	history	NN
cord-324810-92fosk3c	6	21	of	of	IN
cord-324810-92fosk3c	6	22	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	6	23	.	.	.
cord-324810-92fosk3c	7	1	The	the	DT
cord-324810-92fosk3c	7	2	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	7	3	not	not	RB
cord-324810-92fosk3c	7	4	only	only	RB
cord-324810-92fosk3c	7	5	greatly	greatly	RB
cord-324810-92fosk3c	7	6	reduce	reduce	VB
cord-324810-92fosk3c	7	7	the	the	DT
cord-324810-92fosk3c	7	8	quality	quality	NN
cord-324810-92fosk3c	7	9	of	of	IN
cord-324810-92fosk3c	7	10	life	life	NN
cord-324810-92fosk3c	7	11	of	of	IN
cord-324810-92fosk3c	7	12	these	these	DT
cord-324810-92fosk3c	7	13	patients	patient	NNS
cord-324810-92fosk3c	7	14	,	,	,
cord-324810-92fosk3c	7	15	but	but	CC
cord-324810-92fosk3c	7	16	also	also	RB
cord-324810-92fosk3c	7	17	result	result	VB
cord-324810-92fosk3c	7	18	in	in	IN
cord-324810-92fosk3c	7	19	hospitalization	hospitalization	NN
cord-324810-92fosk3c	7	20	,	,	,
cord-324810-92fosk3c	7	21	respiratory	respiratory	JJ
cord-324810-92fosk3c	7	22	failure	failure	NN
cord-324810-92fosk3c	7	23	,	,	,
cord-324810-92fosk3c	7	24	and	and	CC
cord-324810-92fosk3c	7	25	death	death	NN
cord-324810-92fosk3c	7	26	.	.	.
cord-324810-92fosk3c	8	1	The	the	DT
cord-324810-92fosk3c	8	2	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	8	3	are	be	VBP
cord-324810-92fosk3c	8	4	the	the	DT
cord-324810-92fosk3c	8	5	major	major	JJ
cord-324810-92fosk3c	8	6	cost	cost	NN
cord-324810-92fosk3c	8	7	drivers	driver	NNS
cord-324810-92fosk3c	8	8	in	in	IN
cord-324810-92fosk3c	8	9	consumption	consumption	NN
cord-324810-92fosk3c	8	10	of	of	IN
cord-324810-92fosk3c	8	11	healthcare	healthcare	NN
cord-324810-92fosk3c	8	12	resources	resource	NNS
cord-324810-92fosk3c	8	13	by	by	IN
cord-324810-92fosk3c	8	14	COPD	COPD	NNP
cord-324810-92fosk3c	8	15	patients	patient	NNS
cord-324810-92fosk3c	8	16	.	.	.
cord-324810-92fosk3c	9	1	Although	although	IN
cord-324810-92fosk3c	9	2	bacterial	bacterial	JJ
cord-324810-92fosk3c	9	3	infections	infection	NNS
cord-324810-92fosk3c	9	4	are	be	VBP
cord-324810-92fosk3c	9	5	the	the	DT
cord-324810-92fosk3c	9	6	most	most	RBS
cord-324810-92fosk3c	9	7	common	common	JJ
cord-324810-92fosk3c	9	8	etiologic	etiologic	JJ
cord-324810-92fosk3c	9	9	agents	agent	NNS
cord-324810-92fosk3c	9	10	,	,	,
cord-324810-92fosk3c	9	11	the	the	DT
cord-324810-92fosk3c	9	12	role	role	NN
cord-324810-92fosk3c	9	13	of	of	IN
cord-324810-92fosk3c	9	14	viruses	virus	NNS
cord-324810-92fosk3c	9	15	in	in	IN
cord-324810-92fosk3c	9	16	COPD	COPD	NNP
cord-324810-92fosk3c	9	17	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	9	18	is	be	VBZ
cord-324810-92fosk3c	9	19	being	be	VBG
cord-324810-92fosk3c	9	20	increasingly	increasingly	RB
cord-324810-92fosk3c	9	21	recognized	recognize	VBN
cord-324810-92fosk3c	9	22	.	.	.
cord-324810-92fosk3c	10	1	The	the	DT
cord-324810-92fosk3c	10	2	efficacy	efficacy	NN
cord-324810-92fosk3c	10	3	of	of	IN
cord-324810-92fosk3c	10	4	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	10	5	therapy	therapy	NN
cord-324810-92fosk3c	10	6	in	in	IN
cord-324810-92fosk3c	10	7	acute	acute	JJ
cord-324810-92fosk3c	10	8	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	10	9	has	have	VBZ
cord-324810-92fosk3c	10	10	established	establish	VBN
cord-324810-92fosk3c	10	11	a	a	DT
cord-324810-92fosk3c	10	12	causative	causative	JJ
cord-324810-92fosk3c	10	13	role	role	NN
cord-324810-92fosk3c	10	14	for	for	IN
cord-324810-92fosk3c	10	15	bacterial	bacterial	JJ
cord-324810-92fosk3c	10	16	infections	infection	NNS
cord-324810-92fosk3c	10	17	.	.	.
cord-324810-92fosk3c	11	1	Recent	recent	JJ
cord-324810-92fosk3c	11	2	molecular	molecular	JJ
cord-324810-92fosk3c	11	3	typing	typing	NN
cord-324810-92fosk3c	11	4	of	of	IN
cord-324810-92fosk3c	11	5	sputum	sputum	NN
cord-324810-92fosk3c	11	6	isolates	isolate	VBZ
cord-324810-92fosk3c	11	7	further	further	RB
cord-324810-92fosk3c	11	8	supports	support	VBZ
cord-324810-92fosk3c	11	9	the	the	DT
cord-324810-92fosk3c	11	10	role	role	NN
cord-324810-92fosk3c	11	11	of	of	IN
cord-324810-92fosk3c	11	12	bacteria	bacteria	NNS
cord-324810-92fosk3c	11	13	in	in	IN
cord-324810-92fosk3c	11	14	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	11	15	.	.	.
cord-324810-92fosk3c	12	1	Isolation	isolation	NN
cord-324810-92fosk3c	12	2	of	of	IN
cord-324810-92fosk3c	12	3	a	a	DT
cord-324810-92fosk3c	12	4	new	new	JJ
cord-324810-92fosk3c	12	5	strain	strain	NN
cord-324810-92fosk3c	12	6	of	of	IN
cord-324810-92fosk3c	12	7	Haemophilus	haemophilus	JJ
cord-324810-92fosk3c	12	8	influenzae	influenzae	NN
cord-324810-92fosk3c	12	9	,	,	,
cord-324810-92fosk3c	12	10	Moraxella	Moraxella	NNP
cord-324810-92fosk3c	12	11	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	12	12	,	,	,
cord-324810-92fosk3c	12	13	or	or	CC
cord-324810-92fosk3c	12	14	Streptococcus	Streptococcus	NNP
cord-324810-92fosk3c	12	15	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	12	16	was	be	VBD
cord-324810-92fosk3c	12	17	associated	associate	VBN
cord-324810-92fosk3c	12	18	with	with	IN
cord-324810-92fosk3c	12	19	a	a	DT
cord-324810-92fosk3c	12	20	considerable	considerable	JJ
cord-324810-92fosk3c	12	21	risk	risk	NN
cord-324810-92fosk3c	12	22	of	of	IN
cord-324810-92fosk3c	12	23	an	an	DT
cord-324810-92fosk3c	12	24	exacerbation	exacerbation	NN
cord-324810-92fosk3c	12	25	.	.	.
cord-324810-92fosk3c	13	1	Lower	lower	VB
cord-324810-92fosk3c	13	2	airway	airway	NN
cord-324810-92fosk3c	13	3	bacterial	bacterial	JJ
cord-324810-92fosk3c	13	4	colonization	colonization	NN
cord-324810-92fosk3c	13	5	in	in	IN
cord-324810-92fosk3c	13	6	stable	stable	JJ
cord-324810-92fosk3c	13	7	patients	patient	NNS
cord-324810-92fosk3c	13	8	with	with	IN
cord-324810-92fosk3c	13	9	COPD	COPD	NNP
cord-324810-92fosk3c	13	10	instigates	instigate	VBZ
cord-324810-92fosk3c	13	11	airway	airway	NN
cord-324810-92fosk3c	13	12	inflammation	inflammation	NN
cord-324810-92fosk3c	13	13	,	,	,
cord-324810-92fosk3c	13	14	which	which	WDT
cord-324810-92fosk3c	13	15	leads	lead	VBZ
cord-324810-92fosk3c	13	16	to	to	IN
cord-324810-92fosk3c	13	17	a	a	DT
cord-324810-92fosk3c	13	18	protracted	protracted	JJ
cord-324810-92fosk3c	13	19	self	self	NN
cord-324810-92fosk3c	13	20	-	-	HYPH
cord-324810-92fosk3c	13	21	perpetuating	perpetuate	VBG
cord-324810-92fosk3c	13	22	vicious	vicious	JJ
cord-324810-92fosk3c	13	23	circle	circle	NN
cord-324810-92fosk3c	13	24	of	of	IN
cord-324810-92fosk3c	13	25	progressive	progressive	JJ
cord-324810-92fosk3c	13	26	lung	lung	NN
cord-324810-92fosk3c	13	27	damage	damage	NN
cord-324810-92fosk3c	13	28	and	and	CC
cord-324810-92fosk3c	13	29	disease	disease	NN
cord-324810-92fosk3c	13	30	progression	progression	NN
cord-324810-92fosk3c	13	31	.	.	.
cord-324810-92fosk3c	14	1	A	a	DT
cord-324810-92fosk3c	14	2	significant	significant	JJ
cord-324810-92fosk3c	14	3	proportion	proportion	NN
cord-324810-92fosk3c	14	4	of	of	IN
cord-324810-92fosk3c	14	5	patients	patient	NNS
cord-324810-92fosk3c	14	6	treated	treat	VBN
cord-324810-92fosk3c	14	7	for	for	IN
cord-324810-92fosk3c	14	8	COPD	COPD	NNP
cord-324810-92fosk3c	14	9	exacerbation	exacerbation	NN
cord-324810-92fosk3c	14	10	demonstrate	demonstrate	VB
cord-324810-92fosk3c	14	11	incomplete	incomplete	JJ
cord-324810-92fosk3c	14	12	recovery	recovery	NN
cord-324810-92fosk3c	14	13	,	,	,
cord-324810-92fosk3c	14	14	and	and	CC
cord-324810-92fosk3c	14	15	frequent	frequent	JJ
cord-324810-92fosk3c	14	16	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	14	17	contribute	contribute	VBP
cord-324810-92fosk3c	14	18	to	to	TO
cord-324810-92fosk3c	14	19	decline	decline	VB
cord-324810-92fosk3c	14	20	in	in	IN
cord-324810-92fosk3c	14	21	lung	lung	NN
cord-324810-92fosk3c	14	22	function	function	NN
cord-324810-92fosk3c	14	23	.	.	.
cord-324810-92fosk3c	15	1	The	the	DT
cord-324810-92fosk3c	15	2	predictors	predictor	NNS
cord-324810-92fosk3c	15	3	of	of	IN
cord-324810-92fosk3c	15	4	poor	poor	JJ
cord-324810-92fosk3c	15	5	outcome	outcome	NN
cord-324810-92fosk3c	15	6	include	include	VBP
cord-324810-92fosk3c	15	7	advanced	advanced	JJ
cord-324810-92fosk3c	15	8	age	age	NN
cord-324810-92fosk3c	15	9	,	,	,
cord-324810-92fosk3c	15	10	significant	significant	JJ
cord-324810-92fosk3c	15	11	impairment	impairment	NN
cord-324810-92fosk3c	15	12	of	of	IN
cord-324810-92fosk3c	15	13	lung	lung	NN
cord-324810-92fosk3c	15	14	function	function	NN
cord-324810-92fosk3c	15	15	,	,	,
cord-324810-92fosk3c	15	16	poor	poor	JJ
cord-324810-92fosk3c	15	17	performance	performance	NN
cord-324810-92fosk3c	15	18	status	status	NN
cord-324810-92fosk3c	15	19	,	,	,
cord-324810-92fosk3c	15	20	comorbid	comorbid	NN
cord-324810-92fosk3c	15	21	conditions	condition	NNS
cord-324810-92fosk3c	15	22	and	and	CC
cord-324810-92fosk3c	15	23	history	history	NN
cord-324810-92fosk3c	15	24	of	of	IN
cord-324810-92fosk3c	15	25	previous	previous	JJ
cord-324810-92fosk3c	15	26	frequent	frequent	JJ
cord-324810-92fosk3c	15	27	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	15	28	requiring	require	VBG
cord-324810-92fosk3c	15	29	antibacterials	antibacterial	NNS
cord-324810-92fosk3c	15	30	or	or	CC
cord-324810-92fosk3c	15	31	systemic	systemic	JJ
cord-324810-92fosk3c	15	32	corticosteroids	corticosteroid	NNS
cord-324810-92fosk3c	15	33	.	.	.
cord-324810-92fosk3c	16	1	These	these	DT
cord-324810-92fosk3c	16	2	high	high	JJ
cord-324810-92fosk3c	16	3	-	-	HYPH
cord-324810-92fosk3c	16	4	risk	risk	NN
cord-324810-92fosk3c	16	5	patients	patient	NNS
cord-324810-92fosk3c	16	6	,	,	,
cord-324810-92fosk3c	16	7	who	who	WP
cord-324810-92fosk3c	16	8	are	be	VBP
cord-324810-92fosk3c	16	9	likely	likely	JJ
cord-324810-92fosk3c	16	10	to	to	TO
cord-324810-92fosk3c	16	11	harbor	harbor	VB
cord-324810-92fosk3c	16	12	organisms	organism	NNS
cord-324810-92fosk3c	16	13	resistant	resistant	JJ
cord-324810-92fosk3c	16	14	to	to	IN
cord-324810-92fosk3c	16	15	commonly	commonly	RB
cord-324810-92fosk3c	16	16	used	use	VBN
cord-324810-92fosk3c	16	17	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	16	18	,	,	,
cord-324810-92fosk3c	16	19	should	should	MD
cord-324810-92fosk3c	16	20	be	be	VB
cord-324810-92fosk3c	16	21	identified	identify	VBN
cord-324810-92fosk3c	16	22	and	and	CC
cord-324810-92fosk3c	16	23	treated	treat	VBN
cord-324810-92fosk3c	16	24	with	with	IN
cord-324810-92fosk3c	16	25	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	16	26	with	with	IN
cord-324810-92fosk3c	16	27	a	a	DT
cord-324810-92fosk3c	16	28	low	low	JJ
cord-324810-92fosk3c	16	29	potential	potential	NN
cord-324810-92fosk3c	16	30	for	for	IN
cord-324810-92fosk3c	16	31	failure	failure	NN
cord-324810-92fosk3c	16	32	.	.	.
cord-324810-92fosk3c	17	1	An	an	DT
cord-324810-92fosk3c	17	2	aggressive	aggressive	JJ
cord-324810-92fosk3c	17	3	management	management	NN
cord-324810-92fosk3c	17	4	approach	approach	NN
cord-324810-92fosk3c	17	5	in	in	IN
cord-324810-92fosk3c	17	6	complicated	complicated	JJ
cord-324810-92fosk3c	17	7	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	17	8	may	may	MD
cord-324810-92fosk3c	17	9	reduce	reduce	VB
cord-324810-92fosk3c	17	10	costs	cost	NNS
cord-324810-92fosk3c	17	11	by	by	IN
cord-324810-92fosk3c	17	12	reducing	reduce	VBG
cord-324810-92fosk3c	17	13	healthcare	healthcare	NN
cord-324810-92fosk3c	17	14	utilization	utilization	NN
cord-324810-92fosk3c	17	15	and	and	CC
cord-324810-92fosk3c	17	16	hospitalization	hospitalization	NN
cord-324810-92fosk3c	17	17	.	.	.
cord-324810-92fosk3c	18	1	First	first	RB
cord-324810-92fosk3c	18	2	described	describe	VBN
cord-324810-92fosk3c	18	3	by	by	IN
cord-324810-92fosk3c	18	4	Badham	Badham	NNP
cord-324810-92fosk3c	18	5	in	in	IN
cord-324810-92fosk3c	18	6	1808	1808	CD
cord-324810-92fosk3c	18	7	and	and	CC
cord-324810-92fosk3c	18	8	then	then	RB
cord-324810-92fosk3c	18	9	by	by	IN
cord-324810-92fosk3c	18	10	Laennec	Laennec	NNP
cord-324810-92fosk3c	18	11	in	in	IN
cord-324810-92fosk3c	18	12	tial	tial	JJ
cord-324810-92fosk3c	18	13	part	part	NN
cord-324810-92fosk3c	18	14	of	of	IN
cord-324810-92fosk3c	18	15	the	the	DT
cord-324810-92fosk3c	18	16	natural	natural	JJ
cord-324810-92fosk3c	18	17	history	history	NN
cord-324810-92fosk3c	18	18	,	,	,
cord-324810-92fosk3c	18	19	is	be	VBZ
cord-324810-92fosk3c	18	20	a	a	DT
cord-324810-92fosk3c	18	21	common	common	JJ
cord-324810-92fosk3c	18	22	cause	cause	NN
cord-324810-92fosk3c	18	23	of	of	IN
cord-324810-92fosk3c	18	24	medical	medical	JJ
cord-324810-92fosk3c	18	25	visits	visit	NNS
cord-324810-92fosk3c	18	26	,	,	,
cord-324810-92fosk3c	18	27	hospital	hospital	NN
cord-324810-92fosk3c	18	28	admissions	admission	NNS
cord-324810-92fosk3c	18	29	and	and	CC
cord-324810-92fosk3c	18	30	death	death	NN
cord-324810-92fosk3c	18	31	in	in	IN
cord-324810-92fosk3c	18	32	COPD	COPD	NNP
cord-324810-92fosk3c	18	33	.	.	.
cord-324810-92fosk3c	19	1	[	[	-LRB-
cord-324810-92fosk3c	19	2	6	6	CD
cord-324810-92fosk3c	19	3	]	]	-RRB-
cord-324810-92fosk3c	19	4	We	-PRON-	PRP
cord-324810-92fosk3c	19	5	reviewed	review	VBD
cord-324810-92fosk3c	19	6	published	publish	VBN
cord-324810-92fosk3c	19	7	1827	1827	CD
cord-324810-92fosk3c	19	8	,	,	,
cord-324810-92fosk3c	19	9	COPD	COPD	NNP
cord-324810-92fosk3c	19	10	is	be	VBZ
cord-324810-92fosk3c	19	11	a	a	DT
cord-324810-92fosk3c	19	12	devastating	devastating	JJ
cord-324810-92fosk3c	19	13	respiratory	respiratory	JJ
cord-324810-92fosk3c	19	14	illness	illness	NN
cord-324810-92fosk3c	19	15	that	that	WDT
cord-324810-92fosk3c	19	16	affects	affect	VBZ
cord-324810-92fosk3c	19	17	a	a	DT
cord-324810-92fosk3c	19	18	literature	literature	NN
cord-324810-92fosk3c	19	19	on	on	IN
cord-324810-92fosk3c	19	20	the	the	DT
cord-324810-92fosk3c	19	21	etiology	etiology	NN
cord-324810-92fosk3c	19	22	,	,	,
cord-324810-92fosk3c	19	23	pathophysiology	pathophysiology	NN
cord-324810-92fosk3c	19	24	,	,	,
cord-324810-92fosk3c	19	25	treatment	treatment	NN
cord-324810-92fosk3c	19	26	and	and	CC
cord-324810-92fosk3c	19	27	outcome	outcome	VB
cord-324810-92fosk3c	19	28	sizeable	sizeable	JJ
cord-324810-92fosk3c	19	29	world	world	NN
cord-324810-92fosk3c	19	30	population	population	NN
cord-324810-92fosk3c	19	31	and	and	CC
cord-324810-92fosk3c	19	32	is	be	VBZ
cord-324810-92fosk3c	19	33	the	the	DT
cord-324810-92fosk3c	19	34	fourth	fourth	JJ
cord-324810-92fosk3c	19	35	leading	leading	JJ
cord-324810-92fosk3c	19	36	cause	cause	NN
cord-324810-92fosk3c	19	37	of	of	IN
cord-324810-92fosk3c	19	38	death	death	NN
cord-324810-92fosk3c	19	39	of	of	IN
cord-324810-92fosk3c	19	40	acute	acute	JJ
cord-324810-92fosk3c	19	41	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	19	42	of	of	IN
cord-324810-92fosk3c	19	43	COPD	COPD	NNP
cord-324810-92fosk3c	19	44	(	(	-LRB-
cord-324810-92fosk3c	19	45	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	19	46	)	)	-RRB-
cord-324810-92fosk3c	19	47	by	by	IN
cord-324810-92fosk3c	19	48	searching	search	VBG
cord-324810-92fosk3c	19	49	MEDin	MEDin	NNP
cord-324810-92fosk3c	19	50	US	US	NNP
cord-324810-92fosk3c	19	51	after	after	IN
cord-324810-92fosk3c	19	52	heart	heart	NN
cord-324810-92fosk3c	19	53	disease	disease	NN
cord-324810-92fosk3c	19	54	,	,	,
cord-324810-92fosk3c	19	55	cancer	cancer	NN
cord-324810-92fosk3c	19	56	and	and	CC
cord-324810-92fosk3c	19	57	stroke	stroke	NN
cord-324810-92fosk3c	19	58	.	.	.
cord-324810-92fosk3c	20	1	[	[	-LRB-
cord-324810-92fosk3c	20	2	1	1	CD
cord-324810-92fosk3c	20	3	,	,	,
cord-324810-92fosk3c	20	4	2	2	CD
cord-324810-92fosk3c	20	5	]	]	-RRB-
cord-324810-92fosk3c	20	6	Primarily	primarily	RB
cord-324810-92fosk3c	20	7	a	a	DT
cord-324810-92fosk3c	20	8	conse	conse	NN
cord-324810-92fosk3c	20	9	-	-	HYPH
cord-324810-92fosk3c	20	10	LINE	line	NN
cord-324810-92fosk3c	20	11	,	,	,
cord-324810-92fosk3c	20	12	EMBASE	EMBASE	NNP
cord-324810-92fosk3c	20	13	,	,	,
cord-324810-92fosk3c	20	14	and	and	CC
cord-324810-92fosk3c	20	15	CINAHL	CINAHL	NNP
cord-324810-92fosk3c	20	16	®	®	VBP
cord-324810-92fosk3c	20	17	databases	database	NNS
cord-324810-92fosk3c	20	18	.	.	.
cord-324810-92fosk3c	21	1	The	the	DT
cord-324810-92fosk3c	21	2	following	follow	VBG
cord-324810-92fosk3c	21	3	search	search	NN
cord-324810-92fosk3c	21	4	quence	quence	NN
cord-324810-92fosk3c	21	5	of	of	IN
cord-324810-92fosk3c	21	6	tobacco	tobacco	NN
cord-324810-92fosk3c	21	7	consumption	consumption	NN
cord-324810-92fosk3c	21	8	in	in	IN
cord-324810-92fosk3c	21	9	the	the	DT
cord-324810-92fosk3c	21	10	developed	develop	VBN
cord-324810-92fosk3c	21	11	world	world	NN
cord-324810-92fosk3c	21	12	,	,	,
cord-324810-92fosk3c	21	13	COPD	COPD	NNP
cord-324810-92fosk3c	21	14	terms	term	NNS
cord-324810-92fosk3c	21	15	were	be	VBD
cord-324810-92fosk3c	21	16	used	use	VBN
cord-324810-92fosk3c	21	17	:	:	:
cord-324810-92fosk3c	21	18	acute	acute	JJ
cord-324810-92fosk3c	21	19	exacerbation	exacerbation	NN
cord-324810-92fosk3c	21	20	of	of	IN
cord-324810-92fosk3c	21	21	COPD	COPD	NNP
cord-324810-92fosk3c	21	22	,	,	,
cord-324810-92fosk3c	21	23	COPD	COPD	NNP
cord-324810-92fosk3c	21	24	exacerbaaffects	exacerbaaffect	NNS
cord-324810-92fosk3c	21	25	patient	patient	NN
cord-324810-92fosk3c	21	26	's	's	POS
cord-324810-92fosk3c	21	27	quality	quality	NN
cord-324810-92fosk3c	21	28	of	of	IN
cord-324810-92fosk3c	21	29	life	life	NN
cord-324810-92fosk3c	21	30	,	,	,
cord-324810-92fosk3c	21	31	utilization	utilization	NN
cord-324810-92fosk3c	21	32	of	of	IN
cord-324810-92fosk3c	21	33	healthcare	healthcare	NN
cord-324810-92fosk3c	21	34	resources	resource	NNS
cord-324810-92fosk3c	21	35	,	,	,
cord-324810-92fosk3c	21	36	tion	tion	NN
cord-324810-92fosk3c	21	37	,	,	,
cord-324810-92fosk3c	21	38	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	21	39	,	,	,
cord-324810-92fosk3c	21	40	acute	acute	JJ
cord-324810-92fosk3c	21	41	exacerbation	exacerbation	NN
cord-324810-92fosk3c	21	42	of	of	IN
cord-324810-92fosk3c	21	43	chronic	chronic	JJ
cord-324810-92fosk3c	21	44	bronchitis	bronchitis	NN
cord-324810-92fosk3c	21	45	and	and	CC
cord-324810-92fosk3c	21	46	and	and	CC
cord-324810-92fosk3c	21	47	also	also	RB
cord-324810-92fosk3c	21	48	has	have	VBZ
cord-324810-92fosk3c	21	49	adverse	adverse	JJ
cord-324810-92fosk3c	21	50	economic	economic	JJ
cord-324810-92fosk3c	21	51	impacts	impact	NNS
cord-324810-92fosk3c	21	52	on	on	IN
cord-324810-92fosk3c	21	53	the	the	DT
cord-324810-92fosk3c	21	54	patient	patient	NN
cord-324810-92fosk3c	21	55	and	and	CC
cord-324810-92fosk3c	21	56	society	society	NN
cord-324810-92fosk3c	21	57	.	.	.
cord-324810-92fosk3c	22	1	AECB	AECB	NNP
cord-324810-92fosk3c	22	2	.	.	.
cord-324810-92fosk3c	23	1	The	the	DT
cord-324810-92fosk3c	23	2	search	search	NN
cord-324810-92fosk3c	23	3	encompassed	encompass	VBD
cord-324810-92fosk3c	23	4	all	all	DT
cord-324810-92fosk3c	23	5	publications	publication	NNS
cord-324810-92fosk3c	23	6	from	from	IN
cord-324810-92fosk3c	23	7	1966	1966	CD
cord-324810-92fosk3c	23	8	until	until	IN
cord-324810-92fosk3c	23	9	At	at	IN
cord-324810-92fosk3c	23	10	present	present	JJ
cord-324810-92fosk3c	23	11	,	,	,
cord-324810-92fosk3c	23	12	more	more	JJR
cord-324810-92fosk3c	23	13	than	than	IN
cord-324810-92fosk3c	23	14	16	16	CD
cord-324810-92fosk3c	23	15	million	million	CD
cord-324810-92fosk3c	23	16	adults	adult	NNS
cord-324810-92fosk3c	23	17	have	have	VBP
cord-324810-92fosk3c	23	18	COPD	COPD	NNP
cord-324810-92fosk3c	23	19	in	in	IN
cord-324810-92fosk3c	23	20	the	the	DT
cord-324810-92fosk3c	23	21	US	US	NNP
cord-324810-92fosk3c	23	22	and	and	CC
cord-324810-92fosk3c	23	23	31	31	CD
cord-324810-92fosk3c	23	24	December	December	NNP
cord-324810-92fosk3c	23	25	2004	2004	CD
cord-324810-92fosk3c	23	26	.	.	.
cord-324810-92fosk3c	24	1	Additionally	additionally	RB
cord-324810-92fosk3c	24	2	,	,	,
cord-324810-92fosk3c	24	3	consensus	consensus	NN
cord-324810-92fosk3c	24	4	statements	statement	NNS
cord-324810-92fosk3c	24	5	,	,	,
cord-324810-92fosk3c	24	6	review	review	VBP
cord-324810-92fosk3c	24	7	52	52	CD
cord-324810-92fosk3c	24	8	million	million	CD
cord-324810-92fosk3c	24	9	worldwide	worldwide	RB
cord-324810-92fosk3c	24	10	,	,	,
cord-324810-92fosk3c	24	11	and	and	CC
cord-324810-92fosk3c	24	12	the	the	DT
cord-324810-92fosk3c	24	13	disease	disease	NN
cord-324810-92fosk3c	24	14	accounts	account	VBZ
cord-324810-92fosk3c	24	15	for	for	IN
cord-324810-92fosk3c	24	16	approximately	approximately	RB
cord-324810-92fosk3c	24	17	articles	article	NNS
cord-324810-92fosk3c	24	18	,	,	,
cord-324810-92fosk3c	24	19	and	and	CC
cord-324810-92fosk3c	24	20	articles	article	NNS
cord-324810-92fosk3c	24	21	written	write	VBN
cord-324810-92fosk3c	24	22	by	by	IN
cord-324810-92fosk3c	24	23	selected	select	VBN
cord-324810-92fosk3c	24	24	authorities	authority	NNS
cord-324810-92fosk3c	24	25	were	be	VBD
cord-324810-92fosk3c	24	26	reviewed	review	VBN
cord-324810-92fosk3c	24	27	.	.	.
cord-324810-92fosk3c	25	1	125	125	CD
cord-324810-92fosk3c	25	2	500	500	CD
cord-324810-92fosk3c	25	3	deaths	death	NNS
cord-324810-92fosk3c	25	4	in	in	IN
cord-324810-92fosk3c	25	5	the	the	DT
cord-324810-92fosk3c	25	6	US	US	NNP
cord-324810-92fosk3c	25	7	and	and	CC
cord-324810-92fosk3c	25	8	2.74	2.74	CD
cord-324810-92fosk3c	25	9	million	million	CD
cord-324810-92fosk3c	25	10	globally	globally	RB
cord-324810-92fosk3c	25	11	annually	annually	RB
cord-324810-92fosk3c	25	12	.	.	.
cord-324810-92fosk3c	26	1	[	[	-LRB-
cord-324810-92fosk3c	26	2	3	3	CD
cord-324810-92fosk3c	26	3	,	,	,
cord-324810-92fosk3c	26	4	4	4	CD
cord-324810-92fosk3c	26	5	]	]	-RRB-
cord-324810-92fosk3c	27	1	The	the	DT
cord-324810-92fosk3c	27	2	prevalence	prevalence	NN
cord-324810-92fosk3c	27	3	of	of	IN
cord-324810-92fosk3c	27	4	COPD	COPD	NNP
cord-324810-92fosk3c	27	5	has	have	VBZ
cord-324810-92fosk3c	27	6	continued	continue	VBN
cord-324810-92fosk3c	27	7	to	to	TO
cord-324810-92fosk3c	27	8	increase	increase	VB
cord-324810-92fosk3c	27	9	internationally	internationally	RB
cord-324810-92fosk3c	27	10	1	1	CD
cord-324810-92fosk3c	27	11	.	.	.
cord-324810-92fosk3c	28	1	Definition	definition	NN
cord-324810-92fosk3c	28	2	of	of	IN
cord-324810-92fosk3c	28	3	Acute	acute	JJ
cord-324810-92fosk3c	28	4	Exacerbation	Exacerbation	NNP
cord-324810-92fosk3c	28	5	of	of	IN
cord-324810-92fosk3c	28	6	Chronic	Chronic	NNP
cord-324810-92fosk3c	28	7	because	because	IN
cord-324810-92fosk3c	28	8	of	of	IN
cord-324810-92fosk3c	28	9	rapidly	rapidly	RB
cord-324810-92fosk3c	28	10	increasing	increase	VBG
cord-324810-92fosk3c	28	11	smoking	smoking	NN
cord-324810-92fosk3c	28	12	rates	rate	NNS
cord-324810-92fosk3c	28	13	in	in	IN
cord-324810-92fosk3c	28	14	developing	develop	VBG
cord-324810-92fosk3c	28	15	nations	nation	NNS
cord-324810-92fosk3c	28	16	.	.	.
cord-324810-92fosk3c	29	1	Obstructive	obstructive	JJ
cord-324810-92fosk3c	29	2	Pulmonary	Pulmonary	NNP
cord-324810-92fosk3c	29	3	Disease	Disease	NNP
cord-324810-92fosk3c	29	4	(	(	-LRB-
cord-324810-92fosk3c	29	5	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	29	6	)	)	-RRB-
cord-324810-92fosk3c	30	1	By	by	IN
cord-324810-92fosk3c	30	2	the	the	DT
cord-324810-92fosk3c	30	3	year	year	NN
cord-324810-92fosk3c	30	4	2020	2020	CD
cord-324810-92fosk3c	30	5	,	,	,
cord-324810-92fosk3c	30	6	COPD	COPD	NNP
cord-324810-92fosk3c	30	7	is	be	VBZ
cord-324810-92fosk3c	30	8	predicted	predict	VBN
cord-324810-92fosk3c	30	9	to	to	TO
cord-324810-92fosk3c	30	10	become	become	VB
cord-324810-92fosk3c	30	11	the	the	DT
cord-324810-92fosk3c	30	12	fifth	fifth	JJ
cord-324810-92fosk3c	30	13	leading	leading	JJ
cord-324810-92fosk3c	30	14	cause	cause	NN
cord-324810-92fosk3c	30	15	of	of	IN
cord-324810-92fosk3c	30	16	death	death	NN
cord-324810-92fosk3c	30	17	and	and	CC
cord-324810-92fosk3c	30	18	disability	disability	NN
cord-324810-92fosk3c	30	19	worldwide	worldwide	RB
cord-324810-92fosk3c	30	20	.	.	.
cord-324810-92fosk3c	31	1	[	[	-LRB-
cord-324810-92fosk3c	31	2	5	5	CD
cord-324810-92fosk3c	31	3	]	]	-RRB-
cord-324810-92fosk3c	31	4	Acute	acute	JJ
cord-324810-92fosk3c	31	5	deterioration	deterioration	NN
cord-324810-92fosk3c	31	6	of	of	IN
cord-324810-92fosk3c	31	7	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	31	8	lacks	lack	VBZ
cord-324810-92fosk3c	31	9	a	a	DT
cord-324810-92fosk3c	31	10	uniform	uniform	NN
cord-324810-92fosk3c	31	11	and	and	CC
cord-324810-92fosk3c	31	12	widely	widely	RB
cord-324810-92fosk3c	31	13	accepted	accept	VBN
cord-324810-92fosk3c	31	14	definition	definition	NN
cord-324810-92fosk3c	31	15	in	in	IN
cord-324810-92fosk3c	31	16	the	the	DT
cord-324810-92fosk3c	31	17	chronic	chronic	JJ
cord-324810-92fosk3c	31	18	symptoms	symptom	NNS
cord-324810-92fosk3c	31	19	frequently	frequently	RB
cord-324810-92fosk3c	31	20	occurs	occur	VBZ
cord-324810-92fosk3c	31	21	and	and	CC
cord-324810-92fosk3c	31	22	besides	besides	IN
cord-324810-92fosk3c	31	23	being	be	VBG
cord-324810-92fosk3c	31	24	an	an	DT
cord-324810-92fosk3c	31	25	essen	essen	NNP
cord-324810-92fosk3c	31	26	-	-	HYPH
cord-324810-92fosk3c	31	27	published	publish	VBN
cord-324810-92fosk3c	31	28	literature	literature	NN
cord-324810-92fosk3c	31	29	.	.	.
cord-324810-92fosk3c	32	1	Worsening	worsen	VBG
cord-324810-92fosk3c	32	2	of	of	IN
cord-324810-92fosk3c	32	3	one	one	CD
cord-324810-92fosk3c	32	4	or	or	CC
cord-324810-92fosk3c	32	5	more	more	JJR
cord-324810-92fosk3c	32	6	chronic	chronic	JJ
cord-324810-92fosk3c	32	7	symptoms	symptom	NNS
cord-324810-92fosk3c	32	8	including	include	VBG
cord-324810-92fosk3c	32	9	dyspnea	dyspnea	NN
cord-324810-92fosk3c	32	10	,	,	,
cord-324810-92fosk3c	32	11	cough	cough	NN
cord-324810-92fosk3c	32	12	,	,	,
cord-324810-92fosk3c	32	13	sputum	sputum	NN
cord-324810-92fosk3c	32	14	production	production	NN
cord-324810-92fosk3c	32	15	,	,	,
cord-324810-92fosk3c	32	16	or	or	CC
cord-324810-92fosk3c	32	17	sputum	sputum	NN
cord-324810-92fosk3c	32	18	purulence	purulence	NN
cord-324810-92fosk3c	32	19	appears	appear	VBZ
cord-324810-92fosk3c	32	20	to	to	TO
cord-324810-92fosk3c	32	21	be	be	VB
cord-324810-92fosk3c	32	22	the	the	DT
cord-324810-92fosk3c	32	23	most	most	RBS
cord-324810-92fosk3c	32	24	commonly	commonly	RB
cord-324810-92fosk3c	32	25	accepted	accept	VBN
cord-324810-92fosk3c	32	26	definition	definition	NN
cord-324810-92fosk3c	32	27	.	.	.
cord-324810-92fosk3c	33	1	[	[	-LRB-
cord-324810-92fosk3c	33	2	7	7	CD
cord-324810-92fosk3c	33	3	]	]	-RRB-
cord-324810-92fosk3c	34	1	Currently	currently	RB
cord-324810-92fosk3c	34	2	,	,	,
cord-324810-92fosk3c	34	3	the	the	DT
cord-324810-92fosk3c	34	4	clinical	clinical	JJ
cord-324810-92fosk3c	34	5	practice	practice	NN
cord-324810-92fosk3c	34	6	guidelines	guideline	NNS
cord-324810-92fosk3c	34	7	have	have	VBP
cord-324810-92fosk3c	34	8	incorporated	incorporate	VBN
cord-324810-92fosk3c	34	9	Winnipeg	Winnipeg	NNP
cord-324810-92fosk3c	34	10	criteria	criterion	NNS
cord-324810-92fosk3c	34	11	(	(	-LRB-
cord-324810-92fosk3c	34	12	increased	increase	VBN
cord-324810-92fosk3c	34	13	dyspnea	dyspnea	NN
cord-324810-92fosk3c	34	14	,	,	,
cord-324810-92fosk3c	34	15	increased	increase	VBN
cord-324810-92fosk3c	34	16	sputum	sputum	NN
cord-324810-92fosk3c	34	17	volumes	volume	NNS
cord-324810-92fosk3c	34	18	and	and	CC
cord-324810-92fosk3c	34	19	increased	increase	VBN
cord-324810-92fosk3c	34	20	sputum	sputum	NN
cord-324810-92fosk3c	34	21	purulence	purulence	NN
cord-324810-92fosk3c	34	22	)	)	-RRB-
cord-324810-92fosk3c	34	23	to	to	TO
cord-324810-92fosk3c	34	24	define	define	VB
cord-324810-92fosk3c	34	25	and	and	CC
cord-324810-92fosk3c	34	26	grade	grade	VB
cord-324810-92fosk3c	34	27	the	the	DT
cord-324810-92fosk3c	34	28	severity	severity	NN
cord-324810-92fosk3c	34	29	of	of	IN
cord-324810-92fosk3c	34	30	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	34	31	(	(	-LRB-
cord-324810-92fosk3c	34	32	table	table	NN
cord-324810-92fosk3c	34	33	I	-PRON-	PRP
cord-324810-92fosk3c	34	34	)	)	-RRB-
cord-324810-92fosk3c	34	35	.	.	.
cord-324810-92fosk3c	35	1	Anthonisen	Anthonisen	NNP
cord-324810-92fosk3c	35	2	et	et	NNP
cord-324810-92fosk3c	35	3	al	al	NNP
cord-324810-92fosk3c	35	4	.	.	.
cord-324810-92fosk3c	36	1	[	[	-LRB-
cord-324810-92fosk3c	36	2	8	8	CD
cord-324810-92fosk3c	36	3	]	]	-RRB-
cord-324810-92fosk3c	36	4	showed	show	VBD
cord-324810-92fosk3c	36	5	that	that	IN
cord-324810-92fosk3c	36	6	the	the	DT
cord-324810-92fosk3c	36	7	presence	presence	NN
cord-324810-92fosk3c	36	8	of	of	IN
cord-324810-92fosk3c	36	9	two	two	CD
cord-324810-92fosk3c	36	10	or	or	CC
cord-324810-92fosk3c	36	11	more	more	JJR
cord-324810-92fosk3c	36	12	of	of	IN
cord-324810-92fosk3c	36	13	these	these	DT
cord-324810-92fosk3c	36	14	clinical	clinical	JJ
cord-324810-92fosk3c	36	15	features	feature	NNS
cord-324810-92fosk3c	36	16	predicted	predict	VBN
cord-324810-92fosk3c	36	17	benefit	benefit	NN
cord-324810-92fosk3c	36	18	of	of	IN
cord-324810-92fosk3c	36	19	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	36	20	therapy	therapy	NN
cord-324810-92fosk3c	36	21	in	in	IN
cord-324810-92fosk3c	36	22	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	36	23	.	.	.
cord-324810-92fosk3c	37	1	An	an	DT
cord-324810-92fosk3c	37	2	American	american	JJ
cord-324810-92fosk3c	37	3	-	-	HYPH
cord-324810-92fosk3c	37	4	European	european	JJ
cord-324810-92fosk3c	37	5	working	working	NN
cord-324810-92fosk3c	37	6	II	II	NNP
cord-324810-92fosk3c	37	7	Two	two	CD
cord-324810-92fosk3c	37	8	of	of	IN
cord-324810-92fosk3c	37	9	the	the	DT
cord-324810-92fosk3c	37	10	above	above	JJ
cord-324810-92fosk3c	37	11	three	three	CD
cord-324810-92fosk3c	37	12	symptoms	symptom	NNS
cord-324810-92fosk3c	37	13	present	present	JJ
cord-324810-92fosk3c	38	1	III	iii	CD
cord-324810-92fosk3c	38	2	One	one	CD
cord-324810-92fosk3c	38	3	of	of	IN
cord-324810-92fosk3c	38	4	the	the	DT
cord-324810-92fosk3c	38	5	above	above	JJ
cord-324810-92fosk3c	38	6	symptoms	symptom	NNS
cord-324810-92fosk3c	38	7	present	present	JJ
cord-324810-92fosk3c	38	8	plus	plus	CC
cord-324810-92fosk3c	38	9	at	at	RB
cord-324810-92fosk3c	38	10	least	least	RBS
cord-324810-92fosk3c	38	11	one	one	CD
cord-324810-92fosk3c	38	12	of	of	IN
cord-324810-92fosk3c	38	13	the	the	DT
cord-324810-92fosk3c	38	14	following	following	JJ
cord-324810-92fosk3c	38	15	:	:	:
cord-324810-92fosk3c	38	16	upper	upper	JJ
cord-324810-92fosk3c	38	17	respiratory	respiratory	JJ
cord-324810-92fosk3c	38	18	tract	tract	NN
cord-324810-92fosk3c	38	19	infection	infection	NN
cord-324810-92fosk3c	38	20	in	in	IN
cord-324810-92fosk3c	38	21	the	the	DT
cord-324810-92fosk3c	38	22	last	last	JJ
cord-324810-92fosk3c	38	23	5	5	CD
cord-324810-92fosk3c	38	24	days	day	NNS
cord-324810-92fosk3c	38	25	,	,	,
cord-324810-92fosk3c	38	26	fever	fever	NN
cord-324810-92fosk3c	38	27	,	,	,
cord-324810-92fosk3c	38	28	increased	increase	VBN
cord-324810-92fosk3c	38	29	wheezing	wheeze	VBG
cord-324810-92fosk3c	38	30	,	,	,
cord-324810-92fosk3c	38	31	and	and	CC
cord-324810-92fosk3c	38	32	increased	increase	VBN
cord-324810-92fosk3c	38	33	cough	cough	NN
cord-324810-92fosk3c	38	34	group	group	NN
cord-324810-92fosk3c	38	35	proposed	propose	VBD
cord-324810-92fosk3c	38	36	a	a	DT
cord-324810-92fosk3c	38	37	widely	widely	RB
cord-324810-92fosk3c	38	38	accepted	accept	VBN
cord-324810-92fosk3c	38	39	definition	definition	NN
cord-324810-92fosk3c	38	40	of	of	IN
cord-324810-92fosk3c	38	41	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	38	42	as	as	IN
cord-324810-92fosk3c	38	43	follows	follow	VBZ
cord-324810-92fosk3c	38	44	:	:	:
cord-324810-92fosk3c	38	45	"	"	``
cord-324810-92fosk3c	38	46	A	a	DT
cord-324810-92fosk3c	38	47	sustained	sustained	JJ
cord-324810-92fosk3c	38	48	worsening	worsening	NN
cord-324810-92fosk3c	38	49	of	of	IN
cord-324810-92fosk3c	38	50	the	the	DT
cord-324810-92fosk3c	38	51	patients	patient	NNS
cord-324810-92fosk3c	38	52	'	'	POS
cord-324810-92fosk3c	38	53	condition	condition	NN
cord-324810-92fosk3c	38	54	,	,	,
cord-324810-92fosk3c	38	55	from	from	IN
cord-324810-92fosk3c	38	56	were	be	VBD
cord-324810-92fosk3c	38	57	considered	consider	VBN
cord-324810-92fosk3c	38	58	to	to	TO
cord-324810-92fosk3c	38	59	be	be	VB
cord-324810-92fosk3c	38	60	a	a	DT
cord-324810-92fosk3c	38	61	consequence	consequence	NN
cord-324810-92fosk3c	38	62	of	of	IN
cord-324810-92fosk3c	38	63	infection	infection	NN
cord-324810-92fosk3c	38	64	with	with	IN
cord-324810-92fosk3c	38	65	respiratory	respiratory	JJ
cord-324810-92fosk3c	38	66	the	the	DT
cord-324810-92fosk3c	38	67	stable	stable	JJ
cord-324810-92fosk3c	38	68	state	state	NN
cord-324810-92fosk3c	38	69	and	and	CC
cord-324810-92fosk3c	38	70	beyond	beyond	IN
cord-324810-92fosk3c	38	71	normal	normal	JJ
cord-324810-92fosk3c	38	72	day	day	NN
cord-324810-92fosk3c	38	73	-	-	HYPH
cord-324810-92fosk3c	38	74	to	to	IN
cord-324810-92fosk3c	38	75	-	-	HYPH
cord-324810-92fosk3c	38	76	day	day	NN
cord-324810-92fosk3c	38	77	variations	variation	NNS
cord-324810-92fosk3c	38	78	,	,	,
cord-324810-92fosk3c	38	79	necessiviruses	necessiviruse	NNS
cord-324810-92fosk3c	38	80	.	.	.
cord-324810-92fosk3c	39	1	[	[	-LRB-
cord-324810-92fosk3c	39	2	21	21	CD
cord-324810-92fosk3c	39	3	]	]	-RRB-
cord-324810-92fosk3c	39	4	tating	tat	VBG
cord-324810-92fosk3c	39	5	a	a	DT
cord-324810-92fosk3c	39	6	change	change	NN
cord-324810-92fosk3c	39	7	in	in	IN
cord-324810-92fosk3c	39	8	regular	regular	JJ
cord-324810-92fosk3c	39	9	medication	medication	NN
cord-324810-92fosk3c	39	10	in	in	IN
cord-324810-92fosk3c	39	11	a	a	DT
cord-324810-92fosk3c	39	12	patient	patient	NN
cord-324810-92fosk3c	39	13	with	with	IN
cord-324810-92fosk3c	39	14	underlying	underlie	VBG
cord-324810-92fosk3c	39	15	COPD	COPD	NNP
cord-324810-92fosk3c	39	16	.	.	.
cord-324810-92fosk3c	40	1	"	"	``
cord-324810-92fosk3c	40	2	[	[	-LRB-
cord-324810-92fosk3c	40	3	9	9	CD
cord-324810-92fosk3c	40	4	]	]	-RRB-
cord-324810-92fosk3c	40	5	Atypical	atypical	JJ
cord-324810-92fosk3c	40	6	bacteria	bacteria	NNS
cord-324810-92fosk3c	40	7	are	be	VBP
cord-324810-92fosk3c	40	8	difficult	difficult	JJ
cord-324810-92fosk3c	40	9	to	to	TO
cord-324810-92fosk3c	40	10	isolate	isolate	VB
cord-324810-92fosk3c	40	11	but	but	CC
cord-324810-92fosk3c	40	12	the	the	DT
cord-324810-92fosk3c	40	13	investigators	investigator	NNS
cord-324810-92fosk3c	40	14	have	have	VBP
cord-324810-92fosk3c	40	15	performed	perform	VBN
cord-324810-92fosk3c	40	16	serologic	serologic	JJ
cord-324810-92fosk3c	40	17	testing	testing	NN
cord-324810-92fosk3c	40	18	to	to	TO
cord-324810-92fosk3c	40	19	evaluate	evaluate	VB
cord-324810-92fosk3c	40	20	the	the	DT
cord-324810-92fosk3c	40	21	role	role	NN
cord-324810-92fosk3c	40	22	of	of	IN
cord-324810-92fosk3c	40	23	chlamydia	chlamydia	NNS
cord-324810-92fosk3c	40	24	and	and	CC
cord-324810-92fosk3c	40	25	mycoplasma	mycoplasma	NN
cord-324810-92fosk3c	40	26	in	in	IN
cord-324810-92fosk3c	40	27	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	40	28	.	.	.
cord-324810-92fosk3c	41	1	Although	although	IN
cord-324810-92fosk3c	41	2	mycoplasma	mycoplasma	NN
cord-324810-92fosk3c	41	3	infection	infection	NN
cord-324810-92fosk3c	41	4	as	as	IN
cord-324810-92fosk3c	41	5	2	2	CD
cord-324810-92fosk3c	41	6	.	.	.
cord-324810-92fosk3c	42	1	Role	role	NN
cord-324810-92fosk3c	42	2	of	of	IN
cord-324810-92fosk3c	42	3	Bacteria	Bacteria	NNS
cord-324810-92fosk3c	42	4	in	in	IN
cord-324810-92fosk3c	42	5	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	42	6	a	a	DT
cord-324810-92fosk3c	42	7	cause	cause	NN
cord-324810-92fosk3c	42	8	of	of	IN
cord-324810-92fosk3c	42	9	exacerbation	exacerbation	NN
cord-324810-92fosk3c	42	10	is	be	VBZ
cord-324810-92fosk3c	42	11	uncommon	uncommon	JJ
cord-324810-92fosk3c	42	12	,	,	,
cord-324810-92fosk3c	42	13	Chlamydia	Chlamydia	NNP
cord-324810-92fosk3c	42	14	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	42	15	infection	infection	NN
cord-324810-92fosk3c	42	16	is	be	VBZ
cord-324810-92fosk3c	42	17	reported	report	VBN
cord-324810-92fosk3c	42	18	to	to	TO
cord-324810-92fosk3c	42	19	account	account	VB
cord-324810-92fosk3c	42	20	for	for	IN
cord-324810-92fosk3c	42	21	5	5	CD
cord-324810-92fosk3c	42	22	-	-	SYM
cord-324810-92fosk3c	42	23	10	10	CD
cord-324810-92fosk3c	42	24	%	%	NN
cord-324810-92fosk3c	42	25	of	of	IN
cord-324810-92fosk3c	42	26	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	42	27	,	,	,
cord-324810-92fosk3c	42	28	although	although	IN
cord-324810-92fosk3c	42	29	a	a	DT
cord-324810-92fosk3c	42	30	concomitant	concomitant	JJ
cord-324810-92fosk3c	42	31	bacterial	bacterial	JJ
cord-324810-92fosk3c	42	32	pathogen	pathogen	NN
cord-324810-92fosk3c	42	33	may	may	MD
cord-324810-92fosk3c	42	34	also	also	RB
cord-324810-92fosk3c	42	35	be	be	VB
cord-324810-92fosk3c	42	36	present	present	JJ
cord-324810-92fosk3c	42	37	.	.	.
cord-324810-92fosk3c	43	1	[	[	-LRB-
cord-324810-92fosk3c	43	2	15	15	CD
cord-324810-92fosk3c	43	3	]	]	-RRB-
cord-324810-92fosk3c	43	4	2.1	2.1	CD
cord-324810-92fosk3c	43	5	Pathogens	pathogen	NNS
cord-324810-92fosk3c	43	6	in	in	IN
cord-324810-92fosk3c	43	7	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	44	1	The	the	DT
cord-324810-92fosk3c	44	2	predominant	predominant	JJ
cord-324810-92fosk3c	44	3	pathogens	pathogen	NNS
cord-324810-92fosk3c	44	4	and	and	CC
cord-324810-92fosk3c	44	5	their	-PRON-	PRP$
cord-324810-92fosk3c	44	6	relative	relative	JJ
cord-324810-92fosk3c	44	7	frequency	frequency	NN
cord-324810-92fosk3c	44	8	in	in	IN
cord-324810-92fosk3c	44	9	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	44	10	are	be	VBP
cord-324810-92fosk3c	44	11	listed	list	VBN
cord-324810-92fosk3c	44	12	in	in	IN
cord-324810-92fosk3c	44	13	table	table	NN
cord-324810-92fosk3c	44	14	II	II	NNP
cord-324810-92fosk3c	44	15	.	.	.
cord-324810-92fosk3c	45	1	Approximately	approximately	RB
cord-324810-92fosk3c	45	2	half	half	NN
cord-324810-92fosk3c	45	3	of	of	IN
cord-324810-92fosk3c	45	4	the	the	DT
cord-324810-92fosk3c	45	5	exacer	exacer	NN
cord-324810-92fosk3c	45	6	-	-	:
cord-324810-92fosk3c	45	7	At	at	RB
cord-324810-92fosk3c	45	8	least	least	RBS
cord-324810-92fosk3c	45	9	80	80	CD
cord-324810-92fosk3c	45	10	%	%	NN
cord-324810-92fosk3c	45	11	of	of	IN
cord-324810-92fosk3c	45	12	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	45	13	are	be	VBP
cord-324810-92fosk3c	45	14	caused	cause	VBN
cord-324810-92fosk3c	45	15	by	by	IN
cord-324810-92fosk3c	45	16	infections	infection	NNS
cord-324810-92fosk3c	45	17	,	,	,
cord-324810-92fosk3c	45	18	although	although	IN
cord-324810-92fosk3c	45	19	bations	bation	NNS
cord-324810-92fosk3c	45	20	yield	yield	VBP
cord-324810-92fosk3c	45	21	positive	positive	JJ
cord-324810-92fosk3c	45	22	sputum	sputum	NN
cord-324810-92fosk3c	45	23	cultures	culture	NNS
cord-324810-92fosk3c	45	24	for	for	IN
cord-324810-92fosk3c	45	25	aerobic	aerobic	JJ
cord-324810-92fosk3c	45	26	bacteria	bacteria	NNS
cord-324810-92fosk3c	45	27	.	.	.
cord-324810-92fosk3c	46	1	Fagon	Fagon	NNP
cord-324810-92fosk3c	46	2	other	other	JJ
cord-324810-92fosk3c	46	3	causes	cause	NNS
cord-324810-92fosk3c	46	4	including	include	VBG
cord-324810-92fosk3c	46	5	environmental	environmental	JJ
cord-324810-92fosk3c	46	6	factors	factor	NNS
cord-324810-92fosk3c	46	7	(	(	-LRB-
cord-324810-92fosk3c	46	8	air	air	NN
cord-324810-92fosk3c	46	9	pollution	pollution	NN
cord-324810-92fosk3c	46	10	,	,	,
cord-324810-92fosk3c	46	11	cold	cold	JJ
cord-324810-92fosk3c	46	12	et	et	FW
cord-324810-92fosk3c	46	13	al	al	NNP
cord-324810-92fosk3c	46	14	.	.	.
cord-324810-92fosk3c	47	1	[	[	-LRB-
cord-324810-92fosk3c	47	2	16	16	CD
cord-324810-92fosk3c	47	3	]	]	-RRB-
cord-324810-92fosk3c	47	4	performed	perform	VBN
cord-324810-92fosk3c	47	5	bronchoscopy	bronchoscopy	NN
cord-324810-92fosk3c	47	6	with	with	IN
cord-324810-92fosk3c	47	7	protected	protect	VBN
cord-324810-92fosk3c	47	8	specimen	specimen	JJ
cord-324810-92fosk3c	47	9	brush	brush	NN
cord-324810-92fosk3c	47	10	air	air	NN
cord-324810-92fosk3c	47	11	,	,	,
cord-324810-92fosk3c	47	12	allergens	allergen	NNS
cord-324810-92fosk3c	47	13	)	)	-RRB-
cord-324810-92fosk3c	47	14	may	may	MD
cord-324810-92fosk3c	47	15	be	be	VB
cord-324810-92fosk3c	47	16	responsible	responsible	JJ
cord-324810-92fosk3c	47	17	.	.	.
cord-324810-92fosk3c	48	1	[	[	-LRB-
cord-324810-92fosk3c	48	2	10	10	CD
cord-324810-92fosk3c	48	3	]	]	-RRB-
cord-324810-92fosk3c	49	1	The	the	DT
cord-324810-92fosk3c	49	2	common	common	JJ
cord-324810-92fosk3c	49	3	etiologic	etiologic	JJ
cord-324810-92fosk3c	49	4	orgabefore	orgabefore	NN
cord-324810-92fosk3c	49	5	empiric	empiric	JJ
cord-324810-92fosk3c	49	6	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	49	7	therapy	therapy	NN
cord-324810-92fosk3c	49	8	in	in	IN
cord-324810-92fosk3c	49	9	54	54	CD
cord-324810-92fosk3c	49	10	patients	patient	NNS
cord-324810-92fosk3c	49	11	requiring	require	VBG
cord-324810-92fosk3c	49	12	nisms	nism	NNS
cord-324810-92fosk3c	49	13	are	be	VBP
cord-324810-92fosk3c	49	14	bacteria	bacteria	NNS
cord-324810-92fosk3c	49	15	(	(	-LRB-
cord-324810-92fosk3c	49	16	40	40	CD
cord-324810-92fosk3c	49	17	-	-	SYM
cord-324810-92fosk3c	49	18	50	50	CD
cord-324810-92fosk3c	49	19	%	%	NN
cord-324810-92fosk3c	49	20	)	)	-RRB-
cord-324810-92fosk3c	49	21	,	,	,
cord-324810-92fosk3c	49	22	viruses	virus	NNS
cord-324810-92fosk3c	49	23	(	(	-LRB-
cord-324810-92fosk3c	49	24	30	30	CD
cord-324810-92fosk3c	49	25	-	-	SYM
cord-324810-92fosk3c	49	26	50	50	CD
cord-324810-92fosk3c	49	27	%	%	NN
cord-324810-92fosk3c	49	28	)	)	-RRB-
cord-324810-92fosk3c	49	29	and	and	CC
cord-324810-92fosk3c	49	30	atypical	atypical	JJ
cord-324810-92fosk3c	49	31	bacmechanical	bacmechanical	JJ
cord-324810-92fosk3c	49	32	ventilation	ventilation	NN
cord-324810-92fosk3c	49	33	for	for	IN
cord-324810-92fosk3c	49	34	respiratory	respiratory	JJ
cord-324810-92fosk3c	49	35	failure	failure	NN
cord-324810-92fosk3c	49	36	due	due	IN
cord-324810-92fosk3c	49	37	to	to	IN
cord-324810-92fosk3c	49	38	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	49	39	.	.	.
cord-324810-92fosk3c	50	1	teria	teria	NNP
cord-324810-92fosk3c	50	2	(	(	-LRB-
cord-324810-92fosk3c	50	3	5	5	CD
cord-324810-92fosk3c	50	4	-	-	SYM
cord-324810-92fosk3c	50	5	10	10	CD
cord-324810-92fosk3c	50	6	%	%	NN
cord-324810-92fosk3c	50	7	)	)	-RRB-
cord-324810-92fosk3c	50	8	.	.	.
cord-324810-92fosk3c	51	1	Interestingly	interestingly	RB
cord-324810-92fosk3c	51	2	,	,	,
cord-324810-92fosk3c	51	3	more	more	JJR
cord-324810-92fosk3c	51	4	than	than	IN
cord-324810-92fosk3c	51	5	one	one	CD
cord-324810-92fosk3c	51	6	infectious	infectious	JJ
cord-324810-92fosk3c	51	7	agent	agent	NN
cord-324810-92fosk3c	51	8	is	be	VBZ
cord-324810-92fosk3c	51	9	the	the	DT
cord-324810-92fosk3c	51	10	The	the	DT
cord-324810-92fosk3c	51	11	findings	finding	NNS
cord-324810-92fosk3c	51	12	were	be	VBD
cord-324810-92fosk3c	51	13	similar	similar	JJ
cord-324810-92fosk3c	51	14	to	to	IN
cord-324810-92fosk3c	51	15	that	that	DT
cord-324810-92fosk3c	51	16	of	of	IN
cord-324810-92fosk3c	51	17	sputum	sputum	NN
cord-324810-92fosk3c	51	18	culture	culture	NN
cord-324810-92fosk3c	51	19	and	and	CC
cord-324810-92fosk3c	51	20	showed	show	VBD
cord-324810-92fosk3c	51	21	culprit	culprit	NN
cord-324810-92fosk3c	51	22	in	in	IN
cord-324810-92fosk3c	51	23	10	10	CD
cord-324810-92fosk3c	51	24	-	-	SYM
cord-324810-92fosk3c	51	25	20	20	CD
cord-324810-92fosk3c	51	26	%	%	NN
cord-324810-92fosk3c	51	27	of	of	IN
cord-324810-92fosk3c	51	28	all	all	DT
cord-324810-92fosk3c	51	29	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	51	30	.	.	.
cord-324810-92fosk3c	52	1	[	[	-LRB-
cord-324810-92fosk3c	52	2	11	11	CD
cord-324810-92fosk3c	52	3	]	]	-RRB-
cord-324810-92fosk3c	52	4	[	[	-LRB-
cord-324810-92fosk3c	52	5	12	12	CD
cord-324810-92fosk3c	52	6	]	]	-RRB-
cord-324810-92fosk3c	52	7	[	[	-LRB-
cord-324810-92fosk3c	52	8	13	13	CD
cord-324810-92fosk3c	52	9	]	]	-RRB-
cord-324810-92fosk3c	53	1	that	that	DT
cord-324810-92fosk3c	53	2	Haemophilus	haemophilus	JJ
cord-324810-92fosk3c	53	3	parainfluenzae	parainfluenzae	NN
cord-324810-92fosk3c	53	4	was	be	VBD
cord-324810-92fosk3c	53	5	the	the	DT
cord-324810-92fosk3c	53	6	most	most	RBS
cord-324810-92fosk3c	53	7	common	common	JJ
cord-324810-92fosk3c	53	8	pathogen	pathogen	NN
cord-324810-92fosk3c	54	1	The	the	DT
cord-324810-92fosk3c	54	2	role	role	NN
cord-324810-92fosk3c	54	3	of	of	IN
cord-324810-92fosk3c	54	4	viruses	virus	NNS
cord-324810-92fosk3c	54	5	in	in	IN
cord-324810-92fosk3c	54	6	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	54	7	was	be	VBD
cord-324810-92fosk3c	54	8	previously	previously	RB
cord-324810-92fosk3c	54	9	examined	examine	VBN
cord-324810-92fosk3c	54	10	with	with	IN
cord-324810-92fosk3c	54	11	(	(	-LRB-
cord-324810-92fosk3c	54	12	11	11	CD
cord-324810-92fosk3c	54	13	of	of	IN
cord-324810-92fosk3c	54	14	44	44	CD
cord-324810-92fosk3c	54	15	organisms	organism	NNS
cord-324810-92fosk3c	54	16	)	)	-RRB-
cord-324810-92fosk3c	54	17	,	,	,
cord-324810-92fosk3c	54	18	followed	follow	VBN
cord-324810-92fosk3c	54	19	by	by	IN
cord-324810-92fosk3c	54	20	Streptococcus	streptococcus	NN
cord-324810-92fosk3c	54	21	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	54	22	(	(	-LRB-
cord-324810-92fosk3c	54	23	7	7	CD
cord-324810-92fosk3c	54	24	of	of	IN
cord-324810-92fosk3c	54	25	serial	serial	JJ
cord-324810-92fosk3c	54	26	serology	serology	NN
cord-324810-92fosk3c	54	27	and	and	CC
cord-324810-92fosk3c	54	28	viral	viral	JJ
cord-324810-92fosk3c	54	29	cultures	culture	NNS
cord-324810-92fosk3c	54	30	but	but	CC
cord-324810-92fosk3c	54	31	more	more	JJR
cord-324810-92fosk3c	54	32	recent	recent	JJ
cord-324810-92fosk3c	54	33	studies	study	NNS
cord-324810-92fosk3c	54	34	have	have	VBP
cord-324810-92fosk3c	54	35	44	44	CD
cord-324810-92fosk3c	54	36	)	)	-RRB-
cord-324810-92fosk3c	54	37	,	,	,
cord-324810-92fosk3c	54	38	non	non	JJ
cord-324810-92fosk3c	54	39	-	-	JJ
cord-324810-92fosk3c	54	40	typeable	typeable	JJ
cord-324810-92fosk3c	54	41	H.	h.	NN
cord-324810-92fosk3c	54	42	influenzae	influenzae	NN
cord-324810-92fosk3c	54	43	(	(	-LRB-
cord-324810-92fosk3c	54	44	6	6	CD
cord-324810-92fosk3c	54	45	of	of	IN
cord-324810-92fosk3c	54	46	44	44	CD
cord-324810-92fosk3c	54	47	)	)	-RRB-
cord-324810-92fosk3c	54	48	,	,	,
cord-324810-92fosk3c	54	49	and	and	CC
cord-324810-92fosk3c	54	50	Moraxella	Moraxella	NNP
cord-324810-92fosk3c	54	51	catarutilized	catarutilize	VBD
cord-324810-92fosk3c	54	52	polymerase	polymerase	NN
cord-324810-92fosk3c	54	53	chain	chain	NN
cord-324810-92fosk3c	54	54	reaction	reaction	NN
cord-324810-92fosk3c	54	55	(	(	-LRB-
cord-324810-92fosk3c	54	56	PCR	PCR	NNP
cord-324810-92fosk3c	54	57	)	)	-RRB-
cord-324810-92fosk3c	54	58	techniques	technique	NNS
cord-324810-92fosk3c	54	59	.	.	.
cord-324810-92fosk3c	55	1	The	the	DT
cord-324810-92fosk3c	55	2	specific	specific	JJ
cord-324810-92fosk3c	55	3	rhalis	rhali	NNS
cord-324810-92fosk3c	55	4	(	(	-LRB-
cord-324810-92fosk3c	55	5	3	3	CD
cord-324810-92fosk3c	55	6	of	of	IN
cord-324810-92fosk3c	55	7	44	44	CD
cord-324810-92fosk3c	55	8	)	)	-RRB-
cord-324810-92fosk3c	55	9	.	.	.
cord-324810-92fosk3c	56	1	A	a	DT
cord-324810-92fosk3c	56	2	variety	variety	NN
cord-324810-92fosk3c	56	3	of	of	IN
cord-324810-92fosk3c	56	4	other	other	JJ
cord-324810-92fosk3c	56	5	Gram	gram	NN
cord-324810-92fosk3c	56	6	-	-	HYPH
cord-324810-92fosk3c	56	7	negative	negative	JJ
cord-324810-92fosk3c	56	8	(	(	-LRB-
cord-324810-92fosk3c	56	9	8	8	CD
cord-324810-92fosk3c	56	10	of	of	IN
cord-324810-92fosk3c	56	11	44	44	CD
cord-324810-92fosk3c	56	12	)	)	-RRB-
cord-324810-92fosk3c	56	13	and	and	CC
cord-324810-92fosk3c	56	14	viruses	virus	NNS
cord-324810-92fosk3c	56	15	and	and	CC
cord-324810-92fosk3c	56	16	proportion	proportion	NN
cord-324810-92fosk3c	56	17	of	of	IN
cord-324810-92fosk3c	56	18	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	56	19	caused	cause	VBN
cord-324810-92fosk3c	56	20	by	by	IN
cord-324810-92fosk3c	56	21	each	each	DT
cord-324810-92fosk3c	56	22	of	of	IN
cord-324810-92fosk3c	56	23	these	these	DT
cord-324810-92fosk3c	56	24	Gram	Gram	NNP
cord-324810-92fosk3c	56	25	-	-	HYPH
cord-324810-92fosk3c	56	26	positive	positive	JJ
cord-324810-92fosk3c	56	27	(	(	-LRB-
cord-324810-92fosk3c	56	28	9	9	CD
cord-324810-92fosk3c	56	29	of	of	IN
cord-324810-92fosk3c	56	30	44	44	CD
cord-324810-92fosk3c	56	31	)	)	-RRB-
cord-324810-92fosk3c	57	1	bacteria	bacteria	NNS
cord-324810-92fosk3c	57	2	were	be	VBD
cord-324810-92fosk3c	57	3	also	also	RB
cord-324810-92fosk3c	57	4	isolated	isolate	VBN
cord-324810-92fosk3c	57	5	.	.	.
cord-324810-92fosk3c	58	1	are	be	VBP
cord-324810-92fosk3c	58	2	detailed	detail	VBN
cord-324810-92fosk3c	58	3	in	in	IN
cord-324810-92fosk3c	58	4	table	table	NN
cord-324810-92fosk3c	58	5	II	II	NNP
cord-324810-92fosk3c	58	6	.	.	.
cord-324810-92fosk3c	59	1	Soler	Soler	NNP
cord-324810-92fosk3c	59	2	et	et	NNP
cord-324810-92fosk3c	59	3	al	al	NNP
cord-324810-92fosk3c	59	4	.	.	.
cord-324810-92fosk3c	60	1	[	[	-LRB-
cord-324810-92fosk3c	60	2	11	11	CD
cord-324810-92fosk3c	60	3	]	]	-RRB-
cord-324810-92fosk3c	60	4	analyzed	analyze	VBN
cord-324810-92fosk3c	60	5	serologic	serologic	JJ
cord-324810-92fosk3c	60	6	samples	sample	NNS
cord-324810-92fosk3c	60	7	for	for	IN
cord-324810-92fosk3c	60	8	viruses	virus	NNS
cord-324810-92fosk3c	60	9	in	in	IN
cord-324810-92fosk3c	60	10	38	38	CD
cord-324810-92fosk3c	60	11	of	of	IN
cord-324810-92fosk3c	60	12	50	50	CD
cord-324810-92fosk3c	60	13	patients	patient	NNS
cord-324810-92fosk3c	60	14	with	with	IN
cord-324810-92fosk3c	60	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	60	16	of	of	IN
cord-324810-92fosk3c	60	17	COPD	COPD	NNP
cord-324810-92fosk3c	60	18	that	that	IN
cord-324810-92fosk3c	60	19	Monso	Monso	NNP
cord-324810-92fosk3c	60	20	et	et	NNP
cord-324810-92fosk3c	60	21	al	al	NNP
cord-324810-92fosk3c	60	22	.	.	.
cord-324810-92fosk3c	61	1	[	[	-LRB-
cord-324810-92fosk3c	61	2	17	17	CD
cord-324810-92fosk3c	61	3	]	]	-RRB-
cord-324810-92fosk3c	61	4	performed	perform	VBN
cord-324810-92fosk3c	61	5	bronchoscopies	bronchoscopie	NNS
cord-324810-92fosk3c	61	6	and	and	CC
cord-324810-92fosk3c	61	7	protected	protect	VBN
cord-324810-92fosk3c	61	8	specirequired	specirequired	JJ
cord-324810-92fosk3c	61	9	intensive	intensive	JJ
cord-324810-92fosk3c	61	10	care	care	NN
cord-324810-92fosk3c	61	11	admission	admission	NN
cord-324810-92fosk3c	61	12	.	.	.
cord-324810-92fosk3c	62	1	Viruses	virus	NNS
cord-324810-92fosk3c	62	2	were	be	VBD
cord-324810-92fosk3c	62	3	isolated	isolate	VBN
cord-324810-92fosk3c	62	4	in	in	IN
cord-324810-92fosk3c	62	5	six	six	CD
cord-324810-92fosk3c	62	6	men	man	NNS
cord-324810-92fosk3c	62	7	brush	brush	VBP
cord-324810-92fosk3c	62	8	cultures	culture	NNS
cord-324810-92fosk3c	62	9	in	in	IN
cord-324810-92fosk3c	62	10	a	a	DT
cord-324810-92fosk3c	62	11	group	group	NN
cord-324810-92fosk3c	62	12	of	of	IN
cord-324810-92fosk3c	62	13	40	40	CD
cord-324810-92fosk3c	62	14	patients	patient	NNS
cord-324810-92fosk3c	62	15	with	with	IN
cord-324810-92fosk3c	62	16	moderately	moderately	RB
cord-324810-92fosk3c	62	17	(	(	-LRB-
cord-324810-92fosk3c	62	18	15.8	15.8	CD
cord-324810-92fosk3c	62	19	%	%	NN
cord-324810-92fosk3c	62	20	)	)	-RRB-
cord-324810-92fosk3c	62	21	of	of	IN
cord-324810-92fosk3c	62	22	the	the	DT
cord-324810-92fosk3c	62	23	cases	case	NNS
cord-324810-92fosk3c	62	24	,	,	,
cord-324810-92fosk3c	62	25	influenza	influenza	NN
cord-324810-92fosk3c	62	26	virus	virus	NN
cord-324810-92fosk3c	62	27	in	in	IN
cord-324810-92fosk3c	62	28	five	five	CD
cord-324810-92fosk3c	62	29	and	and	CC
cord-324810-92fosk3c	62	30	respiratory	respiratory	JJ
cord-324810-92fosk3c	62	31	severe	severe	JJ
cord-324810-92fosk3c	62	32	stable	stable	JJ
cord-324810-92fosk3c	62	33	COPD	COPD	NNP
cord-324810-92fosk3c	62	34	and	and	CC
cord-324810-92fosk3c	62	35	in	in	IN
cord-324810-92fosk3c	62	36	29	29	CD
cord-324810-92fosk3c	62	37	patients	patient	NNS
cord-324810-92fosk3c	62	38	who	who	WP
cord-324810-92fosk3c	62	39	were	be	VBD
cord-324810-92fosk3c	62	40	experiencing	experience	VBG
cord-324810-92fosk3c	62	41	an	an	DT
cord-324810-92fosk3c	62	42	syncytial	syncytial	JJ
cord-324810-92fosk3c	62	43	virus	virus	NN
cord-324810-92fosk3c	62	44	in	in	IN
cord-324810-92fosk3c	62	45	one	one	CD
cord-324810-92fosk3c	62	46	exacerbation	exacerbation	NN
cord-324810-92fosk3c	62	47	.	.	.
cord-324810-92fosk3c	63	1	In	in	IN
cord-324810-92fosk3c	63	2	three	three	CD
cord-324810-92fosk3c	63	3	of	of	IN
cord-324810-92fosk3c	63	4	the	the	DT
cord-324810-92fosk3c	63	5	five	five	CD
cord-324810-92fosk3c	63	6	influenza	influenza	NN
cord-324810-92fosk3c	63	7	acute	acute	JJ
cord-324810-92fosk3c	63	8	exacerbation	exacerbation	NN
cord-324810-92fosk3c	63	9	.	.	.
cord-324810-92fosk3c	64	1	In	in	IN
cord-324810-92fosk3c	64	2	the	the	DT
cord-324810-92fosk3c	64	3	stable	stable	JJ
cord-324810-92fosk3c	64	4	group	group	NN
cord-324810-92fosk3c	64	5	,	,	,
cord-324810-92fosk3c	64	6	25	25	CD
cord-324810-92fosk3c	64	7	%	%	NN
cord-324810-92fosk3c	64	8	of	of	IN
cord-324810-92fosk3c	64	9	protected	protect	VBN
cord-324810-92fosk3c	64	10	speciinfections	speciinfection	NNS
cord-324810-92fosk3c	64	11	,	,	,
cord-324810-92fosk3c	64	12	a	a	DT
cord-324810-92fosk3c	64	13	concomitant	concomitant	JJ
cord-324810-92fosk3c	64	14	bacterial	bacterial	JJ
cord-324810-92fosk3c	64	15	pathogen	pathogen	NN
cord-324810-92fosk3c	64	16	was	be	VBD
cord-324810-92fosk3c	64	17	also	also	RB
cord-324810-92fosk3c	64	18	present	present	JJ
cord-324810-92fosk3c	64	19	.	.	.
cord-324810-92fosk3c	65	1	men	man	NNS
cord-324810-92fosk3c	65	2	brush	brush	VBP
cord-324810-92fosk3c	65	3	cultures	culture	NNS
cord-324810-92fosk3c	65	4	isolated	isolate	VBN
cord-324810-92fosk3c	65	5	bacterial	bacterial	JJ
cord-324810-92fosk3c	65	6	pathogens	pathogen	NNS
cord-324810-92fosk3c	65	7	(	(	-LRB-
cord-324810-92fosk3c	65	8	>	>	NFP
cord-324810-92fosk3c	65	9	10	10	CD
cord-324810-92fosk3c	65	10	3	3	CD
cord-324810-92fosk3c	65	11	cfu	cfu	NN
cord-324810-92fosk3c	65	12	/	/	SYM
cord-324810-92fosk3c	65	13	mL	ml	NN
cord-324810-92fosk3c	65	14	)	)	-RRB-
cord-324810-92fosk3c	66	1	More	More	JJR
cord-324810-92fosk3c	66	2	recent	recent	JJ
cord-324810-92fosk3c	66	3	data	datum	NNS
cord-324810-92fosk3c	66	4	have	have	VBP
cord-324810-92fosk3c	66	5	demonstrated	demonstrate	VBN
cord-324810-92fosk3c	66	6	the	the	DT
cord-324810-92fosk3c	66	7	increasing	increase	VBG
cord-324810-92fosk3c	66	8	role	role	NN
cord-324810-92fosk3c	66	9	of	of	IN
cord-324810-92fosk3c	66	10	respira	respira	NN
cord-324810-92fosk3c	66	11	-	-	HYPH
cord-324810-92fosk3c	66	12	compared	compare	VBN
cord-324810-92fosk3c	66	13	with	with	IN
cord-324810-92fosk3c	66	14	51.7	51.7	CD
cord-324810-92fosk3c	66	15	%	%	NN
cord-324810-92fosk3c	66	16	of	of	IN
cord-324810-92fosk3c	66	17	culture	culture	NN
cord-324810-92fosk3c	66	18	-	-	HYPH
cord-324810-92fosk3c	66	19	positive	positive	JJ
cord-324810-92fosk3c	66	20	samples	sample	NNS
cord-324810-92fosk3c	66	21	in	in	IN
cord-324810-92fosk3c	66	22	the	the	DT
cord-324810-92fosk3c	66	23	exacerbatory	exacerbatory	NNP
cord-324810-92fosk3c	66	24	viruses	virus	NNS
cord-324810-92fosk3c	66	25	in	in	IN
cord-324810-92fosk3c	66	26	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	66	27	.	.	.
cord-324810-92fosk3c	67	1	Seemungal	Seemungal	NNP
cord-324810-92fosk3c	67	2	et	et	FW
cord-324810-92fosk3c	67	3	al	al	NNP
cord-324810-92fosk3c	67	4	.	.	.
cord-324810-92fosk3c	68	1	[	[	-LRB-
cord-324810-92fosk3c	68	2	20	20	CD
cord-324810-92fosk3c	68	3	]	]	-RRB-
cord-324810-92fosk3c	68	4	observed	observe	VBD
cord-324810-92fosk3c	68	5	that	that	IN
cord-324810-92fosk3c	68	6	64	64	CD
cord-324810-92fosk3c	68	7	%	%	NN
cord-324810-92fosk3c	68	8	tion	tion	NN
cord-324810-92fosk3c	68	9	group	group	NN
cord-324810-92fosk3c	68	10	.	.	.
cord-324810-92fosk3c	69	1	Non	non	JJ
cord-324810-92fosk3c	69	2	-	-	JJ
cord-324810-92fosk3c	69	3	typeable	typeable	JJ
cord-324810-92fosk3c	69	4	H.	h.	NN
cord-324810-92fosk3c	69	5	influenzae	influenzae	NN
cord-324810-92fosk3c	69	6	was	be	VBD
cord-324810-92fosk3c	69	7	the	the	DT
cord-324810-92fosk3c	69	8	most	most	RBS
cord-324810-92fosk3c	69	9	common	common	JJ
cord-324810-92fosk3c	69	10	of	of	IN
cord-324810-92fosk3c	69	11	all	all	DT
cord-324810-92fosk3c	69	12	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	69	13	were	be	VBD
cord-324810-92fosk3c	69	14	preceded	precede	VBN
cord-324810-92fosk3c	69	15	by	by	IN
cord-324810-92fosk3c	69	16	a	a	DT
cord-324810-92fosk3c	69	17	cold	cold	NN
cord-324810-92fosk3c	69	18	.	.	.
cord-324810-92fosk3c	70	1	In	in	IN
cord-324810-92fosk3c	70	2	an	an	DT
cord-324810-92fosk3c	70	3	East	East	NNP
cord-324810-92fosk3c	70	4	London	London	NNP
cord-324810-92fosk3c	70	5	bacterial	bacterial	JJ
cord-324810-92fosk3c	70	6	pathogen	pathogen	NN
cord-324810-92fosk3c	70	7	in	in	IN
cord-324810-92fosk3c	70	8	both	both	DT
cord-324810-92fosk3c	70	9	groups	group	NNS
cord-324810-92fosk3c	70	10	.	.	.
cord-324810-92fosk3c	71	1	Soler	Soler	NNP
cord-324810-92fosk3c	71	2	et	et	NNP
cord-324810-92fosk3c	71	3	al	al	NNP
cord-324810-92fosk3c	71	4	.	.	.
cord-324810-92fosk3c	72	1	[	[	-LRB-
cord-324810-92fosk3c	72	2	11	11	CD
cord-324810-92fosk3c	72	3	]	]	-RRB-
cord-324810-92fosk3c	72	4	also	also	RB
cord-324810-92fosk3c	72	5	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	72	6	COPD	COPD	NNP
cord-324810-92fosk3c	72	7	study	study	NN
cord-324810-92fosk3c	72	8	,	,	,
cord-324810-92fosk3c	72	9	83	83	CD
cord-324810-92fosk3c	72	10	patients	patient	NNS
cord-324810-92fosk3c	72	11	developed	develop	VBD
cord-324810-92fosk3c	72	12	168	168	CD
cord-324810-92fosk3c	72	13	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	72	14	.	.	.
cord-324810-92fosk3c	73	1	[	[	-LRB-
cord-324810-92fosk3c	73	2	20	20	CD
cord-324810-92fosk3c	73	3	]	]	-RRB-
cord-324810-92fosk3c	73	4	Viruses	virus	NNS
cord-324810-92fosk3c	73	5	positive	positive	JJ
cord-324810-92fosk3c	73	6	cultures	culture	NNS
cord-324810-92fosk3c	73	7	in	in	IN
cord-324810-92fosk3c	73	8	bronchoscopic	bronchoscopic	NNP
cord-324810-92fosk3c	73	9	samples	sample	NNS
cord-324810-92fosk3c	73	10	during	during	IN
cord-324810-92fosk3c	73	11	an	an	DT
cord-324810-92fosk3c	73	12	acute	acute	JJ
cord-324810-92fosk3c	73	13	exacerwere	exacerwere	NN
cord-324810-92fosk3c	73	14	detected	detect	VBN
cord-324810-92fosk3c	73	15	by	by	IN
cord-324810-92fosk3c	73	16	reverse	reverse	JJ
cord-324810-92fosk3c	73	17	transcriptase	transcriptase	NN
cord-324810-92fosk3c	73	18	PCR	pcr	NN
cord-324810-92fosk3c	73	19	,	,	,
cord-324810-92fosk3c	73	20	viral	viral	JJ
cord-324810-92fosk3c	73	21	culture	culture	NN
cord-324810-92fosk3c	73	22	of	of	IN
cord-324810-92fosk3c	73	23	nasal	nasal	NN
cord-324810-92fosk3c	73	24	bation	bation	NN
cord-324810-92fosk3c	73	25	.	.	.
cord-324810-92fosk3c	74	1	Interestingly	interestingly	RB
cord-324810-92fosk3c	74	2	,	,	,
cord-324810-92fosk3c	74	3	a	a	DT
cord-324810-92fosk3c	74	4	remarkably	remarkably	RB
cord-324810-92fosk3c	74	5	high	high	JJ
cord-324810-92fosk3c	74	6	incidence	incidence	NN
cord-324810-92fosk3c	74	7	of	of	IN
cord-324810-92fosk3c	74	8	Pseuaspirates	Pseuaspirates	NNPS
cord-324810-92fosk3c	74	9	and	and	CC
cord-324810-92fosk3c	74	10	serology	serology	NN
cord-324810-92fosk3c	74	11	in	in	IN
cord-324810-92fosk3c	74	12	66	66	CD
cord-324810-92fosk3c	74	13	(	(	-LRB-
cord-324810-92fosk3c	74	14	39.2	39.2	CD
cord-324810-92fosk3c	74	15	%	%	NN
cord-324810-92fosk3c	74	16	)	)	-RRB-
cord-324810-92fosk3c	74	17	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	74	18	.	.	.
cord-324810-92fosk3c	75	1	The	the	DT
cord-324810-92fosk3c	75	2	role	role	NN
cord-324810-92fosk3c	75	3	of	of	IN
cord-324810-92fosk3c	75	4	domonas	domona	NNS
cord-324810-92fosk3c	75	5	aeruginosa	aeruginosa	NN
cord-324810-92fosk3c	75	6	and	and	CC
cord-324810-92fosk3c	75	7	other	other	JJ
cord-324810-92fosk3c	75	8	Gram	gram	NN
cord-324810-92fosk3c	75	9	-	-	HYPH
cord-324810-92fosk3c	75	10	negative	negative	JJ
cord-324810-92fosk3c	75	11	bacilli	bacilli	NN
cord-324810-92fosk3c	75	12	(	(	-LRB-
cord-324810-92fosk3c	75	13	14	14	CD
cord-324810-92fosk3c	75	14	of	of	IN
cord-324810-92fosk3c	75	15	50	50	CD
cord-324810-92fosk3c	75	16	viruses	virus	NNS
cord-324810-92fosk3c	75	17	in	in	IN
cord-324810-92fosk3c	75	18	COPD	COPD	NNP
cord-324810-92fosk3c	75	19	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	75	20	is	be	VBZ
cord-324810-92fosk3c	75	21	becoming	become	VBG
cord-324810-92fosk3c	75	22	clearer	clear	JJR
cord-324810-92fosk3c	75	23	:	:	:
cord-324810-92fosk3c	75	24	viruses	virus	NNS
cord-324810-92fosk3c	75	25	cause	cause	VBP
cord-324810-92fosk3c	75	26	patients	patient	NNS
cord-324810-92fosk3c	75	27	)	)	-RRB-
cord-324810-92fosk3c	75	28	was	be	VBD
cord-324810-92fosk3c	75	29	evident	evident	JJ
cord-324810-92fosk3c	75	30	in	in	IN
cord-324810-92fosk3c	75	31	this	this	DT
cord-324810-92fosk3c	75	32	study	study	NN
cord-324810-92fosk3c	75	33	.	.	.
cord-324810-92fosk3c	76	1	Colonization	colonization	NN
cord-324810-92fosk3c	76	2	and	and	CC
cord-324810-92fosk3c	76	3	infection	infection	NN
cord-324810-92fosk3c	76	4	with	with	IN
cord-324810-92fosk3c	76	5	more	more	JJR
cord-324810-92fosk3c	76	6	severe	severe	JJ
cord-324810-92fosk3c	76	7	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	76	8	,	,	,
cord-324810-92fosk3c	76	9	increase	increase	VB
cord-324810-92fosk3c	76	10	airway	airway	NN
cord-324810-92fosk3c	76	11	obstruction	obstruction	NN
cord-324810-92fosk3c	76	12	,	,	,
cord-324810-92fosk3c	76	13	slow	slow	JJ
cord-324810-92fosk3c	76	14	Gram	gram	NN
cord-324810-92fosk3c	76	15	-	-	HYPH
cord-324810-92fosk3c	76	16	negative	negative	JJ
cord-324810-92fosk3c	76	17	organisms	organism	NNS
cord-324810-92fosk3c	76	18	including	include	VBG
cord-324810-92fosk3c	76	19	P.	P.	NNP
cord-324810-92fosk3c	76	20	aeruginosa	aeruginosa	NN
cord-324810-92fosk3c	76	21	occurred	occur	VBD
cord-324810-92fosk3c	76	22	in	in	IN
cord-324810-92fosk3c	76	23	symptom	symptom	NN
cord-324810-92fosk3c	76	24	resolution	resolution	NN
cord-324810-92fosk3c	76	25	and	and	CC
cord-324810-92fosk3c	76	26	induce	induce	VB
cord-324810-92fosk3c	76	27	systemic	systemic	JJ
cord-324810-92fosk3c	76	28	and	and	CC
cord-324810-92fosk3c	76	29	airway	airway	NN
cord-324810-92fosk3c	76	30	inflamma	inflamma	NNP
cord-324810-92fosk3c	76	31	-	-	:
cord-324810-92fosk3c	76	32	patients	patient	NNS
cord-324810-92fosk3c	76	33	who	who	WP
cord-324810-92fosk3c	76	34	had	have	VBD
cord-324810-92fosk3c	76	35	repeated	repeat	VBN
cord-324810-92fosk3c	76	36	courses	course	NNS
cord-324810-92fosk3c	76	37	of	of	IN
cord-324810-92fosk3c	76	38	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	76	39	therapy	therapy	NN
cord-324810-92fosk3c	76	40	,	,	,
cord-324810-92fosk3c	76	41	as	as	IN
cord-324810-92fosk3c	76	42	is	be	VBZ
cord-324810-92fosk3c	76	43	tion	tion	NN
cord-324810-92fosk3c	76	44	.	.	.
cord-324810-92fosk3c	77	1	[	[	-LRB-
cord-324810-92fosk3c	77	2	14	14	CD
cord-324810-92fosk3c	77	3	,	,	,
cord-324810-92fosk3c	77	4	20	20	CD
cord-324810-92fosk3c	77	5	]	]	-RRB-
cord-324810-92fosk3c	77	6	Rhinoviruses	Rhinoviruses	NNP
cord-324810-92fosk3c	77	7	were	be	VBD
cord-324810-92fosk3c	77	8	detected	detect	VBN
cord-324810-92fosk3c	77	9	in	in	IN
cord-324810-92fosk3c	77	10	39.2	39.2	CD
cord-324810-92fosk3c	77	11	%	%	NN
cord-324810-92fosk3c	77	12	of	of	IN
cord-324810-92fosk3c	77	13	168	168	CD
cord-324810-92fosk3c	77	14	exacerba	exacerba	NN
cord-324810-92fosk3c	77	15	-	-	:
cord-324810-92fosk3c	77	16	often	often	RB
cord-324810-92fosk3c	77	17	the	the	DT
cord-324810-92fosk3c	77	18	case	case	NN
cord-324810-92fosk3c	77	19	in	in	IN
cord-324810-92fosk3c	77	20	bronchiectasis	bronchiectasis	NN
cord-324810-92fosk3c	77	21	.	.	.
cord-324810-92fosk3c	78	1	[	[	-LRB-
cord-324810-92fosk3c	78	2	18	18	CD
cord-324810-92fosk3c	78	3	]	]	-RRB-
cord-324810-92fosk3c	79	1	The	the	DT
cord-324810-92fosk3c	79	2	consistent	consistent	JJ
cord-324810-92fosk3c	79	3	results	result	NNS
cord-324810-92fosk3c	79	4	of	of	IN
cord-324810-92fosk3c	79	5	these	these	DT
cord-324810-92fosk3c	79	6	tions	tion	NNS
cord-324810-92fosk3c	79	7	;	;	:
cord-324810-92fosk3c	79	8	viral	viral	JJ
cord-324810-92fosk3c	79	9	infections	infection	NNS
cord-324810-92fosk3c	79	10	caused	cause	VBD
cord-324810-92fosk3c	79	11	higher	high	JJR
cord-324810-92fosk3c	79	12	symptom	symptom	NN
cord-324810-92fosk3c	79	13	scores	score	NNS
cord-324810-92fosk3c	79	14	and	and	CC
cord-324810-92fosk3c	79	15	increased	increase	VBN
cord-324810-92fosk3c	79	16	studies	study	NNS
cord-324810-92fosk3c	79	17	prove	prove	VBP
cord-324810-92fosk3c	79	18	that	that	IN
cord-324810-92fosk3c	79	19	the	the	DT
cord-324810-92fosk3c	79	20	bacteria	bacteria	NNS
cord-324810-92fosk3c	79	21	are	be	VBP
cord-324810-92fosk3c	79	22	recovered	recover	VBN
cord-324810-92fosk3c	79	23	in	in	IN
cord-324810-92fosk3c	79	24	the	the	DT
cord-324810-92fosk3c	79	25	distal	distal	JJ
cord-324810-92fosk3c	79	26	airways	airway	NNS
cord-324810-92fosk3c	79	27	levels	level	NNS
cord-324810-92fosk3c	79	28	of	of	IN
cord-324810-92fosk3c	79	29	inflammatory	inflammatory	JJ
cord-324810-92fosk3c	79	30	markers	marker	NNS
cord-324810-92fosk3c	79	31	(	(	-LRB-
cord-324810-92fosk3c	79	32	plasma	plasma	NN
cord-324810-92fosk3c	79	33	fibrinogen	fibrinogen	NN
cord-324810-92fosk3c	79	34	and	and	CC
cord-324810-92fosk3c	79	35	in	in	IN
cord-324810-92fosk3c	79	36	-	-	HYPH
cord-324810-92fosk3c	79	37	of	of	IN
cord-324810-92fosk3c	79	38	COPD	COPD	NNP
cord-324810-92fosk3c	79	39	patients	patient	NNS
cord-324810-92fosk3c	79	40	during	during	IN
cord-324810-92fosk3c	79	41	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	79	42	and	and	CC
cord-324810-92fosk3c	79	43	may	may	MD
cord-324810-92fosk3c	79	44	be	be	VB
cord-324810-92fosk3c	79	45	responsible	responsible	JJ
cord-324810-92fosk3c	79	46	for	for	IN
cord-324810-92fosk3c	79	47	terleukin-6	terleukin-6	NNP
cord-324810-92fosk3c	79	48	)	)	-RRB-
cord-324810-92fosk3c	79	49	.	.	.
cord-324810-92fosk3c	80	1	In	in	IN
cord-324810-92fosk3c	80	2	addition	addition	NN
cord-324810-92fosk3c	80	3	,	,	,
cord-324810-92fosk3c	80	4	more	more	RBR
cord-324810-92fosk3c	80	5	severe	severe	JJ
cord-324810-92fosk3c	80	6	and	and	CC
cord-324810-92fosk3c	80	7	frequent	frequent	JJ
cord-324810-92fosk3c	80	8	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	80	9	the	the	DT
cord-324810-92fosk3c	80	10	observed	observed	JJ
cord-324810-92fosk3c	80	11	clinical	clinical	JJ
cord-324810-92fosk3c	80	12	symptoms	symptom	NNS
cord-324810-92fosk3c	80	13	.	.	.
cord-324810-92fosk3c	81	1	In	in	IN
cord-324810-92fosk3c	81	2	the	the	DT
cord-324810-92fosk3c	81	3	literature	literature	NN
cord-324810-92fosk3c	81	4	there	there	RB
cord-324810-92fosk3c	81	5	exists	exist	VBZ
cord-324810-92fosk3c	81	6	criticism	criticism	NN
cord-324810-92fosk3c	81	7	of	of	IN
cord-324810-92fosk3c	81	8	data	datum	NNS
cord-324810-92fosk3c	81	9	incriminating	incriminate	VBG
cord-324810-92fosk3c	81	10	ber	ber	NN
cord-324810-92fosk3c	81	11	of	of	IN
cord-324810-92fosk3c	81	12	bacteria	bacteria	NNS
cord-324810-92fosk3c	81	13	and	and	CC
cord-324810-92fosk3c	81	14	neutrophils	neutrophil	NNS
cord-324810-92fosk3c	81	15	in	in	IN
cord-324810-92fosk3c	81	16	the	the	DT
cord-324810-92fosk3c	81	17	sputum	sputum	NN
cord-324810-92fosk3c	81	18	during	during	IN
cord-324810-92fosk3c	81	19	exacerbabacteria	exacerbabacteria	NNP
cord-324810-92fosk3c	81	20	as	as	IN
cord-324810-92fosk3c	81	21	causative	causative	JJ
cord-324810-92fosk3c	81	22	agents	agent	NNS
cord-324810-92fosk3c	81	23	of	of	IN
cord-324810-92fosk3c	81	24	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	81	25	.	.	.
cord-324810-92fosk3c	82	1	In	in	IN
cord-324810-92fosk3c	82	2	support	support	NN
cord-324810-92fosk3c	82	3	,	,	,
cord-324810-92fosk3c	82	4	Hirschtions	Hirschtions	NNP
cord-324810-92fosk3c	82	5	.	.	.
cord-324810-92fosk3c	83	1	[	[	-LRB-
cord-324810-92fosk3c	83	2	18	18	CD
cord-324810-92fosk3c	83	3	,	,	,
cord-324810-92fosk3c	83	4	23	23	CD
cord-324810-92fosk3c	83	5	,	,	,
cord-324810-92fosk3c	83	6	24	24	CD
cord-324810-92fosk3c	83	7	]	]	-RRB-
cord-324810-92fosk3c	83	8	Bacteria	Bacteria	NNS
cord-324810-92fosk3c	83	9	were	be	VBD
cord-324810-92fosk3c	83	10	thought	think	VBN
cord-324810-92fosk3c	83	11	not	not	RB
cord-324810-92fosk3c	83	12	only	only	RB
cord-324810-92fosk3c	83	13	to	to	TO
cord-324810-92fosk3c	83	14	be	be	VB
cord-324810-92fosk3c	83	15	the	the	DT
cord-324810-92fosk3c	83	16	primary	primary	JJ
cord-324810-92fosk3c	83	17	mann	mann	NNP
cord-324810-92fosk3c	83	18	[	[	-LRB-
cord-324810-92fosk3c	83	19	19	19	CD
cord-324810-92fosk3c	83	20	,	,	,
cord-324810-92fosk3c	83	21	22	22	CD
cord-324810-92fosk3c	83	22	]	]	-RRB-
cord-324810-92fosk3c	83	23	eloquently	eloquently	RB
cord-324810-92fosk3c	83	24	debated	debate	VBD
cord-324810-92fosk3c	83	25	that	that	IN
cord-324810-92fosk3c	83	26	current	current	JJ
cord-324810-92fosk3c	83	27	evidence	evidence	NN
cord-324810-92fosk3c	83	28	does	do	VBZ
cord-324810-92fosk3c	83	29	not	not	RB
cord-324810-92fosk3c	83	30	subcause	subcause	VB
cord-324810-92fosk3c	83	31	of	of	IN
cord-324810-92fosk3c	83	32	the	the	DT
cord-324810-92fosk3c	83	33	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	84	1	but	but	CC
cord-324810-92fosk3c	84	2	were	be	VBD
cord-324810-92fosk3c	84	3	also	also	RB
cord-324810-92fosk3c	84	4	considered	consider	VBN
cord-324810-92fosk3c	84	5	to	to	TO
cord-324810-92fosk3c	84	6	be	be	VB
cord-324810-92fosk3c	84	7	the	the	DT
cord-324810-92fosk3c	84	8	stantiate	stantiate	NNP
cord-324810-92fosk3c	84	9	the	the	DT
cord-324810-92fosk3c	84	10	role	role	NN
cord-324810-92fosk3c	84	11	of	of	IN
cord-324810-92fosk3c	84	12	bacteria	bacteria	NNS
cord-324810-92fosk3c	85	1	because	because	IN
cord-324810-92fosk3c	85	2	:	:	:
cord-324810-92fosk3c	85	3	(	(	-LRB-
cord-324810-92fosk3c	85	4	i	i	NN
cord-324810-92fosk3c	85	5	)	)	-RRB-
cord-324810-92fosk3c	85	6	bacterial	bacterial	JJ
cord-324810-92fosk3c	85	7	colonization	colonization	NN
cord-324810-92fosk3c	85	8	is	be	VBZ
cord-324810-92fosk3c	85	9	secondary	secondary	JJ
cord-324810-92fosk3c	85	10	invaders	invader	NNS
cord-324810-92fosk3c	85	11	following	follow	VBG
cord-324810-92fosk3c	85	12	acute	acute	JJ
cord-324810-92fosk3c	85	13	viral	viral	JJ
cord-324810-92fosk3c	85	14	or	or	CC
cord-324810-92fosk3c	85	15	mycoplasma	mycoplasma	NN
cord-324810-92fosk3c	85	16	infection	infection	NN
cord-324810-92fosk3c	85	17	.	.	.
cord-324810-92fosk3c	86	1	not	not	RB
cord-324810-92fosk3c	86	2	prevalent	prevalent	JJ
cord-324810-92fosk3c	86	3	during	during	IN
cord-324810-92fosk3c	86	4	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	86	5	,	,	,
cord-324810-92fosk3c	86	6	and	and	CC
cord-324810-92fosk3c	86	7	available	available	JJ
cord-324810-92fosk3c	86	8	pathologic	pathologic	JJ
cord-324810-92fosk3c	86	9	and	and	CC
cord-324810-92fosk3c	86	10	Patel	Patel	NNP
cord-324810-92fosk3c	86	11	et	et	NNP
cord-324810-92fosk3c	86	12	al	al	NNP
cord-324810-92fosk3c	86	13	.	.	.
cord-324810-92fosk3c	87	1	[	[	-LRB-
cord-324810-92fosk3c	87	2	25	25	CD
cord-324810-92fosk3c	87	3	]	]	-RRB-
cord-324810-92fosk3c	87	4	recently	recently	RB
cord-324810-92fosk3c	87	5	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	87	6	that	that	IN
cord-324810-92fosk3c	87	7	lower	low	JJR
cord-324810-92fosk3c	87	8	airway	airway	NN
cord-324810-92fosk3c	87	9	colonizaserologic	colonizaserologic	NNP
cord-324810-92fosk3c	87	10	data	datum	NNS
cord-324810-92fosk3c	87	11	fail	fail	VBP
cord-324810-92fosk3c	87	12	to	to	TO
cord-324810-92fosk3c	87	13	demonstrate	demonstrate	VB
cord-324810-92fosk3c	87	14	activation	activation	NN
cord-324810-92fosk3c	87	15	of	of	IN
cord-324810-92fosk3c	87	16	host	host	NN
cord-324810-92fosk3c	87	17	defense	defense	NN
cord-324810-92fosk3c	87	18	retion	retion	NN
cord-324810-92fosk3c	87	19	in	in	IN
cord-324810-92fosk3c	87	20	the	the	DT
cord-324810-92fosk3c	87	21	stable	stable	JJ
cord-324810-92fosk3c	87	22	state	state	NN
cord-324810-92fosk3c	87	23	was	be	VBD
cord-324810-92fosk3c	87	24	associated	associate	VBN
cord-324810-92fosk3c	87	25	with	with	IN
cord-324810-92fosk3c	87	26	increased	increase	VBN
cord-324810-92fosk3c	87	27	exacerbation	exacerbation	NN
cord-324810-92fosk3c	87	28	sponse	sponse	NN
cord-324810-92fosk3c	87	29	;	;	:
cord-324810-92fosk3c	87	30	and	and	CC
cord-324810-92fosk3c	87	31	(	(	-LRB-
cord-324810-92fosk3c	87	32	ii	ii	NN
cord-324810-92fosk3c	87	33	)	)	-RRB-
cord-324810-92fosk3c	87	34	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	87	35	trials	trial	NNS
cord-324810-92fosk3c	87	36	in	in	IN
cord-324810-92fosk3c	87	37	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	87	38	do	do	VBP
cord-324810-92fosk3c	87	39	not	not	RB
cord-324810-92fosk3c	87	40	validate	validate	VB
cord-324810-92fosk3c	87	41	frequency	frequency	NN
cord-324810-92fosk3c	87	42	and	and	CC
cord-324810-92fosk3c	87	43	colonization	colonization	NN
cord-324810-92fosk3c	87	44	.	.	.
cord-324810-92fosk3c	88	1	Furthermore	furthermore	RB
cord-324810-92fosk3c	88	2	,	,	,
cord-324810-92fosk3c	88	3	non	non	JJ
cord-324810-92fosk3c	88	4	-	-	JJ
cord-324810-92fosk3c	88	5	typeable	typeable	JJ
cord-324810-92fosk3c	88	6	H.	h.	NN
cord-324810-92fosk3c	88	7	inadvantage	inadvantage	NN
cord-324810-92fosk3c	88	8	,	,	,
cord-324810-92fosk3c	88	9	and	and	CC
cord-324810-92fosk3c	88	10	symptomatic	symptomatic	JJ
cord-324810-92fosk3c	88	11	improvement	improvement	NN
cord-324810-92fosk3c	88	12	does	do	VBZ
cord-324810-92fosk3c	88	13	not	not	RB
cord-324810-92fosk3c	88	14	coincide	coincide	VB
cord-324810-92fosk3c	88	15	with	with	IN
cord-324810-92fosk3c	88	16	fluenzae	fluenzae	NNP
cord-324810-92fosk3c	88	17	colonization	colonization	NN
cord-324810-92fosk3c	88	18	led	lead	VBD
cord-324810-92fosk3c	88	19	to	to	IN
cord-324810-92fosk3c	88	20	higher	high	JJR
cord-324810-92fosk3c	88	21	total	total	JJ
cord-324810-92fosk3c	88	22	symptom	symptom	NN
cord-324810-92fosk3c	88	23	score	score	NN
cord-324810-92fosk3c	88	24	and	and	CC
cord-324810-92fosk3c	88	25	sputhe	sputhe	NNP
cord-324810-92fosk3c	88	26	eradication	eradication	NN
cord-324810-92fosk3c	88	27	of	of	IN
cord-324810-92fosk3c	88	28	bacteria	bacteria	NNS
cord-324810-92fosk3c	88	29	.	.	.
cord-324810-92fosk3c	89	1	While	while	IN
cord-324810-92fosk3c	89	2	more	more	JJR
cord-324810-92fosk3c	89	3	data	datum	NNS
cord-324810-92fosk3c	89	4	are	be	VBP
cord-324810-92fosk3c	89	5	definitely	definitely	RB
cord-324810-92fosk3c	89	6	needed	need	VBN
cord-324810-92fosk3c	89	7	tum	tum	NNP
cord-324810-92fosk3c	89	8	purulence	purulence	NN
cord-324810-92fosk3c	89	9	.	.	.
cord-324810-92fosk3c	90	1	However	however	RB
cord-324810-92fosk3c	90	2	,	,	,
cord-324810-92fosk3c	90	3	evaluating	evaluate	VBG
cord-324810-92fosk3c	90	4	the	the	DT
cord-324810-92fosk3c	90	5	role	role	NN
cord-324810-92fosk3c	90	6	of	of	IN
cord-324810-92fosk3c	90	7	bacterial	bacterial	JJ
cord-324810-92fosk3c	90	8	infection	infection	NN
cord-324810-92fosk3c	90	9	to	to	TO
cord-324810-92fosk3c	90	10	further	further	RB
cord-324810-92fosk3c	90	11	elucidate	elucidate	VB
cord-324810-92fosk3c	90	12	the	the	DT
cord-324810-92fosk3c	90	13	pathogenesis	pathogenesis	NN
cord-324810-92fosk3c	90	14	of	of	IN
cord-324810-92fosk3c	90	15	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	90	16	,	,	,
cord-324810-92fosk3c	90	17	and	and	CC
cord-324810-92fosk3c	90	18	the	the	DT
cord-324810-92fosk3c	90	19	role	role	NN
cord-324810-92fosk3c	90	20	of	of	IN
cord-324810-92fosk3c	90	21	in	in	IN
cord-324810-92fosk3c	90	22	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	90	23	has	have	VBZ
cord-324810-92fosk3c	90	24	been	be	VBN
cord-324810-92fosk3c	90	25	a	a	DT
cord-324810-92fosk3c	90	26	difficult	difficult	JJ
cord-324810-92fosk3c	90	27	task	task	NN
cord-324810-92fosk3c	90	28	for	for	IN
cord-324810-92fosk3c	90	29	a	a	DT
cord-324810-92fosk3c	90	30	variety	variety	NN
cord-324810-92fosk3c	90	31	of	of	IN
cord-324810-92fosk3c	90	32	reasons	reason	NNS
cord-324810-92fosk3c	90	33	.	.	.
cord-324810-92fosk3c	91	1	bacteria	bacteria	NNS
cord-324810-92fosk3c	91	2	and	and	CC
cord-324810-92fosk3c	91	3	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	91	4	,	,	,
cord-324810-92fosk3c	91	5	the	the	DT
cord-324810-92fosk3c	91	6	evidence	evidence	NN
cord-324810-92fosk3c	91	7	reviewed	review	VBN
cord-324810-92fosk3c	91	8	in	in	IN
cord-324810-92fosk3c	91	9	this	this	DT
cord-324810-92fosk3c	91	10	paper	paper	NN
cord-324810-92fosk3c	91	11	Because	because	IN
cord-324810-92fosk3c	91	12	the	the	DT
cord-324810-92fosk3c	91	13	airways	airway	NNS
cord-324810-92fosk3c	91	14	of	of	IN
cord-324810-92fosk3c	91	15	many	many	JJ
cord-324810-92fosk3c	91	16	stable	stable	JJ
cord-324810-92fosk3c	91	17	patients	patient	NNS
cord-324810-92fosk3c	91	18	with	with	IN
cord-324810-92fosk3c	91	19	COPD	COPD	NNP
cord-324810-92fosk3c	91	20	are	be	VBP
cord-324810-92fosk3c	91	21	definitely	definitely	RB
cord-324810-92fosk3c	91	22	establishes	establish	VBZ
cord-324810-92fosk3c	91	23	the	the	DT
cord-324810-92fosk3c	91	24	importance	importance	NN
cord-324810-92fosk3c	91	25	of	of	IN
cord-324810-92fosk3c	91	26	bacteria	bacteria	NNS
cord-324810-92fosk3c	91	27	and	and	CC
cord-324810-92fosk3c	91	28	the	the	DT
cord-324810-92fosk3c	91	29	use	use	NN
cord-324810-92fosk3c	91	30	of	of	IN
cord-324810-92fosk3c	91	31	colonized	colonize	VBN
cord-324810-92fosk3c	91	32	by	by	IN
cord-324810-92fosk3c	91	33	H.	H.	NNP
cord-324810-92fosk3c	91	34	influenzae	influenzae	NN
cord-324810-92fosk3c	91	35	,	,	,
cord-324810-92fosk3c	91	36	S.	S.	NNP
cord-324810-92fosk3c	91	37	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	91	38	and	and	CC
cord-324810-92fosk3c	91	39	M.	M.	NNP
cord-324810-92fosk3c	91	40	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	91	41	,	,	,
cord-324810-92fosk3c	91	42	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	91	43	in	in	IN
cord-324810-92fosk3c	91	44	patients	patient	NNS
cord-324810-92fosk3c	91	45	presenting	present	VBG
cord-324810-92fosk3c	91	46	with	with	IN
cord-324810-92fosk3c	91	47	two	two	CD
cord-324810-92fosk3c	91	48	or	or	CC
cord-324810-92fosk3c	91	49	more	more	JJR
cord-324810-92fosk3c	91	50	symptoms	symptom	NNS
cord-324810-92fosk3c	91	51	evaluation	evaluation	NN
cord-324810-92fosk3c	91	52	of	of	IN
cord-324810-92fosk3c	91	53	the	the	DT
cord-324810-92fosk3c	91	54	expectorated	expectorate	VBN
cord-324810-92fosk3c	91	55	sputum	sputum	NN
cord-324810-92fosk3c	91	56	during	during	IN
cord-324810-92fosk3c	91	57	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	91	58	may	may	MD
cord-324810-92fosk3c	91	59	of	of	IN
cord-324810-92fosk3c	91	60	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	91	61	.	.	.
cord-324810-92fosk3c	92	1	be	be	VB
cord-324810-92fosk3c	92	2	inconclusive	inconclusive	JJ
cord-324810-92fosk3c	92	3	.	.	.
cord-324810-92fosk3c	93	1	Serologic	Serologic	NNP
cord-324810-92fosk3c	93	2	studies	study	NNS
cord-324810-92fosk3c	93	3	attempted	attempt	VBD
cord-324810-92fosk3c	93	4	to	to	TO
cord-324810-92fosk3c	93	5	establish	establish	VB
cord-324810-92fosk3c	93	6	a	a	DT
cord-324810-92fosk3c	93	7	causal	causal	JJ
cord-324810-92fosk3c	93	8	relationship	relationship	NN
cord-324810-92fosk3c	93	9	between	between	IN
cord-324810-92fosk3c	93	10	bacterial	bacterial	JJ
cord-324810-92fosk3c	93	11	infection	infection	NN
cord-324810-92fosk3c	93	12	and	and	CC
cord-324810-92fosk3c	93	13	acute	acute	JJ
cord-324810-92fosk3c	93	14	exacerbation	exacerbation	NN
cord-324810-92fosk3c	93	15	by	by	IN
cord-324810-92fosk3c	93	16	finding	find	VBG
cord-324810-92fosk3c	93	17	an	an	DT
cord-324810-92fosk3c	93	18	acute	acute	JJ
cord-324810-92fosk3c	93	19	antibody	antibody	NN
cord-324810-92fosk3c	93	20	response	response	NN
cord-324810-92fosk3c	93	21	in	in	IN
cord-324810-92fosk3c	93	22	serum	serum	NN
cord-324810-92fosk3c	93	23	to	to	IN
cord-324810-92fosk3c	93	24	these	these	DT
cord-324810-92fosk3c	93	25	bacteria	bacteria	NNS
cord-324810-92fosk3c	93	26	.	.	.
cord-324810-92fosk3c	94	1	[	[	-LRB-
cord-324810-92fosk3c	94	2	26	26	CD
cord-324810-92fosk3c	94	3	]	]	-RRB-
cord-324810-92fosk3c	94	4	 	 	_SP
cord-324810-92fosk3c	95	1	These	these	DT
cord-324810-92fosk3c	95	2	studies	study	NNS
cord-324810-92fosk3c	95	3	had	have	VBD
cord-324810-92fosk3c	95	4	conflicting	conflict	VBG
cord-324810-92fosk3c	95	5	results	result	NNS
cord-324810-92fosk3c	95	6	and	and	CC
cord-324810-92fosk3c	95	7	,	,	,
cord-324810-92fosk3c	95	8	in	in	IN
cord-324810-92fosk3c	95	9	general	general	JJ
cord-324810-92fosk3c	95	10	,	,	,
cord-324810-92fosk3c	95	11	failed	fail	VBD
cord-324810-92fosk3c	95	12	to	to	TO
cord-324810-92fosk3c	95	13	establish	establish	VB
cord-324810-92fosk3c	95	14	a	a	DT
cord-324810-92fosk3c	95	15	correlation	correlation	NN
cord-324810-92fosk3c	95	16	between	between	IN
cord-324810-92fosk3c	95	17	the	the	DT
cord-324810-92fosk3c	95	18	antibody	antibody	NN
cord-324810-92fosk3c	95	19	titers	titer	NNS
cord-324810-92fosk3c	95	20	and	and	CC
cord-324810-92fosk3c	95	21	exacerba-	exacerba-	NN
cord-324810-92fosk3c	96	1	The	the	DT
cord-324810-92fosk3c	96	2	role	role	NN
cord-324810-92fosk3c	96	3	of	of	IN
cord-324810-92fosk3c	96	4	infection	infection	NN
cord-324810-92fosk3c	96	5	in	in	IN
cord-324810-92fosk3c	96	6	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	96	7	has	have	VBZ
cord-324810-92fosk3c	96	8	been	be	VBN
cord-324810-92fosk3c	96	9	controversial	controversial	JJ
cord-324810-92fosk3c	96	10	for	for	IN
cord-324810-92fosk3c	96	11	a	a	DT
cord-324810-92fosk3c	96	12	tions	tion	NNS
cord-324810-92fosk3c	96	13	.	.	.
cord-324810-92fosk3c	97	1	[	[	-LRB-
cord-324810-92fosk3c	97	2	27	27	CD
cord-324810-92fosk3c	97	3	]	]	-RRB-
cord-324810-92fosk3c	97	4	Most	Most	JJS
cord-324810-92fosk3c	97	5	studies	study	NNS
cord-324810-92fosk3c	97	6	used	use	VBD
cord-324810-92fosk3c	97	7	the	the	DT
cord-324810-92fosk3c	97	8	whole	whole	JJ
cord-324810-92fosk3c	97	9	organism	organism	NN
cord-324810-92fosk3c	97	10	preparations	preparation	NNS
cord-324810-92fosk3c	97	11	of	of	IN
cord-324810-92fosk3c	97	12	long	long	JJ
cord-324810-92fosk3c	97	13	time	time	NN
cord-324810-92fosk3c	97	14	,	,	,
cord-324810-92fosk3c	97	15	although	although	IN
cord-324810-92fosk3c	97	16	the	the	DT
cord-324810-92fosk3c	97	17	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	97	18	are	be	VBP
cord-324810-92fosk3c	97	19	prescribed	prescribe	VBN
cord-324810-92fosk3c	97	20	frequently	frequently	RB
cord-324810-92fosk3c	97	21	to	to	IN
cord-324810-92fosk3c	97	22	unrelated	unrelated	JJ
cord-324810-92fosk3c	97	23	strains	strain	NNS
cord-324810-92fosk3c	97	24	as	as	IN
cord-324810-92fosk3c	97	25	the	the	DT
cord-324810-92fosk3c	97	26	antigen	antigen	NN
cord-324810-92fosk3c	97	27	for	for	IN
cord-324810-92fosk3c	97	28	serologic	serologic	NNP
cord-324810-92fosk3c	97	29	studies	study	NNS
cord-324810-92fosk3c	97	30	,	,	,
cord-324810-92fosk3c	97	31	and	and	CC
cord-324810-92fosk3c	97	32	therefore	therefore	RB
cord-324810-92fosk3c	97	33	treat	treat	VB
cord-324810-92fosk3c	97	34	these	these	DT
cord-324810-92fosk3c	97	35	patients	patient	NNS
cord-324810-92fosk3c	97	36	.	.	.
cord-324810-92fosk3c	98	1	Early	early	JJ
cord-324810-92fosk3c	98	2	investigators	investigator	NNS
cord-324810-92fosk3c	98	3	identified	identify	VBD
cord-324810-92fosk3c	98	4	increased	increase	VBD
cord-324810-92fosk3c	98	5	nummeasured	nummeasure	VBD
cord-324810-92fosk3c	98	6	a	a	DT
cord-324810-92fosk3c	98	7	mixture	mixture	NN
cord-324810-92fosk3c	98	8	of	of	IN
cord-324810-92fosk3c	98	9	antibodies	antibody	NNS
cord-324810-92fosk3c	98	10	to	to	IN
cord-324810-92fosk3c	98	11	a	a	DT
cord-324810-92fosk3c	98	12	combination	combination	NN
cord-324810-92fosk3c	98	13	of	of	IN
cord-324810-92fosk3c	98	14	antigens	antigen	NNS
cord-324810-92fosk3c	98	15	.	.	.
cord-324810-92fosk3c	99	1	[	[	-LRB-
cord-324810-92fosk3c	99	2	26	26	CD
cord-324810-92fosk3c	99	3	]	]	-RRB-
cord-324810-92fosk3c	99	4	[	[	-LRB-
cord-324810-92fosk3c	99	5	27	27	CD
cord-324810-92fosk3c	99	6	]	]	-RRB-
cord-324810-92fosk3c	99	7	[	[	-LRB-
cord-324810-92fosk3c	99	8	28	28	CD
cord-324810-92fosk3c	99	9	]	]	-RRB-
cord-324810-92fosk3c	100	1	Future	future	JJ
cord-324810-92fosk3c	100	2	studies	study	NNS
cord-324810-92fosk3c	100	3	may	may	MD
cord-324810-92fosk3c	100	4	utilize	utilize	VB
cord-324810-92fosk3c	100	5	antibody	antibody	NN
cord-324810-92fosk3c	100	6	response	response	NN
cord-324810-92fosk3c	100	7	to	to	IN
cord-324810-92fosk3c	100	8	more	more	RBR
cord-324810-92fosk3c	100	9	specific	specific	JJ
cord-324810-92fosk3c	100	10	surface	surface	NN
cord-324810-92fosk3c	100	11	antigens	antigen	NNS
cord-324810-92fosk3c	100	12	of	of	IN
cord-324810-92fosk3c	100	13	bacteria	bacteria	NNS
cord-324810-92fosk3c	100	14	to	to	TO
cord-324810-92fosk3c	100	15	establish	establish	VB
cord-324810-92fosk3c	100	16	the	the	DT
cord-324810-92fosk3c	100	17	importance	importance	NN
cord-324810-92fosk3c	100	18	of	of	IN
cord-324810-92fosk3c	100	19	bacterial	bacterial	JJ
cord-324810-92fosk3c	100	20	infection	infection	NN
cord-324810-92fosk3c	100	21	in	in	IN
cord-324810-92fosk3c	100	22	COPD	COPD	NNP
cord-324810-92fosk3c	100	23	.	.	.
cord-324810-92fosk3c	101	1	Positive	positive	JJ
cord-324810-92fosk3c	101	2	sputum	sputum	NN
cord-324810-92fosk3c	101	3	culture	culture	NN
cord-324810-92fosk3c	101	4	does	do	VBZ
cord-324810-92fosk3c	101	5	not	not	RB
cord-324810-92fosk3c	101	6	predict	predict	VB
cord-324810-92fosk3c	101	7	benefit	benefit	NN
cord-324810-92fosk3c	101	8	of	of	IN
cord-324810-92fosk3c	101	9	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	101	10	therapy	therapy	NN
cord-324810-92fosk3c	101	11	in	in	IN
cord-324810-92fosk3c	101	12	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	101	13	.	.	.
cord-324810-92fosk3c	102	1	[	[	-LRB-
cord-324810-92fosk3c	102	2	17	17	CD
cord-324810-92fosk3c	102	3	]	]	-RRB-
cord-324810-92fosk3c	102	4	Increased	increase	VBN
cord-324810-92fosk3c	102	5	sputum	sputum	NN
cord-324810-92fosk3c	102	6	purulence	purulence	NN
cord-324810-92fosk3c	102	7	was	be	VBD
cord-324810-92fosk3c	102	8	previously	previously	RB
cord-324810-92fosk3c	102	9	thought	think	VBN
cord-324810-92fosk3c	102	10	to	to	TO
cord-324810-92fosk3c	102	11	be	be	VB
cord-324810-92fosk3c	102	12	associated	associate	VBN
cord-324810-92fosk3c	102	13	with	with	IN
cord-324810-92fosk3c	102	14	bacterial	bacterial	JJ
cord-324810-92fosk3c	102	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	102	16	.	.	.
cord-324810-92fosk3c	103	1	[	[	-LRB-
cord-324810-92fosk3c	103	2	29	29	CD
cord-324810-92fosk3c	103	3	]	]	-RRB-
cord-324810-92fosk3c	103	4	Airway	airway	NN
cord-324810-92fosk3c	103	5	infection	infection	NN
cord-324810-92fosk3c	103	6	rather	rather	RB
cord-324810-92fosk3c	103	7	than	than	IN
cord-324810-92fosk3c	103	8	colonization	colonization	NN
cord-324810-92fosk3c	103	9	activate	activate	VBP
cord-324810-92fosk3c	103	10	secondary	secondary	JJ
cord-324810-92fosk3c	103	11	host	host	NN
cord-324810-92fosk3c	103	12	defenses	defense	NNS
cord-324810-92fosk3c	103	13	and	and	CC
cord-324810-92fosk3c	103	14	recruit	recruit	VB
cord-324810-92fosk3c	103	15	neutrophils	neutrophil	NNS
cord-324810-92fosk3c	103	16	to	to	IN
cord-324810-92fosk3c	103	17	the	the	DT
cord-324810-92fosk3c	103	18	airways	airway	NNS
cord-324810-92fosk3c	103	19	.	.	.
cord-324810-92fosk3c	104	1	[	[	-LRB-
cord-324810-92fosk3c	104	2	30	30	CD
cord-324810-92fosk3c	104	3	]	]	-RRB-
cord-324810-92fosk3c	105	1	Therefore	therefore	RB
cord-324810-92fosk3c	105	2	,	,	,
cord-324810-92fosk3c	105	3	an	an	DT
cord-324810-92fosk3c	105	4	acute	acute	JJ
cord-324810-92fosk3c	105	5	exacerbation	exacerbation	NN
cord-324810-92fosk3c	105	6	will	will	MD
cord-324810-92fosk3c	105	7	be	be	VB
cord-324810-92fosk3c	105	8	associated	associate	VBN
cord-324810-92fosk3c	105	9	with	with	IN
cord-324810-92fosk3c	105	10	change	change	NN
cord-324810-92fosk3c	105	11	of	of	IN
cord-324810-92fosk3c	105	12	sputum	sputum	NN
cord-324810-92fosk3c	105	13	color	color	NN
cord-324810-92fosk3c	105	14	from	from	IN
cord-324810-92fosk3c	105	15	mucoid	mucoid	NNP
cord-324810-92fosk3c	105	16	to	to	IN
cord-324810-92fosk3c	105	17	purulent	purulent	JJ
cord-324810-92fosk3c	105	18	(	(	-LRB-
cord-324810-92fosk3c	105	19	myeloperoxidase	myeloperoxidase	NN
cord-324810-92fosk3c	105	20	from	from	IN
cord-324810-92fosk3c	105	21	neutrophil	neutrophil	NN
cord-324810-92fosk3c	105	22	azurophil	azurophil	NNP
cord-324810-92fosk3c	105	23	granules	granule	NNS
cord-324810-92fosk3c	105	24	is	be	VBZ
cord-324810-92fosk3c	105	25	green	green	JJ
cord-324810-92fosk3c	105	26	colored	colored	JJ
cord-324810-92fosk3c	105	27	)	)	-RRB-
cord-324810-92fosk3c	105	28	,	,	,
cord-324810-92fosk3c	105	29	which	which	WDT
cord-324810-92fosk3c	105	30	will	will	MD
cord-324810-92fosk3c	105	31	reverse	reverse	VB
cord-324810-92fosk3c	105	32	on	on	IN
cord-324810-92fosk3c	105	33	resolution	resolution	NN
cord-324810-92fosk3c	105	34	.	.	.
cord-324810-92fosk3c	106	1	[	[	-LRB-
cord-324810-92fosk3c	106	2	30	30	CD
cord-324810-92fosk3c	106	3	]	]	-RRB-
cord-324810-92fosk3c	107	1	Stockley	Stockley	NNP
cord-324810-92fosk3c	107	2	et	et	FW
cord-324810-92fosk3c	107	3	al	al	NNP
cord-324810-92fosk3c	107	4	.	.	.
cord-324810-92fosk3c	108	1	[	[	-LRB-
cord-324810-92fosk3c	108	2	31	31	CD
cord-324810-92fosk3c	108	3	]	]	-RRB-
cord-324810-92fosk3c	108	4	studied	study	VBN
cord-324810-92fosk3c	108	5	sputum	sputum	NN
cord-324810-92fosk3c	108	6	characteristics	characteristic	NNS
cord-324810-92fosk3c	108	7	in	in	IN
cord-324810-92fosk3c	108	8	121	121	CD
cord-324810-92fosk3c	108	9	COPD	COPD	NNP
cord-324810-92fosk3c	108	10	patients	patient	NNS
cord-324810-92fosk3c	108	11	presenting	present	VBG
cord-324810-92fosk3c	108	12	with	with	IN
cord-324810-92fosk3c	108	13	an	an	DT
cord-324810-92fosk3c	108	14	acute	acute	JJ
cord-324810-92fosk3c	108	15	exacerbation	exacerbation	NN
cord-324810-92fosk3c	108	16	.	.	.
cord-324810-92fosk3c	109	1	A	a	DT
cord-324810-92fosk3c	109	2	positive	positive	JJ
cord-324810-92fosk3c	109	3	bacterial	bacterial	JJ
cord-324810-92fosk3c	109	4	culture	culture	NN
cord-324810-92fosk3c	109	5	was	be	VBD
cord-324810-92fosk3c	109	6	obtained	obtain	VBN
cord-324810-92fosk3c	109	7	from	from	IN
cord-324810-92fosk3c	109	8	84	84	CD
cord-324810-92fosk3c	109	9	%	%	NN
cord-324810-92fosk3c	109	10	of	of	IN
cord-324810-92fosk3c	109	11	patients	patient	NNS
cord-324810-92fosk3c	109	12	who	who	WP
cord-324810-92fosk3c	109	13	expectorated	expectorate	VBD
cord-324810-92fosk3c	109	14	green	green	JJ
cord-324810-92fosk3c	109	15	,	,	,
cord-324810-92fosk3c	109	16	purulent	purulent	JJ
cord-324810-92fosk3c	109	17	sputum	sputum	NN
cord-324810-92fosk3c	109	18	.	.	.
cord-324810-92fosk3c	110	1	White	white	JJ
cord-324810-92fosk3c	110	2	or	or	CC
cord-324810-92fosk3c	110	3	clear	clear	JJ
cord-324810-92fosk3c	110	4	sputum	sputum	NN
cord-324810-92fosk3c	110	5	yielded	yield	VBD
cord-324810-92fosk3c	110	6	a	a	DT
cord-324810-92fosk3c	110	7	positive	positive	JJ
cord-324810-92fosk3c	110	8	bacterial	bacterial	JJ
cord-324810-92fosk3c	110	9	culture	culture	NN
cord-324810-92fosk3c	110	10	in	in	IN
cord-324810-92fosk3c	110	11	only	only	RB
cord-324810-92fosk3c	110	12	38	38	CD
cord-324810-92fosk3c	110	13	%	%	NN
cord-324810-92fosk3c	110	14	of	of	IN
cord-324810-92fosk3c	110	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	110	16	.	.	.
cord-324810-92fosk3c	111	1	In	in	IN
cord-324810-92fosk3c	111	2	contrast	contrast	NN
cord-324810-92fosk3c	111	3	,	,	,
cord-324810-92fosk3c	111	4	on	on	IN
cord-324810-92fosk3c	111	5	repeat	repeat	NN
cord-324810-92fosk3c	111	6	sputum	sputum	NN
cord-324810-92fosk3c	111	7	culture	culture	NN
cord-324810-92fosk3c	111	8	in	in	IN
cord-324810-92fosk3c	111	9	stable	stable	JJ
cord-324810-92fosk3c	111	10	state	state	NN
cord-324810-92fosk3c	111	11	,	,	,
cord-324810-92fosk3c	111	12	the	the	DT
cord-324810-92fosk3c	111	13	incidence	incidence	NN
cord-324810-92fosk3c	111	14	of	of	IN
cord-324810-92fosk3c	111	15	positive	positive	JJ
cord-324810-92fosk3c	111	16	bacterial	bacterial	JJ
cord-324810-92fosk3c	111	17	culture	culture	NN
cord-324810-92fosk3c	111	18	was	be	VBD
cord-324810-92fosk3c	111	19	similar	similar	JJ
cord-324810-92fosk3c	111	20	(	(	-LRB-
cord-324810-92fosk3c	111	21	38	38	CD
cord-324810-92fosk3c	111	22	%	%	NN
cord-324810-92fosk3c	111	23	and	and	CC
cord-324810-92fosk3c	111	24	41	41	CD
cord-324810-92fosk3c	111	25	%	%	NN
cord-324810-92fosk3c	111	26	,	,	,
cord-324810-92fosk3c	111	27	respectively	respectively	RB
cord-324810-92fosk3c	111	28	)	)	-RRB-
cord-324810-92fosk3c	111	29	with	with	IN
cord-324810-92fosk3c	111	30	purulent	purulent	JJ
cord-324810-92fosk3c	111	31	and	and	CC
cord-324810-92fosk3c	111	32	mucoid	mucoid	JJ
cord-324810-92fosk3c	111	33	sputum	sputum	NN
cord-324810-92fosk3c	111	34	.	.	.
cord-324810-92fosk3c	112	1	Furthermore	furthermore	RB
cord-324810-92fosk3c	112	2	,	,	,
cord-324810-92fosk3c	112	3	all	all	DT
cord-324810-92fosk3c	112	4	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	112	5	associated	associate	VBN
cord-324810-92fosk3c	112	6	with	with	IN
cord-324810-92fosk3c	112	7	mucoid	mucoid	JJ
cord-324810-92fosk3c	112	8	sputum	sputum	NN
cord-324810-92fosk3c	112	9	improved	improve	VBD
cord-324810-92fosk3c	112	10	without	without	IN
cord-324810-92fosk3c	112	11	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	112	12	.	.	.
cord-324810-92fosk3c	113	1	This	this	DT
cord-324810-92fosk3c	113	2	study	study	NN
cord-324810-92fosk3c	113	3	provides	provide	VBZ
cord-324810-92fosk3c	113	4	additional	additional	JJ
cord-324810-92fosk3c	113	5	evidence	evidence	NN
cord-324810-92fosk3c	113	6	that	that	IN
cord-324810-92fosk3c	113	7	bacteria	bacteria	NNS
cord-324810-92fosk3c	113	8	play	play	VBP
cord-324810-92fosk3c	113	9	an	an	DT
cord-324810-92fosk3c	113	10	important	important	JJ
cord-324810-92fosk3c	113	11	role	role	NN
cord-324810-92fosk3c	113	12	in	in	IN
cord-324810-92fosk3c	113	13	causing	cause	VBG
cord-324810-92fosk3c	113	14	acute	acute	JJ
cord-324810-92fosk3c	113	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	113	16	and	and	CC
cord-324810-92fosk3c	113	17	that	that	IN
cord-324810-92fosk3c	113	18	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	113	19	success	success	NN
cord-324810-92fosk3c	113	20	can	can	MD
cord-324810-92fosk3c	113	21	be	be	VB
cord-324810-92fosk3c	113	22	predicted	predict	VBN
cord-324810-92fosk3c	113	23	simply	simply	RB
cord-324810-92fosk3c	113	24	by	by	IN
cord-324810-92fosk3c	113	25	recognizing	recognize	VBG
cord-324810-92fosk3c	113	26	sputum	sputum	NN
cord-324810-92fosk3c	113	27	color	color	NN
cord-324810-92fosk3c	113	28	.	.	.
cord-324810-92fosk3c	114	1	Table	Table	NNP
cord-324810-92fosk3c	114	2	II	II	NNP
cord-324810-92fosk3c	114	3	.	.	.
cord-324810-92fosk3c	115	1	Pathogens	pathogen	NNS
cord-324810-92fosk3c	115	2	associated	associate	VBN
cord-324810-92fosk3c	115	3	with	with	IN
cord-324810-92fosk3c	115	4	acute	acute	JJ
cord-324810-92fosk3c	115	5	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	115	6	of	of	IN
cord-324810-92fosk3c	115	7	COPD	COPD	NNP
cord-324810-92fosk3c	115	8	[	[	-LRB-
cord-324810-92fosk3c	115	9	11	11	CD
cord-324810-92fosk3c	115	10	]	]	-RRB-
cord-324810-92fosk3c	115	11	[	[	-LRB-
cord-324810-92fosk3c	115	12	12	12	CD
cord-324810-92fosk3c	115	13	]	]	-RRB-
cord-324810-92fosk3c	115	14	[	[	-LRB-
cord-324810-92fosk3c	115	15	13	13	CD
cord-324810-92fosk3c	115	16	]	]	-RRB-
cord-324810-92fosk3c	115	17	[	[	-LRB-
cord-324810-92fosk3c	115	18	14	14	CD
cord-324810-92fosk3c	115	19	]	]	-RRB-
cord-324810-92fosk3c	115	20	[	[	-LRB-
cord-324810-92fosk3c	115	21	15	15	CD
cord-324810-92fosk3c	115	22	]	]	-RRB-
cord-324810-92fosk3c	115	23	[	[	-LRB-
cord-324810-92fosk3c	115	24	16	16	CD
cord-324810-92fosk3c	115	25	]	]	-RRB-
cord-324810-92fosk3c	115	26	[	[	-LRB-
cord-324810-92fosk3c	115	27	17	17	CD
cord-324810-92fosk3c	115	28	]	]	-RRB-
cord-324810-92fosk3c	115	29	[	[	-LRB-
cord-324810-92fosk3c	115	30	18	18	CD
cord-324810-92fosk3c	115	31	]	]	-RRB-
cord-324810-92fosk3c	115	32	[	[	-LRB-
cord-324810-92fosk3c	115	33	19	19	CD
cord-324810-92fosk3c	115	34	]	]	-RRB-
cord-324810-92fosk3c	115	35	Frequency	frequency	NN
cord-324810-92fosk3c	115	36	of	of	IN
cord-324810-92fosk3c	115	37	Specific	specific	JJ
cord-324810-92fosk3c	115	38	organism	organism	NN
cord-324810-92fosk3c	115	39	Proportion	proportion	NN
cord-324810-92fosk3c	115	40	of	of	IN
cord-324810-92fosk3c	115	41	pathogens	pathogen	NNS
cord-324810-92fosk3c	115	42	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	115	43	(	(	-LRB-
cord-324810-92fosk3c	115	44	%	%	NN
cord-324810-92fosk3c	115	45	)	)	-RRB-
cord-324810-92fosk3c	115	46	(	(	-LRB-
cord-324810-92fosk3c	115	47	%	%	NN
cord-324810-92fosk3c	115	48	)	)	-RRB-
cord-324810-92fosk3c	116	1	Influenza	Influenza	NNP
cord-324810-92fosk3c	116	2	Table	Table	NNP
cord-324810-92fosk3c	116	3	III	III	NNP
cord-324810-92fosk3c	116	4	.	.	.
cord-324810-92fosk3c	117	1	Relative	relative	JJ
cord-324810-92fosk3c	117	2	risk	risk	NN
cord-324810-92fosk3c	117	3	of	of	IN
cord-324810-92fosk3c	117	4	an	an	DT
cord-324810-92fosk3c	117	5	exacerbation	exacerbation	NN
cord-324810-92fosk3c	117	6	according	accord	VBG
cord-324810-92fosk3c	117	7	to	to	IN
cord-324810-92fosk3c	117	8	whether	whether	IN
cord-324810-92fosk3c	117	9	a	a	DT
cord-324810-92fosk3c	117	10	new	new	JJ
cord-324810-92fosk3c	117	11	bacterial	bacterial	JJ
cord-324810-92fosk3c	117	12	pathogen	pathogen	NN
cord-324810-92fosk3c	117	13	or	or	CC
cord-324810-92fosk3c	117	14	a	a	DT
cord-324810-92fosk3c	117	15	strain	strain	NN
cord-324810-92fosk3c	117	16	of	of	IN
cord-324810-92fosk3c	117	17	bacterial	bacterial	JJ
cord-324810-92fosk3c	117	18	pathogen	pathogen	NN
cord-324810-92fosk3c	117	19	was	be	VBD
cord-324810-92fosk3c	117	20	isolated	isolate	VBN
cord-324810-92fosk3c	117	21	(	(	-LRB-
cord-324810-92fosk3c	117	22	reproduced	reproduce	VBN
cord-324810-92fosk3c	117	23	from	from	IN
cord-324810-92fosk3c	117	24	Sethi	Sethi	NNP
cord-324810-92fosk3c	117	25	et	et	FW
cord-324810-92fosk3c	117	26	al	al	NNP
cord-324810-92fosk3c	117	27	.	.	NNP
cord-324810-92fosk3c	117	28	,	,	,
cord-324810-92fosk3c	117	29	[	[	-LRB-
cord-324810-92fosk3c	117	30	32	32	CD
cord-324810-92fosk3c	117	31	]	]	-RRB-
cord-324810-92fosk3c	117	32	with	with	IN
cord-324810-92fosk3c	117	33	permission	permission	NN
cord-324810-92fosk3c	117	34	)	)	-RRB-
cord-324810-92fosk3c	118	1	Frequency	frequency	NN
cord-324810-92fosk3c	118	2	of	of	IN
cord-324810-92fosk3c	118	3	exacerbation	exacerbation	NN
cord-324810-92fosk3c	118	4	 	 	_SP
cord-324810-92fosk3c	118	5	Data	Data	NNP
cord-324810-92fosk3c	118	6	published	publish	VBN
cord-324810-92fosk3c	118	7	by	by	IN
cord-324810-92fosk3c	118	8	Sethi	Sethi	NNP
cord-324810-92fosk3c	118	9	[	[	-LRB-
cord-324810-92fosk3c	118	10	33	33	CD
cord-324810-92fosk3c	118	11	]	]	-RRB-
cord-324810-92fosk3c	118	12	lend	lend	VBP
cord-324810-92fosk3c	118	13	credence	credence	NN
cord-324810-92fosk3c	118	14	to	to	IN
cord-324810-92fosk3c	118	15	their	-PRON-	PRP$
cord-324810-92fosk3c	118	16	previously	previously	RB
cord-324810-92fosk3c	118	17	Sethi	Sethi	NNP
cord-324810-92fosk3c	118	18	et	et	FW
cord-324810-92fosk3c	118	19	al	al	NNP
cord-324810-92fosk3c	118	20	.	.	.
cord-324810-92fosk3c	119	1	[	[	-LRB-
cord-324810-92fosk3c	119	2	32	32	CD
cord-324810-92fosk3c	119	3	]	]	-RRB-
cord-324810-92fosk3c	119	4	recently	recently	RB
cord-324810-92fosk3c	119	5	published	publish	VBN
cord-324810-92fosk3c	119	6	data	datum	NNS
cord-324810-92fosk3c	119	7	strongly	strongly	RB
cord-324810-92fosk3c	119	8	supporting	support	VBG
cord-324810-92fosk3c	119	9	the	the	DT
cord-324810-92fosk3c	119	10	advanced	advanced	JJ
cord-324810-92fosk3c	119	11	model	model	NN
cord-324810-92fosk3c	119	12	of	of	IN
cord-324810-92fosk3c	119	13	recurrent	recurrent	JJ
cord-324810-92fosk3c	119	14	bacterial	bacterial	JJ
cord-324810-92fosk3c	119	15	infections	infection	NNS
cord-324810-92fosk3c	119	16	,	,	,
cord-324810-92fosk3c	119	17	where	where	WRB
cord-324810-92fosk3c	119	18	virulence	virulence	NN
cord-324810-92fosk3c	119	19	bacterial	bacterial	JJ
cord-324810-92fosk3c	119	20	etiology	etiology	NN
cord-324810-92fosk3c	119	21	of	of	IN
cord-324810-92fosk3c	119	22	some	some	DT
cord-324810-92fosk3c	119	23	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	119	24	(	(	-LRB-
cord-324810-92fosk3c	119	25	table	table	NN
cord-324810-92fosk3c	119	26	III	III	NNP
cord-324810-92fosk3c	119	27	)	)	-RRB-
cord-324810-92fosk3c	119	28	.	.	.
cord-324810-92fosk3c	120	1	They	-PRON-	PRP
cord-324810-92fosk3c	120	2	cultured	cultured	JJ
cord-324810-92fosk3c	120	3	of	of	IN
cord-324810-92fosk3c	120	4	the	the	DT
cord-324810-92fosk3c	120	5	infecting	infect	VBG
cord-324810-92fosk3c	120	6	organism	organism	NN
cord-324810-92fosk3c	120	7	and	and	CC
cord-324810-92fosk3c	120	8	the	the	DT
cord-324810-92fosk3c	120	9	strain	strain	NN
cord-324810-92fosk3c	120	10	-	-	HYPH
cord-324810-92fosk3c	120	11	specific	specific	JJ
cord-324810-92fosk3c	120	12	immune	immune	JJ
cord-324810-92fosk3c	120	13	response	response	NN
cord-324810-92fosk3c	120	14	sputum	sputum	NN
cord-324810-92fosk3c	120	15	samples	sample	NNS
cord-324810-92fosk3c	120	16	for	for	IN
cord-324810-92fosk3c	120	17	pathogenic	pathogenic	JJ
cord-324810-92fosk3c	120	18	bacteria	bacteria	NNS
cord-324810-92fosk3c	120	19	on	on	IN
cord-324810-92fosk3c	120	20	a	a	DT
cord-324810-92fosk3c	120	21	monthly	monthly	JJ
cord-324810-92fosk3c	120	22	basis	basis	NN
cord-324810-92fosk3c	120	23	in	in	IN
cord-324810-92fosk3c	120	24	appear	appear	VBP
cord-324810-92fosk3c	120	25	to	to	TO
cord-324810-92fosk3c	120	26	be	be	VB
cord-324810-92fosk3c	120	27	important	important	JJ
cord-324810-92fosk3c	120	28	determinants	determinant	NNS
cord-324810-92fosk3c	120	29	of	of	IN
cord-324810-92fosk3c	120	30	acute	acute	JJ
cord-324810-92fosk3c	120	31	exacerbation	exacerbation	NN
cord-324810-92fosk3c	120	32	.	.	.
cord-324810-92fosk3c	121	1	Acqui	Acqui	NNP
cord-324810-92fosk3c	121	2	-	-	HYPH
cord-324810-92fosk3c	121	3	COPD	COPD	NNP
cord-324810-92fosk3c	121	4	patients	patient	NNS
cord-324810-92fosk3c	121	5	during	during	IN
cord-324810-92fosk3c	121	6	stable	stable	JJ
cord-324810-92fosk3c	121	7	state	state	NN
cord-324810-92fosk3c	121	8	as	as	RB
cord-324810-92fosk3c	121	9	well	well	RB
cord-324810-92fosk3c	121	10	as	as	IN
cord-324810-92fosk3c	121	11	during	during	IN
cord-324810-92fosk3c	121	12	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	121	13	sition	sition	NN
cord-324810-92fosk3c	121	14	of	of	IN
cord-324810-92fosk3c	121	15	a	a	DT
cord-324810-92fosk3c	121	16	new	new	JJ
cord-324810-92fosk3c	121	17	strain	strain	NN
cord-324810-92fosk3c	121	18	of	of	IN
cord-324810-92fosk3c	121	19	organism	organism	NN
cord-324810-92fosk3c	121	20	by	by	IN
cord-324810-92fosk3c	121	21	a	a	DT
cord-324810-92fosk3c	121	22	patient	patient	NN
cord-324810-92fosk3c	121	23	who	who	WP
cord-324810-92fosk3c	121	24	possesses	possess	VBZ
cord-324810-92fosk3c	121	25	preand	preand	NN
cord-324810-92fosk3c	121	26	typed	type	VBD
cord-324810-92fosk3c	121	27	the	the	DT
cord-324810-92fosk3c	121	28	strains	strain	NNS
cord-324810-92fosk3c	121	29	of	of	IN
cord-324810-92fosk3c	121	30	bacteria	bacteria	NNS
cord-324810-92fosk3c	121	31	using	use	VBG
cord-324810-92fosk3c	121	32	molecular	molecular	JJ
cord-324810-92fosk3c	121	33	methods	method	NNS
cord-324810-92fosk3c	121	34	.	.	.
cord-324810-92fosk3c	122	1	About	about	IN
cord-324810-92fosk3c	122	2	existing	exist	VBG
cord-324810-92fosk3c	122	3	protective	protective	JJ
cord-324810-92fosk3c	122	4	antibodies	antibody	NNS
cord-324810-92fosk3c	122	5	will	will	MD
cord-324810-92fosk3c	122	6	lead	lead	VB
cord-324810-92fosk3c	122	7	to	to	IN
cord-324810-92fosk3c	122	8	no	no	DT
cord-324810-92fosk3c	122	9	increase	increase	NN
cord-324810-92fosk3c	122	10	in	in	IN
cord-324810-92fosk3c	122	11	symptoms	symptom	NNS
cord-324810-92fosk3c	122	12	48	48	CD
cord-324810-92fosk3c	122	13	%	%	NN
cord-324810-92fosk3c	122	14	of	of	IN
cord-324810-92fosk3c	122	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	122	16	were	be	VBD
cord-324810-92fosk3c	122	17	associated	associate	VBN
cord-324810-92fosk3c	122	18	with	with	IN
cord-324810-92fosk3c	122	19	positive	positive	JJ
cord-324810-92fosk3c	122	20	sputum	sputum	NN
cord-324810-92fosk3c	122	21	culand	culand	NN
cord-324810-92fosk3c	122	22	hence	hence	RB
cord-324810-92fosk3c	122	23	colonization	colonization	NN
cord-324810-92fosk3c	122	24	.	.	.
cord-324810-92fosk3c	123	1	The	the	DT
cord-324810-92fosk3c	123	2	absence	absence	NN
cord-324810-92fosk3c	123	3	of	of	IN
cord-324810-92fosk3c	123	4	defending	defend	VBG
cord-324810-92fosk3c	123	5	antibodies	antibody	NNS
cord-324810-92fosk3c	123	6	to	to	IN
cord-324810-92fosk3c	123	7	tures	ture	NNS
cord-324810-92fosk3c	123	8	.	.	.
cord-324810-92fosk3c	124	1	About	about	IN
cord-324810-92fosk3c	124	2	48	48	CD
cord-324810-92fosk3c	124	3	%	%	NN
cord-324810-92fosk3c	124	4	of	of	IN
cord-324810-92fosk3c	124	5	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	124	6	were	be	VBD
cord-324810-92fosk3c	124	7	associated	associate	VBN
cord-324810-92fosk3c	124	8	with	with	IN
cord-324810-92fosk3c	124	9	positive	positive	JJ
cord-324810-92fosk3c	124	10	the	the	DT
cord-324810-92fosk3c	124	11	newly	newly	RB
cord-324810-92fosk3c	124	12	acquired	acquire	VBN
cord-324810-92fosk3c	124	13	bacterial	bacterial	JJ
cord-324810-92fosk3c	124	14	strain	strain	NN
cord-324810-92fosk3c	124	15	will	will	MD
cord-324810-92fosk3c	124	16	cause	cause	VB
cord-324810-92fosk3c	124	17	an	an	DT
cord-324810-92fosk3c	124	18	exacerbation	exacerbation	NN
cord-324810-92fosk3c	124	19	.	.	.
cord-324810-92fosk3c	125	1	sputum	sputum	NN
cord-324810-92fosk3c	125	2	cultures	culture	NNS
cord-324810-92fosk3c	125	3	.	.	.
cord-324810-92fosk3c	126	1	A	a	DT
cord-324810-92fosk3c	126	2	bacterial	bacterial	JJ
cord-324810-92fosk3c	126	3	pathogen	pathogen	NN
cord-324810-92fosk3c	126	4	was	be	VBD
cord-324810-92fosk3c	126	5	isolated	isolate	VBN
cord-324810-92fosk3c	126	6	in	in	IN
cord-324810-92fosk3c	126	7	23.6	23.6	CD
cord-324810-92fosk3c	126	8	%	%	NN
cord-324810-92fosk3c	126	9	of	of	IN
cord-324810-92fosk3c	126	10	Development	Development	NNP
cord-324810-92fosk3c	126	11	of	of	IN
cord-324810-92fosk3c	126	12	antibodies	antibody	NNS
cord-324810-92fosk3c	126	13	to	to	IN
cord-324810-92fosk3c	126	14	the	the	DT
cord-324810-92fosk3c	126	15	infecting	infect	VBG
cord-324810-92fosk3c	126	16	bacteria	bacteria	NNS
cord-324810-92fosk3c	126	17	will	will	MD
cord-324810-92fosk3c	126	18	help	help	VB
cord-324810-92fosk3c	126	19	clear	clear	VB
cord-324810-92fosk3c	126	20	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	126	21	compared	compare	VBN
cord-324810-92fosk3c	126	22	with	with	IN
cord-324810-92fosk3c	126	23	18	18	CD
cord-324810-92fosk3c	126	24	%	%	NN
cord-324810-92fosk3c	126	25	with	with	IN
cord-324810-92fosk3c	126	26	no	no	DT
cord-324810-92fosk3c	126	27	pathogen	pathogen	NN
cord-324810-92fosk3c	126	28	(	(	-LRB-
cord-324810-92fosk3c	126	29	p	p	NN
cord-324810-92fosk3c	126	30	<	<	XX
cord-324810-92fosk3c	126	31	0.001	0.001	CD
cord-324810-92fosk3c	126	32	)	)	-RRB-
cord-324810-92fosk3c	126	33	.	.	.
cord-324810-92fosk3c	127	1	the	the	DT
cord-324810-92fosk3c	127	2	organism	organism	NN
cord-324810-92fosk3c	127	3	.	.	.
cord-324810-92fosk3c	128	1	Recurrent	recurrent	JJ
cord-324810-92fosk3c	128	2	infections	infection	NNS
cord-324810-92fosk3c	128	3	from	from	IN
cord-324810-92fosk3c	128	4	antigenically	antigenically	RB
cord-324810-92fosk3c	128	5	different	different	JJ
cord-324810-92fosk3c	128	6	virulent	virulent	JJ
cord-324810-92fosk3c	128	7	strains	strain	NNS
cord-324810-92fosk3c	128	8	in	in	IN
cord-324810-92fosk3c	128	9	repetitive	repetitive	JJ
cord-324810-92fosk3c	128	10	fashion	fashion	NN
cord-324810-92fosk3c	128	11	are	be	VBP
cord-324810-92fosk3c	128	12	an	an	DT
cord-324810-92fosk3c	128	13	attractive	attractive	JJ
cord-324810-92fosk3c	128	14	model	model	NN
cord-324810-92fosk3c	128	15	of	of	IN
cord-324810-92fosk3c	128	16	Interestingly	interestingly	RB
cord-324810-92fosk3c	128	17	,	,	,
cord-324810-92fosk3c	128	18	a	a	DT
cord-324810-92fosk3c	128	19	new	new	JJ
cord-324810-92fosk3c	128	20	bacterial	bacterial	JJ
cord-324810-92fosk3c	128	21	strain	strain	NN
cord-324810-92fosk3c	128	22	was	be	VBD
cord-324810-92fosk3c	128	23	isolated	isolate	VBN
cord-324810-92fosk3c	128	24	in	in	IN
cord-324810-92fosk3c	128	25	33	33	CD
cord-324810-92fosk3c	128	26	%	%	NN
cord-324810-92fosk3c	128	27	of	of	IN
cord-324810-92fosk3c	128	28	exacerpathogenesis	exacerpathogenesis	NN
cord-324810-92fosk3c	128	29	of	of	IN
cord-324810-92fosk3c	128	30	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	128	31	(	(	-LRB-
cord-324810-92fosk3c	128	32	figure	figure	NN
cord-324810-92fosk3c	128	33	1	1	CD
cord-324810-92fosk3c	128	34	)	)	-RRB-
cord-324810-92fosk3c	128	35	.	.	.
cord-324810-92fosk3c	129	1	[	[	-LRB-
cord-324810-92fosk3c	129	2	32	32	CD
cord-324810-92fosk3c	129	3	]	]	-RRB-
cord-324810-92fosk3c	129	4	bations	bation	NNS
cord-324810-92fosk3c	129	5	compared	compare	VBN
cord-324810-92fosk3c	129	6	with	with	IN
cord-324810-92fosk3c	129	7	15.4	15.4	CD
cord-324810-92fosk3c	129	8	%	%	NN
cord-324810-92fosk3c	129	9	of	of	IN
cord-324810-92fosk3c	129	10	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	129	11	in	in	IN
cord-324810-92fosk3c	129	12	which	which	WDT
cord-324810-92fosk3c	129	13	no	no	DT
cord-324810-92fosk3c	129	14	new	new	JJ
cord-324810-92fosk3c	129	15	strains	strain	NNS
cord-324810-92fosk3c	129	16	were	be	VBD
cord-324810-92fosk3c	129	17	identified	identify	VBN
cord-324810-92fosk3c	129	18	(	(	-LRB-
cord-324810-92fosk3c	129	19	p	p	NN
cord-324810-92fosk3c	129	20	<	<	XX
cord-324810-92fosk3c	129	21	0.001	0.001	CD
cord-324810-92fosk3c	129	22	)	)	-RRB-
cord-324810-92fosk3c	129	23	.	.	.
cord-324810-92fosk3c	130	1	In	in	IN
cord-324810-92fosk3c	130	2	particular	particular	JJ
cord-324810-92fosk3c	130	3	,	,	,
cord-324810-92fosk3c	130	4	acquiring	acquire	VBG
cord-324810-92fosk3c	130	5	a	a	DT
cord-324810-92fosk3c	130	6	new	new	JJ
cord-324810-92fosk3c	130	7	3	3	CD
cord-324810-92fosk3c	130	8	.	.	.
cord-324810-92fosk3c	131	1	Trials	trial	NNS
cord-324810-92fosk3c	131	2	of	of	IN
cord-324810-92fosk3c	131	3	Antimicrobial	Antimicrobial	NNP
cord-324810-92fosk3c	131	4	Therapy	Therapy	NNP
cord-324810-92fosk3c	131	5	in	in	IN
cord-324810-92fosk3c	131	6	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	131	7	strain	strain	NN
cord-324810-92fosk3c	131	8	of	of	IN
cord-324810-92fosk3c	131	9	H.	h.	NN
cord-324810-92fosk3c	131	10	influenzae	influenzae	NN
cord-324810-92fosk3c	131	11	,	,	,
cord-324810-92fosk3c	131	12	S.	S.	NNP
cord-324810-92fosk3c	131	13	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	131	14	,	,	,
cord-324810-92fosk3c	131	15	and	and	CC
cord-324810-92fosk3c	131	16	M.	M.	NNP
cord-324810-92fosk3c	131	17	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	131	18	correlated	correlate	VBD
cord-324810-92fosk3c	131	19	with	with	IN
cord-324810-92fosk3c	131	20	a	a	DT
cord-324810-92fosk3c	131	21	significantly	significantly	RB
cord-324810-92fosk3c	131	22	higher	high	JJR
cord-324810-92fosk3c	131	23	rate	rate	NN
cord-324810-92fosk3c	131	24	of	of	IN
cord-324810-92fosk3c	131	25	acute	acute	JJ
cord-324810-92fosk3c	131	26	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	131	27	,	,	,
cord-324810-92fosk3c	131	28	there-	there-	JJ
cord-324810-92fosk3c	132	1	The	the	DT
cord-324810-92fosk3c	132	2	role	role	NN
cord-324810-92fosk3c	132	3	of	of	IN
cord-324810-92fosk3c	132	4	bacterial	bacterial	JJ
cord-324810-92fosk3c	132	5	infection	infection	NN
cord-324810-92fosk3c	132	6	in	in	IN
cord-324810-92fosk3c	132	7	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	132	8	can	can	MD
cord-324810-92fosk3c	132	9	also	also	RB
cord-324810-92fosk3c	132	10	be	be	VB
cord-324810-92fosk3c	132	11	assessed	assess	VBN
cord-324810-92fosk3c	132	12	fore	fore	RB
cord-324810-92fosk3c	132	13	providing	provide	VBG
cord-324810-92fosk3c	132	14	credibility	credibility	NN
cord-324810-92fosk3c	132	15	to	to	IN
cord-324810-92fosk3c	132	16	the	the	DT
cord-324810-92fosk3c	132	17	concept	concept	NN
cord-324810-92fosk3c	132	18	that	that	WDT
cord-324810-92fosk3c	132	19	bacteria	bacteria	NNS
cord-324810-92fosk3c	132	20	play	play	VBP
cord-324810-92fosk3c	132	21	a	a	DT
cord-324810-92fosk3c	132	22	by	by	IN
cord-324810-92fosk3c	132	23	systematically	systematically	RB
cord-324810-92fosk3c	132	24	evaluating	evaluate	VBG
cord-324810-92fosk3c	132	25	the	the	DT
cord-324810-92fosk3c	132	26	efficacy	efficacy	NN
cord-324810-92fosk3c	132	27	of	of	IN
cord-324810-92fosk3c	132	28	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	132	29	therapy	therapy	NN
cord-324810-92fosk3c	132	30	.	.	.
cord-324810-92fosk3c	133	1	causative	causative	JJ
cord-324810-92fosk3c	133	2	role	role	NN
cord-324810-92fosk3c	133	3	in	in	IN
cord-324810-92fosk3c	133	4	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	133	5	.	.	.
cord-324810-92fosk3c	134	1	Anthonisen	Anthonisen	NNP
cord-324810-92fosk3c	134	2	et	et	NNP
cord-324810-92fosk3c	134	3	al	al	NNP
cord-324810-92fosk3c	134	4	.	.	.
cord-324810-92fosk3c	135	1	[	[	-LRB-
cord-324810-92fosk3c	135	2	8	8	CD
cord-324810-92fosk3c	135	3	]	]	-RRB-
cord-324810-92fosk3c	135	4	helped	help	VBD
cord-324810-92fosk3c	135	5	settle	settle	VB
cord-324810-92fosk3c	135	6	the	the	DT
cord-324810-92fosk3c	135	7	controversy	controversy	NN
cord-324810-92fosk3c	135	8	over	over	IN
cord-324810-92fosk3c	135	9	the	the	DT
cord-324810-92fosk3c	135	10	roles	role	NNS
cord-324810-92fosk3c	135	11	of	of	IN
cord-324810-92fosk3c	135	12	bacterial	bacterial	JJ
cord-324810-92fosk3c	135	13	infection	infection	NN
cord-324810-92fosk3c	135	14	and	and	CC
cord-324810-92fosk3c	135	15	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	135	16	in	in	IN
cord-324810-92fosk3c	135	17	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	135	18	.	.	.
cord-324810-92fosk3c	136	1	Over	over	IN
cord-324810-92fosk3c	136	2	a	a	DT
cord-324810-92fosk3c	136	3	3-year	3-year	CD
cord-324810-92fosk3c	136	4	period	period	NN
cord-324810-92fosk3c	136	5	,	,	,
cord-324810-92fosk3c	136	6	173	173	CD
cord-324810-92fosk3c	136	7	patients	patient	NNS
cord-324810-92fosk3c	136	8	with	with	IN
cord-324810-92fosk3c	136	9	COPD	COPD	NNP
cord-324810-92fosk3c	136	10	developed	develop	VBD
cord-324810-92fosk3c	136	11	362	362	CD
cord-324810-92fosk3c	136	12	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	136	13	;	;	:
cord-324810-92fosk3c	136	14	180	180	CD
cord-324810-92fosk3c	136	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	136	16	were	be	VBD
cord-324810-92fosk3c	136	17	treated	treat	VBN
cord-324810-92fosk3c	136	18	with	with	IN
cord-324810-92fosk3c	136	19	placebo	placebo	NN
cord-324810-92fosk3c	136	20	and	and	CC
cord-324810-92fosk3c	136	21	182	182	CD
cord-324810-92fosk3c	136	22	with	with	IN
cord-324810-92fosk3c	136	23	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	136	24	therapy	therapy	NN
cord-324810-92fosk3c	136	25	.	.	.
cord-324810-92fosk3c	137	1	The	the	DT
cord-324810-92fosk3c	137	2	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	137	3	were	be	VBD
cord-324810-92fosk3c	137	4	classified	classify	VBN
cord-324810-92fosk3c	137	5	according	accord	VBG
cord-324810-92fosk3c	137	6	to	to	IN
cord-324810-92fosk3c	137	7	the	the	DT
cord-324810-92fosk3c	137	8	Winnipeg	Winnipeg	NNP
cord-324810-92fosk3c	137	9	criteria	criterion	NNS
cord-324810-92fosk3c	137	10	based	base	VBN
cord-324810-92fosk3c	137	11	on	on	IN
cord-324810-92fosk3c	137	12	symptoms	symptom	NNS
cord-324810-92fosk3c	137	13	of	of	IN
cord-324810-92fosk3c	137	14	increased	increase	VBN
cord-324810-92fosk3c	137	15	dyspnea	dyspnea	NN
cord-324810-92fosk3c	137	16	,	,	,
cord-324810-92fosk3c	137	17	increased	increase	VBN
cord-324810-92fosk3c	137	18	sputum	sputum	NN
cord-324810-92fosk3c	137	19	volume	volume	NN
cord-324810-92fosk3c	137	20	,	,	,
cord-324810-92fosk3c	137	21	and	and	CC
cord-324810-92fosk3c	137	22	increased	increase	VBN
cord-324810-92fosk3c	137	23	sputum	sputum	NN
cord-324810-92fosk3c	137	24	purulence	purulence	NN
cord-324810-92fosk3c	137	25	.	.	.
cord-324810-92fosk3c	138	1	A	a	DT
cord-324810-92fosk3c	138	2	type	type	NN
cord-324810-92fosk3c	138	3	I	-PRON-	PRP
cord-324810-92fosk3c	138	4	exacerbation	exacerbation	NN
cord-324810-92fosk3c	138	5	was	be	VBD
cord-324810-92fosk3c	138	6	defined	define	VBN
cord-324810-92fosk3c	138	7	when	when	WRB
cord-324810-92fosk3c	138	8	all	all	DT
cord-324810-92fosk3c	138	9	three	three	CD
cord-324810-92fosk3c	138	10	symptoms	symptom	NNS
cord-324810-92fosk3c	138	11	were	be	VBD
cord-324810-92fosk3c	138	12	present	present	JJ
cord-324810-92fosk3c	138	13	,	,	,
cord-324810-92fosk3c	138	14	type	type	NN
cord-324810-92fosk3c	138	15	II	ii	NN
cord-324810-92fosk3c	138	16	when	when	WRB
cord-324810-92fosk3c	138	17	two	two	CD
cord-324810-92fosk3c	138	18	symptoms	symptom	NNS
cord-324810-92fosk3c	138	19	were	be	VBD
cord-324810-92fosk3c	138	20	present	present	JJ
cord-324810-92fosk3c	138	21	and	and	CC
cord-324810-92fosk3c	138	22	type	type	NN
cord-324810-92fosk3c	138	23	III	iii	NN
cord-324810-92fosk3c	138	24	when	when	WRB
cord-324810-92fosk3c	138	25	there	there	EX
cord-324810-92fosk3c	138	26	was	be	VBD
cord-324810-92fosk3c	138	27	only	only	RB
cord-324810-92fosk3c	138	28	one	one	CD
cord-324810-92fosk3c	138	29	symptom	symptom	NN
cord-324810-92fosk3c	138	30	(	(	-LRB-
cord-324810-92fosk3c	138	31	table	table	NN
cord-324810-92fosk3c	138	32	I	-PRON-	PRP
cord-324810-92fosk3c	138	33	)	)	-RRB-
cord-324810-92fosk3c	138	34	.	.	.
cord-324810-92fosk3c	139	1	Therapeutic	therapeutic	JJ
cord-324810-92fosk3c	139	2	success	success	NN
cord-324810-92fosk3c	139	3	was	be	VBD
cord-324810-92fosk3c	139	4	defined	define	VBN
cord-324810-92fosk3c	139	5	as	as	IN
cord-324810-92fosk3c	139	6	'	'	``
cord-324810-92fosk3c	139	7	resolution	resolution	NN
cord-324810-92fosk3c	139	8	'	'	''
cord-324810-92fosk3c	139	9	if	if	IN
cord-324810-92fosk3c	139	10	all	all	DT
cord-324810-92fosk3c	139	11	symptoms	symptom	NNS
cord-324810-92fosk3c	139	12	returned	return	VBD
cord-324810-92fosk3c	139	13	to	to	IN
cord-324810-92fosk3c	139	14	baseline	baseline	NN
cord-324810-92fosk3c	139	15	within	within	IN
cord-324810-92fosk3c	139	16	21	21	CD
cord-324810-92fosk3c	139	17	days	day	NNS
cord-324810-92fosk3c	139	18	,	,	,
cord-324810-92fosk3c	139	19	'	'	''
cord-324810-92fosk3c	139	20	no	no	DT
cord-324810-92fosk3c	139	21	resolution	resolution	NN
cord-324810-92fosk3c	139	22	'	'	''
cord-324810-92fosk3c	139	23	if	if	IN
cord-324810-92fosk3c	139	24	all	all	DT
cord-324810-92fosk3c	139	25	symptoms	symptom	NNS
cord-324810-92fosk3c	139	26	did	do	VBD
cord-324810-92fosk3c	139	27	not	not	RB
cord-324810-92fosk3c	139	28	resolve	resolve	VB
cord-324810-92fosk3c	139	29	and	and	CC
cord-324810-92fosk3c	139	30	'	'	''
cord-324810-92fosk3c	139	31	failure	failure	NN
cord-324810-92fosk3c	139	32	with	with	IN
cord-324810-92fosk3c	139	33	deterioration	deterioration	NN
cord-324810-92fosk3c	139	34	'	'	''
cord-324810-92fosk3c	139	35	when	when	WRB
cord-324810-92fosk3c	139	36	symptoms	symptom	NNS
cord-324810-92fosk3c	139	37	worsened	worsen	VBD
cord-324810-92fosk3c	139	38	.	.	.
cord-324810-92fosk3c	140	1	Considering	consider	VBG
cord-324810-92fosk3c	140	2	all	all	DT
cord-324810-92fosk3c	140	3	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	140	4	,	,	,
cord-324810-92fosk3c	140	5	treatment	treatment	NN
cord-324810-92fosk3c	140	6	with	with	IN
cord-324810-92fosk3c	140	7	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	140	8	led	lead	VBD
cord-324810-92fosk3c	140	9	to	to	IN
cord-324810-92fosk3c	140	10	higher	high	JJR
cord-324810-92fosk3c	140	11	resolution	resolution	NN
cord-324810-92fosk3c	140	12	(	(	-LRB-
cord-324810-92fosk3c	140	13	68.1	68.1	CD
cord-324810-92fosk3c	140	14	%	%	NN
cord-324810-92fosk3c	140	15	)	)	-RRB-
cord-324810-92fosk3c	140	16	compared	compare	VBN
cord-324810-92fosk3c	140	17	with	with	IN
cord-324810-92fosk3c	140	18	placebo	placebo	NN
cord-324810-92fosk3c	140	19	(	(	-LRB-
cord-324810-92fosk3c	140	20	55	55	CD
cord-324810-92fosk3c	140	21	%	%	NN
cord-324810-92fosk3c	140	22	,	,	,
cord-324810-92fosk3c	140	23	p	p	NN
cord-324810-92fosk3c	140	24	<	<	XX
cord-324810-92fosk3c	140	25	0.05	0.05	CD
cord-324810-92fosk3c	140	26	)	)	-RRB-
cord-324810-92fosk3c	140	27	[	[	-LRB-
cord-324810-92fosk3c	140	28	figure	figure	NN
cord-324810-92fosk3c	140	29	2	2	CD
cord-324810-92fosk3c	140	30	]	]	-RRB-
cord-324810-92fosk3c	140	31	.	.	.
cord-324810-92fosk3c	141	1	Deterioration	deterioration	NN
cord-324810-92fosk3c	141	2	occurred	occur	VBD
cord-324810-92fosk3c	141	3	in	in	IN
cord-324810-92fosk3c	141	4	9.9	9.9	CD
cord-324810-92fosk3c	141	5	%	%	NN
cord-324810-92fosk3c	141	6	of	of	IN
cord-324810-92fosk3c	141	7	those	those	DT
cord-324810-92fosk3c	141	8	treated	treat	VBN
cord-324810-92fosk3c	141	9	with	with	IN
cord-324810-92fosk3c	141	10	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	141	11	,	,	,
cord-324810-92fosk3c	141	12	compared	compare	VBN
cord-324810-92fosk3c	141	13	with	with	IN
cord-324810-92fosk3c	141	14	18.9	18.9	CD
cord-324810-92fosk3c	141	15	%	%	NN
cord-324810-92fosk3c	141	16	with	with	IN
cord-324810-92fosk3c	141	17	placebo	placebo	NN
cord-324810-92fosk3c	141	18	(	(	-LRB-
cord-324810-92fosk3c	141	19	figure	figure	NN
cord-324810-92fosk3c	141	20	3	3	CD
cord-324810-92fosk3c	141	21	)	)	-RRB-
cord-324810-92fosk3c	141	22	.	.	.
cord-324810-92fosk3c	142	1	The	the	DT
cord-324810-92fosk3c	142	2	rate	rate	NN
cord-324810-92fosk3c	142	3	of	of	IN
cord-324810-92fosk3c	142	4	peak	peak	JJ
cord-324810-92fosk3c	142	5	flow	flow	NN
cord-324810-92fosk3c	142	6	recovery	recovery	NN
cord-324810-92fosk3c	142	7	was	be	VBD
cord-324810-92fosk3c	142	8	faster	fast	JJR
cord-324810-92fosk3c	142	9	with	with	IN
cord-324810-92fosk3c	142	10	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	142	11	treatment	treatment	NN
cord-324810-92fosk3c	142	12	compared	compare	VBN
cord-324810-92fosk3c	142	13	with	with	IN
cord-324810-92fosk3c	142	14	placebo	placebo	NN
cord-324810-92fosk3c	142	15	.	.	.
cord-324810-92fosk3c	143	1	Analysis	analysis	NN
cord-324810-92fosk3c	143	2	according	accord	VBG
cord-324810-92fosk3c	143	3	to	to	IN
cord-324810-92fosk3c	143	4	the	the	DT
cord-324810-92fosk3c	143	5	a	a	FW
cord-324810-92fosk3c	143	6	priori	priori	FW
cord-324810-92fosk3c	143	7	subgroups	subgroup	NNS
cord-324810-92fosk3c	143	8	showed	show	VBD
cord-324810-92fosk3c	143	9	that	that	IN
cord-324810-92fosk3c	143	10	the	the	DT
cord-324810-92fosk3c	143	11	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	143	12	classified	classify	VBN
cord-324810-92fosk3c	143	13	as	as	IN
cord-324810-92fosk3c	143	14	type	type	NN
cord-324810-92fosk3c	143	15	I	-PRON-	PRP
cord-324810-92fosk3c	143	16	achieved	achieve	VBD
cord-324810-92fosk3c	143	17	the	the	DT
cord-324810-92fosk3c	143	18	greatest	great	JJS
cord-324810-92fosk3c	143	19	success	success	NN
cord-324810-92fosk3c	143	20	with	with	IN
cord-324810-92fosk3c	143	21	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	143	22	therapy	therapy	NN
cord-324810-92fosk3c	143	23	(	(	-LRB-
cord-324810-92fosk3c	143	24	62.9	62.9	CD
cord-324810-92fosk3c	143	25	%	%	NN
cord-324810-92fosk3c	143	26	vs	vs	IN
cord-324810-92fosk3c	143	27	43	43	CD
cord-324810-92fosk3c	143	28	%	%	NN
cord-324810-92fosk3c	143	29	with	with	IN
cord-324810-92fosk3c	143	30	placebo	placebo	NN
cord-324810-92fosk3c	143	31	,	,	,
cord-324810-92fosk3c	143	32	p	p	NN
cord-324810-92fosk3c	143	33	<	<	XX
cord-324810-92fosk3c	143	34	0.05	0.05	CD
cord-324810-92fosk3c	143	35	)	)	-RRB-
cord-324810-92fosk3c	143	36	.	.	.
cord-324810-92fosk3c	144	1	In	in	IN
cord-324810-92fosk3c	144	2	type	type	NN
cord-324810-92fosk3c	144	3	II	II	NNP
cord-324810-92fosk3c	144	4	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	144	5	,	,	,
cord-324810-92fosk3c	144	6	the	the	DT
cord-324810-92fosk3c	144	7	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	144	8	were	be	VBD
cord-324810-92fosk3c	144	9	still	still	RB
cord-324810-92fosk3c	144	10	associated	associate	VBN
cord-324810-92fosk3c	144	11	with	with	IN
cord-324810-92fosk3c	144	12	better	well	JJR
cord-324810-92fosk3c	144	13	outcome	outcome	NN
cord-324810-92fosk3c	144	14	than	than	IN
cord-324810-92fosk3c	144	15	placebo	placebo	NN
cord-324810-92fosk3c	144	16	,	,	,
cord-324810-92fosk3c	144	17	whereas	whereas	IN
cord-324810-92fosk3c	144	18	the	the	DT
cord-324810-92fosk3c	144	19	success	success	NN
cord-324810-92fosk3c	144	20	with	with	IN
cord-324810-92fosk3c	144	21	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	144	22	therapy	therapy	NN
cord-324810-92fosk3c	144	23	was	be	VBD
cord-324810-92fosk3c	144	24	not	not	RB
cord-324810-92fosk3c	144	25	significantly	significantly	RB
cord-324810-92fosk3c	144	26	better	well	JJR
cord-324810-92fosk3c	144	27	than	than	IN
cord-324810-92fosk3c	144	28	placebo	placebo	NN
cord-324810-92fosk3c	144	29	in	in	IN
cord-324810-92fosk3c	144	30	type	type	NN
cord-324810-92fosk3c	144	31	III	iii	CD
cord-324810-92fosk3c	144	32	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	144	33	.	.	.
cord-324810-92fosk3c	145	1	Correspondingly	correspondingly	RB
cord-324810-92fosk3c	145	2	,	,	,
cord-324810-92fosk3c	145	3	deterioration	deterioration	NN
cord-324810-92fosk3c	145	4	occurred	occur	VBD
cord-324810-92fosk3c	145	5	less	less	RBR
cord-324810-92fosk3c	145	6	frequently	frequently	RB
cord-324810-92fosk3c	145	7	on	on	IN
cord-324810-92fosk3c	145	8	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	145	9	therapy	therapy	NN
cord-324810-92fosk3c	145	10	in	in	IN
cord-324810-92fosk3c	145	11	patients	patient	NNS
cord-324810-92fosk3c	145	12	categorized	categorize	VBN
cord-324810-92fosk3c	145	13	as	as	IN
cord-324810-92fosk3c	145	14	type	type	NN
cord-324810-92fosk3c	145	15	I	-PRON-	PRP
cord-324810-92fosk3c	145	16	or	or	CC
cord-324810-92fosk3c	145	17	type	type	NN
cord-324810-92fosk3c	145	18	II	ii	CD
cord-324810-92fosk3c	145	19	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	145	20	.	.	.
cord-324810-92fosk3c	146	1	Overall	overall	RB
cord-324810-92fosk3c	146	2	,	,	,
cord-324810-92fosk3c	146	3	the	the	DT
cord-324810-92fosk3c	146	4	length	length	NN
cord-324810-92fosk3c	146	5	of	of	IN
cord-324810-92fosk3c	146	6	illness	illness	NN
cord-324810-92fosk3c	146	7	was	be	VBD
cord-324810-92fosk3c	146	8	2	2	CD
cord-324810-92fosk3c	146	9	days	day	NNS
cord-324810-92fosk3c	146	10	shorter	short	JJR
cord-324810-92fosk3c	146	11	for	for	IN
cord-324810-92fosk3c	146	12	the	the	DT
cord-324810-92fosk3c	146	13	antimicrobial	antimicrobial	RB
cord-324810-92fosk3c	146	14	-	-	HYPH
cord-324810-92fosk3c	146	15	treated	treat	VBN
cord-324810-92fosk3c	146	16	group	group	NN
cord-324810-92fosk3c	146	17	compared	compare	VBN
cord-324810-92fosk3c	146	18	with	with	IN
cord-324810-92fosk3c	146	19	the	the	DT
cord-324810-92fosk3c	146	20	placebo	placebo	NN
cord-324810-92fosk3c	146	21	-	-	HYPH
cord-324810-92fosk3c	146	22	treated	treat	VBN
cord-324810-92fosk3c	146	23	group	group	NN
cord-324810-92fosk3c	146	24	.	.	.
cord-324810-92fosk3c	147	1	A	a	DT
cord-324810-92fosk3c	147	2	meta	meta	JJ
cord-324810-92fosk3c	147	3	-	-	HYPH
cord-324810-92fosk3c	147	4	analysis	analysis	NN
cord-324810-92fosk3c	147	5	by	by	IN
cord-324810-92fosk3c	147	6	Saint	Saint	NNP
cord-324810-92fosk3c	147	7	et	et	NNP
cord-324810-92fosk3c	147	8	al	al	NNP
cord-324810-92fosk3c	147	9	.	.	.
cord-324810-92fosk3c	148	1	[	[	-LRB-
cord-324810-92fosk3c	148	2	34	34	CD
cord-324810-92fosk3c	148	3	]	]	-RRB-
cord-324810-92fosk3c	148	4	reviewed	review	VBD
cord-324810-92fosk3c	148	5	nine	nine	CD
cord-324810-92fosk3c	148	6	randomized	randomize	VBN
cord-324810-92fosk3c	148	7	controlled	control	VBN
cord-324810-92fosk3c	148	8	trials	trial	NNS
cord-324810-92fosk3c	148	9	published	publish	VBN
cord-324810-92fosk3c	148	10	from	from	IN
cord-324810-92fosk3c	148	11	1955	1955	CD
cord-324810-92fosk3c	148	12	through	through	IN
cord-324810-92fosk3c	148	13	to	to	IN
cord-324810-92fosk3c	148	14	1994	1994	CD
cord-324810-92fosk3c	148	15	.	.	.
cord-324810-92fosk3c	149	1	The	the	DT
cord-324810-92fosk3c	149	2	outcome	outcome	NN
cord-324810-92fosk3c	149	3	data	datum	NNS
cord-324810-92fosk3c	149	4	were	be	VBD
cord-324810-92fosk3c	149	5	retrieved	retrieve	VBN
cord-324810-92fosk3c	149	6	from	from	IN
cord-324810-92fosk3c	149	7	each	each	DT
cord-324810-92fosk3c	149	8	of	of	IN
cord-324810-92fosk3c	149	9	the	the	DT
cord-324810-92fosk3c	149	10	studies	study	NNS
cord-324810-92fosk3c	149	11	and	and	CC
cord-324810-92fosk3c	149	12	transformed	transform	VBN
cord-324810-92fosk3c	149	13	complex	complex	JJ
cord-324810-92fosk3c	149	14	organisms	organism	NNS
cord-324810-92fosk3c	149	15	such	such	JJ
cord-324810-92fosk3c	149	16	as	as	IN
cord-324810-92fosk3c	149	17	Enterobacteriaceae	Enterobacteriaceae	NNP
cord-324810-92fosk3c	149	18	and	and	CC
cord-324810-92fosk3c	149	19	Pseudomonas	Pseudomonas	NNP
cord-324810-92fosk3c	149	20	into	into	IN
cord-324810-92fosk3c	149	21	units	unit	NNS
cord-324810-92fosk3c	149	22	of	of	IN
cord-324810-92fosk3c	149	23	standard	standard	JJ
cord-324810-92fosk3c	149	24	deviation	deviation	NN
cord-324810-92fosk3c	149	25	,	,	,
cord-324810-92fosk3c	149	26	and	and	CC
cord-324810-92fosk3c	149	27	the	the	DT
cord-324810-92fosk3c	149	28	effect	effect	NN
cord-324810-92fosk3c	149	29	size	size	NN
cord-324810-92fosk3c	149	30	was	be	VBD
cord-324810-92fosk3c	149	31	calculated	calculate	VBN
cord-324810-92fosk3c	149	32	.	.	.
cord-324810-92fosk3c	150	1	spp	spp	NNP
cord-324810-92fosk3c	150	2	.	.	.
cord-324810-92fosk3c	151	1	Similarly	similarly	RB
cord-324810-92fosk3c	151	2	Miravitlles	Miravitlles	NNP
cord-324810-92fosk3c	151	3	et	et	FW
cord-324810-92fosk3c	151	4	al	al	NNP
cord-324810-92fosk3c	151	5	.	.	.
cord-324810-92fosk3c	152	1	[	[	-LRB-
cord-324810-92fosk3c	152	2	37	37	CD
cord-324810-92fosk3c	152	3	]	]	-RRB-
cord-324810-92fosk3c	152	4	found	find	VBD
cord-324810-92fosk3c	152	5	that	that	IN
cord-324810-92fosk3c	152	6	H.	h.	NN
cord-324810-92fosk3c	152	7	influenzae	influenzae	NN
cord-324810-92fosk3c	152	8	and	and	CC
cord-324810-92fosk3c	153	1	P.	p.	LS
cord-324810-92fosk3c	153	2	The	the	DT
cord-324810-92fosk3c	153	3	overall	overall	JJ
cord-324810-92fosk3c	153	4	effect	effect	NN
cord-324810-92fosk3c	153	5	size	size	NN
cord-324810-92fosk3c	153	6	was	be	VBD
cord-324810-92fosk3c	153	7	0.22	0.22	CD
cord-324810-92fosk3c	153	8	(	(	-LRB-
cord-324810-92fosk3c	153	9	95	95	CD
cord-324810-92fosk3c	153	10	%	%	NN
cord-324810-92fosk3c	153	11	CI	CI	NNP
cord-324810-92fosk3c	153	12	0.10	0.10	CD
cord-324810-92fosk3c	153	13	,	,	,
cord-324810-92fosk3c	153	14	0.34	0.34	CD
cord-324810-92fosk3c	153	15	)	)	-RRB-
cord-324810-92fosk3c	153	16	,	,	,
cord-324810-92fosk3c	153	17	thus	thus	RB
cord-324810-92fosk3c	153	18	,	,	,
cord-324810-92fosk3c	153	19	estabaeruginosa	estabaeruginosa	NNP
cord-324810-92fosk3c	153	20	were	be	VBD
cord-324810-92fosk3c	153	21	more	more	RBR
cord-324810-92fosk3c	153	22	common	common	JJ
cord-324810-92fosk3c	153	23	in	in	IN
cord-324810-92fosk3c	153	24	patients	patient	NNS
cord-324810-92fosk3c	153	25	with	with	IN
cord-324810-92fosk3c	153	26	FEV1	FEV1	NNP
cord-324810-92fosk3c	153	27	values	value	NNS
cord-324810-92fosk3c	153	28	of	of	IN
cord-324810-92fosk3c	153	29	lishing	lishe	VBG
cord-324810-92fosk3c	153	30	a	a	DT
cord-324810-92fosk3c	153	31	benefit	benefit	NN
cord-324810-92fosk3c	153	32	with	with	IN
cord-324810-92fosk3c	153	33	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	153	34	therapy	therapy	NN
cord-324810-92fosk3c	153	35	compared	compare	VBN
cord-324810-92fosk3c	153	36	with	with	IN
cord-324810-92fosk3c	153	37	place-<50	place-<50	NNP
cord-324810-92fosk3c	153	38	%	%	NN
cord-324810-92fosk3c	153	39	of	of	IN
cord-324810-92fosk3c	153	40	predicted	predict	VBN
cord-324810-92fosk3c	153	41	.	.	.
cord-324810-92fosk3c	154	1	These	these	DT
cord-324810-92fosk3c	154	2	studies	study	NNS
cord-324810-92fosk3c	154	3	further	further	RB
cord-324810-92fosk3c	154	4	corroborate	corroborate	VBP
cord-324810-92fosk3c	154	5	that	that	IN
cord-324810-92fosk3c	154	6	patients	patient	NNS
cord-324810-92fosk3c	154	7	bo	bo	RB
cord-324810-92fosk3c	154	8	.	.	.
cord-324810-92fosk3c	155	1	The	the	DT
cord-324810-92fosk3c	155	2	mean	mean	JJ
cord-324810-92fosk3c	155	3	change	change	NN
cord-324810-92fosk3c	155	4	in	in	IN
cord-324810-92fosk3c	155	5	PEFR	PEFR	NNS
cord-324810-92fosk3c	155	6	favored	favor	VBD
cord-324810-92fosk3c	155	7	the	the	DT
cord-324810-92fosk3c	155	8	antimicrobial	antimicrobial	RB
cord-324810-92fosk3c	155	9	-	-	HYPH
cord-324810-92fosk3c	155	10	treated	treat	VBN
cord-324810-92fosk3c	155	11	with	with	IN
cord-324810-92fosk3c	155	12	poor	poor	JJ
cord-324810-92fosk3c	155	13	lung	lung	NN
cord-324810-92fosk3c	155	14	function	function	NN
cord-324810-92fosk3c	155	15	tended	tend	VBD
cord-324810-92fosk3c	155	16	to	to	TO
cord-324810-92fosk3c	155	17	have	have	VB
cord-324810-92fosk3c	155	18	more	more	RBR
cord-324810-92fosk3c	155	19	frequent	frequent	JJ
cord-324810-92fosk3c	155	20	exacerbagroup	exacerbagroup	NN
cord-324810-92fosk3c	155	21	by	by	IN
cord-324810-92fosk3c	155	22	a	a	DT
cord-324810-92fosk3c	155	23	difference	difference	NN
cord-324810-92fosk3c	155	24	of	of	IN
cord-324810-92fosk3c	155	25	10.75	10.75	CD
cord-324810-92fosk3c	155	26	L	l	NN
cord-324810-92fosk3c	155	27	/	/	SYM
cord-324810-92fosk3c	155	28	min	min	NN
cord-324810-92fosk3c	155	29	(	(	-LRB-
cord-324810-92fosk3c	155	30	95	95	CD
cord-324810-92fosk3c	155	31	%	%	NN
cord-324810-92fosk3c	155	32	CI	CI	NNP
cord-324810-92fosk3c	155	33	4.96	4.96	CD
cord-324810-92fosk3c	155	34	,	,	,
cord-324810-92fosk3c	155	35	16.54	16.54	CD
cord-324810-92fosk3c	155	36	,	,	,
cord-324810-92fosk3c	155	37	tions	tion	NNS
cord-324810-92fosk3c	155	38	,	,	,
cord-324810-92fosk3c	155	39	and	and	CC
cord-324810-92fosk3c	155	40	received	receive	VBD
cord-324810-92fosk3c	155	41	repeated	repeat	VBN
cord-324810-92fosk3c	155	42	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	155	43	therapy	therapy	NN
cord-324810-92fosk3c	155	44	that	that	WDT
cord-324810-92fosk3c	155	45	likely	likely	RB
cord-324810-92fosk3c	155	46	led	lead	VBD
cord-324810-92fosk3c	155	47	to	to	IN
cord-324810-92fosk3c	155	48	p	p	NN
cord-324810-92fosk3c	155	49	<	<	XX
cord-324810-92fosk3c	155	50	0.05	0.05	CD
cord-324810-92fosk3c	155	51	)	)	-RRB-
cord-324810-92fosk3c	155	52	.	.	.
cord-324810-92fosk3c	156	1	The	the	DT
cord-324810-92fosk3c	156	2	meta	meta	JJ
cord-324810-92fosk3c	156	3	-	-	HYPH
cord-324810-92fosk3c	156	4	analysis	analysis	NN
cord-324810-92fosk3c	156	5	also	also	RB
cord-324810-92fosk3c	156	6	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	156	7	that	that	IN
cord-324810-92fosk3c	156	8	the	the	DT
cord-324810-92fosk3c	156	9	studies	study	NNS
cord-324810-92fosk3c	156	10	alteration	alteration	NN
cord-324810-92fosk3c	156	11	of	of	IN
cord-324810-92fosk3c	156	12	the	the	DT
cord-324810-92fosk3c	156	13	airway	airway	NN
cord-324810-92fosk3c	156	14	microbial	microbial	JJ
cord-324810-92fosk3c	156	15	flora	flora	NNS
cord-324810-92fosk3c	156	16	.	.	.
cord-324810-92fosk3c	157	1	that	that	DT
cord-324810-92fosk3c	157	2	included	include	VBD
cord-324810-92fosk3c	157	3	a	a	DT
cord-324810-92fosk3c	157	4	large	large	JJ
cord-324810-92fosk3c	157	5	number	number	NN
cord-324810-92fosk3c	157	6	of	of	IN
cord-324810-92fosk3c	157	7	patients	patient	NNS
cord-324810-92fosk3c	157	8	and	and	CC
cord-324810-92fosk3c	157	9	also	also	RB
cord-324810-92fosk3c	157	10	inpatients	inpatient	NNS
cord-324810-92fosk3c	157	11	displayed	display	VBD
cord-324810-92fosk3c	157	12	a	a	DT
cord-324810-92fosk3c	157	13	greater	great	JJR
cord-324810-92fosk3c	157	14	benefit	benefit	NN
cord-324810-92fosk3c	157	15	from	from	IN
cord-324810-92fosk3c	157	16	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	157	17	therapy	therapy	NN
cord-324810-92fosk3c	157	18	,	,	,
cord-324810-92fosk3c	157	19	possibly	possibly	RB
cord-324810-92fosk3c	157	20	be-4	be-4	RB
cord-324810-92fosk3c	157	21	.	.	.
cord-324810-92fosk3c	157	22	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	157	23	and	and	CC
cord-324810-92fosk3c	157	24	Natural	Natural	NNP
cord-324810-92fosk3c	157	25	History	history	NN
cord-324810-92fosk3c	157	26	of	of	IN
cord-324810-92fosk3c	157	27	COPD	COPD	NNP
cord-324810-92fosk3c	157	28	cause	cause	VBP
cord-324810-92fosk3c	157	29	these	these	DT
cord-324810-92fosk3c	157	30	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	157	31	were	be	VBD
cord-324810-92fosk3c	157	32	more	more	RBR
cord-324810-92fosk3c	157	33	severe	severe	JJ
cord-324810-92fosk3c	157	34	.	.	.
cord-324810-92fosk3c	158	1	Discrepancies	discrepancy	NNS
cord-324810-92fosk3c	158	2	in	in	IN
cord-324810-92fosk3c	158	3	outcome	outcome	NN
cord-324810-92fosk3c	158	4	in	in	IN
cord-324810-92fosk3c	158	5	these	these	DT
cord-324810-92fosk3c	158	6	studies	study	NNS
cord-324810-92fosk3c	158	7	were	be	VBD
cord-324810-92fosk3c	158	8	possibly	possibly	RB
cord-324810-92fosk3c	158	9	secondary	secondary	JJ
cord-324810-92fosk3c	158	10	to	to	TO
cord-324810-92fosk3c	158	11	design	design	VB
cord-324810-92fosk3c	158	12	flaws	flaw	NNS
cord-324810-92fosk3c	158	13	,	,	,
cord-324810-92fosk3c	158	14	small	small	JJ
cord-324810-92fosk3c	158	15	numbers	number	NNS
cord-324810-92fosk3c	158	16	of	of	IN
cord-324810-92fosk3c	158	17	patients	patient	NNS
cord-324810-92fosk3c	158	18	,	,	,
cord-324810-92fosk3c	158	19	unclear	unclear	JJ
cord-324810-92fosk3c	158	20	selection	selection	NN
cord-324810-92fosk3c	158	21	criteria	criterion	NNS
cord-324810-92fosk3c	158	22	,	,	,
cord-324810-92fosk3c	158	23	non	non	JJ
cord-324810-92fosk3c	158	24	-	-	JJ
cord-324810-92fosk3c	158	25	standard	standard	JJ
cord-324810-92fosk3c	158	26	4.1	4.1	CD
cord-324810-92fosk3c	158	27	Vicious	Vicious	NNP
cord-324810-92fosk3c	158	28	Circle	Circle	NNP
cord-324810-92fosk3c	158	29	Hypothesis	Hypothesis	NNP
cord-324810-92fosk3c	158	30	evaluation	evaluation	NN
cord-324810-92fosk3c	158	31	criteria	criterion	NNS
cord-324810-92fosk3c	158	32	and	and	CC
cord-324810-92fosk3c	158	33	lack	lack	NN
cord-324810-92fosk3c	158	34	of	of	IN
cord-324810-92fosk3c	158	35	patient	patient	JJ
cord-324810-92fosk3c	158	36	stratification	stratification	NN
cord-324810-92fosk3c	158	37	.	.	.
cord-324810-92fosk3c	159	1	[	[	-LRB-
cord-324810-92fosk3c	159	2	34	34	CD
cord-324810-92fosk3c	159	3	]	]	-RRB-
cord-324810-92fosk3c	159	4	[	[	-LRB-
cord-324810-92fosk3c	159	5	35	35	CD
cord-324810-92fosk3c	159	6	]	]	-RRB-
cord-324810-92fosk3c	159	7	[	[	-LRB-
cord-324810-92fosk3c	159	8	36	36	CD
cord-324810-92fosk3c	159	9	]	]	-RRB-
cord-324810-92fosk3c	160	1	Patients	patient	NNS
cord-324810-92fosk3c	160	2	It	-PRON-	PRP
cord-324810-92fosk3c	160	3	has	have	VBZ
cord-324810-92fosk3c	160	4	been	be	VBN
cord-324810-92fosk3c	160	5	suggested	suggest	VBN
cord-324810-92fosk3c	160	6	that	that	IN
cord-324810-92fosk3c	160	7	the	the	DT
cord-324810-92fosk3c	160	8	progressive	progressive	JJ
cord-324810-92fosk3c	160	9	deterioration	deterioration	NN
cord-324810-92fosk3c	160	10	of	of	IN
cord-324810-92fosk3c	160	11	lung	lung	NN
cord-324810-92fosk3c	160	12	with	with	IN
cord-324810-92fosk3c	160	13	different	different	JJ
cord-324810-92fosk3c	160	14	severities	severity	NNS
cord-324810-92fosk3c	160	15	of	of	IN
cord-324810-92fosk3c	160	16	COPD	COPD	NNP
cord-324810-92fosk3c	160	17	have	have	VBP
cord-324810-92fosk3c	160	18	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	160	19	with	with	IN
cord-324810-92fosk3c	160	20	diverse	diverse	JJ
cord-324810-92fosk3c	160	21	function	function	NN
cord-324810-92fosk3c	160	22	in	in	IN
cord-324810-92fosk3c	160	23	patients	patient	NNS
cord-324810-92fosk3c	160	24	with	with	IN
cord-324810-92fosk3c	160	25	COPD	COPD	NNP
cord-324810-92fosk3c	160	26	is	be	VBZ
cord-324810-92fosk3c	160	27	produced	produce	VBN
cord-324810-92fosk3c	160	28	by	by	IN
cord-324810-92fosk3c	160	29	bacterial	bacterial	JJ
cord-324810-92fosk3c	160	30	colonizaorganisms	colonizaorganism	NNS
cord-324810-92fosk3c	160	31	;	;	:
cord-324810-92fosk3c	160	32	therefore	therefore	RB
cord-324810-92fosk3c	160	33	,	,	,
cord-324810-92fosk3c	160	34	further	further	JJ
cord-324810-92fosk3c	160	35	studies	study	NNS
cord-324810-92fosk3c	160	36	should	should	MD
cord-324810-92fosk3c	160	37	be	be	VB
cord-324810-92fosk3c	160	38	conducted	conduct	VBN
cord-324810-92fosk3c	160	39	to	to	TO
cord-324810-92fosk3c	160	40	assess	assess	VB
cord-324810-92fosk3c	160	41	tion	tion	NN
cord-324810-92fosk3c	160	42	of	of	IN
cord-324810-92fosk3c	160	43	the	the	DT
cord-324810-92fosk3c	160	44	lower	low	JJR
cord-324810-92fosk3c	160	45	respiratory	respiratory	JJ
cord-324810-92fosk3c	160	46	tract	tract	NN
cord-324810-92fosk3c	160	47	and	and	CC
cord-324810-92fosk3c	160	48	recurrent	recurrent	JJ
cord-324810-92fosk3c	160	49	infective	infective	JJ
cord-324810-92fosk3c	160	50	exacerbadifferent	exacerbadifferent	JJ
cord-324810-92fosk3c	160	51	classes	class	NNS
cord-324810-92fosk3c	160	52	of	of	IN
cord-324810-92fosk3c	160	53	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	160	54	in	in	IN
cord-324810-92fosk3c	160	55	specific	specific	JJ
cord-324810-92fosk3c	160	56	clinical	clinical	JJ
cord-324810-92fosk3c	160	57	situations	situation	NNS
cord-324810-92fosk3c	160	58	.	.	.
cord-324810-92fosk3c	161	1	In	in	IN
cord-324810-92fosk3c	161	2	tions	tion	NNS
cord-324810-92fosk3c	161	3	.	.	.
cord-324810-92fosk3c	162	1	Airway	airway	JJ
cord-324810-92fosk3c	162	2	colonization	colonization	NN
cord-324810-92fosk3c	162	3	in	in	IN
cord-324810-92fosk3c	162	4	low	low	JJ
cord-324810-92fosk3c	162	5	numbers	number	NNS
cord-324810-92fosk3c	162	6	may	may	MD
cord-324810-92fosk3c	162	7	not	not	RB
cord-324810-92fosk3c	162	8	engender	engender	VB
cord-324810-92fosk3c	162	9	an	an	DT
cord-324810-92fosk3c	162	10	patients	patient	NNS
cord-324810-92fosk3c	162	11	with	with	IN
cord-324810-92fosk3c	162	12	more	more	RBR
cord-324810-92fosk3c	162	13	severe	severe	JJ
cord-324810-92fosk3c	162	14	air	air	NN
cord-324810-92fosk3c	162	15	flow	flow	NN
cord-324810-92fosk3c	162	16	obstruction	obstruction	NN
cord-324810-92fosk3c	162	17	,	,	,
cord-324810-92fosk3c	162	18	the	the	DT
cord-324810-92fosk3c	162	19	bacteriology	bacteriology	NN
cord-324810-92fosk3c	162	20	inflammatory	inflammatory	JJ
cord-324810-92fosk3c	162	21	response	response	NN
cord-324810-92fosk3c	162	22	.	.	.
cord-324810-92fosk3c	163	1	[	[	-LRB-
cord-324810-92fosk3c	163	2	29	29	CD
cord-324810-92fosk3c	163	3	]	]	-RRB-
cord-324810-92fosk3c	164	1	As	as	IN
cord-324810-92fosk3c	164	2	bacterial	bacterial	JJ
cord-324810-92fosk3c	164	3	counts	count	NNS
cord-324810-92fosk3c	164	4	increase	increase	NN
cord-324810-92fosk3c	164	5	,	,	,
cord-324810-92fosk3c	164	6	neutroshifted	neutroshifte	VBN
cord-324810-92fosk3c	164	7	from	from	IN
cord-324810-92fosk3c	164	8	Pneumococcus	Pneumococcus	NNP
cord-324810-92fosk3c	164	9	spp	spp	NNS
cord-324810-92fosk3c	164	10	.	.	.
cord-324810-92fosk3c	165	1	and	and	CC
cord-324810-92fosk3c	165	2	Haemophilus	Haemophilus	NNP
cord-324810-92fosk3c	165	3	spp	spp	NNS
cord-324810-92fosk3c	165	4	.	.	.
cord-324810-92fosk3c	166	1	to	to	IN
cord-324810-92fosk3c	166	2	more	more	RBR
cord-324810-92fosk3c	166	3	philic	philic	JJ
cord-324810-92fosk3c	166	4	host	host	NN
cord-324810-92fosk3c	166	5	response	response	NN
cord-324810-92fosk3c	166	6	leads	lead	VBZ
cord-324810-92fosk3c	166	7	to	to	TO
cord-324810-92fosk3c	166	8	release	release	VB
cord-324810-92fosk3c	166	9	of	of	IN
cord-324810-92fosk3c	166	10	pro	pro	JJ
cord-324810-92fosk3c	166	11	-	-	JJ
cord-324810-92fosk3c	166	12	inflammatory	inflammatory	JJ
cord-324810-92fosk3c	166	13	cytokines	cytokine	NNS
cord-324810-92fosk3c	166	14	,	,	,
cord-324810-92fosk3c	166	15	and	and	CC
cord-324810-92fosk3c	166	16	activated	activate	VBN
cord-324810-92fosk3c	166	17	proteinases	proteinases	NNP
cord-324810-92fosk3c	166	18	.	.	.
cord-324810-92fosk3c	167	1	Wilkinson	Wilkinson	NNP
cord-324810-92fosk3c	167	2	et	et	NNP
cord-324810-92fosk3c	167	3	al	al	NNP
cord-324810-92fosk3c	167	4	.	.	.
cord-324810-92fosk3c	168	1	[	[	-LRB-
cord-324810-92fosk3c	168	2	38	38	CD
cord-324810-92fosk3c	168	3	]	]	-RRB-
cord-324810-92fosk3c	168	4	have	have	VBP
cord-324810-92fosk3c	168	5	recently	recently	RB
cord-324810-92fosk3c	168	6	shown	show	VBN
cord-324810-92fosk3c	168	7	that	that	IN
cord-324810-92fosk3c	168	8	increase	increase	NN
cord-324810-92fosk3c	168	9	in	in	IN
cord-324810-92fosk3c	168	10	airway	airway	JJ
cord-324810-92fosk3c	168	11	bacterial	bacterial	JJ
cord-324810-92fosk3c	168	12	load	load	NN
cord-324810-92fosk3c	168	13	and	and	CC
cord-324810-92fosk3c	168	14	change	change	NN
cord-324810-92fosk3c	168	15	in	in	IN
cord-324810-92fosk3c	168	16	the	the	DT
cord-324810-92fosk3c	168	17	colonizing	colonize	VBG
cord-324810-92fosk3c	168	18	bacterial	bacterial	JJ
cord-324810-92fosk3c	168	19	type	type	NN
cord-324810-92fosk3c	168	20	contributed	contribute	VBD
cord-324810-92fosk3c	168	21	to	to	IN
cord-324810-92fosk3c	168	22	greater	great	JJR
cord-324810-92fosk3c	168	23	airway	airway	NN
cord-324810-92fosk3c	168	24	inflammation	inflammation	NN
cord-324810-92fosk3c	168	25	and	and	CC
cord-324810-92fosk3c	168	26	accelerated	accelerated	JJ
cord-324810-92fosk3c	168	27	decline	decline	NN
cord-324810-92fosk3c	168	28	in	in	IN
cord-324810-92fosk3c	168	29	FEV1	FEV1	NNP
cord-324810-92fosk3c	168	30	.	.	.
cord-324810-92fosk3c	169	1	In	in	IN
cord-324810-92fosk3c	169	2	30	30	CD
cord-324810-92fosk3c	169	3	stable	stable	JJ
cord-324810-92fosk3c	169	4	COPD	COPD	NNP
cord-324810-92fosk3c	169	5	patients	patient	NNS
cord-324810-92fosk3c	169	6	,	,	,
cord-324810-92fosk3c	169	7	the	the	DT
cord-324810-92fosk3c	169	8	relationship	relationship	NN
cord-324810-92fosk3c	169	9	between	between	IN
cord-324810-92fosk3c	169	10	absolute	absolute	JJ
cord-324810-92fosk3c	169	11	FEV1	FEV1	NNP
cord-324810-92fosk3c	169	12	and	and	CC
cord-324810-92fosk3c	169	13	change	change	NN
cord-324810-92fosk3c	169	14	in	in	IN
cord-324810-92fosk3c	169	15	bacterial	bacterial	JJ
cord-324810-92fosk3c	169	16	load	load	NN
cord-324810-92fosk3c	169	17	was	be	VBD
cord-324810-92fosk3c	169	18	statistically	statistically	RB
cord-324810-92fosk3c	169	19	significant	significant	JJ
cord-324810-92fosk3c	169	20	(	(	-LRB-
cord-324810-92fosk3c	169	21	r	r	NN
cord-324810-92fosk3c	169	22	=	=	SYM
cord-324810-92fosk3c	169	23	0.593	0.593	CD
cord-324810-92fosk3c	169	24	,	,	,
cord-324810-92fosk3c	169	25	p	p	NN
cord-324810-92fosk3c	169	26	<	<	XX
cord-324810-92fosk3c	169	27	0.001	0.001	CD
cord-324810-92fosk3c	169	28	)	)	-RRB-
cord-324810-92fosk3c	169	29	.	.	.
cord-324810-92fosk3c	170	1	Stockley	Stockley	NNP
cord-324810-92fosk3c	170	2	et	et	FW
cord-324810-92fosk3c	170	3	al	al	NNP
cord-324810-92fosk3c	170	4	.	.	.
cord-324810-92fosk3c	171	1	[	[	-LRB-
cord-324810-92fosk3c	171	2	39	39	CD
cord-324810-92fosk3c	171	3	]	]	-RRB-
cord-324810-92fosk3c	171	4	recently	recently	RB
cord-324810-92fosk3c	171	5	confirmed	confirm	VBD
cord-324810-92fosk3c	171	6	that	that	IN
cord-324810-92fosk3c	171	7	purulent	purulent	JJ
cord-324810-92fosk3c	171	8	sputum	sputum	NN
cord-324810-92fosk3c	171	9	correlated	correlate	VBN
cord-324810-92fosk3c	171	10	directly	directly	RB
cord-324810-92fosk3c	171	11	with	with	IN
cord-324810-92fosk3c	171	12	the	the	DT
cord-324810-92fosk3c	171	13	myeloperoxidase	myeloperoxidase	NN
cord-324810-92fosk3c	171	14	content	content	NN
cord-324810-92fosk3c	171	15	of	of	IN
cord-324810-92fosk3c	171	16	sputum	sputum	NN
cord-324810-92fosk3c	171	17	and	and	CC
cord-324810-92fosk3c	171	18	with	with	IN
cord-324810-92fosk3c	171	19	various	various	JJ
cord-324810-92fosk3c	171	20	other	other	JJ
cord-324810-92fosk3c	171	21	indicators	indicator	NNS
cord-324810-92fosk3c	171	22	of	of	IN
cord-324810-92fosk3c	171	23	airway	airway	JJ
cord-324810-92fosk3c	171	24	inflammation	inflammation	NN
cord-324810-92fosk3c	171	25	.	.	.
cord-324810-92fosk3c	172	1	Visual	visual	JJ
cord-324810-92fosk3c	172	2	measurements	measurement	NNS
cord-324810-92fosk3c	172	3	of	of	IN
cord-324810-92fosk3c	172	4	sputum	sputum	NN
cord-324810-92fosk3c	172	5	color	color	NN
cord-324810-92fosk3c	172	6	correlated	correlate	VBD
cord-324810-92fosk3c	172	7	strongly	strongly	RB
cord-324810-92fosk3c	172	8	with	with	IN
cord-324810-92fosk3c	172	9	myeloperoxidase	myeloperoxidase	NN
cord-324810-92fosk3c	172	10	,	,	,
cord-324810-92fosk3c	172	11	interleukin-8	interleukin-8	NNP
cord-324810-92fosk3c	172	12	,	,	,
cord-324810-92fosk3c	172	13	leukocyte	leukocyte	NN
cord-324810-92fosk3c	172	14	elastase	elastase	NN
cord-324810-92fosk3c	172	15	(	(	-LRB-
cord-324810-92fosk3c	172	16	both	both	DT
cord-324810-92fosk3c	172	17	activity	activity	NN
cord-324810-92fosk3c	172	18	and	and	CC
cord-324810-92fosk3c	172	19	total	total	JJ
cord-324810-92fosk3c	172	20	quantity	quantity	NN
cord-324810-92fosk3c	172	21	)	)	-RRB-
cord-324810-92fosk3c	172	22	,	,	,
cord-324810-92fosk3c	172	23	sputum	sputum	NN
cord-324810-92fosk3c	172	24	volume	volume	NN
cord-324810-92fosk3c	172	25	,	,	,
cord-324810-92fosk3c	172	26	protein	protein	NN
cord-324810-92fosk3c	172	27	leak	leak	NN
cord-324810-92fosk3c	172	28	,	,	,
cord-324810-92fosk3c	172	29	and	and	CC
cord-324810-92fosk3c	172	30	secretory	secretory	JJ
cord-324810-92fosk3c	172	31	leukocyte	leukocyte	NN
cord-324810-92fosk3c	172	32	proteinase	proteinase	NN
cord-324810-92fosk3c	172	33	inhibitor	inhibitor	NN
cord-324810-92fosk3c	172	34	.	.	.
cord-324810-92fosk3c	173	1	This	this	DT
cord-324810-92fosk3c	173	2	study	study	NN
cord-324810-92fosk3c	173	3	provides	provide	VBZ
cord-324810-92fosk3c	173	4	a	a	DT
cord-324810-92fosk3c	173	5	useful	useful	JJ
cord-324810-92fosk3c	173	6	scientific	scientific	JJ
cord-324810-92fosk3c	173	7	tool	tool	NN
cord-324810-92fosk3c	173	8	for	for	IN
cord-324810-92fosk3c	173	9	improving	improve	VBG
cord-324810-92fosk3c	173	10	the	the	DT
cord-324810-92fosk3c	173	11	monitoring	monitoring	NN
cord-324810-92fosk3c	173	12	of	of	IN
cord-324810-92fosk3c	173	13	chronic	chronic	JJ
cord-324810-92fosk3c	173	14	airways	airway	NNS
cord-324810-92fosk3c	173	15	diseases	disease	NNS
cord-324810-92fosk3c	173	16	and	and	CC
cord-324810-92fosk3c	173	17	response	response	NN
cord-324810-92fosk3c	173	18	to	to	IN
cord-324810-92fosk3c	173	19	treatment	treatment	NN
cord-324810-92fosk3c	173	20	.	.	.
cord-324810-92fosk3c	174	1	Inflammatory	inflammatory	JJ
cord-324810-92fosk3c	174	2	cytokines	cytokine	NNS
cord-324810-92fosk3c	174	3	along	along	IN
cord-324810-92fosk3c	174	4	with	with	IN
cord-324810-92fosk3c	174	5	bacterial	bacterial	JJ
cord-324810-92fosk3c	174	6	products	product	NNS
cord-324810-92fosk3c	175	1	im-	im-	JJ
cord-324810-92fosk3c	176	1	pair	pair	NNP
cord-324810-92fosk3c	176	2	mucociliary	mucociliary	JJ
cord-324810-92fosk3c	176	3	function	function	NN
cord-324810-92fosk3c	176	4	,	,	,
cord-324810-92fosk3c	176	5	mucus	mucus	NN
cord-324810-92fosk3c	176	6	gland	gland	NN
cord-324810-92fosk3c	176	7	hyperplasia	hyperplasia	NN
cord-324810-92fosk3c	176	8	,	,	,
cord-324810-92fosk3c	176	9	mucus	mucus	NN
cord-324810-92fosk3c	176	10	hyper	hyper	RB
cord-324810-92fosk3c	176	11	-	-	JJ
cord-324810-92fosk3c	176	12	tained	tained	JJ
cord-324810-92fosk3c	176	13	different	different	JJ
cord-324810-92fosk3c	176	14	results	result	NNS
cord-324810-92fosk3c	176	15	.	.	.
cord-324810-92fosk3c	177	1	Lung	Lung	NNP
cord-324810-92fosk3c	177	2	Health	Health	NNP
cord-324810-92fosk3c	177	3	Study	Study	NNP
cord-324810-92fosk3c	177	4	data	datum	NNS
cord-324810-92fosk3c	177	5	were	be	VBD
cord-324810-92fosk3c	177	6	analyzed	analyze	VBN
cord-324810-92fosk3c	177	7	to	to	IN
cord-324810-92fosk3c	177	8	secretion	secretion	NN
cord-324810-92fosk3c	177	9	,	,	,
cord-324810-92fosk3c	177	10	and	and	CC
cord-324810-92fosk3c	177	11	tissue	tissue	NN
cord-324810-92fosk3c	177	12	damage	damage	NN
cord-324810-92fosk3c	177	13	,	,	,
cord-324810-92fosk3c	177	14	particularly	particularly	RB
cord-324810-92fosk3c	177	15	of	of	IN
cord-324810-92fosk3c	177	16	the	the	DT
cord-324810-92fosk3c	177	17	small	small	JJ
cord-324810-92fosk3c	177	18	airways	airway	NNS
cord-324810-92fosk3c	177	19	and	and	CC
cord-324810-92fosk3c	177	20	assess	assess	VB
cord-324810-92fosk3c	177	21	the	the	DT
cord-324810-92fosk3c	177	22	influence	influence	NN
cord-324810-92fosk3c	177	23	of	of	IN
cord-324810-92fosk3c	177	24	respiratory	respiratory	JJ
cord-324810-92fosk3c	177	25	illnesses	illness	NNS
cord-324810-92fosk3c	177	26	on	on	IN
cord-324810-92fosk3c	177	27	the	the	DT
cord-324810-92fosk3c	177	28	rate	rate	NN
cord-324810-92fosk3c	177	29	of	of	IN
cord-324810-92fosk3c	177	30	decline	decline	NN
cord-324810-92fosk3c	177	31	the	the	DT
cord-324810-92fosk3c	177	32	alveoli	alveolus	NNS
cord-324810-92fosk3c	177	33	,	,	,
cord-324810-92fosk3c	177	34	leading	lead	VBG
cord-324810-92fosk3c	177	35	to	to	IN
cord-324810-92fosk3c	177	36	airflow	airflow	NN
cord-324810-92fosk3c	177	37	obstruction	obstruction	NN
cord-324810-92fosk3c	177	38	.	.	.
cord-324810-92fosk3c	178	1	Bacterial	bacterial	JJ
cord-324810-92fosk3c	178	2	colonization	colonization	NN
cord-324810-92fosk3c	178	3	is	be	VBZ
cord-324810-92fosk3c	178	4	of	of	IN
cord-324810-92fosk3c	178	5	FEV	FEV	NNP
cord-324810-92fosk3c	178	6	1	1	CD
cord-324810-92fosk3c	178	7	,	,	,
cord-324810-92fosk3c	178	8	over	over	IN
cord-324810-92fosk3c	178	9	the	the	DT
cord-324810-92fosk3c	178	10	5-year	5-year	CD
cord-324810-92fosk3c	178	11	study	study	NN
cord-324810-92fosk3c	178	12	duration	duration	NN
cord-324810-92fosk3c	178	13	.	.	.
cord-324810-92fosk3c	179	1	[	[	-LRB-
cord-324810-92fosk3c	179	2	46	46	CD
cord-324810-92fosk3c	179	3	]	]	-RRB-
cord-324810-92fosk3c	179	4	Acute	acute	JJ
cord-324810-92fosk3c	179	5	respiratory	respiratory	NN
cord-324810-92fosk3c	179	6	relatively	relatively	RB
cord-324810-92fosk3c	179	7	common	common	JJ
cord-324810-92fosk3c	179	8	in	in	IN
cord-324810-92fosk3c	179	9	stable	stable	JJ
cord-324810-92fosk3c	179	10	COPD	COPD	NNP
cord-324810-92fosk3c	179	11	patients	patient	NNS
cord-324810-92fosk3c	179	12	.	.	.
cord-324810-92fosk3c	180	1	Acquisition	acquisition	NN
cord-324810-92fosk3c	180	2	of	of	IN
cord-324810-92fosk3c	180	3	a	a	DT
cord-324810-92fosk3c	180	4	new	new	JJ
cord-324810-92fosk3c	180	5	illnesses	illness	NNS
cord-324810-92fosk3c	180	6	were	be	VBD
cord-324810-92fosk3c	180	7	associated	associate	VBN
cord-324810-92fosk3c	180	8	with	with	IN
cord-324810-92fosk3c	180	9	an	an	DT
cord-324810-92fosk3c	180	10	excessive	excessive	JJ
cord-324810-92fosk3c	180	11	decline	decline	NN
cord-324810-92fosk3c	180	12	in	in	IN
cord-324810-92fosk3c	180	13	lung	lung	NN
cord-324810-92fosk3c	180	14	funcbacterial	funcbacterial	JJ
cord-324810-92fosk3c	180	15	pathogen	pathogen	NN
cord-324810-92fosk3c	180	16	or	or	CC
cord-324810-92fosk3c	180	17	a	a	DT
cord-324810-92fosk3c	180	18	newer	new	JJR
cord-324810-92fosk3c	180	19	strain	strain	NN
cord-324810-92fosk3c	180	20	of	of	IN
cord-324810-92fosk3c	180	21	the	the	DT
cord-324810-92fosk3c	180	22	colonizing	colonize	VBG
cord-324810-92fosk3c	180	23	bacteria	bacteria	NNS
cord-324810-92fosk3c	180	24	tion	tion	NN
cord-324810-92fosk3c	180	25	proportional	proportional	JJ
cord-324810-92fosk3c	180	26	to	to	IN
cord-324810-92fosk3c	180	27	the	the	DT
cord-324810-92fosk3c	180	28	exacerbation	exacerbation	NN
cord-324810-92fosk3c	180	29	frequency	frequency	NN
cord-324810-92fosk3c	180	30	among	among	IN
cord-324810-92fosk3c	180	31	individuals	individual	NNS
cord-324810-92fosk3c	180	32	allows	allow	VBZ
cord-324810-92fosk3c	180	33	proliferation	proliferation	NN
cord-324810-92fosk3c	180	34	of	of	IN
cord-324810-92fosk3c	180	35	organisms	organism	NNS
cord-324810-92fosk3c	180	36	and	and	CC
cord-324810-92fosk3c	180	37	an	an	DT
cord-324810-92fosk3c	180	38	increase	increase	NN
cord-324810-92fosk3c	180	39	in	in	IN
cord-324810-92fosk3c	180	40	the	the	DT
cord-324810-92fosk3c	180	41	bacterial	bacterial	NN
cord-324810-92fosk3c	180	42	who	who	WP
cord-324810-92fosk3c	180	43	continued	continue	VBD
cord-324810-92fosk3c	180	44	to	to	TO
cord-324810-92fosk3c	180	45	smoke	smoke	VB
cord-324810-92fosk3c	180	46	,	,	,
cord-324810-92fosk3c	180	47	as	as	IN
cord-324810-92fosk3c	180	48	opposed	oppose	VBN
cord-324810-92fosk3c	180	49	to	to	IN
cord-324810-92fosk3c	180	50	no	no	DT
cord-324810-92fosk3c	180	51	deterioration	deterioration	NN
cord-324810-92fosk3c	180	52	in	in	IN
cord-324810-92fosk3c	180	53	individload	individload	NN
cord-324810-92fosk3c	180	54	.	.	.
cord-324810-92fosk3c	181	1	The	the	DT
cord-324810-92fosk3c	181	2	higher	high	JJR
cord-324810-92fosk3c	181	3	bacterial	bacterial	JJ
cord-324810-92fosk3c	181	4	load	load	NN
cord-324810-92fosk3c	181	5	facilitates	facilitate	VBZ
cord-324810-92fosk3c	181	6	neutrophilic	neutrophilic	JJ
cord-324810-92fosk3c	181	7	influx	influx	NN
cord-324810-92fosk3c	181	8	and	and	CC
cord-324810-92fosk3c	181	9	uals	ual	NNS
cord-324810-92fosk3c	181	10	who	who	WP
cord-324810-92fosk3c	181	11	ceased	cease	VBD
cord-324810-92fosk3c	181	12	smoking	smoke	VBG
cord-324810-92fosk3c	181	13	.	.	.
cord-324810-92fosk3c	182	1	Kanner	Kanner	NNP
cord-324810-92fosk3c	182	2	et	et	NNP
cord-324810-92fosk3c	182	3	al	al	NNP
cord-324810-92fosk3c	182	4	.	.	.
cord-324810-92fosk3c	183	1	,	,	,
cord-324810-92fosk3c	183	2	[	[	-LRB-
cord-324810-92fosk3c	183	3	47	47	CD
cord-324810-92fosk3c	183	4	]	]	-RRB-
cord-324810-92fosk3c	183	5	who	who	WP
cord-324810-92fosk3c	183	6	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	183	7	that	that	IN
cord-324810-92fosk3c	183	8	inflammatory	inflammatory	JJ
cord-324810-92fosk3c	183	9	response	response	NN
cord-324810-92fosk3c	183	10	ensues	ensue	VBZ
cord-324810-92fosk3c	183	11	.	.	.
cord-324810-92fosk3c	184	1	[	[	-LRB-
cord-324810-92fosk3c	184	2	31	31	CD
cord-324810-92fosk3c	184	3	,	,	,
cord-324810-92fosk3c	184	4	[	[	-LRB-
cord-324810-92fosk3c	184	5	38	38	CD
cord-324810-92fosk3c	184	6	]	]	-RRB-
cord-324810-92fosk3c	184	7	[	[	-LRB-
cord-324810-92fosk3c	184	8	39	39	CD
cord-324810-92fosk3c	184	9	]	]	-RRB-
cord-324810-92fosk3c	184	10	[	[	-LRB-
cord-324810-92fosk3c	184	11	40	40	CD
cord-324810-92fosk3c	184	12	]	]	-RRB-
cord-324810-92fosk3c	184	13	frequent	frequent	JJ
cord-324810-92fosk3c	184	14	respiratory	respiratory	JJ
cord-324810-92fosk3c	184	15	tract	tract	NN
cord-324810-92fosk3c	184	16	infections	infection	NNS
cord-324810-92fosk3c	184	17	in	in	IN
cord-324810-92fosk3c	184	18	patients	patient	NNS
cord-324810-92fosk3c	184	19	with	with	IN
cord-324810-92fosk3c	184	20	COPD	COPD	NNP
cord-324810-92fosk3c	184	21	led	lead	VBD
cord-324810-92fosk3c	184	22	to	to	IN
cord-324810-92fosk3c	184	23	a	a	DT
cord-324810-92fosk3c	184	24	Therefore	therefore	RB
cord-324810-92fosk3c	184	25	,	,	,
cord-324810-92fosk3c	184	26	a	a	DT
cord-324810-92fosk3c	184	27	self	self	NN
cord-324810-92fosk3c	184	28	-	-	HYPH
cord-324810-92fosk3c	184	29	perpetuating	perpetuate	VBG
cord-324810-92fosk3c	184	30	vicious	vicious	JJ
cord-324810-92fosk3c	184	31	circle	circle	NN
cord-324810-92fosk3c	184	32	of	of	IN
cord-324810-92fosk3c	184	33	host	host	NN
cord-324810-92fosk3c	184	34	-	-	:
cord-324810-92fosk3c	184	35	and	and	CC
cord-324810-92fosk3c	184	36	bactemore	bactemore	VB
cord-324810-92fosk3c	184	37	rapid	rapid	JJ
cord-324810-92fosk3c	184	38	decline	decline	NN
cord-324810-92fosk3c	184	39	in	in	IN
cord-324810-92fosk3c	184	40	lung	lung	NN
cord-324810-92fosk3c	184	41	function	function	NN
cord-324810-92fosk3c	184	42	,	,	,
cord-324810-92fosk3c	184	43	supported	support	VBD
cord-324810-92fosk3c	184	44	this	this	DT
cord-324810-92fosk3c	184	45	hypothesis	hypothesis	NN
cord-324810-92fosk3c	184	46	.	.	.
cord-324810-92fosk3c	185	1	ria	ria	NNP
cord-324810-92fosk3c	185	2	-	-	HYPH
cord-324810-92fosk3c	185	3	mediated	mediate	VBN
cord-324810-92fosk3c	185	4	respiratory	respiratory	JJ
cord-324810-92fosk3c	185	5	tract	tract	NN
cord-324810-92fosk3c	185	6	damage	damage	NN
cord-324810-92fosk3c	185	7	sets	set	NNS
cord-324810-92fosk3c	185	8	in	in	RP
cord-324810-92fosk3c	185	9	.	.	.
cord-324810-92fosk3c	186	1	Sustained	sustain	VBN
cord-324810-92fosk3c	186	2	by	by	IN
cord-324810-92fosk3c	186	3	prod	prod	NN
cord-324810-92fosk3c	186	4	-	-	HYPH
cord-324810-92fosk3c	186	5	Recently	recently	RB
cord-324810-92fosk3c	186	6	,	,	,
cord-324810-92fosk3c	186	7	Seemungal	Seemungal	NNP
cord-324810-92fosk3c	186	8	et	et	FW
cord-324810-92fosk3c	186	9	al	al	NNP
cord-324810-92fosk3c	186	10	.	.	.
cord-324810-92fosk3c	187	1	[	[	-LRB-
cord-324810-92fosk3c	187	2	48	48	CD
cord-324810-92fosk3c	187	3	]	]	-RRB-
cord-324810-92fosk3c	187	4	prospectively	prospectively	RB
cord-324810-92fosk3c	187	5	measured	measure	VBN
cord-324810-92fosk3c	187	6	PEF	PEF	NNP
cord-324810-92fosk3c	187	7	in	in	IN
cord-324810-92fosk3c	187	8	ucts	uct	NNS
cord-324810-92fosk3c	187	9	of	of	IN
cord-324810-92fosk3c	187	10	inflammation	inflammation	NN
cord-324810-92fosk3c	187	11	,	,	,
cord-324810-92fosk3c	187	12	this	this	DT
cord-324810-92fosk3c	187	13	cycle	cycle	NN
cord-324810-92fosk3c	187	14	impairs	impair	VBZ
cord-324810-92fosk3c	187	15	host	host	NN
cord-324810-92fosk3c	187	16	defense	defense	NN
cord-324810-92fosk3c	187	17	response	response	NN
cord-324810-92fosk3c	187	18	and	and	CC
cord-324810-92fosk3c	187	19	COPD	COPD	NNP
cord-324810-92fosk3c	187	20	patients	patient	NNS
cord-324810-92fosk3c	187	21	before	before	RB
cord-324810-92fosk3c	187	22	,	,	,
cord-324810-92fosk3c	187	23	during	during	IN
cord-324810-92fosk3c	187	24	,	,	,
cord-324810-92fosk3c	187	25	and	and	CC
cord-324810-92fosk3c	187	26	after	after	IN
cord-324810-92fosk3c	187	27	acute	acute	JJ
cord-324810-92fosk3c	187	28	outpatient	outpatient	NN
cord-324810-92fosk3c	187	29	exacerbapredisposes	exacerbapredispose	NNS
cord-324810-92fosk3c	187	30	to	to	IN
cord-324810-92fosk3c	187	31	further	further	JJ
cord-324810-92fosk3c	187	32	bacterial	bacterial	JJ
cord-324810-92fosk3c	187	33	colonization	colonization	NN
cord-324810-92fosk3c	187	34	and	and	CC
cord-324810-92fosk3c	187	35	infections	infection	NNS
cord-324810-92fosk3c	187	36	.	.	.
cord-324810-92fosk3c	188	1	This	this	DT
cord-324810-92fosk3c	188	2	tions	tion	NNS
cord-324810-92fosk3c	188	3	.	.	.
cord-324810-92fosk3c	189	1	Incomplete	incomplete	JJ
cord-324810-92fosk3c	189	2	recovery	recovery	NN
cord-324810-92fosk3c	189	3	of	of	IN
cord-324810-92fosk3c	189	4	lung	lung	NN
cord-324810-92fosk3c	189	5	function	function	NN
cord-324810-92fosk3c	189	6	was	be	VBD
cord-324810-92fosk3c	189	7	noted	note	VBN
cord-324810-92fosk3c	189	8	in	in	IN
cord-324810-92fosk3c	189	9	25	25	CD
cord-324810-92fosk3c	189	10	%	%	NN
cord-324810-92fosk3c	189	11	of	of	IN
cord-324810-92fosk3c	189	12	process	process	NN
cord-324810-92fosk3c	189	13	has	have	VBZ
cord-324810-92fosk3c	189	14	been	be	VBN
cord-324810-92fosk3c	189	15	termed	term	VBN
cord-324810-92fosk3c	189	16	the	the	DT
cord-324810-92fosk3c	189	17	'	'	``
cord-324810-92fosk3c	189	18	vicious	vicious	JJ
cord-324810-92fosk3c	189	19	circle	circle	NN
cord-324810-92fosk3c	189	20	hypothesis	hypothesis	NN
cord-324810-92fosk3c	189	21	'	'	''
cord-324810-92fosk3c	189	22	and	and	CC
cord-324810-92fosk3c	189	23	is	be	VBZ
cord-324810-92fosk3c	189	24	patients	patient	NNS
cord-324810-92fosk3c	189	25	at	at	IN
cord-324810-92fosk3c	189	26	35	35	CD
cord-324810-92fosk3c	189	27	days	day	NNS
cord-324810-92fosk3c	189	28	,	,	,
cord-324810-92fosk3c	189	29	and	and	CC
cord-324810-92fosk3c	189	30	7	7	CD
cord-324810-92fosk3c	189	31	%	%	NN
cord-324810-92fosk3c	189	32	of	of	IN
cord-324810-92fosk3c	189	33	patients	patient	NNS
cord-324810-92fosk3c	189	34	had	have	VBD
cord-324810-92fosk3c	189	35	not	not	RB
cord-324810-92fosk3c	189	36	returned	return	VBN
cord-324810-92fosk3c	189	37	to	to	IN
cord-324810-92fosk3c	189	38	baseline	baseline	JJ
cord-324810-92fosk3c	189	39	likely	likely	RB
cord-324810-92fosk3c	189	40	responsible	responsible	JJ
cord-324810-92fosk3c	189	41	for	for	IN
cord-324810-92fosk3c	189	42	progressive	progressive	JJ
cord-324810-92fosk3c	189	43	deterioration	deterioration	NN
cord-324810-92fosk3c	189	44	of	of	IN
cord-324810-92fosk3c	189	45	lung	lung	NN
cord-324810-92fosk3c	189	46	function	function	NN
cord-324810-92fosk3c	189	47	lung	lung	NN
cord-324810-92fosk3c	189	48	function	function	NN
cord-324810-92fosk3c	189	49	at	at	IN
cord-324810-92fosk3c	189	50	3	3	CD
cord-324810-92fosk3c	189	51	months	month	NNS
cord-324810-92fosk3c	189	52	.	.	.
cord-324810-92fosk3c	190	1	These	these	DT
cord-324810-92fosk3c	190	2	studies	study	NNS
cord-324810-92fosk3c	190	3	support	support	VBP
cord-324810-92fosk3c	190	4	the	the	DT
cord-324810-92fosk3c	190	5	hypothesis	hypothesis	NN
cord-324810-92fosk3c	190	6	(	(	-LRB-
cord-324810-92fosk3c	190	7	figure	figure	NN
cord-324810-92fosk3c	190	8	4	4	CD
cord-324810-92fosk3c	190	9	)	)	-RRB-
cord-324810-92fosk3c	190	10	.	.	.
cord-324810-92fosk3c	191	1	[	[	-LRB-
cord-324810-92fosk3c	191	2	41	41	CD
cord-324810-92fosk3c	191	3	]	]	-RRB-
cord-324810-92fosk3c	191	4	that	that	WDT
cord-324810-92fosk3c	191	5	repeated	repeat	VBD
cord-324810-92fosk3c	191	6	acute	acute	JJ
cord-324810-92fosk3c	191	7	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	191	8	are	be	VBP
cord-324810-92fosk3c	191	9	a	a	DT
cord-324810-92fosk3c	191	10	factor	factor	NN
cord-324810-92fosk3c	191	11	in	in	IN
cord-324810-92fosk3c	191	12	progressive	progressive	JJ
cord-324810-92fosk3c	191	13	airways	airways	NNP
cord-324810-92fosk3c	191	14	obstruction	obstruction	NN
cord-324810-92fosk3c	191	15	and	and	CC
cord-324810-92fosk3c	191	16	likely	likely	RB
cord-324810-92fosk3c	191	17	affect	affect	VB
cord-324810-92fosk3c	191	18	the	the	DT
cord-324810-92fosk3c	191	19	natural	natural	JJ
cord-324810-92fosk3c	191	20	history	history	NN
cord-324810-92fosk3c	191	21	of	of	IN
cord-324810-92fosk3c	191	22	COPD	COPD	NNP
cord-324810-92fosk3c	191	23	.	.	.
cord-324810-92fosk3c	192	1	[	[	-LRB-
cord-324810-92fosk3c	192	2	46	46	CD
cord-324810-92fosk3c	192	3	]	]	-RRB-
cord-324810-92fosk3c	192	4	[	[	-LRB-
cord-324810-92fosk3c	192	5	47	47	CD
cord-324810-92fosk3c	192	6	]	]	-RRB-
cord-324810-92fosk3c	193	1	[	[	-LRB-
cord-324810-92fosk3c	193	2	48	48	CD
cord-324810-92fosk3c	193	3	]	]	-RRB-
cord-324810-92fosk3c	193	4	[	[	-LRB-
cord-324810-92fosk3c	193	5	49	49	CD
cord-324810-92fosk3c	193	6	]	]	-RRB-
cord-324810-92fosk3c	193	7	 	 	_SP
cord-324810-92fosk3c	194	1	Whether	whether	IN
cord-324810-92fosk3c	194	2	the	the	DT
cord-324810-92fosk3c	194	3	acute	acute	JJ
cord-324810-92fosk3c	194	4	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	194	5	lead	lead	VBP
cord-324810-92fosk3c	194	6	to	to	TO
cord-324810-92fosk3c	194	7	decline	decline	VB
cord-324810-92fosk3c	194	8	in	in	IN
cord-324810-92fosk3c	194	9	lung	lung	NN
cord-324810-92fosk3c	194	10	func-	func-	NN
cord-324810-92fosk3c	194	11	tion	tion	NN
cord-324810-92fosk3c	194	12	or	or	CC
cord-324810-92fosk3c	194	13	contribute	contribute	VB
cord-324810-92fosk3c	194	14	to	to	IN
cord-324810-92fosk3c	194	15	the	the	DT
cord-324810-92fosk3c	194	16	progression	progression	NN
cord-324810-92fosk3c	194	17	of	of	IN
cord-324810-92fosk3c	194	18	COPD	COPD	NNP
cord-324810-92fosk3c	194	19	has	have	VBZ
cord-324810-92fosk3c	194	20	been	be	VBN
cord-324810-92fosk3c	194	21	more	more	RBR
cord-324810-92fosk3c	194	22	clearly	clearly	RB
cord-324810-92fosk3c	194	23	elucidated	elucidate	VBN
cord-324810-92fosk3c	194	24	in	in	IN
cord-324810-92fosk3c	194	25	recent	recent	JJ
cord-324810-92fosk3c	194	26	studies	study	NNS
cord-324810-92fosk3c	194	27	.	.	.
cord-324810-92fosk3c	195	1	The	the	DT
cord-324810-92fosk3c	195	2	early	early	JJ
cord-324810-92fosk3c	195	3	studies	study	NNS
cord-324810-92fosk3c	195	4	of	of	IN
cord-324810-92fosk3c	195	5	Fletch	Fletch	NNP
cord-324810-92fosk3c	195	6	-	-	HYPH
cord-324810-92fosk3c	195	7	Acute	acute	JJ
cord-324810-92fosk3c	195	8	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	195	9	are	be	VBP
cord-324810-92fosk3c	195	10	a	a	DT
cord-324810-92fosk3c	195	11	common	common	JJ
cord-324810-92fosk3c	195	12	cause	cause	NN
cord-324810-92fosk3c	195	13	of	of	IN
cord-324810-92fosk3c	195	14	hospitalization	hospitalization	NN
cord-324810-92fosk3c	195	15	and	and	CC
cord-324810-92fosk3c	196	1	er	er	UH
cord-324810-92fosk3c	196	2	,	,	,
cord-324810-92fosk3c	196	3	[	[	-LRB-
cord-324810-92fosk3c	196	4	43	43	CD
cord-324810-92fosk3c	196	5	]	]	-RRB-
cord-324810-92fosk3c	196	6	Howard	Howard	NNP
cord-324810-92fosk3c	196	7	,	,	,
cord-324810-92fosk3c	196	8	[	[	-LRB-
cord-324810-92fosk3c	196	9	44	44	CD
cord-324810-92fosk3c	196	10	]	]	-RRB-
cord-324810-92fosk3c	196	11	and	and	CC
cord-324810-92fosk3c	196	12	Bates	Bates	NNP
cord-324810-92fosk3c	196	13	[	[	-LRB-
cord-324810-92fosk3c	196	14	45	45	CD
cord-324810-92fosk3c	196	15	]	]	-RRB-
cord-324810-92fosk3c	196	16	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	196	17	that	that	IN
cord-324810-92fosk3c	196	18	acute	acute	JJ
cord-324810-92fosk3c	196	19	respiratory	respiratory	JJ
cord-324810-92fosk3c	196	20	death	death	NN
cord-324810-92fosk3c	196	21	in	in	IN
cord-324810-92fosk3c	196	22	patients	patient	NNS
cord-324810-92fosk3c	196	23	with	with	IN
cord-324810-92fosk3c	196	24	COPD	COPD	NNP
cord-324810-92fosk3c	196	25	.	.	.
cord-324810-92fosk3c	197	1	The	the	DT
cord-324810-92fosk3c	197	2	previously	previously	RB
cord-324810-92fosk3c	197	3	reported	report	VBN
cord-324810-92fosk3c	197	4	mortality	mortality	NN
cord-324810-92fosk3c	197	5	illnesses	illness	NNS
cord-324810-92fosk3c	197	6	did	do	VBD
cord-324810-92fosk3c	197	7	not	not	RB
cord-324810-92fosk3c	197	8	contribute	contribute	VB
cord-324810-92fosk3c	197	9	to	to	IN
cord-324810-92fosk3c	197	10	the	the	DT
cord-324810-92fosk3c	197	11	progression	progression	NN
cord-324810-92fosk3c	197	12	of	of	IN
cord-324810-92fosk3c	197	13	airway	airway	NN
cord-324810-92fosk3c	197	14	obstrucrates	obstrucrate	NNS
cord-324810-92fosk3c	197	15	of	of	IN
cord-324810-92fosk3c	197	16	20	20	CD
cord-324810-92fosk3c	197	17	-	-	SYM
cord-324810-92fosk3c	197	18	40	40	CD
cord-324810-92fosk3c	197	19	%	%	NN
cord-324810-92fosk3c	197	20	[	[	-LRB-
cord-324810-92fosk3c	197	21	50	50	CD
cord-324810-92fosk3c	197	22	]	]	-RRB-
cord-324810-92fosk3c	197	23	have	have	VBP
cord-324810-92fosk3c	197	24	now	now	RB
cord-324810-92fosk3c	197	25	decreased	decrease	VBN
cord-324810-92fosk3c	197	26	to	to	IN
cord-324810-92fosk3c	197	27	11	11	CD
cord-324810-92fosk3c	197	28	%	%	NN
cord-324810-92fosk3c	197	29	,	,	,
cord-324810-92fosk3c	197	30	as	as	IN
cord-324810-92fosk3c	197	31	recently	recently	RB
cord-324810-92fosk3c	197	32	tion	tion	NN
cord-324810-92fosk3c	197	33	over	over	IN
cord-324810-92fosk3c	197	34	the	the	DT
cord-324810-92fosk3c	197	35	long	long	JJ
cord-324810-92fosk3c	197	36	-	-	HYPH
cord-324810-92fosk3c	197	37	term	term	NN
cord-324810-92fosk3c	197	38	.	.	.
cord-324810-92fosk3c	198	1	However	however	RB
cord-324810-92fosk3c	198	2	,	,	,
cord-324810-92fosk3c	198	3	more	more	JJR
cord-324810-92fosk3c	198	4	recent	recent	JJ
cord-324810-92fosk3c	198	5	studies	study	NNS
cord-324810-92fosk3c	198	6	have	have	VBP
cord-324810-92fosk3c	198	7	obreported	obreporte	VBN
cord-324810-92fosk3c	198	8	by	by	IN
cord-324810-92fosk3c	198	9	Connors	Connors	NNP
cord-324810-92fosk3c	198	10	et	et	NNP
cord-324810-92fosk3c	198	11	al	al	NNP
cord-324810-92fosk3c	198	12	.	.	.
cord-324810-92fosk3c	199	1	[	[	-LRB-
cord-324810-92fosk3c	199	2	51	51	CD
cord-324810-92fosk3c	199	3	]	]	-RRB-
cord-324810-92fosk3c	200	1	However	however	RB
cord-324810-92fosk3c	200	2	,	,	,
cord-324810-92fosk3c	200	3	these	these	DT
cord-324810-92fosk3c	200	4	patients	patient	NNS
cord-324810-92fosk3c	200	5	continue	continue	VBP
cord-324810-92fosk3c	200	6	to	to	TO
cord-324810-92fosk3c	200	7	have	have	VB
cord-324810-92fosk3c	200	8	poor	poor	JJ
cord-324810-92fosk3c	200	9	long	long	JJ
cord-324810-92fosk3c	200	10	-	-	HYPH
cord-324810-92fosk3c	200	11	term	term	NN
cord-324810-92fosk3c	200	12	prognosis	prognosis	NN
cord-324810-92fosk3c	200	13	,	,	,
cord-324810-92fosk3c	200	14	as	as	IN
cord-324810-92fosk3c	200	15	a	a	DT
cord-324810-92fosk3c	200	16	mortality	mortality	NN
cord-324810-92fosk3c	200	17	rate	rate	NN
cord-324810-92fosk3c	200	18	of	of	IN
cord-324810-92fosk3c	200	19	43	43	CD
cord-324810-92fosk3c	200	20	%	%	NN
cord-324810-92fosk3c	200	21	at	at	IN
cord-324810-92fosk3c	200	22	1	1	CD
cord-324810-92fosk3c	200	23	year	year	NN
cord-324810-92fosk3c	200	24	and	and	CC
cord-324810-92fosk3c	200	25	49	49	CD
cord-324810-92fosk3c	200	26	%	%	NN
cord-324810-92fosk3c	200	27	at	at	IN
cord-324810-92fosk3c	200	28	2	2	CD
cord-324810-92fosk3c	200	29	years	year	NNS
cord-324810-92fosk3c	200	30	was	be	VBD
cord-324810-92fosk3c	200	31	reported	report	VBN
cord-324810-92fosk3c	200	32	.	.	.
cord-324810-92fosk3c	201	1	The	the	DT
cord-324810-92fosk3c	201	2	predictors	predictor	NNS
cord-324810-92fosk3c	201	3	of	of	IN
cord-324810-92fosk3c	201	4	high	high	JJ
cord-324810-92fosk3c	201	5	long	long	JJ
cord-324810-92fosk3c	201	6	-	-	HYPH
cord-324810-92fosk3c	201	7	term	term	NN
cord-324810-92fosk3c	201	8	mortality	mortality	NN
cord-324810-92fosk3c	201	9	have	have	VBP
cord-324810-92fosk3c	201	10	been	be	VBN
cord-324810-92fosk3c	201	11	identified	identify	VBN
cord-324810-92fosk3c	201	12	as	as	IN
cord-324810-92fosk3c	201	13	follows	follow	VBZ
cord-324810-92fosk3c	201	14	:	:	:
cord-324810-92fosk3c	202	1	severity	severity	NN
cord-324810-92fosk3c	202	2	of	of	IN
cord-324810-92fosk3c	202	3	physiologic	physiologic	JJ
cord-324810-92fosk3c	202	4	abnormalities	abnormality	NNS
cord-324810-92fosk3c	202	5	during	during	IN
cord-324810-92fosk3c	202	6	exacerbation	exacerbation	NN
cord-324810-92fosk3c	202	7	,	,	,
cord-324810-92fosk3c	202	8	poor	poor	JJ
cord-324810-92fosk3c	202	9	overall	overall	JJ
cord-324810-92fosk3c	202	10	health	health	NN
cord-324810-92fosk3c	202	11	status	status	NN
cord-324810-92fosk3c	202	12	,	,	,
cord-324810-92fosk3c	202	13	comorbidities	comorbiditie	NNS
cord-324810-92fosk3c	202	14	,	,	,
cord-324810-92fosk3c	202	15	poor	poor	JJ
cord-324810-92fosk3c	202	16	nutrition	nutrition	NN
cord-324810-92fosk3c	202	17	as	as	IN
cord-324810-92fosk3c	202	18	indicated	indicate	VBN
cord-324810-92fosk3c	202	19	by	by	IN
cord-324810-92fosk3c	202	20	low	low	JJ
cord-324810-92fosk3c	202	21	body	body	NN
cord-324810-92fosk3c	202	22	mass	mass	NN
cord-324810-92fosk3c	202	23	index	index	NN
cord-324810-92fosk3c	202	24	,	,	,
cord-324810-92fosk3c	202	25	and	and	CC
cord-324810-92fosk3c	202	26	low	low	JJ
cord-324810-92fosk3c	202	27	serum	serum	NN
cord-324810-92fosk3c	202	28	albumin	albumin	NN
cord-324810-92fosk3c	202	29	.	.	.
cord-324810-92fosk3c	203	1	In	in	IN
cord-324810-92fosk3c	203	2	1995	1995	CD
cord-324810-92fosk3c	203	3	,	,	,
cord-324810-92fosk3c	203	4	Ball	Ball	NNP
cord-324810-92fosk3c	203	5	et	et	FW
cord-324810-92fosk3c	203	6	al	al	NNP
cord-324810-92fosk3c	203	7	.	.	.
cord-324810-92fosk3c	204	1	[	[	-LRB-
cord-324810-92fosk3c	204	2	52	52	CD
cord-324810-92fosk3c	204	3	]	]	-RRB-
cord-324810-92fosk3c	204	4	found	find	VBD
cord-324810-92fosk3c	204	5	that	that	IN
cord-324810-92fosk3c	204	6	the	the	DT
cord-324810-92fosk3c	204	7	presence	presence	NN
cord-324810-92fosk3c	204	8	of	of	IN
cord-324810-92fosk3c	204	9	cardiovascular	cardiovascular	JJ
cord-324810-92fosk3c	204	10	comorbidity	comorbidity	NN
cord-324810-92fosk3c	204	11	and	and	CC
cord-324810-92fosk3c	204	12	more	more	JJR
cord-324810-92fosk3c	204	13	than	than	IN
cord-324810-92fosk3c	204	14	four	four	CD
cord-324810-92fosk3c	204	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	204	16	in	in	IN
cord-324810-92fosk3c	204	17	the	the	DT
cord-324810-92fosk3c	204	18	previous	previous	JJ
cord-324810-92fosk3c	204	19	year	year	NN
cord-324810-92fosk3c	204	20	were	be	VBD
cord-324810-92fosk3c	204	21	associated	associate	VBN
cord-324810-92fosk3c	204	22	with	with	IN
cord-324810-92fosk3c	204	23	treatment	treatment	NN
cord-324810-92fosk3c	204	24	failure	failure	NN
cord-324810-92fosk3c	204	25	.	.	.
cord-324810-92fosk3c	205	1	In	in	IN
cord-324810-92fosk3c	205	2	a	a	DT
cord-324810-92fosk3c	205	3	retrospective	retrospective	JJ
cord-324810-92fosk3c	205	4	study	study	NN
cord-324810-92fosk3c	205	5	of	of	IN
cord-324810-92fosk3c	205	6	232	232	CD
cord-324810-92fosk3c	205	7	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	205	8	in	in	IN
cord-324810-92fosk3c	205	9	107	107	CD
cord-324810-92fosk3c	205	10	patients	patient	NNS
cord-324810-92fosk3c	205	11	with	with	IN
cord-324810-92fosk3c	205	12	COPD	COPD	NNP
cord-324810-92fosk3c	205	13	,	,	,
cord-324810-92fosk3c	205	14	Dewan	Dewan	NNP
cord-324810-92fosk3c	205	15	et	et	NNP
cord-324810-92fosk3c	205	16	al	al	NNP
cord-324810-92fosk3c	205	17	.	.	.
cord-324810-92fosk3c	206	1	[	[	-LRB-
cord-324810-92fosk3c	206	2	53	53	CD
cord-324810-92fosk3c	206	3	]	]	-RRB-
cord-324810-92fosk3c	206	4	identified	identify	VBN
cord-324810-92fosk3c	206	5	patient	patient	JJ
cord-324810-92fosk3c	206	6	host	host	NN
cord-324810-92fosk3c	206	7	factors	factor	NNS
cord-324810-92fosk3c	206	8	and	and	CC
cord-324810-92fosk3c	206	9	not	not	RB
cord-324810-92fosk3c	206	10	the	the	DT
cord-324810-92fosk3c	206	11	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	206	12	choice	choice	NN
cord-324810-92fosk3c	206	13	as	as	IN
cord-324810-92fosk3c	206	14	influencing	influence	VBG
cord-324810-92fosk3c	206	15	treatment	treatment	NN
cord-324810-92fosk3c	206	16	outcome	outcome	NN
cord-324810-92fosk3c	206	17	.	.	.
cord-324810-92fosk3c	207	1	The	the	DT
cord-324810-92fosk3c	207	2	use	use	NN
cord-324810-92fosk3c	207	3	of	of	IN
cord-324810-92fosk3c	207	4	home	home	NN
cord-324810-92fosk3c	207	5	oxygen	oxygen	NN
cord-324810-92fosk3c	207	6	and	and	CC
cord-324810-92fosk3c	207	7	frequency	frequency	NN
cord-324810-92fosk3c	207	8	of	of	IN
cord-324810-92fosk3c	207	9	exacerbation	exacerbation	NN
cord-324810-92fosk3c	207	10	correctly	correctly	RB
cord-324810-92fosk3c	207	11	classified	classify	VBD
cord-324810-92fosk3c	207	12	treatment	treatment	NN
cord-324810-92fosk3c	207	13	failure	failure	NN
cord-324810-92fosk3c	207	14	in	in	IN
cord-324810-92fosk3c	207	15	83	83	CD
cord-324810-92fosk3c	207	16	%	%	NN
cord-324810-92fosk3c	207	17	of	of	IN
cord-324810-92fosk3c	207	18	the	the	DT
cord-324810-92fosk3c	207	19	patients	patient	NNS
cord-324810-92fosk3c	207	20	.	.	.
cord-324810-92fosk3c	208	1	The	the	DT
cord-324810-92fosk3c	208	2	presence	presence	NN
cord-324810-92fosk3c	208	3	of	of	IN
cord-324810-92fosk3c	208	4	cardiovascular	cardiovascular	JJ
cord-324810-92fosk3c	208	5	comorbidity	comorbidity	NN
cord-324810-92fosk3c	208	6	combined	combine	VBN
cord-324810-92fosk3c	208	7	with	with	IN
cord-324810-92fosk3c	208	8	greater	great	JJR
cord-324810-92fosk3c	208	9	than	than	IN
cord-324810-92fosk3c	208	10	four	four	CD
cord-324810-92fosk3c	208	11	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	208	12	in	in	IN
cord-324810-92fosk3c	208	13	the	the	DT
cord-324810-92fosk3c	208	14	previous	previous	JJ
cord-324810-92fosk3c	208	15	year	year	NN
cord-324810-92fosk3c	208	16	has	have	VBZ
cord-324810-92fosk3c	208	17	a	a	DT
cord-324810-92fosk3c	208	18	sensitivity	sensitivity	NN
cord-324810-92fosk3c	208	19	of	of	IN
cord-324810-92fosk3c	208	20	70	70	CD
cord-324810-92fosk3c	208	21	%	%	NN
cord-324810-92fosk3c	208	22	and	and	CC
cord-324810-92fosk3c	208	23	specificity	specificity	NN
cord-324810-92fosk3c	208	24	of	of	IN
cord-324810-92fosk3c	208	25	37	37	CD
cord-324810-92fosk3c	208	26	%	%	NN
cord-324810-92fosk3c	208	27	in	in	IN
cord-324810-92fosk3c	208	28	predicting	predict	VBG
cord-324810-92fosk3c	208	29	treatment	treatment	NN
cord-324810-92fosk3c	208	30	failure	failure	NN
cord-324810-92fosk3c	208	31	.	.	.
cord-324810-92fosk3c	209	1	[	[	-LRB-
cord-324810-92fosk3c	209	2	52	52	CD
cord-324810-92fosk3c	209	3	,	,	,
cord-324810-92fosk3c	209	4	54	54	CD
cord-324810-92fosk3c	209	5	]	]	-RRB-
cord-324810-92fosk3c	210	1	In	in	IN
cord-324810-92fosk3c	210	2	other	other	JJ
cord-324810-92fosk3c	210	3	studies	study	NNS
cord-324810-92fosk3c	210	4	,	,	,
cord-324810-92fosk3c	210	5	advanced	advanced	JJ
cord-324810-92fosk3c	210	6	age	age	NN
cord-324810-92fosk3c	210	7	,	,	,
cord-324810-92fosk3c	210	8	significant	significant	JJ
cord-324810-92fosk3c	210	9	impairment	impairment	NN
cord-324810-92fosk3c	210	10	of	of	IN
cord-324810-92fosk3c	210	11	lung	lung	NN
cord-324810-92fosk3c	210	12	function	function	NN
cord-324810-92fosk3c	210	13	,	,	,
cord-324810-92fosk3c	210	14	poor	poor	JJ
cord-324810-92fosk3c	210	15	performance	performance	NN
cord-324810-92fosk3c	210	16	status	status	NN
cord-324810-92fosk3c	210	17	,	,	,
cord-324810-92fosk3c	210	18	comorbid	comorbid	NN
cord-324810-92fosk3c	210	19	conditions	condition	NNS
cord-324810-92fosk3c	210	20	and	and	CC
cord-324810-92fosk3c	210	21	a	a	DT
cord-324810-92fosk3c	210	22	history	history	NN
cord-324810-92fosk3c	210	23	of	of	IN
cord-324810-92fosk3c	210	24	previous	previous	JJ
cord-324810-92fosk3c	210	25	frequent	frequent	JJ
cord-324810-92fosk3c	210	26	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	210	27	requiring	require	VBG
cord-324810-92fosk3c	210	28	systemic	systemic	JJ
cord-324810-92fosk3c	210	29	corticosteroids	corticosteroid	NNS
cord-324810-92fosk3c	210	30	characterized	characterize	VBD
cord-324810-92fosk3c	210	31	the	the	DT
cord-324810-92fosk3c	210	32	high	high	JJ
cord-324810-92fosk3c	210	33	-	-	HYPH
cord-324810-92fosk3c	210	34	risk	risk	NN
cord-324810-92fosk3c	210	35	group	group	NN
cord-324810-92fosk3c	210	36	.	.	.
cord-324810-92fosk3c	211	1	[	[	-LRB-
cord-324810-92fosk3c	211	2	42	42	CD
cord-324810-92fosk3c	211	3	,	,	,
cord-324810-92fosk3c	211	4	55	55	CD
cord-324810-92fosk3c	211	5	]	]	-RRB-
cord-324810-92fosk3c	212	1	Additionally	additionally	RB
cord-324810-92fosk3c	212	2	,	,	,
cord-324810-92fosk3c	212	3	the	the	DT
cord-324810-92fosk3c	212	4	risk	risk	NN
cord-324810-92fosk3c	212	5	factors	factor	NNS
cord-324810-92fosk3c	212	6	for	for	IN
cord-324810-92fosk3c	212	7	relapse	relapse	NN
cord-324810-92fosk3c	212	8	are	be	VBP
cord-324810-92fosk3c	212	9	increasing	increase	VBG
cord-324810-92fosk3c	212	10	number	number	NN
cord-324810-92fosk3c	212	11	of	of	IN
cord-324810-92fosk3c	212	12	previous	previous	JJ
cord-324810-92fosk3c	212	13	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	212	14	,	,	,
cord-324810-92fosk3c	212	15	severity	severity	NN
cord-324810-92fosk3c	212	16	of	of	IN
cord-324810-92fosk3c	212	17	airflow	airflow	NN
cord-324810-92fosk3c	212	18	obstruction	obstruction	NN
cord-324810-92fosk3c	212	19	,	,	,
cord-324810-92fosk3c	212	20	and	and	CC
cord-324810-92fosk3c	212	21	increasing	increase	VBG
cord-324810-92fosk3c	212	22	baseline	baseline	JJ
cord-324810-92fosk3c	212	23	dyspnea	dyspnea	NN
cord-324810-92fosk3c	212	24	.	.	.
cord-324810-92fosk3c	213	1	[	[	-LRB-
cord-324810-92fosk3c	213	2	 	 	_SP
cord-324810-92fosk3c	213	3	Treatment	Treatment	NNP
cord-324810-92fosk3c	213	4	failures	failure	NNS
cord-324810-92fosk3c	213	5	in	in	IN
cord-324810-92fosk3c	213	6	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	213	7	lead	lead	VBP
cord-324810-92fosk3c	213	8	to	to	TO
cord-324810-92fosk3c	213	9	return	return	VB
cord-324810-92fosk3c	213	10	physician	physician	NN
cord-324810-92fosk3c	213	11	or	or	CC
cord-324810-92fosk3c	213	12	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	213	13	are	be	VBP
cord-324810-92fosk3c	213	14	associated	associate	VBN
cord-324810-92fosk3c	213	15	with	with	IN
cord-324810-92fosk3c	213	16	a	a	DT
cord-324810-92fosk3c	213	17	significant	significant	JJ
cord-324810-92fosk3c	213	18	increase	increase	NN
cord-324810-92fosk3c	213	19	in	in	IN
cord-324810-92fosk3c	213	20	healthclinic	healthclinic	JJ
cord-324810-92fosk3c	213	21	visits	visit	NNS
cord-324810-92fosk3c	213	22	,	,	,
cord-324810-92fosk3c	213	23	require	require	VBP
cord-324810-92fosk3c	213	24	repeated	repeat	VBN
cord-324810-92fosk3c	213	25	courses	course	NNS
cord-324810-92fosk3c	213	26	of	of	IN
cord-324810-92fosk3c	213	27	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	213	28	therapy	therapy	NN
cord-324810-92fosk3c	213	29	,	,	,
cord-324810-92fosk3c	213	30	risk	risk	NN
cord-324810-92fosk3c	213	31	care	care	NN
cord-324810-92fosk3c	213	32	utilization	utilization	NN
cord-324810-92fosk3c	213	33	and	and	CC
cord-324810-92fosk3c	213	34	are	be	VBP
cord-324810-92fosk3c	213	35	a	a	DT
cord-324810-92fosk3c	213	36	frequent	frequent	JJ
cord-324810-92fosk3c	213	37	cause	cause	NN
cord-324810-92fosk3c	213	38	of	of	IN
cord-324810-92fosk3c	213	39	hospital	hospital	NN
cord-324810-92fosk3c	213	40	admishospitalization	admishospitalization	NN
cord-324810-92fosk3c	213	41	,	,	,
cord-324810-92fosk3c	213	42	and	and	CC
cord-324810-92fosk3c	213	43	increase	increase	VB
cord-324810-92fosk3c	213	44	overall	overall	JJ
cord-324810-92fosk3c	213	45	costs	cost	NNS
cord-324810-92fosk3c	213	46	.	.	.
cord-324810-92fosk3c	214	1	[	[	-LRB-
cord-324810-92fosk3c	214	2	74	74	CD
cord-324810-92fosk3c	214	3	]	]	-RRB-
cord-324810-92fosk3c	215	1	Furthermore	furthermore	RB
cord-324810-92fosk3c	215	2	,	,	,
cord-324810-92fosk3c	215	3	pasion	pasion	NNP
cord-324810-92fosk3c	215	4	.	.	.
cord-324810-92fosk3c	216	1	[	[	-LRB-
cord-324810-92fosk3c	216	2	57	57	CD
cord-324810-92fosk3c	216	3	]	]	-RRB-
cord-324810-92fosk3c	216	4	[	[	-LRB-
cord-324810-92fosk3c	216	5	58	58	CD
cord-324810-92fosk3c	216	6	]	]	-RRB-
cord-324810-92fosk3c	217	1	[	[	-LRB-
cord-324810-92fosk3c	217	2	59	59	CD
cord-324810-92fosk3c	217	3	]	]	-RRB-
cord-324810-92fosk3c	218	1	[	[	-LRB-
cord-324810-92fosk3c	218	2	60	60	CD
cord-324810-92fosk3c	218	3	]	]	-RRB-
cord-324810-92fosk3c	219	1	Therefore	therefore	RB
cord-324810-92fosk3c	219	2	,	,	,
cord-324810-92fosk3c	219	3	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	219	4	are	be	VBP
cord-324810-92fosk3c	219	5	the	the	DT
cord-324810-92fosk3c	219	6	major	major	JJ
cord-324810-92fosk3c	219	7	cost	cost	NN
cord-324810-92fosk3c	219	8	drivers	driver	NNS
cord-324810-92fosk3c	219	9	in	in	IN
cord-324810-92fosk3c	219	10	tients	tient	NNS
cord-324810-92fosk3c	219	11	with	with	IN
cord-324810-92fosk3c	219	12	severe	severe	JJ
cord-324810-92fosk3c	219	13	COPD	COPD	NNP
cord-324810-92fosk3c	219	14	have	have	VBP
cord-324810-92fosk3c	219	15	limited	limit	VBN
cord-324810-92fosk3c	219	16	ventilatory	ventilatory	JJ
cord-324810-92fosk3c	219	17	reserve	reserve	NN
cord-324810-92fosk3c	219	18	,	,	,
cord-324810-92fosk3c	219	19	and	and	CC
cord-324810-92fosk3c	219	20	overall	overall	JJ
cord-324810-92fosk3c	219	21	cost	cost	NN
cord-324810-92fosk3c	219	22	of	of	IN
cord-324810-92fosk3c	219	23	COPD	COPD	NNP
cord-324810-92fosk3c	219	24	,	,	,
cord-324810-92fosk3c	219	25	which	which	WDT
cord-324810-92fosk3c	219	26	consumes	consume	VBZ
cord-324810-92fosk3c	219	27	significant	significant	JJ
cord-324810-92fosk3c	219	28	healthcare	healthcare	NN
cord-324810-92fosk3c	219	29	acute	acute	JJ
cord-324810-92fosk3c	219	30	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	219	31	are	be	VBP
cord-324810-92fosk3c	219	32	a	a	DT
cord-324810-92fosk3c	219	33	common	common	JJ
cord-324810-92fosk3c	219	34	cause	cause	NN
cord-324810-92fosk3c	219	35	of	of	IN
cord-324810-92fosk3c	219	36	acute	acute	JJ
cord-324810-92fosk3c	219	37	respiratory	respiratory	JJ
cord-324810-92fosk3c	219	38	resources	resource	NNS
cord-324810-92fosk3c	219	39	.	.	.
cord-324810-92fosk3c	220	1	[	[	-LRB-
cord-324810-92fosk3c	220	2	61	61	CD
cord-324810-92fosk3c	220	3	,	,	,
cord-324810-92fosk3c	220	4	62	62	CD
cord-324810-92fosk3c	220	5	]	]	-RRB-
cord-324810-92fosk3c	221	1	Several	several	JJ
cord-324810-92fosk3c	221	2	investigators	investigator	NNS
cord-324810-92fosk3c	221	3	estimated	estimate	VBD
cord-324810-92fosk3c	221	4	the	the	DT
cord-324810-92fosk3c	221	5	cost	cost	NN
cord-324810-92fosk3c	221	6	of	of	IN
cord-324810-92fosk3c	221	7	acute	acute	JJ
cord-324810-92fosk3c	221	8	failure	failure	NN
cord-324810-92fosk3c	221	9	requiring	require	VBG
cord-324810-92fosk3c	221	10	intubation	intubation	NN
cord-324810-92fosk3c	221	11	and	and	CC
cord-324810-92fosk3c	221	12	mechanical	mechanical	JJ
cord-324810-92fosk3c	221	13	ventilation	ventilation	NN
cord-324810-92fosk3c	221	14	.	.	.
cord-324810-92fosk3c	222	1	[	[	-LRB-
cord-324810-92fosk3c	222	2	75	75	CD
cord-324810-92fosk3c	222	3	]	]	-RRB-
cord-324810-92fosk3c	222	4	Stratifiexacerbation	Stratifiexacerbation	NNP
cord-324810-92fosk3c	222	5	in	in	IN
cord-324810-92fosk3c	222	6	patients	patient	NNS
cord-324810-92fosk3c	222	7	above	above	IN
cord-324810-92fosk3c	222	8	the	the	DT
cord-324810-92fosk3c	222	9	age	age	NN
cord-324810-92fosk3c	222	10	of	of	IN
cord-324810-92fosk3c	222	11	65	65	CD
cord-324810-92fosk3c	222	12	years	year	NNS
cord-324810-92fosk3c	222	13	to	to	TO
cord-324810-92fosk3c	222	14	be	be	VB
cord-324810-92fosk3c	222	15	$	$	$
cord-324810-92fosk3c	222	16	US1.2	us1.2	JJ
cord-324810-92fosk3c	222	17	cation	cation	NN
cord-324810-92fosk3c	222	18	of	of	IN
cord-324810-92fosk3c	222	19	patients	patient	NNS
cord-324810-92fosk3c	222	20	into	into	IN
cord-324810-92fosk3c	222	21	risk	risk	NN
cord-324810-92fosk3c	222	22	categories	category	NNS
cord-324810-92fosk3c	222	23	may	may	MD
cord-324810-92fosk3c	222	24	allow	allow	VB
cord-324810-92fosk3c	222	25	physicians	physician	NNS
cord-324810-92fosk3c	222	26	to	to	IN
cord-324810-92fosk3c	222	27	billion	billion	CD
cord-324810-92fosk3c	222	28	,	,	,
cord-324810-92fosk3c	222	29	and	and	CC
cord-324810-92fosk3c	222	30	$	$	$
cord-324810-92fosk3c	222	31	US419	us419	CD
cord-324810-92fosk3c	222	32	million	million	CD
cord-324810-92fosk3c	222	33	for	for	IN
cord-324810-92fosk3c	222	34	patients	patient	NNS
cord-324810-92fosk3c	222	35	below	below	IN
cord-324810-92fosk3c	222	36	this	this	DT
cord-324810-92fosk3c	222	37	age	age	NN
cord-324810-92fosk3c	222	38	.	.	.
cord-324810-92fosk3c	223	1	[	[	-LRB-
cord-324810-92fosk3c	223	2	61	61	CD
cord-324810-92fosk3c	223	3	]	]	-RRB-
cord-324810-92fosk3c	224	1	The	the	DT
cord-324810-92fosk3c	224	2	select	select	JJ
cord-324810-92fosk3c	224	3	appropriate	appropriate	JJ
cord-324810-92fosk3c	224	4	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	224	5	therapy	therapy	NN
cord-324810-92fosk3c	224	6	,	,	,
cord-324810-92fosk3c	224	7	so	so	IN
cord-324810-92fosk3c	224	8	as	as	IN
cord-324810-92fosk3c	224	9	to	to	TO
cord-324810-92fosk3c	224	10	avoid	avoid	VB
cord-324810-92fosk3c	224	11	treatment	treatment	NN
cord-324810-92fosk3c	224	12	annual	annual	JJ
cord-324810-92fosk3c	224	13	costs	cost	NNS
cord-324810-92fosk3c	224	14	of	of	IN
cord-324810-92fosk3c	224	15	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	224	16	in	in	IN
cord-324810-92fosk3c	224	17	England	England	NNP
cord-324810-92fosk3c	224	18	and	and	CC
cord-324810-92fosk3c	224	19	Wales	Wales	NNP
cord-324810-92fosk3c	224	20	were	be	VBD
cord-324810-92fosk3c	224	21	estimated	estimate	VBN
cord-324810-92fosk3c	224	22	to	to	IN
cord-324810-92fosk3c	224	23	failure	failure	NN
cord-324810-92fosk3c	224	24	and	and	CC
cord-324810-92fosk3c	224	25	improve	improve	VB
cord-324810-92fosk3c	224	26	outcome	outcome	NN
cord-324810-92fosk3c	224	27	in	in	IN
cord-324810-92fosk3c	224	28	an	an	DT
cord-324810-92fosk3c	224	29	era	era	NN
cord-324810-92fosk3c	224	30	of	of	IN
cord-324810-92fosk3c	224	31	increasing	increase	VBG
cord-324810-92fosk3c	224	32	antimicrobial	antimicrobial	NN
cord-324810-92fosk3c	224	33	be	be	VB
cord-324810-92fosk3c	224	34	£	£	$
cord-324810-92fosk3c	224	35	45	45	CD
cord-324810-92fosk3c	224	36	million	million	CD
cord-324810-92fosk3c	224	37	by	by	IN
cord-324810-92fosk3c	224	38	McGuire	McGuire	NNP
cord-324810-92fosk3c	224	39	et	et	NNP
cord-324810-92fosk3c	224	40	al	al	NNP
cord-324810-92fosk3c	224	41	.	.	NNP
cord-324810-92fosk3c	224	42	;	;	:
cord-324810-92fosk3c	224	43	[	[	-LRB-
cord-324810-92fosk3c	224	44	63	63	CD
cord-324810-92fosk3c	224	45	]	]	-RRB-
cord-324810-92fosk3c	224	46	this	this	DT
cord-324810-92fosk3c	224	47	represents	represent	VBZ
cord-324810-92fosk3c	224	48	0.1	0.1	CD
cord-324810-92fosk3c	224	49	%	%	NN
cord-324810-92fosk3c	224	50	and	and	CC
cord-324810-92fosk3c	224	51	0.2	0.2	CD
cord-324810-92fosk3c	224	52	%	%	NN
cord-324810-92fosk3c	224	53	resistance	resistance	NN
cord-324810-92fosk3c	224	54	.	.	.
cord-324810-92fosk3c	225	1	[	[	-LRB-
cord-324810-92fosk3c	225	2	74	74	CD
cord-324810-92fosk3c	225	3	]	]	-RRB-
cord-324810-92fosk3c	225	4	[	[	-LRB-
cord-324810-92fosk3c	225	5	75	75	CD
cord-324810-92fosk3c	225	6	]	]	-RRB-
cord-324810-92fosk3c	225	7	[	[	-LRB-
cord-324810-92fosk3c	225	8	76	76	CD
cord-324810-92fosk3c	225	9	]	]	-RRB-
cord-324810-92fosk3c	225	10	[	[	-LRB-
cord-324810-92fosk3c	225	11	77	77	CD
cord-324810-92fosk3c	225	12	]	]	-RRB-
cord-324810-92fosk3c	226	1	[	[	-LRB-
cord-324810-92fosk3c	226	2	78	78	CD
cord-324810-92fosk3c	226	3	]	]	-RRB-
cord-324810-92fosk3c	226	4	of	of	IN
cord-324810-92fosk3c	226	5	the	the	DT
cord-324810-92fosk3c	226	6	National	National	NNP
cord-324810-92fosk3c	226	7	Health	Health	NNP
cord-324810-92fosk3c	226	8	Services	Services	NNP
cord-324810-92fosk3c	226	9	budget	budget	NN
cord-324810-92fosk3c	226	10	,	,	,
cord-324810-92fosk3c	226	11	respectively	respectively	RB
cord-324810-92fosk3c	226	12	.	.	.
cord-324810-92fosk3c	227	1	Data	datum	NNS
cord-324810-92fosk3c	227	2	from	from	IN
cord-324810-92fosk3c	227	3	France	France	NNP
cord-324810-92fosk3c	227	4	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	227	5	that	that	IN
cord-324810-92fosk3c	227	6	direct	direct	JJ
cord-324810-92fosk3c	227	7	healthcare	healthcare	NN
cord-324810-92fosk3c	227	8	costs	cost	NNS
cord-324810-92fosk3c	227	9	per	per	IN
cord-324810-92fosk3c	227	10	acute	acute	JJ
cord-324810-92fosk3c	227	11	exacer-	exacer-	JJ
cord-324810-92fosk3c	227	12	bation	bation	NNP
cord-324810-92fosk3c	227	13	were	be	VBD
cord-324810-92fosk3c	227	14	about	about	IN
cord-324810-92fosk3c	227	15	FF3289	FF3289	NNP
cord-324810-92fosk3c	227	16	,	,	,
cord-324810-92fosk3c	227	17	of	of	IN
cord-324810-92fosk3c	227	18	which	which	WDT
cord-324810-92fosk3c	227	19	60	60	CD
cord-324810-92fosk3c	227	20	%	%	NN
cord-324810-92fosk3c	227	21	were	be	VBD
cord-324810-92fosk3c	227	22	hospital	hospital	NN
cord-324810-92fosk3c	227	23	related	relate	VBN
cord-324810-92fosk3c	227	24	.	.	.
cord-324810-92fosk3c	228	1	[	[	-LRB-
cord-324810-92fosk3c	228	2	64	64	CD
cord-324810-92fosk3c	228	3	]	]	-RRB-
cord-324810-92fosk3c	229	1	Several	several	JJ
cord-324810-92fosk3c	229	2	risk	risk	NN
cord-324810-92fosk3c	229	3	stratification	stratification	NN
cord-324810-92fosk3c	229	4	schemes	scheme	NNS
cord-324810-92fosk3c	229	5	have	have	VBP
cord-324810-92fosk3c	229	6	been	be	VBN
cord-324810-92fosk3c	229	7	proposed	propose	VBN
cord-324810-92fosk3c	229	8	to	to	IN
cord-324810-92fosk3c	229	9	im-	im-	XX
cord-324810-92fosk3c	230	1	In	in	IN
cord-324810-92fosk3c	230	2	a	a	DT
cord-324810-92fosk3c	230	3	recent	recent	JJ
cord-324810-92fosk3c	230	4	Swedish	swedish	JJ
cord-324810-92fosk3c	230	5	study	study	NN
cord-324810-92fosk3c	230	6	,	,	,
cord-324810-92fosk3c	230	7	the	the	DT
cord-324810-92fosk3c	230	8	average	average	JJ
cord-324810-92fosk3c	230	9	healthcare	healthcare	NN
cord-324810-92fosk3c	230	10	costs	cost	NNS
cord-324810-92fosk3c	230	11	per	per	IN
cord-324810-92fosk3c	230	12	exacerprove	exacerprove	NN
cord-324810-92fosk3c	230	13	initial	initial	JJ
cord-324810-92fosk3c	230	14	microbial	microbial	JJ
cord-324810-92fosk3c	230	15	selection	selection	NN
cord-324810-92fosk3c	230	16	.	.	.
cord-324810-92fosk3c	231	1	Lode	Lode	NNP
cord-324810-92fosk3c	231	2	[	[	-LRB-
cord-324810-92fosk3c	231	3	75	75	CD
cord-324810-92fosk3c	231	4	]	]	-RRB-
cord-324810-92fosk3c	231	5	in	in	IN
cord-324810-92fosk3c	231	6	1991	1991	CD
cord-324810-92fosk3c	231	7	proposed	propose	VBD
cord-324810-92fosk3c	231	8	that	that	IN
cord-324810-92fosk3c	231	9	bation	bation	NN
cord-324810-92fosk3c	231	10	were	be	VBD
cord-324810-92fosk3c	231	11	SEK120	SEK120	NNP
cord-324810-92fosk3c	231	12	,	,	,
cord-324810-92fosk3c	231	13	SEK354	SEK354	NNP
cord-324810-92fosk3c	231	14	,	,	,
cord-324810-92fosk3c	231	15	SEK2111	sek2111	NN
cord-324810-92fosk3c	231	16	and	and	CC
cord-324810-92fosk3c	231	17	SEK21852	sek21852	NN
cord-324810-92fosk3c	231	18	for	for	IN
cord-324810-92fosk3c	231	19	mild	mild	JJ
cord-324810-92fosk3c	231	20	,	,	,
cord-324810-92fosk3c	231	21	patients	patient	NNS
cord-324810-92fosk3c	231	22	be	be	VB
cord-324810-92fosk3c	231	23	divided	divide	VBN
cord-324810-92fosk3c	231	24	into	into	IN
cord-324810-92fosk3c	231	25	three	three	CD
cord-324810-92fosk3c	231	26	groups	group	NNS
cord-324810-92fosk3c	231	27	based	base	VBN
cord-324810-92fosk3c	231	28	on	on	IN
cord-324810-92fosk3c	231	29	severity	severity	NN
cord-324810-92fosk3c	231	30	of	of	IN
cord-324810-92fosk3c	231	31	lung	lung	NN
cord-324810-92fosk3c	231	32	mild	mild	JJ
cord-324810-92fosk3c	231	33	/	/	SYM
cord-324810-92fosk3c	231	34	moderate	moderate	JJ
cord-324810-92fosk3c	231	35	,	,	,
cord-324810-92fosk3c	231	36	moderate	moderate	JJ
cord-324810-92fosk3c	231	37	and	and	CC
cord-324810-92fosk3c	231	38	severe	severe	JJ
cord-324810-92fosk3c	231	39	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	231	40	,	,	,
cord-324810-92fosk3c	231	41	respectivefunction	respectivefunction	NN
cord-324810-92fosk3c	231	42	,	,	,
cord-324810-92fosk3c	231	43	number	number	NN
cord-324810-92fosk3c	231	44	of	of	IN
cord-324810-92fosk3c	231	45	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	231	46	each	each	DT
cord-324810-92fosk3c	231	47	year	year	NN
cord-324810-92fosk3c	231	48	,	,	,
cord-324810-92fosk3c	231	49	and	and	CC
cord-324810-92fosk3c	231	50	presence	presence	NN
cord-324810-92fosk3c	231	51	of	of	IN
cord-324810-92fosk3c	231	52	a	a	DT
cord-324810-92fosk3c	231	53	ly	ly	XX
cord-324810-92fosk3c	231	54	.	.	.
cord-324810-92fosk3c	232	1	[	[	-LRB-
cord-324810-92fosk3c	232	2	65	65	CD
cord-324810-92fosk3c	232	3	]	]	-RRB-
cord-324810-92fosk3c	233	1	These	these	DT
cord-324810-92fosk3c	233	2	translated	translate	VBN
cord-324810-92fosk3c	233	3	to	to	IN
cord-324810-92fosk3c	233	4	SEK1.7	SEK1.7	NNP
cord-324810-92fosk3c	233	5	billion	billion	CD
cord-324810-92fosk3c	233	6	per	per	IN
cord-324810-92fosk3c	233	7	year	year	NN
cord-324810-92fosk3c	233	8	nationally	nationally	RB
cord-324810-92fosk3c	233	9	where	where	WRB
cord-324810-92fosk3c	233	10	comorbidity	comorbidity	NN
cord-324810-92fosk3c	233	11	.	.	.
cord-324810-92fosk3c	234	1	Treatment	treatment	NN
cord-324810-92fosk3c	234	2	with	with	IN
cord-324810-92fosk3c	234	3	oral	oral	JJ
cord-324810-92fosk3c	234	4	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	234	5	,	,	,
cord-324810-92fosk3c	234	6	doxycycline	doxycycline	NNP
cord-324810-92fosk3c	234	7	,	,	,
cord-324810-92fosk3c	234	8	hospitalization	hospitalization	NN
cord-324810-92fosk3c	234	9	was	be	VBD
cord-324810-92fosk3c	234	10	the	the	DT
cord-324810-92fosk3c	234	11	key	key	JJ
cord-324810-92fosk3c	234	12	cost	cost	NN
cord-324810-92fosk3c	234	13	driver	driver	NN
cord-324810-92fosk3c	234	14	,	,	,
cord-324810-92fosk3c	234	15	accounting	account	VBG
cord-324810-92fosk3c	234	16	for	for	IN
cord-324810-92fosk3c	234	17	67	67	CD
cord-324810-92fosk3c	234	18	%	%	NN
cord-324810-92fosk3c	234	19	of	of	IN
cord-324810-92fosk3c	234	20	the	the	DT
cord-324810-92fosk3c	234	21	trimethoprim	trimethoprim	NNP
cord-324810-92fosk3c	234	22	/	/	SYM
cord-324810-92fosk3c	234	23	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	234	24	(	(	-LRB-
cord-324810-92fosk3c	234	25	co	co	JJ
cord-324810-92fosk3c	234	26	-	-	JJ
cord-324810-92fosk3c	234	27	trimoxazole	trimoxazole	JJ
cord-324810-92fosk3c	234	28	)	)	-RRB-
cord-324810-92fosk3c	234	29	or	or	CC
cord-324810-92fosk3c	234	30	a	a	DT
cord-324810-92fosk3c	234	31	macrolide	macrolide	JJ
cord-324810-92fosk3c	234	32	total	total	JJ
cord-324810-92fosk3c	234	33	cost	cost	NN
cord-324810-92fosk3c	234	34	.	.	.
cord-324810-92fosk3c	235	1	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	235	2	is	be	VBZ
cord-324810-92fosk3c	235	3	costly	costly	JJ
cord-324810-92fosk3c	235	4	;	;	:
cord-324810-92fosk3c	235	5	the	the	DT
cord-324810-92fosk3c	235	6	costs	cost	NNS
cord-324810-92fosk3c	235	7	are	be	VBP
cord-324810-92fosk3c	235	8	variable	variable	JJ
cord-324810-92fosk3c	235	9	but	but	CC
cord-324810-92fosk3c	235	10	higher	high	JJR
cord-324810-92fosk3c	235	11	for	for	IN
cord-324810-92fosk3c	235	12	was	be	VBD
cord-324810-92fosk3c	235	13	recommended	recommend	VBN
cord-324810-92fosk3c	235	14	for	for	IN
cord-324810-92fosk3c	235	15	low	low	JJ
cord-324810-92fosk3c	235	16	-	-	HYPH
cord-324810-92fosk3c	235	17	risk	risk	NN
cord-324810-92fosk3c	235	18	patients	patient	NNS
cord-324810-92fosk3c	235	19	(	(	-LRB-
cord-324810-92fosk3c	235	20	first	first	JJ
cord-324810-92fosk3c	235	21	degree	degree	NN
cord-324810-92fosk3c	235	22	)	)	-RRB-
cord-324810-92fosk3c	235	23	.	.	.
cord-324810-92fosk3c	236	1	Patients	patient	NNS
cord-324810-92fosk3c	236	2	severe	severe	JJ
cord-324810-92fosk3c	236	3	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	236	4	and	and	CC
cord-324810-92fosk3c	236	5	in	in	IN
cord-324810-92fosk3c	236	6	patients	patient	NNS
cord-324810-92fosk3c	236	7	requiring	require	VBG
cord-324810-92fosk3c	236	8	hospitalization	hospitalization	NN
cord-324810-92fosk3c	236	9	.	.	.
cord-324810-92fosk3c	237	1	A	a	DT
cord-324810-92fosk3c	237	2	with	with	IN
cord-324810-92fosk3c	237	3	a	a	DT
cord-324810-92fosk3c	237	4	longer	long	JJR
cord-324810-92fosk3c	237	5	history	history	NN
cord-324810-92fosk3c	237	6	of	of	IN
cord-324810-92fosk3c	237	7	COPD	COPD	NNP
cord-324810-92fosk3c	237	8	,	,	,
cord-324810-92fosk3c	237	9	several	several	JJ
cord-324810-92fosk3c	237	10	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	237	11	each	each	DT
cord-324810-92fosk3c	237	12	year	year	NN
cord-324810-92fosk3c	237	13	,	,	,
cord-324810-92fosk3c	237	14	retrospective	retrospective	JJ
cord-324810-92fosk3c	237	15	study	study	NN
cord-324810-92fosk3c	237	16	by	by	IN
cord-324810-92fosk3c	237	17	Destache	Destache	NNP
cord-324810-92fosk3c	237	18	et	et	NNP
cord-324810-92fosk3c	237	19	al	al	NNP
cord-324810-92fosk3c	237	20	.	.	.
cord-324810-92fosk3c	238	1	[	[	-LRB-
cord-324810-92fosk3c	238	2	66	66	CD
cord-324810-92fosk3c	238	3	]	]	-RRB-
cord-324810-92fosk3c	238	4	reported	report	VBN
cord-324810-92fosk3c	238	5	reduced	reduce	VBN
cord-324810-92fosk3c	238	6	overall	overall	JJ
cord-324810-92fosk3c	238	7	other	other	JJ
cord-324810-92fosk3c	238	8	comorbidity	comorbidity	NN
cord-324810-92fosk3c	238	9	,	,	,
cord-324810-92fosk3c	238	10	impaired	impair	VBN
cord-324810-92fosk3c	238	11	lung	lung	NN
cord-324810-92fosk3c	238	12	function	function	NN
cord-324810-92fosk3c	238	13	and	and	CC
cord-324810-92fosk3c	238	14	inpatients	inpatient	NNS
cord-324810-92fosk3c	238	15	were	be	VBD
cord-324810-92fosk3c	238	16	healthcare	healthcare	NN
cord-324810-92fosk3c	238	17	costs	cost	NNS
cord-324810-92fosk3c	238	18	with	with	IN
cord-324810-92fosk3c	238	19	the	the	DT
cord-324810-92fosk3c	238	20	use	use	NN
cord-324810-92fosk3c	238	21	of	of	IN
cord-324810-92fosk3c	238	22	newer	new	JJR
cord-324810-92fosk3c	238	23	agents	agent	NNS
cord-324810-92fosk3c	238	24	compared	compare	VBN
cord-324810-92fosk3c	238	25	with	with	IN
cord-324810-92fosk3c	238	26	firstconsidered	firstconsidered	JJ
cord-324810-92fosk3c	238	27	high	high	JJ
cord-324810-92fosk3c	238	28	-	-	HYPH
cord-324810-92fosk3c	238	29	risk	risk	NN
cord-324810-92fosk3c	238	30	patients	patient	NNS
cord-324810-92fosk3c	238	31	(	(	-LRB-
cord-324810-92fosk3c	238	32	second	second	JJ
cord-324810-92fosk3c	238	33	and	and	CC
cord-324810-92fosk3c	238	34	third	third	JJ
cord-324810-92fosk3c	238	35	degree	degree	NN
cord-324810-92fosk3c	238	36	)	)	-RRB-
cord-324810-92fosk3c	238	37	.	.	.
cord-324810-92fosk3c	239	1	line	line	NN
cord-324810-92fosk3c	239	2	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	239	3	.	.	.
cord-324810-92fosk3c	240	1	Another	another	DT
cord-324810-92fosk3c	240	2	such	such	JJ
cord-324810-92fosk3c	240	3	study	study	NN
cord-324810-92fosk3c	240	4	by	by	IN
cord-324810-92fosk3c	240	5	Torrance	Torrance	NNP
cord-324810-92fosk3c	240	6	et	et	NNP
cord-324810-92fosk3c	240	7	al	al	NNP
cord-324810-92fosk3c	240	8	.	.	.
cord-324810-92fosk3c	241	1	[	[	-LRB-
cord-324810-92fosk3c	241	2	67	67	CD
cord-324810-92fosk3c	241	3	]	]	-RRB-
cord-324810-92fosk3c	242	1	In	in	IN
cord-324810-92fosk3c	242	2	1994	1994	CD
cord-324810-92fosk3c	242	3	,	,	,
cord-324810-92fosk3c	242	4	Balter	Balter	NNP
cord-324810-92fosk3c	242	5	et	et	NNP
cord-324810-92fosk3c	242	6	al	al	NNP
cord-324810-92fosk3c	242	7	.	.	.
cord-324810-92fosk3c	243	1	[	[	-LRB-
cord-324810-92fosk3c	243	2	79	79	CD
cord-324810-92fosk3c	243	3	]	]	-RRB-
cord-324810-92fosk3c	243	4	initially	initially	RB
cord-324810-92fosk3c	243	5	suggested	suggest	VBD
cord-324810-92fosk3c	243	6	a	a	DT
cord-324810-92fosk3c	243	7	five	five	CD
cord-324810-92fosk3c	243	8	-	-	HYPH
cord-324810-92fosk3c	243	9	group	group	NN
cord-324810-92fosk3c	243	10	classifidemonstrated	classifidemonstrate	VBN
cord-324810-92fosk3c	243	11	benefit	benefit	NN
cord-324810-92fosk3c	243	12	and	and	CC
cord-324810-92fosk3c	243	13	lower	low	JJR
cord-324810-92fosk3c	243	14	total	total	JJ
cord-324810-92fosk3c	243	15	costs	cost	NNS
cord-324810-92fosk3c	243	16	with	with	IN
cord-324810-92fosk3c	243	17	fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	243	18	cation	cation	NN
cord-324810-92fosk3c	243	19	of	of	IN
cord-324810-92fosk3c	243	20	patients	patient	NNS
cord-324810-92fosk3c	243	21	with	with	IN
cord-324810-92fosk3c	243	22	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	243	23	,	,	,
cord-324810-92fosk3c	243	24	and	and	CC
cord-324810-92fosk3c	243	25	in	in	IN
cord-324810-92fosk3c	243	26	a	a	DT
cord-324810-92fosk3c	243	27	recent	recent	JJ
cord-324810-92fosk3c	243	28	publication	publication	NN
cord-324810-92fosk3c	243	29	these	these	DT
cord-324810-92fosk3c	243	30	in	in	IN
cord-324810-92fosk3c	243	31	patients	patient	NNS
cord-324810-92fosk3c	243	32	who	who	WP
cord-324810-92fosk3c	243	33	had	have	VBD
cord-324810-92fosk3c	243	34	a	a	DT
cord-324810-92fosk3c	243	35	history	history	NN
cord-324810-92fosk3c	243	36	of	of	IN
cord-324810-92fosk3c	243	37	moderate	moderate	JJ
cord-324810-92fosk3c	243	38	-	-	HYPH
cord-324810-92fosk3c	243	39	to	to	IN
cord-324810-92fosk3c	243	40	-	-	HYPH
cord-324810-92fosk3c	243	41	severe	severe	JJ
cord-324810-92fosk3c	243	42	bronchitis	bronchitis	NN
cord-324810-92fosk3c	243	43	and	and	CC
cord-324810-92fosk3c	243	44	patient	patient	NN
cord-324810-92fosk3c	243	45	are	be	VBP
cord-324810-92fosk3c	243	46	classified	classify	VBN
cord-324810-92fosk3c	243	47	into	into	IN
cord-324810-92fosk3c	243	48	four	four	CD
cord-324810-92fosk3c	243	49	groups	group	NNS
cord-324810-92fosk3c	243	50	.	.	.
cord-324810-92fosk3c	244	1	[	[	-LRB-
cord-324810-92fosk3c	244	2	80	80	CD
cord-324810-92fosk3c	244	3	]	]	-RRB-
cord-324810-92fosk3c	245	1	The	the	DT
cord-324810-92fosk3c	245	2	patients	patient	NNS
cord-324810-92fosk3c	245	3	with	with	IN
cord-324810-92fosk3c	245	4	acute	acute	NN
cord-324810-92fosk3c	245	5	at	at	RB
cord-324810-92fosk3c	245	6	least	least	JJS
cord-324810-92fosk3c	245	7	four	four	CD
cord-324810-92fosk3c	245	8	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	245	9	in	in	IN
cord-324810-92fosk3c	245	10	the	the	DT
cord-324810-92fosk3c	245	11	previous	previous	JJ
cord-324810-92fosk3c	245	12	year	year	NN
cord-324810-92fosk3c	245	13	.	.	.
cord-324810-92fosk3c	246	1	simple	simple	JJ
cord-324810-92fosk3c	246	2	bronchitis	bronchitis	NN
cord-324810-92fosk3c	246	3	and	and	CC
cord-324810-92fosk3c	246	4	no	no	DT
cord-324810-92fosk3c	246	5	previous	previous	JJ
cord-324810-92fosk3c	246	6	respiratory	respiratory	JJ
cord-324810-92fosk3c	246	7	problems	problem	NNS
cord-324810-92fosk3c	246	8	were	be	VBD
cord-324810-92fosk3c	246	9	Several	several	JJ
cord-324810-92fosk3c	246	10	recent	recent	JJ
cord-324810-92fosk3c	246	11	studies	study	NNS
cord-324810-92fosk3c	246	12	have	have	VBP
cord-324810-92fosk3c	246	13	supported	support	VBN
cord-324810-92fosk3c	246	14	the	the	DT
cord-324810-92fosk3c	246	15	use	use	NN
cord-324810-92fosk3c	246	16	of	of	IN
cord-324810-92fosk3c	246	17	different	different	JJ
cord-324810-92fosk3c	246	18	classified	classify	VBN
cord-324810-92fosk3c	246	19	as	as	IN
cord-324810-92fosk3c	246	20	Group	Group	NNP
cord-324810-92fosk3c	246	21	0	0	CD
cord-324810-92fosk3c	246	22	,	,	,
cord-324810-92fosk3c	246	23	the	the	DT
cord-324810-92fosk3c	246	24	Group	Group	NNP
cord-324810-92fosk3c	247	1	I	-PRON-	PRP
cord-324810-92fosk3c	247	2	patients	patient	NNS
cord-324810-92fosk3c	247	3	had	have	VBD
cord-324810-92fosk3c	247	4	simple	simple	JJ
cord-324810-92fosk3c	247	5	chronic	chronic	JJ
cord-324810-92fosk3c	247	6	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	247	7	based	base	VBN
cord-324810-92fosk3c	247	8	on	on	IN
cord-324810-92fosk3c	247	9	patient	patient	JJ
cord-324810-92fosk3c	247	10	stratification	stratification	NN
cord-324810-92fosk3c	247	11	.	.	.
cord-324810-92fosk3c	248	1	[	[	-LRB-
cord-324810-92fosk3c	248	2	68	68	CD
cord-324810-92fosk3c	248	3	]	]	-RRB-
cord-324810-92fosk3c	248	4	[	[	-LRB-
cord-324810-92fosk3c	248	5	69	69	CD
cord-324810-92fosk3c	248	6	]	]	-RRB-
cord-324810-92fosk3c	248	7	[	[	-LRB-
cord-324810-92fosk3c	248	8	70	70	CD
cord-324810-92fosk3c	248	9	]	]	-RRB-
cord-324810-92fosk3c	249	1	[	[	-LRB-
cord-324810-92fosk3c	249	2	71	71	CD
cord-324810-92fosk3c	249	3	]	]	-RRB-
cord-324810-92fosk3c	250	1	These	these	DT
cord-324810-92fosk3c	250	2	studies	study	NNS
cord-324810-92fosk3c	250	3	bronchitis	bronchitis	VBP
cord-324810-92fosk3c	250	4	with	with	IN
cord-324810-92fosk3c	250	5	minimal	minimal	JJ
cord-324810-92fosk3c	250	6	or	or	CC
cord-324810-92fosk3c	250	7	no	no	DT
cord-324810-92fosk3c	250	8	impairment	impairment	NN
cord-324810-92fosk3c	250	9	of	of	IN
cord-324810-92fosk3c	250	10	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	250	11	function	function	NN
cord-324810-92fosk3c	250	12	utilized	utilize	VBN
cord-324810-92fosk3c	250	13	either	either	CC
cord-324810-92fosk3c	250	14	computerized	computerized	JJ
cord-324810-92fosk3c	250	15	modeling	modeling	NN
cord-324810-92fosk3c	250	16	or	or	CC
cord-324810-92fosk3c	250	17	a	a	DT
cord-324810-92fosk3c	250	18	prospective	prospective	JJ
cord-324810-92fosk3c	250	19	study	study	NN
cord-324810-92fosk3c	250	20	and	and	CC
cord-324810-92fosk3c	250	21	without	without	IN
cord-324810-92fosk3c	250	22	any	any	DT
cord-324810-92fosk3c	250	23	risk	risk	NN
cord-324810-92fosk3c	250	24	factors	factor	NNS
cord-324810-92fosk3c	250	25	.	.	.
cord-324810-92fosk3c	251	1	Group	group	NN
cord-324810-92fosk3c	251	2	II	ii	CD
cord-324810-92fosk3c	251	3	patients	patient	NNS
cord-324810-92fosk3c	251	4	were	be	VBD
cord-324810-92fosk3c	251	5	similar	similar	JJ
cord-324810-92fosk3c	251	6	to	to	IN
cord-324810-92fosk3c	251	7	design	design	VB
cord-324810-92fosk3c	251	8	.	.	.
cord-324810-92fosk3c	252	1	The	the	DT
cord-324810-92fosk3c	252	2	use	use	NN
cord-324810-92fosk3c	252	3	of	of	IN
cord-324810-92fosk3c	252	4	newer	new	JJR
cord-324810-92fosk3c	252	5	broad	broad	JJ
cord-324810-92fosk3c	252	6	-	-	HYPH
cord-324810-92fosk3c	252	7	spectrum	spectrum	NN
cord-324810-92fosk3c	252	8	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	252	9	was	be	VBD
cord-324810-92fosk3c	252	10	Group	Group	NNP
cord-324810-92fosk3c	252	11	I	-PRON-	PRP
cord-324810-92fosk3c	252	12	but	but	CC
cord-324810-92fosk3c	252	13	had	have	VBD
cord-324810-92fosk3c	252	14	one	one	CD
cord-324810-92fosk3c	252	15	or	or	CC
cord-324810-92fosk3c	252	16	more	more	RBR
cord-324810-92fosk3c	252	17	significant	significant	JJ
cord-324810-92fosk3c	252	18	comorbid	comorbid	NN
cord-324810-92fosk3c	252	19	illnesses	illness	NNS
cord-324810-92fosk3c	252	20	such	such	JJ
cord-324810-92fosk3c	252	21	as	as	IN
cord-324810-92fosk3c	252	22	associated	associate	VBN
cord-324810-92fosk3c	252	23	with	with	IN
cord-324810-92fosk3c	252	24	better	well	JJR
cord-324810-92fosk3c	252	25	clinical	clinical	JJ
cord-324810-92fosk3c	252	26	outcomes	outcome	NNS
cord-324810-92fosk3c	252	27	and	and	CC
cord-324810-92fosk3c	252	28	lower	low	JJR
cord-324810-92fosk3c	252	29	healthcare	healthcare	NN
cord-324810-92fosk3c	252	30	costs	cost	NNS
cord-324810-92fosk3c	252	31	congestive	congestive	JJ
cord-324810-92fosk3c	252	32	heart	heart	NN
cord-324810-92fosk3c	252	33	failure	failure	NN
cord-324810-92fosk3c	252	34	,	,	,
cord-324810-92fosk3c	252	35	diabetes	diabetes	NN
cord-324810-92fosk3c	252	36	mellitus	mellitus	NN
cord-324810-92fosk3c	252	37	,	,	,
cord-324810-92fosk3c	252	38	chronic	chronic	JJ
cord-324810-92fosk3c	252	39	renal	renal	JJ
cord-324810-92fosk3c	252	40	failure	failure	NN
cord-324810-92fosk3c	252	41	or	or	CC
cord-324810-92fosk3c	252	42	in	in	IN
cord-324810-92fosk3c	252	43	patients	patient	NNS
cord-324810-92fosk3c	252	44	with	with	IN
cord-324810-92fosk3c	252	45	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	252	46	who	who	WP
cord-324810-92fosk3c	252	47	had	have	VBD
cord-324810-92fosk3c	252	48	moderate	moderate	JJ
cord-324810-92fosk3c	252	49	-	-	HYPH
cord-324810-92fosk3c	252	50	to	to	IN
cord-324810-92fosk3c	252	51	-	-	HYPH
cord-324810-92fosk3c	252	52	severe	severe	JJ
cord-324810-92fosk3c	252	53	exacerbachronic	exacerbachronic	JJ
cord-324810-92fosk3c	252	54	liver	liver	NN
cord-324810-92fosk3c	252	55	disease	disease	NN
cord-324810-92fosk3c	252	56	.	.	.
cord-324810-92fosk3c	253	1	Group	group	NN
cord-324810-92fosk3c	253	2	III	iii	CD
cord-324810-92fosk3c	253	3	patients	patient	NNS
cord-324810-92fosk3c	253	4	were	be	VBD
cord-324810-92fosk3c	253	5	classified	classify	VBN
cord-324810-92fosk3c	253	6	as	as	IN
cord-324810-92fosk3c	253	7	having	have	VBG
cord-324810-92fosk3c	253	8	tions	tion	NNS
cord-324810-92fosk3c	253	9	and	and	CC
cord-324810-92fosk3c	253	10	comorbid	comorbid	NN
cord-324810-92fosk3c	253	11	conditions	condition	NNS
cord-324810-92fosk3c	253	12	.	.	.
cord-324810-92fosk3c	254	1	Outpatient	outpatient	JJ
cord-324810-92fosk3c	254	2	drug	drug	NN
cord-324810-92fosk3c	254	3	costs	cost	NNS
cord-324810-92fosk3c	254	4	,	,	,
cord-324810-92fosk3c	254	5	an	an	DT
cord-324810-92fosk3c	254	6	important	important	JJ
cord-324810-92fosk3c	254	7	chronic	chronic	JJ
cord-324810-92fosk3c	254	8	bronchial	bronchial	JJ
cord-324810-92fosk3c	254	9	sepsis	sepsis	NN
cord-324810-92fosk3c	254	10	.	.	.
cord-324810-92fosk3c	255	1	This	this	DT
cord-324810-92fosk3c	255	2	scheme	scheme	NN
cord-324810-92fosk3c	255	3	is	be	VBZ
cord-324810-92fosk3c	255	4	problematic	problematic	JJ
cord-324810-92fosk3c	255	5	and	and	CC
cord-324810-92fosk3c	255	6	impracticomponent	impracticomponent	JJ
cord-324810-92fosk3c	255	7	of	of	IN
cord-324810-92fosk3c	255	8	total	total	JJ
cord-324810-92fosk3c	255	9	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	255	10	expenditure	expenditure	NN
cord-324810-92fosk3c	255	11	,	,	,
cord-324810-92fosk3c	255	12	vary	vary	VBP
cord-324810-92fosk3c	255	13	inversely	inversely	RB
cord-324810-92fosk3c	255	14	with	with	IN
cord-324810-92fosk3c	255	15	cal	cal	NNP
cord-324810-92fosk3c	255	16	for	for	IN
cord-324810-92fosk3c	255	17	various	various	JJ
cord-324810-92fosk3c	255	18	reasons	reason	NNS
cord-324810-92fosk3c	255	19	,	,	,
cord-324810-92fosk3c	255	20	as	as	IN
cord-324810-92fosk3c	255	21	Group	group	NN
cord-324810-92fosk3c	255	22	0	0	CD
cord-324810-92fosk3c	255	23	patients	patient	NNS
cord-324810-92fosk3c	255	24	do	do	VBP
cord-324810-92fosk3c	255	25	not	not	RB
cord-324810-92fosk3c	255	26	have	have	VB
cord-324810-92fosk3c	255	27	COPD	COPD	NNP
cord-324810-92fosk3c	255	28	and	and	CC
cord-324810-92fosk3c	255	29	severity	severity	NN
cord-324810-92fosk3c	255	30	of	of	IN
cord-324810-92fosk3c	255	31	exacerbation	exacerbation	NN
cord-324810-92fosk3c	255	32	.	.	.
cord-324810-92fosk3c	256	1	Van	Van	NNP
cord-324810-92fosk3c	256	2	Barlingen	Barlingen	NNP
cord-324810-92fosk3c	256	3	et	et	NNP
cord-324810-92fosk3c	256	4	al	al	NNP
cord-324810-92fosk3c	256	5	.	.	.
cord-324810-92fosk3c	257	1	[	[	-LRB-
cord-324810-92fosk3c	257	2	71	71	CD
cord-324810-92fosk3c	257	3	]	]	-RRB-
cord-324810-92fosk3c	257	4	reported	report	VBD
cord-324810-92fosk3c	257	5	lower	low	JJR
cord-324810-92fosk3c	257	6	Group	Group	NNP
cord-324810-92fosk3c	257	7	III	iii	CD
cord-324810-92fosk3c	257	8	patients	patient	NNS
cord-324810-92fosk3c	257	9	are	be	VBP
cord-324810-92fosk3c	257	10	those	those	DT
cord-324810-92fosk3c	257	11	who	who	WP
cord-324810-92fosk3c	257	12	have	have	VBP
cord-324810-92fosk3c	257	13	bronchiectasis	bronchiectasis	NN
cord-324810-92fosk3c	257	14	or	or	CC
cord-324810-92fosk3c	257	15	are	be	VBP
cord-324810-92fosk3c	257	16	fredrug	fredrug	NN
cord-324810-92fosk3c	257	17	utilization	utilization	NN
cord-324810-92fosk3c	257	18	costs	cost	NNS
cord-324810-92fosk3c	257	19	in	in	IN
cord-324810-92fosk3c	257	20	severe	severe	JJ
cord-324810-92fosk3c	257	21	(	(	-LRB-
cord-324810-92fosk3c	257	22	7	7	CD
cord-324810-92fosk3c	257	23	%	%	NN
cord-324810-92fosk3c	257	24	)	)	-RRB-
cord-324810-92fosk3c	257	25	compared	compare	VBN
cord-324810-92fosk3c	257	26	with	with	IN
cord-324810-92fosk3c	257	27	mild	mild	JJ
cord-324810-92fosk3c	257	28	(	(	-LRB-
cord-324810-92fosk3c	257	29	17	17	CD
cord-324810-92fosk3c	257	30	%	%	NN
cord-324810-92fosk3c	257	31	)	)	-RRB-
cord-324810-92fosk3c	257	32	quently	quently	RB
cord-324810-92fosk3c	257	33	colonized	colonize	VBN
cord-324810-92fosk3c	257	34	by	by	IN
cord-324810-92fosk3c	257	35	Gram	gram	NN
cord-324810-92fosk3c	257	36	-	-	HYPH
cord-324810-92fosk3c	257	37	negative	negative	JJ
cord-324810-92fosk3c	257	38	bacterial	bacterial	JJ
cord-324810-92fosk3c	257	39	pathogens	pathogen	NNS
cord-324810-92fosk3c	257	40	,	,	,
cord-324810-92fosk3c	257	41	which	which	WDT
cord-324810-92fosk3c	257	42	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	257	43	.	.	.
cord-324810-92fosk3c	258	1	may	may	MD
cord-324810-92fosk3c	258	2	not	not	RB
cord-324810-92fosk3c	258	3	be	be	VB
cord-324810-92fosk3c	258	4	the	the	DT
cord-324810-92fosk3c	258	5	causative	causative	JJ
cord-324810-92fosk3c	258	6	pathogen	pathogen	NN
cord-324810-92fosk3c	258	7	.	.	.
cord-324810-92fosk3c	259	1	In	in	IN
cord-324810-92fosk3c	259	2	the	the	DT
cord-324810-92fosk3c	259	3	older	old	JJR
cord-324810-92fosk3c	259	4	classification	classification	NN
cord-324810-92fosk3c	259	5	,	,	,
cord-324810-92fosk3c	259	6	the	the	DT
cord-324810-92fosk3c	259	7	Current	current	JJ
cord-324810-92fosk3c	259	8	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	259	9	trials	trial	NNS
cord-324810-92fosk3c	259	10	in	in	IN
cord-324810-92fosk3c	259	11	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	259	12	are	be	VBP
cord-324810-92fosk3c	259	13	focusing	focus	VBG
cord-324810-92fosk3c	259	14	on	on	IN
cord-324810-92fosk3c	259	15	sympdivision	sympdivision	NN
cord-324810-92fosk3c	259	16	between	between	IN
cord-324810-92fosk3c	259	17	Group	Group	NNP
cord-324810-92fosk3c	259	18	3	3	CD
cord-324810-92fosk3c	259	19	and	and	CC
cord-324810-92fosk3c	259	20	Group	Group	NNP
cord-324810-92fosk3c	259	21	4	4	CD
cord-324810-92fosk3c	259	22	was	be	VBD
cord-324810-92fosk3c	259	23	arbitrary	arbitrary	JJ
cord-324810-92fosk3c	259	24	and	and	CC
cord-324810-92fosk3c	259	25	the	the	DT
cord-324810-92fosk3c	259	26	tomatic	tomatic	JJ
cord-324810-92fosk3c	259	27	improvement	improvement	NN
cord-324810-92fosk3c	259	28	as	as	IN
cord-324810-92fosk3c	259	29	the	the	DT
cord-324810-92fosk3c	259	30	outcome	outcome	NN
cord-324810-92fosk3c	259	31	measure	measure	NN
cord-324810-92fosk3c	259	32	.	.	.
cord-324810-92fosk3c	260	1	[	[	-LRB-
cord-324810-92fosk3c	260	2	8	8	CD
cord-324810-92fosk3c	260	3	,	,	,
cord-324810-92fosk3c	260	4	34	34	CD
cord-324810-92fosk3c	260	5	,	,	,
cord-324810-92fosk3c	260	6	35	35	CD
cord-324810-92fosk3c	260	7	,	,	,
cord-324810-92fosk3c	260	8	43	43	CD
cord-324810-92fosk3c	260	9	,	,	,
cord-324810-92fosk3c	260	10	[	[	-LRB-
cord-324810-92fosk3c	260	11	50	50	CD
cord-324810-92fosk3c	260	12	]	]	-RRB-
cord-324810-92fosk3c	260	13	[	[	-LRB-
cord-324810-92fosk3c	260	14	51	51	CD
cord-324810-92fosk3c	260	15	]	]	-RRB-
cord-324810-92fosk3c	261	1	[	[	-LRB-
cord-324810-92fosk3c	261	2	52	52	CD
cord-324810-92fosk3c	261	3	]	]	-RRB-
cord-324810-92fosk3c	261	4	55	55	CD
cord-324810-92fosk3c	261	5	]	]	-RRB-
cord-324810-92fosk3c	261	6	treatment	treatment	NN
cord-324810-92fosk3c	261	7	recommendations	recommendation	NNS
cord-324810-92fosk3c	261	8	were	be	VBD
cord-324810-92fosk3c	261	9	identical	identical	JJ
cord-324810-92fosk3c	261	10	.	.	.
cord-324810-92fosk3c	262	1	[	[	-LRB-
cord-324810-92fosk3c	262	2	79	79	CD
cord-324810-92fosk3c	262	3	]	]	-RRB-
cord-324810-92fosk3c	263	1	Since	since	IN
cord-324810-92fosk3c	263	2	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	263	3	frequently	frequently	RB
cord-324810-92fosk3c	263	4	recur	recur	VBP
cord-324810-92fosk3c	263	5	,	,	,
cord-324810-92fosk3c	263	6	a	a	DT
cord-324810-92fosk3c	263	7	disease	disease	NN
cord-324810-92fosk3c	263	8	-	-	HYPH
cord-324810-92fosk3c	263	9	free	free	JJ
cord-324810-92fosk3c	263	10	interval	interval	NN
cord-324810-92fosk3c	263	11	(	(	-LRB-
cord-324810-92fosk3c	263	12	DFI	DFI	NNP
cord-324810-92fosk3c	263	13	)	)	-RRB-
cord-324810-92fosk3c	263	14	may	may	MD
cord-324810-92fosk3c	263	15	be	be	VB
cord-324810-92fosk3c	263	16	more	more	RBR
cord-324810-92fosk3c	263	17	meaningful	meaningful	JJ
cord-324810-92fosk3c	263	18	.	.	.
cord-324810-92fosk3c	264	1	DFI	DFI	NNP
cord-324810-92fosk3c	264	2	is	be	VBZ
cord-324810-92fosk3c	264	3	defined	define	VBN
cord-324810-92fosk3c	264	4	as	as	IN
cord-324810-92fosk3c	264	5	"	"	``
cord-324810-92fosk3c	264	6	the	the	DT
cord-324810-92fosk3c	264	7	length	length	NN
cord-324810-92fosk3c	264	8	of	of	IN
cord-324810-92fosk3c	264	9	time	time	NN
cord-324810-92fosk3c	264	10	in	in	IN
cord-324810-92fosk3c	264	11	6.2	6.2	CD
cord-324810-92fosk3c	264	12	A	a	DT
cord-324810-92fosk3c	264	13	Practical	Practical	NNP
cord-324810-92fosk3c	264	14	Approach	Approach	NNP
cord-324810-92fosk3c	264	15	days	day	NNS
cord-324810-92fosk3c	264	16	between	between	IN
cord-324810-92fosk3c	264	17	the	the	DT
cord-324810-92fosk3c	264	18	end	end	NN
cord-324810-92fosk3c	264	19	of	of	IN
cord-324810-92fosk3c	264	20	therapy	therapy	NN
cord-324810-92fosk3c	264	21	and	and	CC
cord-324810-92fosk3c	264	22	the	the	DT
cord-324810-92fosk3c	264	23	beginning	beginning	NN
cord-324810-92fosk3c	264	24	of	of	IN
cord-324810-92fosk3c	264	25	next	next	JJ
cord-324810-92fosk3c	264	26	episode	episode	NN
cord-324810-92fosk3c	264	27	"	"	''
cord-324810-92fosk3c	264	28	.	.	.
cord-324810-92fosk3c	265	1	[	[	-LRB-
cord-324810-92fosk3c	265	2	72	72	CD
cord-324810-92fosk3c	265	3	]	]	-RRB-
cord-324810-92fosk3c	266	1	An	an	DT
cord-324810-92fosk3c	266	2	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	266	3	agent	agent	NN
cord-324810-92fosk3c	266	4	successful	successful	JJ
cord-324810-92fosk3c	266	5	in	in	IN
cord-324810-92fosk3c	266	6	eradicating	eradicate	VBG
cord-324810-92fosk3c	266	7	bacteri	bacteri	NN
cord-324810-92fosk3c	266	8	-	-	HYPH
cord-324810-92fosk3c	266	9	Modified	modify	VBN
cord-324810-92fosk3c	266	10	from	from	IN
cord-324810-92fosk3c	266	11	the	the	DT
cord-324810-92fosk3c	266	12	publications	publication	NNS
cord-324810-92fosk3c	266	13	of	of	IN
cord-324810-92fosk3c	266	14	Wilson	Wilson	NNP
cord-324810-92fosk3c	266	15	,	,	,
cord-324810-92fosk3c	266	16	[	[	-LRB-
cord-324810-92fosk3c	266	17	42	42	CD
cord-324810-92fosk3c	266	18	]	]	-RRB-
cord-324810-92fosk3c	266	19	Grossman	Grossman	NNP
cord-324810-92fosk3c	266	20	[	[	-LRB-
cord-324810-92fosk3c	266	21	81	81	CD
cord-324810-92fosk3c	266	22	]	]	-RRB-
cord-324810-92fosk3c	266	23	and	and	CC
cord-324810-92fosk3c	266	24	al	al	NNP
cord-324810-92fosk3c	266	25	colonization	colonization	NN
cord-324810-92fosk3c	266	26	from	from	IN
cord-324810-92fosk3c	266	27	the	the	DT
cord-324810-92fosk3c	266	28	lower	low	JJR
cord-324810-92fosk3c	266	29	airways	airway	NNS
cord-324810-92fosk3c	266	30	will	will	MD
cord-324810-92fosk3c	266	31	delay	delay	VB
cord-324810-92fosk3c	266	32	the	the	DT
cord-324810-92fosk3c	266	33	recur	recur	NN
cord-324810-92fosk3c	266	34	-	-	:
cord-324810-92fosk3c	266	35	Balter	Balter	NNP
cord-324810-92fosk3c	266	36	et	et	NNP
cord-324810-92fosk3c	266	37	al	al	NNP
cord-324810-92fosk3c	266	38	.	.	.
cord-324810-92fosk3c	267	1	[	[	-LRB-
cord-324810-92fosk3c	267	2	79	79	CD
cord-324810-92fosk3c	267	3	,	,	,
cord-324810-92fosk3c	267	4	80	80	CD
cord-324810-92fosk3c	267	5	]	]	-RRB-
cord-324810-92fosk3c	267	6	we	-PRON-	PRP
cord-324810-92fosk3c	267	7	proposed	propose	VBD
cord-324810-92fosk3c	267	8	a	a	DT
cord-324810-92fosk3c	267	9	simpler	simple	JJR
cord-324810-92fosk3c	267	10	risk	risk	NN
cord-324810-92fosk3c	267	11	scheme	scheme	NN
cord-324810-92fosk3c	267	12	to	to	TO
cord-324810-92fosk3c	267	13	stratify	stratify	VB
cord-324810-92fosk3c	267	14	rence	rence	NNP
cord-324810-92fosk3c	267	15	.	.	.
cord-324810-92fosk3c	268	1	[	[	-LRB-
cord-324810-92fosk3c	268	2	73	73	CD
cord-324810-92fosk3c	268	3	]	]	-RRB-
cord-324810-92fosk3c	268	4	DFI	DFI	NNP
cord-324810-92fosk3c	268	5	is	be	VBZ
cord-324810-92fosk3c	268	6	an	an	DT
cord-324810-92fosk3c	268	7	outcome	outcome	NN
cord-324810-92fosk3c	268	8	measure	measure	NN
cord-324810-92fosk3c	268	9	that	that	WDT
cord-324810-92fosk3c	268	10	should	should	MD
cord-324810-92fosk3c	268	11	be	be	VB
cord-324810-92fosk3c	268	12	evaluated	evaluate	VBN
cord-324810-92fosk3c	268	13	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	268	14	(	(	-LRB-
cord-324810-92fosk3c	268	15	table	table	NN
cord-324810-92fosk3c	268	16	IV	IV	NNP
cord-324810-92fosk3c	268	17	)	)	-RRB-
cord-324810-92fosk3c	268	18	.	.	.
cord-324810-92fosk3c	269	1	[	[	-LRB-
cord-324810-92fosk3c	269	2	82	82	CD
cord-324810-92fosk3c	269	3	]	]	-RRB-
cord-324810-92fosk3c	269	4	It	-PRON-	PRP
cord-324810-92fosk3c	269	5	may	may	MD
cord-324810-92fosk3c	269	6	be	be	VB
cord-324810-92fosk3c	269	7	more	more	RBR
cord-324810-92fosk3c	269	8	practical	practical	JJ
cord-324810-92fosk3c	269	9	to	to	TO
cord-324810-92fosk3c	269	10	categorize	categorize	VB
cord-324810-92fosk3c	269	11	all	all	DT
cord-324810-92fosk3c	269	12	additionally	additionally	RB
cord-324810-92fosk3c	269	13	in	in	IN
cord-324810-92fosk3c	269	14	future	future	JJ
cord-324810-92fosk3c	269	15	clinical	clinical	JJ
cord-324810-92fosk3c	269	16	trials	trial	NNS
cord-324810-92fosk3c	269	17	,	,	,
cord-324810-92fosk3c	269	18	to	to	TO
cord-324810-92fosk3c	269	19	demonstrate	demonstrate	VB
cord-324810-92fosk3c	269	20	clinical	clinical	JJ
cord-324810-92fosk3c	269	21	success	success	NN
cord-324810-92fosk3c	269	22	patients	patient	NNS
cord-324810-92fosk3c	269	23	with	with	IN
cord-324810-92fosk3c	269	24	Anthonisen	Anthonisen	NNP
cord-324810-92fosk3c	269	25	's	's	POS
cord-324810-92fosk3c	269	26	type	type	NN
cord-324810-92fosk3c	269	27	I	-PRON-	PRP
cord-324810-92fosk3c	269	28	and	and	CC
cord-324810-92fosk3c	269	29	type	type	NN
cord-324810-92fosk3c	269	30	II	ii	CD
cord-324810-92fosk3c	269	31	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	269	32	into	into	IN
cord-324810-92fosk3c	269	33	of	of	IN
cord-324810-92fosk3c	269	34	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	269	35	therapy	therapy	NN
cord-324810-92fosk3c	269	36	.	.	.
cord-324810-92fosk3c	270	1	either	either	CC
cord-324810-92fosk3c	270	2	simple	simple	JJ
cord-324810-92fosk3c	270	3	or	or	CC
cord-324810-92fosk3c	270	4	complicated	complicated	JJ
cord-324810-92fosk3c	270	5	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	270	6	.	.	.
cord-324810-92fosk3c	271	1	[	[	-LRB-
cord-324810-92fosk3c	271	2	83	83	CD
cord-324810-92fosk3c	271	3	]	]	-RRB-
cord-324810-92fosk3c	272	1	Since	since	IN
cord-324810-92fosk3c	272	2	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	272	3	First	first	JJ
cord-324810-92fosk3c	272	4	-	-	HYPH
cord-324810-92fosk3c	272	5	line	line	NN
cord-324810-92fosk3c	272	6	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	272	7	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	272	8	equivalent	equivalent	JJ
cord-324810-92fosk3c	272	9	efficacy	efficacy	NN
cord-324810-92fosk3c	272	10	in	in	IN
cord-324810-92fosk3c	272	11	the	the	DT
cord-324810-92fosk3c	272	12	study	study	NN
cord-324810-92fosk3c	272	13	by	by	IN
cord-324810-92fosk3c	272	14	Anthonisen	Anthonisen	NNP
cord-324810-92fosk3c	272	15	et	et	NNP
cord-324810-92fosk3c	272	16	al	al	NNP
cord-324810-92fosk3c	272	17	.	.	.
cord-324810-92fosk3c	273	1	[	[	-LRB-
cord-324810-92fosk3c	273	2	8	8	CD
cord-324810-92fosk3c	273	3	]	]	-RRB-
cord-324810-92fosk3c	274	1	Since	since	IN
cord-324810-92fosk3c	274	2	then	then	RB
cord-324810-92fosk3c	274	3	an	an	DT
cord-324810-92fosk3c	274	4	array	array	NN
cord-324810-92fosk3c	274	5	of	of	IN
cord-324810-92fosk3c	274	6	newer	new	JJR
cord-324810-92fosk3c	274	7	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	274	8	agents	agent	NNS
cord-324810-92fosk3c	274	9	have	have	VBP
cord-324810-92fosk3c	274	10	become	become	VBN
cord-324810-92fosk3c	274	11	available	available	JJ
cord-324810-92fosk3c	274	12	.	.	.
cord-324810-92fosk3c	275	1	These	these	DT
cord-324810-92fosk3c	275	2	agents	agent	NNS
cord-324810-92fosk3c	275	3	have	have	VBP
cord-324810-92fosk3c	275	4	generally	generally	RB
cord-324810-92fosk3c	275	5	been	be	VBN
cord-324810-92fosk3c	275	6	as	as	RB
cord-324810-92fosk3c	275	7	successful	successful	JJ
cord-324810-92fosk3c	275	8	in	in	IN
cord-324810-92fosk3c	275	9	treating	treat	VBG
cord-324810-92fosk3c	275	10	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	275	11	as	as	IN
cord-324810-92fosk3c	275	12	previously	previously	RB
cord-324810-92fosk3c	275	13	approved	approve	VBN
cord-324810-92fosk3c	275	14	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	275	15	.	.	.
cord-324810-92fosk3c	276	1	Whether	whether	IN
cord-324810-92fosk3c	276	2	one	one	CD
cord-324810-92fosk3c	276	3	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	276	4	agent	agent	NN
cord-324810-92fosk3c	276	5	is	be	VBZ
cord-324810-92fosk3c	276	6	superior	superior	JJ
cord-324810-92fosk3c	276	7	to	to	IN
cord-324810-92fosk3c	276	8	another	another	DT
cord-324810-92fosk3c	276	9	is	be	VBZ
cord-324810-92fosk3c	276	10	not	not	RB
cord-324810-92fosk3c	276	11	known	know	VBN
cord-324810-92fosk3c	276	12	,	,	,
cord-324810-92fosk3c	276	13	because	because	IN
cord-324810-92fosk3c	276	14	the	the	DT
cord-324810-92fosk3c	276	15	trials	trial	NNS
cord-324810-92fosk3c	276	16	have	have	VBP
cord-324810-92fosk3c	276	17	not	not	RB
cord-324810-92fosk3c	276	18	been	be	VBN
cord-324810-92fosk3c	276	19	designed	design	VBN
cord-324810-92fosk3c	276	20	with	with	IN
cord-324810-92fosk3c	276	21	this	this	DT
cord-324810-92fosk3c	276	22	goal	goal	NN
cord-324810-92fosk3c	276	23	in	in	IN
cord-324810-92fosk3c	276	24	mind	mind	NN
cord-324810-92fosk3c	276	25	.	.	.
cord-324810-92fosk3c	277	1	A	a	DT
cord-324810-92fosk3c	277	2	retrospective	retrospective	JJ
cord-324810-92fosk3c	277	3	study	study	NN
cord-324810-92fosk3c	277	4	by	by	IN
cord-324810-92fosk3c	277	5	Adams	Adams	NNP
cord-324810-92fosk3c	277	6	et	et	NNP
cord-324810-92fosk3c	277	7	al	al	NNP
cord-324810-92fosk3c	277	8	.	.	.
cord-324810-92fosk3c	278	1	[	[	-LRB-
cord-324810-92fosk3c	278	2	84	84	CD
cord-324810-92fosk3c	278	3	]	]	-RRB-
cord-324810-92fosk3c	278	4	looked	look	VBD
cord-324810-92fosk3c	278	5	at	at	IN
cord-324810-92fosk3c	278	6	the	the	DT
cord-324810-92fosk3c	278	7	risk	risk	NN
cord-324810-92fosk3c	278	8	factors	factor	NNS
cord-324810-92fosk3c	278	9	for	for	IN
cord-324810-92fosk3c	278	10	treatment	treatment	NN
cord-324810-92fosk3c	278	11	failure	failure	NN
cord-324810-92fosk3c	278	12	at	at	IN
cord-324810-92fosk3c	278	13	14	14	CD
cord-324810-92fosk3c	278	14	days	day	NNS
cord-324810-92fosk3c	278	15	after	after	IN
cord-324810-92fosk3c	278	16	onset	onset	NN
cord-324810-92fosk3c	278	17	of	of	IN
cord-324810-92fosk3c	278	18	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	278	19	.	.	.
cord-324810-92fosk3c	279	1	A	a	DT
cord-324810-92fosk3c	279	2	return	return	NN
cord-324810-92fosk3c	279	3	visit	visit	NN
cord-324810-92fosk3c	279	4	within	within	IN
cord-324810-92fosk3c	279	5	14	14	CD
cord-324810-92fosk3c	279	6	days	day	NNS
cord-324810-92fosk3c	279	7	with	with	IN
cord-324810-92fosk3c	279	8	persistent	persistent	JJ
cord-324810-92fosk3c	279	9	or	or	CC
cord-324810-92fosk3c	279	10	worsening	worsen	VBG
cord-324810-92fosk3c	279	11	symptoms	symptom	NNS
cord-324810-92fosk3c	279	12	was	be	VBD
cord-324810-92fosk3c	279	13	defined	define	VBN
cord-324810-92fosk3c	279	14	as	as	IN
cord-324810-92fosk3c	279	15	treatment	treatment	NN
cord-324810-92fosk3c	279	16	failure	failure	NN
cord-324810-92fosk3c	279	17	.	.	.
cord-324810-92fosk3c	280	1	The	the	DT
cord-324810-92fosk3c	280	2	failure	failure	NN
cord-324810-92fosk3c	280	3	Table	Table	NNP
cord-324810-92fosk3c	280	4	IV	IV	NNP
cord-324810-92fosk3c	280	5	.	.	.
cord-324810-92fosk3c	281	1	Risk	risk	NN
cord-324810-92fosk3c	281	2	stratification	stratification	NN
cord-324810-92fosk3c	281	3	of	of	IN
cord-324810-92fosk3c	281	4	patients	patient	NNS
cord-324810-92fosk3c	281	5	with	with	IN
cord-324810-92fosk3c	281	6	acute	acute	JJ
cord-324810-92fosk3c	281	7	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	281	8	of	of	IN
cord-324810-92fosk3c	281	9	chronic	chronic	JJ
cord-324810-92fosk3c	281	10	obstructive	obstructive	JJ
cord-324810-92fosk3c	281	11	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	281	12	disease	disease	NN
cord-324810-92fosk3c	281	13	[	[	-LRB-
cord-324810-92fosk3c	281	14	82	82	CD
cord-324810-92fosk3c	281	15	]	]	-RRB-
cord-324810-92fosk3c	281	16	Classification	classification	NN
cord-324810-92fosk3c	281	17	Characteristics	characteristic	NNS
cord-324810-92fosk3c	281	18	Patients	patient	NNS
cord-324810-92fosk3c	281	19	with	with	IN
cord-324810-92fosk3c	281	20	chronic	chronic	JJ
cord-324810-92fosk3c	281	21	bronchitis	bronchitis	NN
cord-324810-92fosk3c	281	22	and	and	CC
cord-324810-92fosk3c	281	23	two	two	CD
cord-324810-92fosk3c	281	24	or	or	CC
cord-324810-92fosk3c	281	25	more	more	JJR
cord-324810-92fosk3c	281	26	of	of	IN
cord-324810-92fosk3c	281	27	the	the	DT
cord-324810-92fosk3c	281	28	chronic	chronic	JJ
cord-324810-92fosk3c	281	29	following	follow	VBG
cord-324810-92fosk3c	281	30	symptoms	symptom	NNS
cord-324810-92fosk3c	281	31	(	(	-LRB-
cord-324810-92fosk3c	281	32	Anthonisen	Anthonisen	NNP
cord-324810-92fosk3c	281	33	's	's	POS
cord-324810-92fosk3c	281	34	type	type	NN
cord-324810-92fosk3c	281	35	I	-PRON-	PRP
cord-324810-92fosk3c	281	36	and	and	CC
cord-324810-92fosk3c	281	37	II	II	NNP
cord-324810-92fosk3c	281	38	)	)	-RRB-
cord-324810-92fosk3c	281	39	:	:	:
cord-324810-92fosk3c	282	1	bronchitis	bronchitis	NN
cord-324810-92fosk3c	282	2	increased	increase	VBN
cord-324810-92fosk3c	282	3	cough	cough	NN
cord-324810-92fosk3c	282	4	;	;	,
cord-324810-92fosk3c	282	5	increased	increase	VBN
cord-324810-92fosk3c	282	6	sputum	sputum	NN
cord-324810-92fosk3c	282	7	volume	volume	NN
cord-324810-92fosk3c	282	8	;	;	,
cord-324810-92fosk3c	282	9	increased	increase	VBN
cord-324810-92fosk3c	282	10	dyspnea	dyspnea	NN
cord-324810-92fosk3c	282	11	Patients	patient	NNS
cord-324810-92fosk3c	282	12	with	with	IN
cord-324810-92fosk3c	282	13	chronic	chronic	JJ
cord-324810-92fosk3c	282	14	bronchitis	bronchitis	NN
cord-324810-92fosk3c	282	15	and	and	CC
cord-324810-92fosk3c	282	16	Anthonisen	Anthonisen	NNP
cord-324810-92fosk3c	282	17	's	's	POS
cord-324810-92fosk3c	282	18	type	type	NN
cord-324810-92fosk3c	282	19	I	-PRON-	PRP
cord-324810-92fosk3c	282	20	chronic	chronic	VBP
cord-324810-92fosk3c	282	21	and	and	CC
cord-324810-92fosk3c	282	22	II	II	NNP
cord-324810-92fosk3c	282	23	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	282	24	and	and	CC
cord-324810-92fosk3c	282	25	at	at	RB
cord-324810-92fosk3c	282	26	least	least	RBS
cord-324810-92fosk3c	282	27	one	one	CD
cord-324810-92fosk3c	282	28	of	of	IN
cord-324810-92fosk3c	282	29	the	the	DT
cord-324810-92fosk3c	282	30	following	follow	VBG
cord-324810-92fosk3c	282	31	bronchitis	bronchitis	NN
cord-324810-92fosk3c	282	32	risk	risk	NN
cord-324810-92fosk3c	282	33	factors	factor	NNS
cord-324810-92fosk3c	282	34	:	:	:
cord-324810-92fosk3c	282	35	FEV1	fev1	NN
cord-324810-92fosk3c	282	36	<	<	XX
cord-324810-92fosk3c	282	37	50	50	CD
cord-324810-92fosk3c	282	38	%	%	NN
cord-324810-92fosk3c	282	39	predicted	predict	VBN
cord-324810-92fosk3c	282	40	;	;	:
cord-324810-92fosk3c	282	41	experience	experience	VB
cord-324810-92fosk3c	282	42	more	more	JJR
cord-324810-92fosk3c	282	43	than	than	IN
cord-324810-92fosk3c	282	44	four	four	CD
cord-324810-92fosk3c	282	45	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	282	46	/	/	SYM
cord-324810-92fosk3c	282	47	year	year	NN
cord-324810-92fosk3c	282	48	;	;	,
cord-324810-92fosk3c	282	49	comorbid	comorbid	VBN
cord-324810-92fosk3c	282	50	medical	medical	JJ
cord-324810-92fosk3c	282	51	illness	illness	NN
cord-324810-92fosk3c	283	1	(	(	-LRB-
cord-324810-92fosk3c	283	2	congestive	congestive	JJ
cord-324810-92fosk3c	283	3	heart	heart	NN
cord-324810-92fosk3c	283	4	failure	failure	NN
cord-324810-92fosk3c	283	5	,	,	,
cord-324810-92fosk3c	283	6	diabetes	diabetes	NN
cord-324810-92fosk3c	283	7	mellitus	mellitus	NN
cord-324810-92fosk3c	283	8	,	,	,
cord-324810-92fosk3c	283	9	chronic	chronic	JJ
cord-324810-92fosk3c	283	10	renal	renal	JJ
cord-324810-92fosk3c	283	11	failure	failure	NN
cord-324810-92fosk3c	283	12	,	,	,
cord-324810-92fosk3c	283	13	or	or	CC
cord-324810-92fosk3c	283	14	chronic	chronic	JJ
cord-324810-92fosk3c	283	15	liver	liver	NN
cord-324810-92fosk3c	283	16	disease	disease	NN
cord-324810-92fosk3c	283	17	)	)	-RRB-
cord-324810-92fosk3c	283	18	rates	rate	NNS
cord-324810-92fosk3c	283	19	were	be	VBD
cord-324810-92fosk3c	283	20	reported	report	VBN
cord-324810-92fosk3c	283	21	to	to	TO
cord-324810-92fosk3c	283	22	be	be	VB
cord-324810-92fosk3c	283	23	54	54	CD
cord-324810-92fosk3c	283	24	%	%	NN
cord-324810-92fosk3c	283	25	with	with	IN
cord-324810-92fosk3c	283	26	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	283	27	,	,	,
cord-324810-92fosk3c	283	28	8	8	CD
cord-324810-92fosk3c	283	29	%	%	NN
cord-324810-92fosk3c	283	30	with	with	IN
cord-324810-92fosk3c	283	31	amoxiciltherapy	amoxiciltherapy	NNP
cord-324810-92fosk3c	283	32	has	have	VBZ
cord-324810-92fosk3c	283	33	not	not	RB
cord-324810-92fosk3c	283	34	been	be	VBN
cord-324810-92fosk3c	283	35	shown	show	VBN
cord-324810-92fosk3c	283	36	to	to	TO
cord-324810-92fosk3c	283	37	benefit	benefit	VB
cord-324810-92fosk3c	283	38	type	type	NN
cord-324810-92fosk3c	283	39	III	iii	CD
cord-324810-92fosk3c	283	40	exacerbation	exacerbation	NN
cord-324810-92fosk3c	283	41	,	,	,
cord-324810-92fosk3c	283	42	lin	lin	NNP
cord-324810-92fosk3c	283	43	/	/	SYM
cord-324810-92fosk3c	283	44	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	283	45	acid	acid	NN
cord-324810-92fosk3c	283	46	,	,	,
cord-324810-92fosk3c	283	47	11	11	CD
cord-324810-92fosk3c	283	48	%	%	NN
cord-324810-92fosk3c	283	49	with	with	IN
cord-324810-92fosk3c	283	50	trimethoprim	trimethoprim	NNP
cord-324810-92fosk3c	283	51	/	/	SYM
cord-324810-92fosk3c	283	52	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	283	53	,	,	,
cord-324810-92fosk3c	283	54	and	and	CC
cord-324810-92fosk3c	283	55	21	21	CD
cord-324810-92fosk3c	283	56	%	%	NN
cord-324810-92fosk3c	283	57	with	with	IN
cord-324810-92fosk3c	283	58	macrolides	macrolide	NNS
cord-324810-92fosk3c	283	59	.	.	.
cord-324810-92fosk3c	284	1	Another	another	DT
cord-324810-92fosk3c	284	2	retrospective	retrospective	JJ
cord-324810-92fosk3c	284	3	study	study	NN
cord-324810-92fosk3c	284	4	by	by	IN
cord-324810-92fosk3c	284	5	Destache	Destache	NNP
cord-324810-92fosk3c	284	6	et	et	NNP
cord-324810-92fosk3c	284	7	therefore	therefore	RB
cord-324810-92fosk3c	284	8	,	,	,
cord-324810-92fosk3c	284	9	symptomatic	symptomatic	JJ
cord-324810-92fosk3c	284	10	therapy	therapy	NN
cord-324810-92fosk3c	284	11	suffices	suffice	VBZ
cord-324810-92fosk3c	284	12	for	for	IN
cord-324810-92fosk3c	284	13	these	these	DT
cord-324810-92fosk3c	284	14	patients	patient	NNS
cord-324810-92fosk3c	284	15	.	.	.
cord-324810-92fosk3c	285	1	Patients	patient	NNS
cord-324810-92fosk3c	285	2	al	al	NNP
cord-324810-92fosk3c	285	3	.	.	.
cord-324810-92fosk3c	286	1	[	[	-LRB-
cord-324810-92fosk3c	286	2	66	66	CD
cord-324810-92fosk3c	286	3	]	]	-RRB-
cord-324810-92fosk3c	286	4	analyzed	analyze	VBD
cord-324810-92fosk3c	286	5	224	224	CD
cord-324810-92fosk3c	286	6	episodes	episode	NNS
cord-324810-92fosk3c	286	7	of	of	IN
cord-324810-92fosk3c	286	8	AECOPD	AECOPD	NNS
cord-324810-92fosk3c	286	9	requiring	require	VBG
cord-324810-92fosk3c	286	10	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	286	11	with	with	IN
cord-324810-92fosk3c	286	12	simple	simple	JJ
cord-324810-92fosk3c	286	13	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	286	14	will	will	MD
cord-324810-92fosk3c	286	15	have	have	VB
cord-324810-92fosk3c	286	16	only	only	RB
cord-324810-92fosk3c	286	17	mild	mild	JJ
cord-324810-92fosk3c	286	18	-	-	HYPH
cord-324810-92fosk3c	286	19	to	to	IN
cord-324810-92fosk3c	286	20	-	-	HYPH
cord-324810-92fosk3c	286	21	moderate	moderate	JJ
cord-324810-92fosk3c	286	22	impairin	impairin	NNP
cord-324810-92fosk3c	286	23	60	60	CD
cord-324810-92fosk3c	286	24	outpatients	outpatient	NNS
cord-324810-92fosk3c	286	25	.	.	.
cord-324810-92fosk3c	287	1	The	the	DT
cord-324810-92fosk3c	287	2	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	287	3	were	be	VBD
cord-324810-92fosk3c	287	4	divided	divide	VBN
cord-324810-92fosk3c	287	5	into	into	IN
cord-324810-92fosk3c	287	6	three	three	CD
cord-324810-92fosk3c	287	7	ment	ment	NN
cord-324810-92fosk3c	287	8	of	of	IN
cord-324810-92fosk3c	287	9	lung	lung	NN
cord-324810-92fosk3c	287	10	function	function	NN
cord-324810-92fosk3c	287	11	(	(	-LRB-
cord-324810-92fosk3c	287	12	FEV	FEV	NNP
cord-324810-92fosk3c	287	13	1	1	CD
cord-324810-92fosk3c	287	14	>	>	SYM
cord-324810-92fosk3c	287	15	50	50	CD
cord-324810-92fosk3c	287	16	%	%	NN
cord-324810-92fosk3c	287	17	predicted	predict	VBN
cord-324810-92fosk3c	287	18	)	)	-RRB-
cord-324810-92fosk3c	287	19	,	,	,
cord-324810-92fosk3c	287	20	have	have	VBP
cord-324810-92fosk3c	287	21	fewer	few	JJR
cord-324810-92fosk3c	287	22	than	than	IN
cord-324810-92fosk3c	287	23	groups	group	NNS
cord-324810-92fosk3c	287	24	:	:	:
cord-324810-92fosk3c	287	25	first	first	JJ
cord-324810-92fosk3c	287	26	-	-	HYPH
cord-324810-92fosk3c	287	27	line	line	NN
cord-324810-92fosk3c	287	28	(	(	-LRB-
cord-324810-92fosk3c	287	29	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	287	30	,	,	,
cord-324810-92fosk3c	287	31	trimethoprim	trimethoprim	NNP
cord-324810-92fosk3c	287	32	/	/	SYM
cord-324810-92fosk3c	287	33	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	287	34	,	,	,
cord-324810-92fosk3c	287	35	four	four	CD
cord-324810-92fosk3c	287	36	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	287	37	per	per	IN
cord-324810-92fosk3c	287	38	year	year	NN
cord-324810-92fosk3c	287	39	and	and	CC
cord-324810-92fosk3c	287	40	are	be	VBP
cord-324810-92fosk3c	287	41	likely	likely	JJ
cord-324810-92fosk3c	287	42	to	to	TO
cord-324810-92fosk3c	287	43	be	be	VB
cord-324810-92fosk3c	287	44	colonized	colonize	VBN
cord-324810-92fosk3c	287	45	with	with	IN
cord-324810-92fosk3c	287	46	tetracycline	tetracycline	NNP
cord-324810-92fosk3c	287	47	,	,	,
cord-324810-92fosk3c	287	48	erythromycin	erythromycin	NN
cord-324810-92fosk3c	287	49	)	)	-RRB-
cord-324810-92fosk3c	287	50	,	,	,
cord-324810-92fosk3c	287	51	second	second	JJ
cord-324810-92fosk3c	287	52	-	-	HYPH
cord-324810-92fosk3c	287	53	line	line	NN
cord-324810-92fosk3c	287	54	(	(	-LRB-
cord-324810-92fosk3c	287	55	cefuroxime	cefuroxime	NNP
cord-324810-92fosk3c	287	56	,	,	,
cord-324810-92fosk3c	287	57	cefaclor	cefaclor	NNP
cord-324810-92fosk3c	287	58	,	,	,
cord-324810-92fosk3c	287	59	usual	usual	JJ
cord-324810-92fosk3c	287	60	strains	strain	NNS
cord-324810-92fosk3c	287	61	of	of	IN
cord-324810-92fosk3c	287	62	H.	h.	NN
cord-324810-92fosk3c	287	63	influenzae	influenzae	NN
cord-324810-92fosk3c	287	64	,	,	,
cord-324810-92fosk3c	287	65	S.	S.	NNP
cord-324810-92fosk3c	287	66	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	287	67	,	,	,
cord-324810-92fosk3c	287	68	and	and	CC
cord-324810-92fosk3c	287	69	M.	M.	NNP
cord-324810-92fosk3c	287	70	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	287	71	,	,	,
cord-324810-92fosk3c	287	72	cefprozil	cefprozil	NNP
cord-324810-92fosk3c	287	73	)	)	-RRB-
cord-324810-92fosk3c	287	74	,	,	,
cord-324810-92fosk3c	287	75	and	and	CC
cord-324810-92fosk3c	287	76	third	third	JJ
cord-324810-92fosk3c	287	77	-	-	HYPH
cord-324810-92fosk3c	287	78	line	line	NN
cord-324810-92fosk3c	287	79	(	(	-LRB-
cord-324810-92fosk3c	287	80	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	287	81	/	/	SYM
cord-324810-92fosk3c	287	82	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	287	83	acid	acid	NNP
cord-324810-92fosk3c	287	84	,	,	,
cord-324810-92fosk3c	287	85	azithroalthough	azithroalthough	NNP
cord-324810-92fosk3c	287	86	viral	viral	JJ
cord-324810-92fosk3c	287	87	infections	infection	NNS
cord-324810-92fosk3c	287	88	often	often	RB
cord-324810-92fosk3c	287	89	precede	precede	VBP
cord-324810-92fosk3c	287	90	bacterial	bacterial	JJ
cord-324810-92fosk3c	287	91	superinfection	superinfection	NN
cord-324810-92fosk3c	287	92	.	.	.
cord-324810-92fosk3c	288	1	mycin	mycin	NNP
cord-324810-92fosk3c	288	2	,	,	,
cord-324810-92fosk3c	288	3	ciprofloxacin	ciprofloxacin	NNP
cord-324810-92fosk3c	288	4	)	)	-RRB-
cord-324810-92fosk3c	288	5	.	.	.
cord-324810-92fosk3c	289	1	Deterioration	deterioration	NN
cord-324810-92fosk3c	289	2	of	of	IN
cord-324810-92fosk3c	289	3	symptoms	symptom	NNS
cord-324810-92fosk3c	289	4	requiring	require	VBG
cord-324810-92fosk3c	289	5	addi	addi	NN
cord-324810-92fosk3c	289	6	-	-	HYPH
cord-324810-92fosk3c	289	7	Recommendations	recommendation	NNS
cord-324810-92fosk3c	289	8	are	be	VBP
cord-324810-92fosk3c	289	9	to	to	TO
cord-324810-92fosk3c	289	10	use	use	VB
cord-324810-92fosk3c	289	11	any	any	DT
cord-324810-92fosk3c	289	12	first	first	JJ
cord-324810-92fosk3c	289	13	-	-	HYPH
cord-324810-92fosk3c	289	14	line	line	NN
cord-324810-92fosk3c	289	15	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	289	16	agent	agent	NN
cord-324810-92fosk3c	289	17	,	,	,
cord-324810-92fosk3c	289	18	as	as	IN
cord-324810-92fosk3c	289	19	tional	tional	JJ
cord-324810-92fosk3c	289	20	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	289	21	within	within	IN
cord-324810-92fosk3c	289	22	2	2	CD
cord-324810-92fosk3c	289	23	weeks	week	NNS
cord-324810-92fosk3c	289	24	of	of	IN
cord-324810-92fosk3c	289	25	initial	initial	JJ
cord-324810-92fosk3c	289	26	therapy	therapy	NN
cord-324810-92fosk3c	289	27	was	be	VBD
cord-324810-92fosk3c	289	28	defined	define	VBN
cord-324810-92fosk3c	289	29	the	the	DT
cord-324810-92fosk3c	289	30	consequences	consequence	NNS
cord-324810-92fosk3c	289	31	of	of	IN
cord-324810-92fosk3c	289	32	treatment	treatment	NN
cord-324810-92fosk3c	289	33	failure	failure	NN
cord-324810-92fosk3c	289	34	are	be	VBP
cord-324810-92fosk3c	289	35	not	not	RB
cord-324810-92fosk3c	289	36	likely	likely	JJ
cord-324810-92fosk3c	289	37	to	to	TO
cord-324810-92fosk3c	289	38	be	be	VB
cord-324810-92fosk3c	289	39	grave	grave	JJ
cord-324810-92fosk3c	289	40	.	.	.
cord-324810-92fosk3c	290	1	as	as	IN
cord-324810-92fosk3c	290	2	treatment	treatment	NN
cord-324810-92fosk3c	290	3	failure	failure	NN
cord-324810-92fosk3c	290	4	.	.	.
cord-324810-92fosk3c	291	1	The	the	DT
cord-324810-92fosk3c	291	2	patients	patient	NNS
cord-324810-92fosk3c	291	3	who	who	WP
cord-324810-92fosk3c	291	4	received	receive	VBD
cord-324810-92fosk3c	291	5	first	first	JJ
cord-324810-92fosk3c	291	6	-	-	HYPH
cord-324810-92fosk3c	291	7	line	line	NN
cord-324810-92fosk3c	291	8	agents	agent	NNS
cord-324810-92fosk3c	292	1	The	the	DT
cord-324810-92fosk3c	292	2	patients	patient	NNS
cord-324810-92fosk3c	292	3	with	with	IN
cord-324810-92fosk3c	292	4	complicated	complicated	JJ
cord-324810-92fosk3c	292	5	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	292	6	have	have	VBP
cord-324810-92fosk3c	292	7	poorer	poor	JJR
cord-324810-92fosk3c	292	8	underlying	underlie	VBG
cord-324810-92fosk3c	292	9	had	have	VBD
cord-324810-92fosk3c	292	10	significantly	significantly	RB
cord-324810-92fosk3c	292	11	higher	high	JJR
cord-324810-92fosk3c	292	12	failure	failure	NN
cord-324810-92fosk3c	292	13	rates	rate	NNS
cord-324810-92fosk3c	292	14	;	;	:
cord-324810-92fosk3c	292	15	the	the	DT
cord-324810-92fosk3c	292	16	patients	patient	NNS
cord-324810-92fosk3c	292	17	treated	treat	VBN
cord-324810-92fosk3c	292	18	with	with	IN
cord-324810-92fosk3c	292	19	lung	lung	NN
cord-324810-92fosk3c	292	20	function	function	NN
cord-324810-92fosk3c	292	21	(	(	-LRB-
cord-324810-92fosk3c	292	22	FEV1	FEV1	NNP
cord-324810-92fosk3c	292	23	<	<	XX
cord-324810-92fosk3c	292	24	50	50	CD
cord-324810-92fosk3c	292	25	%	%	NN
cord-324810-92fosk3c	292	26	predicted	predict	VBD
cord-324810-92fosk3c	292	27	)	)	-RRB-
cord-324810-92fosk3c	292	28	,	,	,
cord-324810-92fosk3c	292	29	significant	significant	JJ
cord-324810-92fosk3c	292	30	medical	medical	JJ
cord-324810-92fosk3c	292	31	third	third	JJ
cord-324810-92fosk3c	292	32	-	-	HYPH
cord-324810-92fosk3c	292	33	line	line	NN
cord-324810-92fosk3c	292	34	agents	agent	NNS
cord-324810-92fosk3c	292	35	were	be	VBD
cord-324810-92fosk3c	292	36	hospitalized	hospitalize	VBN
cord-324810-92fosk3c	292	37	less	less	RBR
cord-324810-92fosk3c	292	38	frequently	frequently	RB
cord-324810-92fosk3c	292	39	,	,	,
cord-324810-92fosk3c	292	40	and	and	CC
cord-324810-92fosk3c	292	41	had	have	VBD
cord-324810-92fosk3c	292	42	a	a	DT
cord-324810-92fosk3c	292	43	comorbidity	comorbidity	NN
cord-324810-92fosk3c	292	44	(	(	-LRB-
cord-324810-92fosk3c	292	45	e.g.	e.g.	RB
cord-324810-92fosk3c	292	46	diabetes	diabetes	NN
cord-324810-92fosk3c	292	47	,	,	,
cord-324810-92fosk3c	292	48	congestive	congestive	JJ
cord-324810-92fosk3c	292	49	heart	heart	NN
cord-324810-92fosk3c	292	50	failure	failure	NN
cord-324810-92fosk3c	292	51	,	,	,
cord-324810-92fosk3c	292	52	chronic	chronic	JJ
cord-324810-92fosk3c	292	53	renal	renal	JJ
cord-324810-92fosk3c	292	54	longer	long	RBR
cord-324810-92fosk3c	292	55	exacerbation	exacerbation	NN
cord-324810-92fosk3c	292	56	-	-	HYPH
cord-324810-92fosk3c	292	57	free	free	JJ
cord-324810-92fosk3c	292	58	interval	interval	NN
cord-324810-92fosk3c	292	59	.	.	.
cord-324810-92fosk3c	293	1	disease	disease	NN
cord-324810-92fosk3c	293	2	,	,	,
cord-324810-92fosk3c	293	3	chronic	chronic	JJ
cord-324810-92fosk3c	293	4	liver	liver	NN
cord-324810-92fosk3c	293	5	disease	disease	NN
cord-324810-92fosk3c	293	6	)	)	-RRB-
cord-324810-92fosk3c	294	1	and/or	and/or	CC
cord-324810-92fosk3c	294	2	experience	experience	VB
cord-324810-92fosk3c	294	3	four	four	CD
cord-324810-92fosk3c	294	4	or	or	CC
cord-324810-92fosk3c	294	5	more	more	JJR
cord-324810-92fosk3c	294	6	In	in	IN
cord-324810-92fosk3c	294	7	1974	1974	CD
cord-324810-92fosk3c	294	8	,	,	,
cord-324810-92fosk3c	294	9	<	<	XX
cord-324810-92fosk3c	294	10	5	5	CD
cord-324810-92fosk3c	294	11	%	%	NN
cord-324810-92fosk3c	294	12	of	of	IN
cord-324810-92fosk3c	294	13	isolates	isolate	NNS
cord-324810-92fosk3c	294	14	of	of	IN
cord-324810-92fosk3c	294	15	H.	h.	NN
cord-324810-92fosk3c	294	16	influenzae	influenzae	NN
cord-324810-92fosk3c	294	17	were	be	VBD
cord-324810-92fosk3c	294	18	β	β	NN
cord-324810-92fosk3c	294	19	-	-	HYPH
cord-324810-92fosk3c	294	20	lactamase	lactamase	NN
cord-324810-92fosk3c	294	21	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	294	22	per	per	IN
cord-324810-92fosk3c	294	23	year	year	NN
cord-324810-92fosk3c	294	24	.	.	.
cord-324810-92fosk3c	295	1	The	the	DT
cord-324810-92fosk3c	295	2	predominant	predominant	JJ
cord-324810-92fosk3c	295	3	organisms	organism	NNS
cord-324810-92fosk3c	295	4	may	may	MD
cord-324810-92fosk3c	295	5	not	not	RB
cord-324810-92fosk3c	295	6	be	be	VB
cord-324810-92fosk3c	295	7	positive	positive	JJ
cord-324810-92fosk3c	295	8	in	in	IN
cord-324810-92fosk3c	295	9	the	the	DT
cord-324810-92fosk3c	295	10	US	US	NNP
cord-324810-92fosk3c	295	11	.	.	.
cord-324810-92fosk3c	296	1	[	[	-LRB-
cord-324810-92fosk3c	296	2	23	23	CD
cord-324810-92fosk3c	296	3	]	]	-RRB-
cord-324810-92fosk3c	297	1	Since	since	IN
cord-324810-92fosk3c	297	2	then	then	RB
cord-324810-92fosk3c	297	3	,	,	,
cord-324810-92fosk3c	297	4	resistance	resistance	NN
cord-324810-92fosk3c	297	5	to	to	IN
cord-324810-92fosk3c	297	6	the	the	DT
cord-324810-92fosk3c	297	7	commonly	commonly	RB
cord-324810-92fosk3c	297	8	used	use	VBN
cord-324810-92fosk3c	297	9	more	more	RBR
cord-324810-92fosk3c	297	10	likely	likely	JJ
cord-324810-92fosk3c	297	11	to	to	TO
cord-324810-92fosk3c	297	12	be	be	VB
cord-324810-92fosk3c	297	13	resistant	resistant	JJ
cord-324810-92fosk3c	297	14	strains	strain	NNS
cord-324810-92fosk3c	297	15	of	of	IN
cord-324810-92fosk3c	297	16	H.	h.	NN
cord-324810-92fosk3c	297	17	influenzae	influenzae	NN
cord-324810-92fosk3c	297	18	,	,	,
cord-324810-92fosk3c	297	19	S.	S.	NNP
cord-324810-92fosk3c	297	20	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	297	21	,	,	,
cord-324810-92fosk3c	297	22	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	297	23	among	among	IN
cord-324810-92fosk3c	297	24	non	non	JJ
cord-324810-92fosk3c	297	25	-	-	JJ
cord-324810-92fosk3c	297	26	typeable	typeable	JJ
cord-324810-92fosk3c	297	27	H.	h.	NN
cord-324810-92fosk3c	297	28	influenzae	influenzae	NN
cord-324810-92fosk3c	297	29	,	,	,
cord-324810-92fosk3c	297	30	S.	S.	NNP
cord-324810-92fosk3c	297	31	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	297	32	and	and	CC
cord-324810-92fosk3c	297	33	M.	M.	NNP
cord-324810-92fosk3c	297	34	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	297	35	,	,	,
cord-324810-92fosk3c	297	36	but	but	CC
cord-324810-92fosk3c	297	37	since	since	IN
cord-324810-92fosk3c	297	38	treatment	treatment	NN
cord-324810-92fosk3c	297	39	failure	failure	NN
cord-324810-92fosk3c	297	40	may	may	MD
cord-324810-92fosk3c	297	41	have	have	VB
cord-324810-92fosk3c	297	42	major	major	JJ
cord-324810-92fosk3c	297	43	and	and	CC
cord-324810-92fosk3c	297	44	M.	M.	NNP
cord-324810-92fosk3c	297	45	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	297	46	has	have	VBZ
cord-324810-92fosk3c	297	47	dramatically	dramatically	RB
cord-324810-92fosk3c	297	48	risen	rise	VBN
cord-324810-92fosk3c	297	49	over	over	IN
cord-324810-92fosk3c	297	50	the	the	DT
cord-324810-92fosk3c	297	51	past	past	JJ
cord-324810-92fosk3c	297	52	2	2	CD
cord-324810-92fosk3c	297	53	decades	decade	NNS
cord-324810-92fosk3c	297	54	.	.	.
cord-324810-92fosk3c	298	1	implications	implication	NNS
cord-324810-92fosk3c	298	2	,	,	,
cord-324810-92fosk3c	298	3	empiric	empiric	JJ
cord-324810-92fosk3c	298	4	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	298	5	therapy	therapy	NN
cord-324810-92fosk3c	298	6	directed	direct	VBN
cord-324810-92fosk3c	298	7	toward	toward	IN
cord-324810-92fosk3c	298	8	resis	resis	NNP
cord-324810-92fosk3c	299	1	-In	-In	:
cord-324810-92fosk3c	299	2	1997	1997	CD
cord-324810-92fosk3c	299	3	,	,	,
cord-324810-92fosk3c	299	4	the	the	DT
cord-324810-92fosk3c	299	5	prevalence	prevalence	NN
cord-324810-92fosk3c	299	6	of	of	IN
cord-324810-92fosk3c	299	7	β	β	NN
cord-324810-92fosk3c	299	8	-	-	HYPH
cord-324810-92fosk3c	299	9	lactamase	lactamase	NN
cord-324810-92fosk3c	299	10	producing	produce	VBG
cord-324810-92fosk3c	299	11	H.	H.	NNP
cord-324810-92fosk3c	299	12	influenzae	influenzae	NN
cord-324810-92fosk3c	299	13	exceeded	exceed	VBD
cord-324810-92fosk3c	299	14	33	33	CD
cord-324810-92fosk3c	299	15	%	%	NN
cord-324810-92fosk3c	299	16	,	,	,
cord-324810-92fosk3c	299	17	[	[	-LRB-
cord-324810-92fosk3c	299	18	85	85	CD
cord-324810-92fosk3c	299	19	]	]	-RRB-
cord-324810-92fosk3c	299	20	and	and	CC
cord-324810-92fosk3c	300	1	presently	presently	RB
cord-324810-92fosk3c	300	2	30	30	CD
cord-324810-92fosk3c	300	3	%	%	NN
cord-324810-92fosk3c	300	4	of	of	IN
cord-324810-92fosk3c	300	5	all	all	DT
cord-324810-92fosk3c	300	6	H.	H.	NNP
cord-324810-92fosk3c	300	7	influenzae	influenzae	NN
cord-324810-92fosk3c	300	8	strains	strain	NNS
cord-324810-92fosk3c	301	1	tant	tant	JJ
cord-324810-92fosk3c	301	2	organisms	organism	NNS
cord-324810-92fosk3c	301	3	should	should	MD
cord-324810-92fosk3c	301	4	be	be	VB
cord-324810-92fosk3c	301	5	initiated	initiate	VBN
cord-324810-92fosk3c	301	6	.	.	.
cord-324810-92fosk3c	302	1	Second	second	JJ
cord-324810-92fosk3c	302	2	-	-	HYPH
cord-324810-92fosk3c	302	3	line	line	NN
cord-324810-92fosk3c	302	4	antimicrobial	antimicrobial	NN
cord-324810-92fosk3c	302	5	are	be	VBP
cord-324810-92fosk3c	302	6	estimated	estimate	VBN
cord-324810-92fosk3c	302	7	to	to	TO
cord-324810-92fosk3c	302	8	be	be	VB
cord-324810-92fosk3c	302	9	β	β	NN
cord-324810-92fosk3c	302	10	-	-	HYPH
cord-324810-92fosk3c	302	11	lactamase	lactamase	NN
cord-324810-92fosk3c	302	12	positive	positive	JJ
cord-324810-92fosk3c	302	13	.	.	.
cord-324810-92fosk3c	303	1	[	[	-LRB-
cord-324810-92fosk3c	303	2	74	74	CD
cord-324810-92fosk3c	303	3	,	,	,
cord-324810-92fosk3c	303	4	85	85	CD
cord-324810-92fosk3c	303	5	,	,	,
cord-324810-92fosk3c	303	6	86	86	CD
cord-324810-92fosk3c	303	7	]	]	-RRB-
cord-324810-92fosk3c	304	1	Furthermore	furthermore	RB
cord-324810-92fosk3c	304	2	,	,	,
cord-324810-92fosk3c	304	3	35	35	CD
cord-324810-92fosk3c	304	4	%	%	NN
cord-324810-92fosk3c	304	5	agents	agent	NNS
cord-324810-92fosk3c	304	6	such	such	JJ
cord-324810-92fosk3c	304	7	as	as	IN
cord-324810-92fosk3c	304	8	quinolones	quinolones	NNP
cord-324810-92fosk3c	304	9	,	,	,
cord-324810-92fosk3c	304	10	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	304	11	/	/	SYM
cord-324810-92fosk3c	304	12	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	304	13	acid	acid	NN
cord-324810-92fosk3c	304	14	,	,	,
cord-324810-92fosk3c	304	15	second	second	JJ
cord-324810-92fosk3c	304	16	-	-	HYPH
cord-324810-92fosk3c	304	17	or	or	CC
cord-324810-92fosk3c	304	18	of	of	IN
cord-324810-92fosk3c	304	19	H.	h.	NN
cord-324810-92fosk3c	304	20	influenzae	influenzae	NN
cord-324810-92fosk3c	304	21	strains	strain	NNS
cord-324810-92fosk3c	304	22	are	be	VBP
cord-324810-92fosk3c	304	23	known	know	VBN
cord-324810-92fosk3c	304	24	to	to	TO
cord-324810-92fosk3c	304	25	possess	possess	VB
cord-324810-92fosk3c	304	26	multiple	multiple	JJ
cord-324810-92fosk3c	304	27	mechanisms	mechanism	NNS
cord-324810-92fosk3c	304	28	third	third	JJ
cord-324810-92fosk3c	304	29	-	-	HYPH
cord-324810-92fosk3c	304	30	generation	generation	NN
cord-324810-92fosk3c	304	31	cephalosporins	cephalosporin	NNS
cord-324810-92fosk3c	304	32	or	or	CC
cord-324810-92fosk3c	304	33	second	second	JJ
cord-324810-92fosk3c	304	34	-	-	HYPH
cord-324810-92fosk3c	304	35	generation	generation	NN
cord-324810-92fosk3c	304	36	macrolides	macrolide	NNS
cord-324810-92fosk3c	304	37	of	of	IN
cord-324810-92fosk3c	304	38	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	304	39	resistance	resistance	NN
cord-324810-92fosk3c	304	40	,	,	,
cord-324810-92fosk3c	304	41	including	include	VBG
cord-324810-92fosk3c	304	42	production	production	NN
cord-324810-92fosk3c	304	43	of	of	IN
cord-324810-92fosk3c	304	44	β	β	NN
cord-324810-92fosk3c	304	45	-	-	HYPH
cord-324810-92fosk3c	304	46	lactamase	lactamase	NNP
cord-324810-92fosk3c	304	47	are	be	VBP
cord-324810-92fosk3c	304	48	recommended	recommend	VBN
cord-324810-92fosk3c	304	49	in	in	IN
cord-324810-92fosk3c	304	50	these	these	DT
cord-324810-92fosk3c	304	51	patients	patient	NNS
cord-324810-92fosk3c	304	52	.	.	.
cord-324810-92fosk3c	305	1	Occasional	occasional	JJ
cord-324810-92fosk3c	305	2	patients	patient	NNS
cord-324810-92fosk3c	305	3	with	with	IN
cord-324810-92fosk3c	305	4	repetand	repetand	NN
cord-324810-92fosk3c	305	5	alterations	alteration	NNS
cord-324810-92fosk3c	305	6	in	in	IN
cord-324810-92fosk3c	305	7	penicillin	penicillin	NN
cord-324810-92fosk3c	305	8	binding	binding	NN
cord-324810-92fosk3c	305	9	.	.	.
cord-324810-92fosk3c	306	1	Additionally	additionally	RB
cord-324810-92fosk3c	306	2	,	,	,
cord-324810-92fosk3c	306	3	15	15	CD
cord-324810-92fosk3c	306	4	%	%	NN
cord-324810-92fosk3c	306	5	or	or	CC
cord-324810-92fosk3c	306	6	more	more	JJR
cord-324810-92fosk3c	306	7	H.	h.	NN
cord-324810-92fosk3c	306	8	itive	itive	JJ
cord-324810-92fosk3c	306	9	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	306	10	are	be	VBP
cord-324810-92fosk3c	306	11	likely	likely	JJ
cord-324810-92fosk3c	306	12	to	to	TO
cord-324810-92fosk3c	306	13	become	become	VB
cord-324810-92fosk3c	306	14	colonized	colonize	VBN
cord-324810-92fosk3c	306	15	with	with	IN
cord-324810-92fosk3c	306	16	P.	P.	NNP
cord-324810-92fosk3c	306	17	aerugiinfluenzae	aerugiinfluenzae	NNP
cord-324810-92fosk3c	306	18	are	be	VBP
cord-324810-92fosk3c	306	19	cefaclor	cefaclor	NNP
cord-324810-92fosk3c	306	20	-	-	:
cord-324810-92fosk3c	306	21	and	and	CC
cord-324810-92fosk3c	306	22	cefprozil	cefprozil	NN
cord-324810-92fosk3c	306	23	-	-	HYPH
cord-324810-92fosk3c	306	24	resistant	resistant	JJ
cord-324810-92fosk3c	306	25	,	,	,
cord-324810-92fosk3c	306	26	and	and	CC
cord-324810-92fosk3c	306	27	3	3	CD
cord-324810-92fosk3c	306	28	%	%	NN
cord-324810-92fosk3c	306	29	are	be	VBP
cord-324810-92fosk3c	306	30	nosa	nosa	NNP
cord-324810-92fosk3c	306	31	;	;	:
cord-324810-92fosk3c	306	32	some	some	DT
cord-324810-92fosk3c	306	33	of	of	IN
cord-324810-92fosk3c	306	34	these	these	DT
cord-324810-92fosk3c	306	35	individuals	individual	NNS
cord-324810-92fosk3c	306	36	have	have	VBP
cord-324810-92fosk3c	306	37	underlying	underlie	VBG
cord-324810-92fosk3c	306	38	bronchiectasis	bronchiectasis	NN
cord-324810-92fosk3c	306	39	azithromycin	azithromycin	NN
cord-324810-92fosk3c	306	40	-	-	HYPH
cord-324810-92fosk3c	306	41	resistant	resistant	JJ
cord-324810-92fosk3c	306	42	.	.	.
cord-324810-92fosk3c	307	1	[	[	-LRB-
cord-324810-92fosk3c	307	2	85	85	CD
cord-324810-92fosk3c	307	3	]	]	-RRB-
cord-324810-92fosk3c	308	1	The	the	DT
cord-324810-92fosk3c	308	2	prevalence	prevalence	NN
cord-324810-92fosk3c	308	3	of	of	IN
cord-324810-92fosk3c	308	4	penicillin	penicillin	NN
cord-324810-92fosk3c	308	5	-	-	HYPH
cord-324810-92fosk3c	308	6	resistant	resistant	JJ
cord-324810-92fosk3c	308	7	S.	S.	NNP
cord-324810-92fosk3c	308	8	when	when	WRB
cord-324810-92fosk3c	308	9	studied	study	VBN
cord-324810-92fosk3c	308	10	by	by	IN
cord-324810-92fosk3c	308	11	high	high	JJ
cord-324810-92fosk3c	308	12	-	-	HYPH
cord-324810-92fosk3c	308	13	resolution	resolution	NN
cord-324810-92fosk3c	308	14	imaging	imaging	NN
cord-324810-92fosk3c	308	15	studies	study	NNS
cord-324810-92fosk3c	308	16	.	.	.
cord-324810-92fosk3c	309	1	Since	since	IN
cord-324810-92fosk3c	309	2	many	many	JJ
cord-324810-92fosk3c	309	3	of	of	IN
cord-324810-92fosk3c	309	4	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	309	5	isolates	isolate	NNS
cord-324810-92fosk3c	309	6	increased	increase	VBD
cord-324810-92fosk3c	309	7	from	from	IN
cord-324810-92fosk3c	309	8	3	3	CD
cord-324810-92fosk3c	309	9	-	-	SYM
cord-324810-92fosk3c	309	10	6	6	CD
cord-324810-92fosk3c	309	11	%	%	NN
cord-324810-92fosk3c	309	12	before	before	IN
cord-324810-92fosk3c	309	13	1991	1991	CD
cord-324810-92fosk3c	309	14	to	to	IN
cord-324810-92fosk3c	309	15	43.8	43.8	CD
cord-324810-92fosk3c	309	16	%	%	NN
cord-324810-92fosk3c	309	17	these	these	DT
cord-324810-92fosk3c	309	18	patients	patient	NNS
cord-324810-92fosk3c	309	19	have	have	VBP
cord-324810-92fosk3c	309	20	received	receive	VBN
cord-324810-92fosk3c	309	21	multiple	multiple	JJ
cord-324810-92fosk3c	309	22	courses	course	NNS
cord-324810-92fosk3c	309	23	of	of	IN
cord-324810-92fosk3c	309	24	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	309	25	,	,	,
cord-324810-92fosk3c	309	26	the	the	DT
cord-324810-92fosk3c	309	27	in	in	IN
cord-324810-92fosk3c	309	28	1997	1997	CD
cord-324810-92fosk3c	309	29	.	.	.
cord-324810-92fosk3c	310	1	[	[	-LRB-
cord-324810-92fosk3c	310	2	82	82	CD
cord-324810-92fosk3c	310	3	]	]	-RRB-
cord-324810-92fosk3c	311	1	The	the	DT
cord-324810-92fosk3c	311	2	current	current	JJ
cord-324810-92fosk3c	311	3	data	datum	NNS
cord-324810-92fosk3c	311	4	on	on	IN
cord-324810-92fosk3c	311	5	resistance	resistance	NN
cord-324810-92fosk3c	311	6	are	be	VBP
cord-324810-92fosk3c	311	7	similar	similar	JJ
cord-324810-92fosk3c	311	8	:	:	:
cord-324810-92fosk3c	311	9	[	[	-LRB-
cord-324810-92fosk3c	311	10	85	85	CD
cord-324810-92fosk3c	311	11	]	]	-RRB-
cord-324810-92fosk3c	311	12	[	[	-LRB-
cord-324810-92fosk3c	311	13	86	86	CD
cord-324810-92fosk3c	311	14	]	]	-RRB-
cord-324810-92fosk3c	311	15	[	[	-LRB-
cord-324810-92fosk3c	311	16	87	87	CD
cord-324810-92fosk3c	311	17	]	]	-RRB-
cord-324810-92fosk3c	311	18	[	[	-LRB-
cord-324810-92fosk3c	311	19	88	88	CD
cord-324810-92fosk3c	311	20	]	]	-RRB-
cord-324810-92fosk3c	312	1	a	a	DT
cord-324810-92fosk3c	312	2	presence	presence	NN
cord-324810-92fosk3c	312	3	of	of	IN
cord-324810-92fosk3c	312	4	P.	P.	NNP
cord-324810-92fosk3c	312	5	aeruginosa	aeruginosa	NN
cord-324810-92fosk3c	312	6	represents	represent	VBZ
cord-324810-92fosk3c	312	7	colonization	colonization	NN
cord-324810-92fosk3c	312	8	.	.	.
cord-324810-92fosk3c	313	1	In	in	IN
cord-324810-92fosk3c	313	2	unusual	unusual	JJ
cord-324810-92fosk3c	313	3	survey	survey	NN
cord-324810-92fosk3c	313	4	of	of	IN
cord-324810-92fosk3c	313	5	33	33	CD
cord-324810-92fosk3c	313	6	medical	medical	JJ
cord-324810-92fosk3c	313	7	centers	center	NNS
cord-324810-92fosk3c	313	8	from	from	IN
cord-324810-92fosk3c	313	9	November	November	NNP
cord-324810-92fosk3c	313	10	1999	1999	CD
cord-324810-92fosk3c	313	11	to	to	IN
cord-324810-92fosk3c	313	12	April	April	NNP
cord-324810-92fosk3c	313	13	2000	2000	CD
cord-324810-92fosk3c	313	14	circumstances	circumstance	NNS
cord-324810-92fosk3c	313	15	when	when	WRB
cord-324810-92fosk3c	313	16	infection	infection	NN
cord-324810-92fosk3c	313	17	is	be	VBZ
cord-324810-92fosk3c	313	18	documented	document	VBN
cord-324810-92fosk3c	313	19	,	,	,
cord-324810-92fosk3c	313	20	use	use	NN
cord-324810-92fosk3c	313	21	of	of	IN
cord-324810-92fosk3c	313	22	a	a	DT
cord-324810-92fosk3c	313	23	quinolone	quinolone	NN
cord-324810-92fosk3c	313	24	showed	show	VBD
cord-324810-92fosk3c	313	25	that	that	IN
cord-324810-92fosk3c	313	26	approximately	approximately	RB
cord-324810-92fosk3c	313	27	35	35	CD
cord-324810-92fosk3c	313	28	%	%	NN
cord-324810-92fosk3c	313	29	of	of	IN
cord-324810-92fosk3c	313	30	S.	S.	NNP
cord-324810-92fosk3c	313	31	pneumoniae	pneumoniae	NNS
cord-324810-92fosk3c	313	32	are	be	VBP
cord-324810-92fosk3c	313	33	resistant	resistant	JJ
cord-324810-92fosk3c	313	34	to	to	IN
cord-324810-92fosk3c	313	35	with	with	IN
cord-324810-92fosk3c	313	36	antipseudomonal	antipseudomonal	JJ
cord-324810-92fosk3c	313	37	activity	activity	NN
cord-324810-92fosk3c	313	38	empirically	empirically	RB
cord-324810-92fosk3c	313	39	and	and	CC
cord-324810-92fosk3c	313	40	further	further	RB
cord-324810-92fosk3c	313	41	tailoring	tailor	VBG
cord-324810-92fosk3c	313	42	the	the	DT
cord-324810-92fosk3c	313	43	penicillin	penicillin	NN
cord-324810-92fosk3c	313	44	,	,	,
cord-324810-92fosk3c	313	45	with	with	IN
cord-324810-92fosk3c	313	46	60	60	CD
cord-324810-92fosk3c	313	47	%	%	NN
cord-324810-92fosk3c	313	48	of	of	IN
cord-324810-92fosk3c	313	49	isolates	isolate	NNS
cord-324810-92fosk3c	313	50	exhibiting	exhibit	VBG
cord-324810-92fosk3c	313	51	a	a	DT
cord-324810-92fosk3c	313	52	high	high	JJ
cord-324810-92fosk3c	313	53	level	level	NN
cord-324810-92fosk3c	313	54	of	of	IN
cord-324810-92fosk3c	313	55	resistherapy	resistherapy	NN
cord-324810-92fosk3c	313	56	based	base	VBN
cord-324810-92fosk3c	313	57	on	on	IN
cord-324810-92fosk3c	313	58	sputum	sputum	NN
cord-324810-92fosk3c	313	59	culture	culture	NN
cord-324810-92fosk3c	313	60	is	be	VBZ
cord-324810-92fosk3c	313	61	appropriate	appropriate	JJ
cord-324810-92fosk3c	313	62	.	.	.
cord-324810-92fosk3c	314	1	Although	although	IN
cord-324810-92fosk3c	314	2	none	none	NN
cord-324810-92fosk3c	314	3	of	of	IN
cord-324810-92fosk3c	314	4	tance	tance	NNP
cord-324810-92fosk3c	314	5	(	(	-LRB-
cord-324810-92fosk3c	314	6	minimum	minimum	JJ
cord-324810-92fosk3c	314	7	inhibitory	inhibitory	JJ
cord-324810-92fosk3c	314	8	concentration	concentration	NN
cord-324810-92fosk3c	314	9	≥2	≥2	NNP
cord-324810-92fosk3c	314	10	μg	μg	NNP
cord-324810-92fosk3c	314	11	/	/	SYM
cord-324810-92fosk3c	314	12	mL	mL	NNP
cord-324810-92fosk3c	314	13	)	)	-RRB-
cord-324810-92fosk3c	314	14	.	.	.
cord-324810-92fosk3c	315	1	[	[	-LRB-
cord-324810-92fosk3c	315	2	88	88	CD
cord-324810-92fosk3c	315	3	]	]	-RRB-
cord-324810-92fosk3c	315	4	these	these	DT
cord-324810-92fosk3c	315	5	proposed	propose	VBN
cord-324810-92fosk3c	315	6	classification	classification	NN
cord-324810-92fosk3c	315	7	schemes	scheme	NNS
cord-324810-92fosk3c	315	8	have	have	VBP
cord-324810-92fosk3c	315	9	been	be	VBN
cord-324810-92fosk3c	315	10	prospectively	prospectively	RB
cord-324810-92fosk3c	315	11	Bronchopulmonary	Bronchopulmonary	NNP
cord-324810-92fosk3c	315	12	infections	infection	NNS
cord-324810-92fosk3c	315	13	comprised	comprise	VBD
cord-324810-92fosk3c	315	14	44.5	44.5	CD
cord-324810-92fosk3c	315	15	%	%	NN
cord-324810-92fosk3c	315	16	and	and	CC
cord-324810-92fosk3c	315	17	22.1	22.1	CD
cord-324810-92fosk3c	315	18	%	%	NN
cord-324810-92fosk3c	315	19	of	of	IN
cord-324810-92fosk3c	315	20	tested	test	VBN
cord-324810-92fosk3c	315	21	for	for	IN
cord-324810-92fosk3c	315	22	their	-PRON-	PRP$
cord-324810-92fosk3c	315	23	utility	utility	NN
cord-324810-92fosk3c	315	24	and	and	CC
cord-324810-92fosk3c	315	25	efficacy	efficacy	NN
cord-324810-92fosk3c	315	26	,	,	,
cord-324810-92fosk3c	315	27	they	-PRON-	PRP
cord-324810-92fosk3c	315	28	emphasize	emphasize	VBP
cord-324810-92fosk3c	315	29	that	that	IN
cord-324810-92fosk3c	315	30	potentially	potentially	RB
cord-324810-92fosk3c	315	31	resistant	resistant	JJ
cord-324810-92fosk3c	315	32	infections	infection	NNS
cord-324810-92fosk3c	315	33	with	with	IN
cord-324810-92fosk3c	315	34	S.	S.	NNP
cord-324810-92fosk3c	315	35	pneumoniae	pneumoniae	NNS
cord-324810-92fosk3c	315	36	were	be	VBD
cord-324810-92fosk3c	315	37	from	from	IN
cord-324810-92fosk3c	315	38	patients	patient	NNS
cord-324810-92fosk3c	315	39	≥65	≥65	VBP
cord-324810-92fosk3c	315	40	resistant	resistant	JJ
cord-324810-92fosk3c	315	41	organisms	organism	NNS
cord-324810-92fosk3c	315	42	should	should	MD
cord-324810-92fosk3c	315	43	be	be	VB
cord-324810-92fosk3c	315	44	targeted	target	VBN
cord-324810-92fosk3c	315	45	in	in	IN
cord-324810-92fosk3c	315	46	patients	patient	NNS
cord-324810-92fosk3c	315	47	at	at	IN
cord-324810-92fosk3c	315	48	high	high	JJ
cord-324810-92fosk3c	315	49	risk	risk	NN
cord-324810-92fosk3c	315	50	of	of	IN
cord-324810-92fosk3c	315	51	years	year	NNS
cord-324810-92fosk3c	315	52	of	of	IN
cord-324810-92fosk3c	315	53	age	age	NN
cord-324810-92fosk3c	315	54	.	.	.
cord-324810-92fosk3c	316	1	The	the	DT
cord-324810-92fosk3c	316	2	current	current	JJ
cord-324810-92fosk3c	316	3	overall	overall	JJ
cord-324810-92fosk3c	316	4	pneumococcal	pneumococcal	JJ
cord-324810-92fosk3c	316	5	resistance	resistance	NN
cord-324810-92fosk3c	316	6	prevaantimicrobial	prevaantimicrobial	NN
cord-324810-92fosk3c	316	7	treatment	treatment	NN
cord-324810-92fosk3c	316	8	failure	failure	NN
cord-324810-92fosk3c	316	9	.	.	.
cord-324810-92fosk3c	317	1	lence	lence	NNP
cord-324810-92fosk3c	317	2	in	in	IN
cord-324810-92fosk3c	317	3	the	the	DT
cord-324810-92fosk3c	317	4	US	US	NNP
cord-324810-92fosk3c	317	5	is	be	VBZ
cord-324810-92fosk3c	317	6	:	:	:
cord-324810-92fosk3c	317	7	macrolides	macrolide	NNS
cord-324810-92fosk3c	317	8	25.9	25.9	CD
cord-324810-92fosk3c	317	9	%	%	NN
cord-324810-92fosk3c	317	10	,	,	,
cord-324810-92fosk3c	317	11	clindamycin	clindamycin	NN
cord-324810-92fosk3c	317	12	8.8	8.8	CD
cord-324810-92fosk3c	317	13	%	%	NN
cord-324810-92fosk3c	317	14	,	,	,
cord-324810-92fosk3c	317	15	tetracy	tetracy	NN
cord-324810-92fosk3c	317	16	-	-	HYPH
cord-324810-92fosk3c	317	17	cline	cline	NNP
cord-324810-92fosk3c	317	18	16.4	16.4	CD
cord-324810-92fosk3c	317	19	%	%	NN
cord-324810-92fosk3c	317	20	,	,	,
cord-324810-92fosk3c	317	21	chloramphenicol	chloramphenicol	NNP
cord-324810-92fosk3c	317	22	8.4	8.4	CD
cord-324810-92fosk3c	317	23	%	%	NN
cord-324810-92fosk3c	317	24	,	,	,
cord-324810-92fosk3c	317	25	and	and	CC
cord-324810-92fosk3c	317	26	trimethoprim/	trimethoprim/	NN
cord-324810-92fosk3c	318	1	The	the	DT
cord-324810-92fosk3c	318	2	initial	initial	JJ
cord-324810-92fosk3c	318	3	cure	cure	NN
cord-324810-92fosk3c	318	4	rates	rate	NNS
cord-324810-92fosk3c	318	5	(	(	-LRB-
cord-324810-92fosk3c	318	6	93	93	CD
cord-324810-92fosk3c	318	7	%	%	NN
cord-324810-92fosk3c	318	8	vs	vs	IN
cord-324810-92fosk3c	318	9	95	95	CD
cord-324810-92fosk3c	318	10	%	%	NN
cord-324810-92fosk3c	318	11	,	,	,
cord-324810-92fosk3c	318	12	p	p	NN
cord-324810-92fosk3c	318	13	=	=	SYM
cord-324810-92fosk3c	318	14	0.48	0.48	CD
cord-324810-92fosk3c	318	15	)	)	-RRB-
cord-324810-92fosk3c	318	16	and	and	CC
cord-324810-92fosk3c	318	17	6-month	6-month	CD
cord-324810-92fosk3c	318	18	exacersulfamethoxazole	exacersulfamethoxazole	NNP
cord-324810-92fosk3c	318	19	30.3	30.3	CD
cord-324810-92fosk3c	318	20	%	%	NN
cord-324810-92fosk3c	318	21	.	.	.
cord-324810-92fosk3c	319	1	[	[	-LRB-
cord-324810-92fosk3c	319	2	87	87	CD
cord-324810-92fosk3c	319	3	,	,	,
cord-324810-92fosk3c	319	4	88	88	CD
cord-324810-92fosk3c	319	5	]	]	-RRB-
cord-324810-92fosk3c	320	1	In	in	IN
cord-324810-92fosk3c	320	2	another	another	DT
cord-324810-92fosk3c	320	3	study	study	NN
cord-324810-92fosk3c	320	4	,	,	,
cord-324810-92fosk3c	320	5	a	a	DT
cord-324810-92fosk3c	320	6	total	total	NN
cord-324810-92fosk3c	320	7	of	of	IN
cord-324810-92fosk3c	320	8	6515	6515	CD
cord-324810-92fosk3c	320	9	bation	bation	NN
cord-324810-92fosk3c	320	10	-	-	HYPH
cord-324810-92fosk3c	320	11	free	free	JJ
cord-324810-92fosk3c	320	12	period	period	NN
cord-324810-92fosk3c	320	13	(	(	-LRB-
cord-324810-92fosk3c	320	14	34	34	CD
cord-324810-92fosk3c	320	15	%	%	NN
cord-324810-92fosk3c	320	16	vs	vs	IN
cord-324810-92fosk3c	320	17	28	28	CD
cord-324810-92fosk3c	320	18	%	%	NN
cord-324810-92fosk3c	320	19	,	,	,
cord-324810-92fosk3c	320	20	p	p	NN
cord-324810-92fosk3c	320	21	=	=	SYM
cord-324810-92fosk3c	320	22	0.37	0.37	CD
cord-324810-92fosk3c	320	23	)	)	-RRB-
cord-324810-92fosk3c	320	24	were	be	VBD
cord-324810-92fosk3c	320	25	similar	similar	JJ
cord-324810-92fosk3c	320	26	in	in	IN
cord-324810-92fosk3c	320	27	patients	patient	NNS
cord-324810-92fosk3c	320	28	isolates	isolate	NNS
cord-324810-92fosk3c	320	29	of	of	IN
cord-324810-92fosk3c	320	30	S.	S.	NNP
cord-324810-92fosk3c	320	31	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	320	32	and	and	CC
cord-324810-92fosk3c	320	33	6726	6726	CD
cord-324810-92fosk3c	320	34	H.	h.	NN
cord-324810-92fosk3c	320	35	influenzae	influenzae	NN
cord-324810-92fosk3c	320	36	strains	strain	NNS
cord-324810-92fosk3c	320	37	revealed	reveal	VBD
cord-324810-92fosk3c	320	38	receiving	receive	VBG
cord-324810-92fosk3c	320	39	older	old	JJR
cord-324810-92fosk3c	320	40	versus	versus	IN
cord-324810-92fosk3c	320	41	newer	new	JJR
cord-324810-92fosk3c	320	42	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	320	43	.	.	.
cord-324810-92fosk3c	321	1	[	[	-LRB-
cord-324810-92fosk3c	321	2	97	97	CD
cord-324810-92fosk3c	321	3	]	]	-RRB-
cord-324810-92fosk3c	322	1	Therefore	therefore	RB
cord-324810-92fosk3c	322	2	,	,	,
cord-324810-92fosk3c	322	3	large	large	JJ
cord-324810-92fosk3c	322	4	ampicillin	ampicillin	JJ
cord-324810-92fosk3c	322	5	resistance	resistance	NN
cord-324810-92fosk3c	322	6	of	of	IN
cord-324810-92fosk3c	322	7	approximately	approximately	RB
cord-324810-92fosk3c	322	8	25	25	CD
cord-324810-92fosk3c	322	9	%	%	NN
cord-324810-92fosk3c	322	10	among	among	IN
cord-324810-92fosk3c	322	11	H.	h.	NN
cord-324810-92fosk3c	322	12	influenzae	influenzae	NN
cord-324810-92fosk3c	322	13	clinical	clinical	JJ
cord-324810-92fosk3c	322	14	trials	trial	NNS
cord-324810-92fosk3c	322	15	are	be	VBP
cord-324810-92fosk3c	322	16	needed	need	VBN
cord-324810-92fosk3c	322	17	to	to	TO
cord-324810-92fosk3c	322	18	establish	establish	VB
cord-324810-92fosk3c	322	19	the	the	DT
cord-324810-92fosk3c	322	20	adequacy	adequacy	NN
cord-324810-92fosk3c	322	21	of	of	IN
cord-324810-92fosk3c	322	22	current	current	JJ
cord-324810-92fosk3c	322	23	isolates	isolate	NNS
cord-324810-92fosk3c	322	24	and	and	CC
cord-324810-92fosk3c	322	25	did	do	VBD
cord-324810-92fosk3c	322	26	not	not	RB
cord-324810-92fosk3c	322	27	significantly	significantly	RB
cord-324810-92fosk3c	322	28	differ	differ	VB
cord-324810-92fosk3c	322	29	between	between	IN
cord-324810-92fosk3c	322	30	strains	strain	NNS
cord-324810-92fosk3c	322	31	from	from	IN
cord-324810-92fosk3c	322	32	empiric	empiric	JJ
cord-324810-92fosk3c	322	33	guidelines	guideline	NNS
cord-324810-92fosk3c	322	34	and	and	CC
cord-324810-92fosk3c	322	35	to	to	TO
cord-324810-92fosk3c	322	36	address	address	VB
cord-324810-92fosk3c	322	37	the	the	DT
cord-324810-92fosk3c	322	38	role	role	NN
cord-324810-92fosk3c	322	39	of	of	IN
cord-324810-92fosk3c	322	40	newer	new	JJR
cord-324810-92fosk3c	322	41	broad	broad	JJ
cord-324810-92fosk3c	322	42	-	-	HYPH
cord-324810-92fosk3c	322	43	speccommunity	speccommunity	NN
cord-324810-92fosk3c	322	44	-	-	HYPH
cord-324810-92fosk3c	322	45	acquired	acquire	VBN
cord-324810-92fosk3c	322	46	infections	infection	NNS
cord-324810-92fosk3c	322	47	or	or	CC
cord-324810-92fosk3c	322	48	hospitalized	hospitalize	VBN
cord-324810-92fosk3c	322	49	patients	patient	NNS
cord-324810-92fosk3c	322	50	.	.	.
cord-324810-92fosk3c	323	1	[	[	-LRB-
cord-324810-92fosk3c	323	2	8	8	CD
cord-324810-92fosk3c	323	3	]	]	-RRB-
cord-324810-92fosk3c	323	4	Further	further	JJ
cord-324810-92fosk3c	323	5	-	-	HYPH
cord-324810-92fosk3c	323	6	trum	trum	NN
cord-324810-92fosk3c	323	7	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	323	8	.	.	.
cord-324810-92fosk3c	324	1	more	more	JJR
cord-324810-92fosk3c	324	2	,	,	,
cord-324810-92fosk3c	324	3	β	β	NN
cord-324810-92fosk3c	324	4	-	-	HYPH
cord-324810-92fosk3c	324	5	lactamase	lactamase	JJ
cord-324810-92fosk3c	324	6	-	-	HYPH
cord-324810-92fosk3c	324	7	negative	negative	JJ
cord-324810-92fosk3c	324	8	ampicillin	ampicillin	NN
cord-324810-92fosk3c	324	9	-	-	HYPH
cord-324810-92fosk3c	324	10	resistant	resistant	JJ
cord-324810-92fosk3c	324	11	strains	strain	NNS
cord-324810-92fosk3c	324	12	and	and	CC
cord-324810-92fosk3c	324	13	fluoroquinolone	fluoroquinolone	NN
cord-324810-92fosk3c	324	14	-	-	HYPH
cord-324810-92fosk3c	324	15	refractory	refractory	JJ
cord-324810-92fosk3c	324	16	strains	strain	NNS
cord-324810-92fosk3c	324	17	were	be	VBD
cord-324810-92fosk3c	324	18	rare	rare	JJ
cord-324810-92fosk3c	324	19	(	(	-LRB-
cord-324810-92fosk3c	324	20	0.3	0.3	CD
cord-324810-92fosk3c	324	21	%	%	NN
cord-324810-92fosk3c	324	22	and	and	CC
cord-324810-92fosk3c	324	23	≤0.2	≤0.2	CD
cord-324810-92fosk3c	324	24	%	%	NN
cord-324810-92fosk3c	324	25	,	,	,
cord-324810-92fosk3c	324	26	8	8	CD
cord-324810-92fosk3c	324	27	.	.	.
cord-324810-92fosk3c	325	1	Prescribing	prescribe	VBG
cord-324810-92fosk3c	325	2	the	the	DT
cord-324810-92fosk3c	325	3	Appropriate	Appropriate	NNP
cord-324810-92fosk3c	325	4	Antimicrobial	Antimicrobial	NNP
cord-324810-92fosk3c	325	5	respectively	respectively	RB
cord-324810-92fosk3c	325	6	)	)	-RRB-
cord-324810-92fosk3c	325	7	.	.	.
cord-324810-92fosk3c	326	1	Macrolide	macrolide	NN
cord-324810-92fosk3c	326	2	-	-	HYPH
cord-324810-92fosk3c	326	3	resistance	resistance	NN
cord-324810-92fosk3c	326	4	to	to	IN
cord-324810-92fosk3c	326	5	H.	h.	NN
cord-324810-92fosk3c	326	6	influenzae	influenzae	NN
cord-324810-92fosk3c	326	7	was	be	VBD
cord-324810-92fosk3c	326	8	24.4	24.4	CD
cord-324810-92fosk3c	326	9	%	%	NN
cord-324810-92fosk3c	326	10	(	(	-LRB-
cord-324810-92fosk3c	326	11	clarithromycin	clarithromycin	NNP
cord-324810-92fosk3c	326	12	)	)	-RRB-
cord-324810-92fosk3c	326	13	in	in	IN
cord-324810-92fosk3c	326	14	hospitalized	hospitalize	VBN
cord-324810-92fosk3c	326	15	patients	patient	NNS
cord-324810-92fosk3c	326	16	with	with	IN
cord-324810-92fosk3c	326	17	pneumonia	pneumonia	NN
cord-324810-92fosk3c	326	18	.	.	.
cord-324810-92fosk3c	327	1	Another	another	DT
cord-324810-92fosk3c	327	2	There	there	EX
cord-324810-92fosk3c	327	3	are	be	VBP
cord-324810-92fosk3c	327	4	several	several	JJ
cord-324810-92fosk3c	327	5	theoretical	theoretical	JJ
cord-324810-92fosk3c	327	6	characteristics	characteristic	NNS
cord-324810-92fosk3c	327	7	that	that	WDT
cord-324810-92fosk3c	327	8	would	would	MD
cord-324810-92fosk3c	327	9	be	be	VB
cord-324810-92fosk3c	327	10	desirrecent	desirrecent	NNP
cord-324810-92fosk3c	327	11	study	study	NN
cord-324810-92fosk3c	327	12	from	from	IN
cord-324810-92fosk3c	327	13	North	North	NNP
cord-324810-92fosk3c	327	14	America	America	NNP
cord-324810-92fosk3c	327	15	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	327	16	nonsusceptibility	nonsusceptibility	NN
cord-324810-92fosk3c	327	17	able	able	JJ
cord-324810-92fosk3c	327	18	in	in	IN
cord-324810-92fosk3c	327	19	selecting	select	VBG
cord-324810-92fosk3c	327	20	an	an	DT
cord-324810-92fosk3c	327	21	antimicrobial	antimicrobial	NN
cord-324810-92fosk3c	327	22	for	for	IN
cord-324810-92fosk3c	327	23	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	327	24	:	:	:
cord-324810-92fosk3c	328	1	(	(	-LRB-
cord-324810-92fosk3c	328	2	i	i	NN
cord-324810-92fosk3c	328	3	)	)	-RRB-
cord-324810-92fosk3c	328	4	activity	activity	NN
cord-324810-92fosk3c	328	5	against	against	IN
cord-324810-92fosk3c	328	6	rates	rate	NNS
cord-324810-92fosk3c	328	7	to	to	IN
cord-324810-92fosk3c	328	8	penicillin	penicillin	NN
cord-324810-92fosk3c	328	9	at	at	IN
cord-324810-92fosk3c	328	10	21.0	21.0	CD
cord-324810-92fosk3c	328	11	%	%	NN
cord-324810-92fosk3c	328	12	,	,	,
cord-324810-92fosk3c	328	13	cefotaxime	cefotaxime	NN
cord-324810-92fosk3c	328	14	7.3	7.3	CD
cord-324810-92fosk3c	328	15	%	%	NN
cord-324810-92fosk3c	328	16	,	,	,
cord-324810-92fosk3c	328	17	imipenem	imipenem	NNP
cord-324810-92fosk3c	328	18	3.8	3.8	CD
cord-324810-92fosk3c	328	19	%	%	NN
cord-324810-92fosk3c	328	20	,	,	,
cord-324810-92fosk3c	328	21	the	the	DT
cord-324810-92fosk3c	328	22	most	most	RBS
cord-324810-92fosk3c	328	23	common	common	JJ
cord-324810-92fosk3c	328	24	and	and	CC
cord-324810-92fosk3c	328	25	most	most	RBS
cord-324810-92fosk3c	328	26	likely	likely	JJ
cord-324810-92fosk3c	328	27	etiologic	etiologic	JJ
cord-324810-92fosk3c	328	28	organisms	organism	NNS
cord-324810-92fosk3c	328	29	,	,	,
cord-324810-92fosk3c	328	30	including	include	VBG
cord-324810-92fosk3c	328	31	ciprofloxacin	ciprofloxacin	NN
cord-324810-92fosk3c	328	32	11.2	11.2	CD
cord-324810-92fosk3c	328	33	%	%	NN
cord-324810-92fosk3c	328	34	,	,	,
cord-324810-92fosk3c	328	35	erythromycin	erythromycin	JJ
cord-324810-92fosk3c	328	36	30.3	30.3	CD
cord-324810-92fosk3c	328	37	%	%	NN
cord-324810-92fosk3c	328	38	,	,	,
cord-324810-92fosk3c	328	39	and	and	CC
cord-324810-92fosk3c	328	40	tetracycline	tetracycline	NNP
cord-324810-92fosk3c	328	41	H.	H.	NNP
cord-324810-92fosk3c	328	42	influenzae	influenzae	NN
cord-324810-92fosk3c	328	43	,	,	,
cord-324810-92fosk3c	328	44	S.	S.	NNP
cord-324810-92fosk3c	328	45	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	328	46	and	and	CC
cord-324810-92fosk3c	328	47	M.	M.	NNP
cord-324810-92fosk3c	328	48	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	328	49	;	;	:
cord-324810-92fosk3c	328	50	(	(	-LRB-
cord-324810-92fosk3c	328	51	ii	ii	NN
cord-324810-92fosk3c	328	52	)	)	-RRB-
cord-324810-92fosk3c	328	53	resistance	resistance	NN
cord-324810-92fosk3c	328	54	to	to	IN
cord-324810-92fosk3c	328	55	38.5	38.5	CD
cord-324810-92fosk3c	328	56	%	%	NN
cord-324810-92fosk3c	328	57	.	.	.
cord-324810-92fosk3c	329	1	[	[	-LRB-
cord-324810-92fosk3c	329	2	89	89	CD
cord-324810-92fosk3c	329	3	]	]	-RRB-
cord-324810-92fosk3c	329	4	destruction	destruction	NN
cord-324810-92fosk3c	329	5	by	by	IN
cord-324810-92fosk3c	329	6	β	β	NN
cord-324810-92fosk3c	329	7	-	-	HYPH
cord-324810-92fosk3c	329	8	lactamase	lactamase	NN
cord-324810-92fosk3c	329	9	;	;	:
cord-324810-92fosk3c	329	10	(	(	-LRB-
cord-324810-92fosk3c	329	11	iii	iii	NN
cord-324810-92fosk3c	329	12	)	)	-RRB-
cord-324810-92fosk3c	329	13	narrow	narrow	JJ
cord-324810-92fosk3c	329	14	spectrum	spectrum	NN
cord-324810-92fosk3c	329	15	of	of	IN
cord-324810-92fosk3c	329	16	activity	activity	NN
cord-324810-92fosk3c	329	17	During	during	IN
cord-324810-92fosk3c	329	18	2000	2000	CD
cord-324810-92fosk3c	329	19	-	-	SYM
cord-324810-92fosk3c	329	20	01	01	CD
cord-324810-92fosk3c	329	21	,	,	,
cord-324810-92fosk3c	329	22	Jones	Jones	NNP
cord-324810-92fosk3c	329	23	et	et	NNP
cord-324810-92fosk3c	329	24	al	al	NNP
cord-324810-92fosk3c	329	25	.	.	.
cord-324810-92fosk3c	330	1	[	[	-LRB-
cord-324810-92fosk3c	330	2	90	90	CD
cord-324810-92fosk3c	330	3	]	]	-RRB-
cord-324810-92fosk3c	330	4	prospectively	prospectively	RB
cord-324810-92fosk3c	330	5	collected	collect	VBN
cord-324810-92fosk3c	330	6	1995	1995	CD
cord-324810-92fosk3c	330	7	against	against	IN
cord-324810-92fosk3c	330	8	the	the	DT
cord-324810-92fosk3c	330	9	likely	likely	JJ
cord-324810-92fosk3c	330	10	pathogen	pathogen	NN
cord-324810-92fosk3c	330	11	;	;	:
cord-324810-92fosk3c	330	12	(	(	-LRB-
cord-324810-92fosk3c	330	13	iv	iv	LS
cord-324810-92fosk3c	330	14	)	)	-RRB-
cord-324810-92fosk3c	330	15	good	good	JJ
cord-324810-92fosk3c	330	16	penetration	penetration	NN
cord-324810-92fosk3c	330	17	into	into	IN
cord-324810-92fosk3c	330	18	the	the	DT
cord-324810-92fosk3c	330	19	sputum	sputum	NN
cord-324810-92fosk3c	330	20	,	,	,
cord-324810-92fosk3c	330	21	isolates	isolate	NNS
cord-324810-92fosk3c	330	22	of	of	IN
cord-324810-92fosk3c	330	23	H.	h.	NN
cord-324810-92fosk3c	330	24	influenzae	influenzae	NN
cord-324810-92fosk3c	330	25	,	,	,
cord-324810-92fosk3c	330	26	1870	1870	CD
cord-324810-92fosk3c	330	27	isolates	isolate	NNS
cord-324810-92fosk3c	330	28	of	of	IN
cord-324810-92fosk3c	330	29	S.	S.	NNP
cord-324810-92fosk3c	330	30	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	330	31	and	and	CC
cord-324810-92fosk3c	330	32	649	649	CD
cord-324810-92fosk3c	330	33	bronchial	bronchial	JJ
cord-324810-92fosk3c	330	34	mucosa	mucosa	NN
cord-324810-92fosk3c	330	35	and	and	CC
cord-324810-92fosk3c	330	36	epithelial	epithelial	JJ
cord-324810-92fosk3c	330	37	lining	lining	NN
cord-324810-92fosk3c	330	38	fluid	fluid	NN
cord-324810-92fosk3c	330	39	;	;	:
cord-324810-92fosk3c	330	40	(	(	-LRB-
cord-324810-92fosk3c	330	41	v	v	NN
cord-324810-92fosk3c	330	42	)	)	-RRB-
cord-324810-92fosk3c	330	43	easy	easy	JJ
cord-324810-92fosk3c	330	44	to	to	TO
cord-324810-92fosk3c	330	45	take	take	VB
cord-324810-92fosk3c	330	46	,	,	,
cord-324810-92fosk3c	330	47	with	with	IN
cord-324810-92fosk3c	330	48	isolates	isolate	NNS
cord-324810-92fosk3c	330	49	of	of	IN
cord-324810-92fosk3c	330	50	M.	M.	NNP
cord-324810-92fosk3c	330	51	catarrhalis	catarrhalis	JJ
cord-324810-92fosk3c	330	52	from	from	IN
cord-324810-92fosk3c	330	53	hospital	hospital	NN
cord-324810-92fosk3c	330	54	laboratories	laboratory	NNS
cord-324810-92fosk3c	330	55	in	in	IN
cord-324810-92fosk3c	330	56	France	France	NNP
cord-324810-92fosk3c	330	57	,	,	,
cord-324810-92fosk3c	330	58	few	few	JJ
cord-324810-92fosk3c	330	59	adverse	adverse	JJ
cord-324810-92fosk3c	330	60	effects	effect	NNS
cord-324810-92fosk3c	330	61	;	;	,
cord-324810-92fosk3c	330	62	(	(	-LRB-
cord-324810-92fosk3c	330	63	vi	vi	NNP
cord-324810-92fosk3c	330	64	)	)	-RRB-
cord-324810-92fosk3c	330	65	prolonged	prolong	VBN
cord-324810-92fosk3c	330	66	DFI	DFI	NNP
cord-324810-92fosk3c	330	67	or	or	CC
cord-324810-92fosk3c	330	68	delay	delay	NN
cord-324810-92fosk3c	330	69	of	of	IN
cord-324810-92fosk3c	330	70	the	the	DT
cord-324810-92fosk3c	330	71	next	next	JJ
cord-324810-92fosk3c	330	72	Germany	Germany	NNP
cord-324810-92fosk3c	330	73	,	,	,
cord-324810-92fosk3c	330	74	Greece	Greece	NNP
cord-324810-92fosk3c	330	75	,	,	,
cord-324810-92fosk3c	330	76	Italy	Italy	NNP
cord-324810-92fosk3c	330	77	,	,	,
cord-324810-92fosk3c	330	78	Spain	Spain	NNP
cord-324810-92fosk3c	330	79	,	,	,
cord-324810-92fosk3c	330	80	and	and	CC
cord-324810-92fosk3c	330	81	the	the	DT
cord-324810-92fosk3c	330	82	UK	UK	NNP
cord-324810-92fosk3c	330	83	.	.	.
cord-324810-92fosk3c	331	1	S.	S.	NNP
cord-324810-92fosk3c	331	2	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	331	3	isoexacerbation	isoexacerbation	NN
cord-324810-92fosk3c	331	4	;	;	,
cord-324810-92fosk3c	331	5	(	(	-LRB-
cord-324810-92fosk3c	331	6	vii	vii	NN
cord-324810-92fosk3c	331	7	)	)	-RRB-
cord-324810-92fosk3c	331	8	cost	cost	NN
cord-324810-92fosk3c	331	9	effectiveness	effectiveness	NN
cord-324810-92fosk3c	331	10	,	,	,
cord-324810-92fosk3c	331	11	including	include	VBG
cord-324810-92fosk3c	331	12	the	the	DT
cord-324810-92fosk3c	331	13	drug	drug	NN
cord-324810-92fosk3c	331	14	and	and	CC
cord-324810-92fosk3c	331	15	hoslates	hoslate	NNS
cord-324810-92fosk3c	331	16	were	be	VBD
cord-324810-92fosk3c	331	17	99.6	99.6	CD
cord-324810-92fosk3c	331	18	%	%	NN
cord-324810-92fosk3c	331	19	susceptible	susceptible	JJ
cord-324810-92fosk3c	331	20	to	to	IN
cord-324810-92fosk3c	331	21	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	331	22	,	,	,
cord-324810-92fosk3c	331	23	gatifloxacin	gatifloxacin	NNP
cord-324810-92fosk3c	331	24	and	and	CC
cord-324810-92fosk3c	331	25	pital	pital	JJ
cord-324810-92fosk3c	331	26	costs	cost	NNS
cord-324810-92fosk3c	331	27	and	and	CC
cord-324810-92fosk3c	331	28	the	the	DT
cord-324810-92fosk3c	331	29	costs	cost	NNS
cord-324810-92fosk3c	331	30	of	of	IN
cord-324810-92fosk3c	331	31	treatment	treatment	NN
cord-324810-92fosk3c	331	32	failure	failure	NN
cord-324810-92fosk3c	331	33	(	(	-LRB-
cord-324810-92fosk3c	331	34	table	table	NN
cord-324810-92fosk3c	331	35	V	v	NN
cord-324810-92fosk3c	331	36	)	)	-RRB-
cord-324810-92fosk3c	331	37	.	.	.
cord-324810-92fosk3c	332	1	[	[	-LRB-
cord-324810-92fosk3c	332	2	98	98	CD
cord-324810-92fosk3c	332	3	]	]	-RRB-
cord-324810-92fosk3c	332	4	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	332	5	,	,	,
cord-324810-92fosk3c	332	6	and	and	CC
cord-324810-92fosk3c	332	7	H.	H.	NNP
cord-324810-92fosk3c	332	8	influenzae	influenzae	NN
cord-324810-92fosk3c	332	9	and	and	CC
cord-324810-92fosk3c	332	10	M.	M.	NNP
cord-324810-92fosk3c	332	11	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	332	12	were	be	VBD
cord-324810-92fosk3c	332	13	100	100	CD
cord-324810-92fosk3c	332	14	%	%	NN
cord-324810-92fosk3c	332	15	susceptible	susceptible	JJ
cord-324810-92fosk3c	332	16	.	.	.
cord-324810-92fosk3c	333	1	The	the	DT
cord-324810-92fosk3c	333	2	incidence	incidence	NN
cord-324810-92fosk3c	333	3	of	of	IN
cord-324810-92fosk3c	333	4	penicillin	penicillin	NN
cord-324810-92fosk3c	333	5	non	non	JJ
cord-324810-92fosk3c	333	6	-	-	NN
cord-324810-92fosk3c	333	7	susceptibility	susceptibility	NN
cord-324810-92fosk3c	333	8	to	to	IN
cord-324810-92fosk3c	333	9	S.	S.	NNP
cord-324810-92fosk3c	333	10	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	333	11	remained	remain	VBD
cord-324810-92fosk3c	333	12	similar	similar	JJ
cord-324810-92fosk3c	333	13	to	to	IN
cord-324810-92fosk3c	333	14	or	or	CC
cord-324810-92fosk3c	333	15	higher	high	JJR
cord-324810-92fosk3c	333	16	than	than	IN
cord-324810-92fosk3c	333	17	previously	previously	RB
cord-324810-92fosk3c	333	18	reported	report	VBN
cord-324810-92fosk3c	333	19	:	:	:
cord-324810-92fosk3c	333	20	France	France	NNP
cord-324810-92fosk3c	333	21	,	,	,
cord-324810-92fosk3c	333	22	165	165	CD
cord-324810-92fosk3c	333	23	of	of	IN
cord-324810-92fosk3c	333	24	291	291	CD
cord-324810-92fosk3c	333	25	(	(	-LRB-
cord-324810-92fosk3c	333	26	56.7	56.7	CD
cord-324810-92fosk3c	333	27	%	%	NN
cord-324810-92fosk3c	333	28	)	)	-RRB-
cord-324810-92fosk3c	333	29	;	;	:
cord-324810-92fosk3c	333	30	Germany	Germany	NNP
cord-324810-92fosk3c	333	31	,	,	,
cord-324810-92fosk3c	333	32	46	46	CD
cord-324810-92fosk3c	333	33	of	of	IN
cord-324810-92fosk3c	333	34	506	506	CD
cord-324810-92fosk3c	333	35	(	(	-LRB-
cord-324810-92fosk3c	333	36	9.1	9.1	CD
cord-324810-92fosk3c	333	37	%	%	NN
cord-324810-92fosk3c	333	38	)	)	-RRB-
cord-324810-92fosk3c	333	39	;	;	:
cord-324810-92fosk3c	333	40	Greece	Greece	NNP
cord-324810-92fosk3c	333	41	,	,	,
cord-324810-92fosk3c	333	42	20	20	CD
cord-324810-92fosk3c	333	43	of	of	IN
cord-324810-92fosk3c	333	44	55	55	CD
cord-324810-92fosk3c	333	45	(	(	-LRB-
cord-324810-92fosk3c	333	46	36.4	36.4	CD
cord-324810-92fosk3c	333	47	%	%	NN
cord-324810-92fosk3c	333	48	)	)	-RRB-
cord-324810-92fosk3c	333	49	;	;	:
cord-324810-92fosk3c	333	50	Italy	Italy	NNP
cord-324810-92fosk3c	333	51	,	,	,
cord-324810-92fosk3c	333	52	45	45	CD
cord-324810-92fosk3c	333	53	of	of	IN
cord-324810-92fosk3c	333	54	364	364	CD
cord-324810-92fosk3c	333	55	(	(	-LRB-
cord-324810-92fosk3c	333	56	12.4	12.4	CD
cord-324810-92fosk3c	333	57	%	%	NN
cord-324810-92fosk3c	333	58	)	)	-RRB-
cord-324810-92fosk3c	333	59	;	;	:
cord-324810-92fosk3c	333	60	Spain	Spain	NNP
cord-324810-92fosk3c	333	61	,	,	,
cord-324810-92fosk3c	333	62	146	146	CD
cord-324810-92fosk3c	333	63	of	of	IN
cord-324810-92fosk3c	333	64	268	268	CD
cord-324810-92fosk3c	333	65	(	(	-LRB-
cord-324810-92fosk3c	333	66	54.5	54.5	CD
cord-324810-92fosk3c	333	67	%	%	NN
cord-324810-92fosk3c	333	68	)	)	-RRB-
cord-324810-92fosk3c	333	69	;	;	:
cord-324810-92fosk3c	333	70	and	and	CC
cord-324810-92fosk3c	333	71	the	the	DT
cord-324810-92fosk3c	333	72	UK	UK	NNP
cord-324810-92fosk3c	333	73	,	,	,
cord-324810-92fosk3c	333	74	26	26	CD
cord-324810-92fosk3c	333	75	of	of	IN
cord-324810-92fosk3c	333	76	386	386	CD
cord-324810-92fosk3c	333	77	(	(	-LRB-
cord-324810-92fosk3c	333	78	6.7	6.7	CD
cord-324810-92fosk3c	333	79	%	%	NN
cord-324810-92fosk3c	333	80	)	)	-RRB-
cord-324810-92fosk3c	333	81	.	.	.
cord-324810-92fosk3c	334	1	The	the	DT
cord-324810-92fosk3c	334	2	β	β	NN
cord-324810-92fosk3c	334	3	-	-	HYPH
cord-324810-92fosk3c	334	4	lactamase	lactamase	NN
cord-324810-92fosk3c	334	5	production	production	NN
cord-324810-92fosk3c	334	6	among	among	IN
cord-324810-92fosk3c	334	7	H.	H.	NNP
cord-324810-92fosk3c	334	8	influenzae	influenzae	NN
cord-324810-92fosk3c	334	9	isolates	isolate	NNS
cord-324810-92fosk3c	334	10	ranged	range	VBD
cord-324810-92fosk3c	334	11	from	from	IN
cord-324810-92fosk3c	334	12	6.2	6.2	CD
cord-324810-92fosk3c	334	13	%	%	NN
cord-324810-92fosk3c	334	14	to	to	IN
cord-324810-92fosk3c	334	15	33.1	33.1	CD
cord-324810-92fosk3c	334	16	%	%	NN
cord-324810-92fosk3c	334	17	per	per	IN
cord-324810-92fosk3c	334	18	country	country	NN
cord-324810-92fosk3c	334	19	.	.	.
cord-324810-92fosk3c	335	1	A	a	DT
cord-324810-92fosk3c	335	2	higher	high	JJR
cord-324810-92fosk3c	335	3	resistance	resistance	NN
cord-324810-92fosk3c	335	4	against	against	IN
cord-324810-92fosk3c	335	5	Pneumococcus	Pneumococcus	NNP
cord-324810-92fosk3c	335	6	has	have	VBZ
cord-324810-92fosk3c	335	7	been	be	VBN
cord-324810-92fosk3c	335	8	reported	report	VBN
cord-324810-92fosk3c	335	9	from	from	IN
cord-324810-92fosk3c	335	10	Spain	Spain	NNP
cord-324810-92fosk3c	335	11	(	(	-LRB-
cord-324810-92fosk3c	335	12	53.4	53.4	CD
cord-324810-92fosk3c	335	13	%	%	NN
cord-324810-92fosk3c	335	14	)	)	-RRB-
cord-324810-92fosk3c	335	15	than	than	IN
cord-324810-92fosk3c	335	16	in	in	IN
cord-324810-92fosk3c	335	17	Italy	Italy	NNP
cord-324810-92fosk3c	335	18	(	(	-LRB-
cord-324810-92fosk3c	335	19	15.1	15.1	CD
cord-324810-92fosk3c	335	20	%	%	NN
cord-324810-92fosk3c	335	21	)	)	-RRB-
cord-324810-92fosk3c	335	22	,	,	,
cord-324810-92fosk3c	335	23	whereas	whereas	IN
cord-324810-92fosk3c	335	24	erythromycin	erythromycin	JJ
cord-324810-92fosk3c	335	25	resistance	resistance	NN
cord-324810-92fosk3c	335	26	was	be	VBD
cord-324810-92fosk3c	335	27	higher	high	JJR
cord-324810-92fosk3c	335	28	in	in	IN
cord-324810-92fosk3c	335	29	Italy	Italy	NNP
cord-324810-92fosk3c	335	30	(	(	-LRB-
cord-324810-92fosk3c	335	31	42.9	42.9	CD
cord-324810-92fosk3c	335	32	%	%	NN
cord-324810-92fosk3c	335	33	)	)	-RRB-
cord-324810-92fosk3c	335	34	than	than	IN
cord-324810-92fosk3c	335	35	in	in	IN
cord-324810-92fosk3c	335	36	Spain	Spain	NNP
cord-324810-92fosk3c	335	37	(	(	-LRB-
cord-324810-92fosk3c	335	38	28.6	28.6	CD
cord-324810-92fosk3c	335	39	%	%	NN
cord-324810-92fosk3c	335	40	)	)	-RRB-
cord-324810-92fosk3c	335	41	.	.	.
cord-324810-92fosk3c	336	1	[	[	-LRB-
cord-324810-92fosk3c	336	2	91	91	CD
cord-324810-92fosk3c	336	3	]	]	-RRB-
cord-324810-92fosk3c	337	1	Selective	selective	JJ
cord-324810-92fosk3c	337	2	pressure	pressure	NN
cord-324810-92fosk3c	337	3	from	from	IN
cord-324810-92fosk3c	337	4	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	337	5	prescription	prescription	NN
cord-324810-92fosk3c	337	6	appears	appear	VBZ
cord-324810-92fosk3c	337	7	to	to	TO
cord-324810-92fosk3c	337	8	be	be	VB
cord-324810-92fosk3c	337	9	the	the	DT
cord-324810-92fosk3c	337	10	most	most	RBS
cord-324810-92fosk3c	337	11	important	important	JJ
cord-324810-92fosk3c	337	12	factor	factor	NN
cord-324810-92fosk3c	337	13	associated	associate	VBN
cord-324810-92fosk3c	337	14	with	with	IN
cord-324810-92fosk3c	337	15	drug	drug	NN
cord-324810-92fosk3c	337	16	-	-	HYPH
cord-324810-92fosk3c	337	17	resistant	resistant	JJ
cord-324810-92fosk3c	337	18	S.	S.	NNP
cord-324810-92fosk3c	337	19	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	337	20	.	.	.
cord-324810-92fosk3c	338	1	Resistance	resistance	NN
cord-324810-92fosk3c	338	2	is	be	VBZ
cord-324810-92fosk3c	338	3	encountered	encounter	VBN
cord-324810-92fosk3c	338	4	more	more	RBR
cord-324810-92fosk3c	338	5	commonly	commonly	RB
cord-324810-92fosk3c	338	6	in	in	IN
cord-324810-92fosk3c	338	7	patients	patient	NNS
cord-324810-92fosk3c	338	8	who	who	WP
cord-324810-92fosk3c	338	9	have	have	VBP
cord-324810-92fosk3c	338	10	identifiable	identifiable	JJ
cord-324810-92fosk3c	338	11	risk	risk	NN
cord-324810-92fosk3c	338	12	factors	factor	NNS
cord-324810-92fosk3c	338	13	,	,	,
cord-324810-92fosk3c	338	14	including	include	VBG
cord-324810-92fosk3c	338	15	age	age	NN
cord-324810-92fosk3c	338	16	>	>	XX
cord-324810-92fosk3c	338	17	65	65	CD
cord-324810-92fosk3c	338	18	years	year	NNS
cord-324810-92fosk3c	338	19	,	,	,
cord-324810-92fosk3c	338	20	prescription	prescription	NN
cord-324810-92fosk3c	338	21	of	of	IN
cord-324810-92fosk3c	338	22	β	β	NN
cord-324810-92fosk3c	338	23	-	-	HYPH
cord-324810-92fosk3c	338	24	lactam	lactam	NN
cord-324810-92fosk3c	338	25	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	338	26	during	during	IN
cord-324810-92fosk3c	338	27	the	the	DT
cord-324810-92fosk3c	338	28	past	past	JJ
cord-324810-92fosk3c	338	29	3	3	CD
cord-324810-92fosk3c	338	30	months	month	NNS
cord-324810-92fosk3c	338	31	,	,	,
cord-324810-92fosk3c	338	32	previous	previous	JJ
cord-324810-92fosk3c	338	33	hospitalizations	hospitalization	NNS
cord-324810-92fosk3c	338	34	,	,	,
cord-324810-92fosk3c	338	35	and	and	CC
cord-324810-92fosk3c	338	36	nursing	nursing	NN
cord-324810-92fosk3c	338	37	home	home	NN
cord-324810-92fosk3c	338	38	residence	residence	NN
cord-324810-92fosk3c	338	39	.	.	.
cord-324810-92fosk3c	339	1	[	[	-LRB-
cord-324810-92fosk3c	339	2	86	86	CD
cord-324810-92fosk3c	339	3	,	,	,
cord-324810-92fosk3c	339	4	92	92	CD
cord-324810-92fosk3c	339	5	]	]	-RRB-
cord-324810-92fosk3c	340	1	However	however	RB
cord-324810-92fosk3c	340	2	,	,	,
cord-324810-92fosk3c	340	3	the	the	DT
cord-324810-92fosk3c	340	4	majority	majority	NN
cord-324810-92fosk3c	340	5	of	of	IN
cord-324810-92fosk3c	340	6	studies	study	NNS
cord-324810-92fosk3c	340	7	have	have	VBP
cord-324810-92fosk3c	340	8	not	not	RB
cord-324810-92fosk3c	340	9	classified	classify	VBN
cord-324810-92fosk3c	340	10	the	the	DT
cord-324810-92fosk3c	340	11	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	340	12	in	in	IN
cord-324810-92fosk3c	340	13	detail	detail	NN
cord-324810-92fosk3c	340	14	and	and	CC
cord-324810-92fosk3c	340	15	have	have	VBP
cord-324810-92fosk3c	340	16	not	not	RB
cord-324810-92fosk3c	340	17	demonstrated	demonstrate	VBN
cord-324810-92fosk3c	340	18	a	a	DT
cord-324810-92fosk3c	340	19	difference	difference	NN
cord-324810-92fosk3c	340	20	in	in	IN
cord-324810-92fosk3c	340	21	clinical	clinical	JJ
cord-324810-92fosk3c	340	22	outcomes	outcome	NNS
cord-324810-92fosk3c	340	23	with	with	IN
cord-324810-92fosk3c	340	24	newer	new	JJR
cord-324810-92fosk3c	340	25	or	or	CC
cord-324810-92fosk3c	340	26	the	the	DT
cord-324810-92fosk3c	340	27	older	old	JJR
cord-324810-92fosk3c	340	28	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	340	29	agents	agent	NNS
cord-324810-92fosk3c	340	30	.	.	.
cord-324810-92fosk3c	341	1	[	[	-LRB-
cord-324810-92fosk3c	341	2	93	93	CD
cord-324810-92fosk3c	341	3	]	]	-RRB-
cord-324810-92fosk3c	341	4	[	[	-LRB-
cord-324810-92fosk3c	341	5	94	94	CD
cord-324810-92fosk3c	341	6	]	]	-RRB-
cord-324810-92fosk3c	342	1	[	[	-LRB-
cord-324810-92fosk3c	342	2	95	95	CD
cord-324810-92fosk3c	342	3	]	]	-RRB-
cord-324810-92fosk3c	343	1	Grossman	Grossman	NNP
cord-324810-92fosk3c	343	2	et	et	NNP
cord-324810-92fosk3c	343	3	al	al	NNP
cord-324810-92fosk3c	343	4	.	.	.
cord-324810-92fosk3c	344	1	[	[	-LRB-
cord-324810-92fosk3c	344	2	96	96	CD
cord-324810-92fosk3c	344	3	]	]	-RRB-
cord-324810-92fosk3c	344	4	assessed	assess	VBN
cord-324810-92fosk3c	344	5	safety	safety	NN
cord-324810-92fosk3c	344	6	and	and	CC
cord-324810-92fosk3c	344	7	efficacy	efficacy	NN
cord-324810-92fosk3c	344	8	of	of	IN
cord-324810-92fosk3c	344	9	ciprofloxacin	ciprofloxacin	NN
cord-324810-92fosk3c	344	10	versus	versus	IN
cord-324810-92fosk3c	344	11	standard	standard	JJ
cord-324810-92fosk3c	344	12	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	344	13	care	care	NN
cord-324810-92fosk3c	344	14	in	in	IN
cord-324810-92fosk3c	344	15	patients	patient	NNS
cord-324810-92fosk3c	344	16	with	with	IN
cord-324810-92fosk3c	344	17	moderate	moderate	JJ
cord-324810-92fosk3c	344	18	-	-	HYPH
cord-324810-92fosk3c	344	19	tosevere	tosevere	NN
cord-324810-92fosk3c	344	20	bronchitis	bronchitis	NN
cord-324810-92fosk3c	344	21	and	and	CC
cord-324810-92fosk3c	344	22	at	at	IN
cord-324810-92fosk3c	344	23	least	least	JJS
cord-324810-92fosk3c	344	24	four	four	CD
cord-324810-92fosk3c	344	25	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	344	26	in	in	IN
cord-324810-92fosk3c	344	27	the	the	DT
cord-324810-92fosk3c	344	28	previous	previous	JJ
cord-324810-92fosk3c	344	29	year	year	NN
cord-324810-92fosk3c	344	30	.	.	.
cord-324810-92fosk3c	345	1	A	a	DT
cord-324810-92fosk3c	345	2	trend	trend	NN
cord-324810-92fosk3c	345	3	towards	towards	IN
cord-324810-92fosk3c	345	4	accelerated	accelerated	JJ
cord-324810-92fosk3c	345	5	resolution	resolution	NN
cord-324810-92fosk3c	345	6	with	with	IN
cord-324810-92fosk3c	345	7	ciprofloxacin	ciprofloxacin	NN
cord-324810-92fosk3c	345	8	existed	exist	VBD
cord-324810-92fosk3c	345	9	but	but	CC
cord-324810-92fosk3c	345	10	the	the	DT
cord-324810-92fosk3c	345	11	difference	difference	NN
cord-324810-92fosk3c	345	12	was	be	VBD
cord-324810-92fosk3c	345	13	not	not	RB
cord-324810-92fosk3c	345	14	statistically	statistically	RB
cord-324810-92fosk3c	345	15	significant	significant	JJ
cord-324810-92fosk3c	345	16	in	in	IN
cord-324810-92fosk3c	345	17	this	this	DT
cord-324810-92fosk3c	345	18	open	open	JJ
cord-324810-92fosk3c	345	19	-	-	HYPH
cord-324810-92fosk3c	345	20	label	label	NN
cord-324810-92fosk3c	345	21	,	,	,
cord-324810-92fosk3c	345	22	uncontrolled	uncontrolled	JJ
cord-324810-92fosk3c	345	23	study	study	NN
cord-324810-92fosk3c	345	24	.	.	.
cord-324810-92fosk3c	346	1	A	a	DT
cord-324810-92fosk3c	346	2	retrospective	retrospective	JJ
cord-324810-92fosk3c	346	3	analysis	analysis	NN
cord-324810-92fosk3c	346	4	performed	perform	VBN
cord-324810-92fosk3c	346	5	by	by	IN
cord-324810-92fosk3c	346	6	Madaras	Madaras	NNP
cord-324810-92fosk3c	346	7	-	-	HYPH
cord-324810-92fosk3c	346	8	Kelly	Kelly	NNP
cord-324810-92fosk3c	346	9	et	et	NNP
cord-324810-92fosk3c	346	10	al	al	NNP
cord-324810-92fosk3c	346	11	.	.	.
cord-324810-92fosk3c	347	1	[	[	-LRB-
cord-324810-92fosk3c	347	2	97	97	CD
cord-324810-92fosk3c	347	3	]	]	-RRB-
cord-324810-92fosk3c	347	4	concluded	conclude	VBD
cord-324810-92fosk3c	347	5	that	that	IN
cord-324810-92fosk3c	347	6	the	the	DT
cord-324810-92fosk3c	347	7	use	use	NN
cord-324810-92fosk3c	347	8	of	of	IN
cord-324810-92fosk3c	347	9	older	old	JJR
cord-324810-92fosk3c	347	10	versus	versus	IN
cord-324810-92fosk3c	347	11	newer	new	JJR
cord-324810-92fosk3c	347	12	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	347	13	did	do	VBD
cord-324810-92fosk3c	347	14	not	not	RB
cord-324810-92fosk3c	347	15	independently	independently	RB
cord-324810-92fosk3c	347	16	predict	predict	VB
cord-324810-92fosk3c	347	17	either	either	CC
cord-324810-92fosk3c	347	18	the	the	DT
cord-324810-92fosk3c	347	19	outcome	outcome	NN
cord-324810-92fosk3c	347	20	or	or	CC
cord-324810-92fosk3c	347	21	the	the	DT
cord-324810-92fosk3c	347	22	subsequent	subsequent	JJ
cord-324810-92fosk3c	347	23	development	development	NN
cord-324810-92fosk3c	347	24	of	of	IN
cord-324810-92fosk3c	347	25	an	an	DT
cord-324810-92fosk3c	347	26	exacerbation	exacerbation	NN
cord-324810-92fosk3c	347	27	.	.	.
cord-324810-92fosk3c	347	28	 	 	_SP
cord-324810-92fosk3c	348	1	Trimethoprim	Trimethoprim	NNP
cord-324810-92fosk3c	348	2	/	/	SYM
cord-324810-92fosk3c	348	3	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	348	4	,	,	,
cord-324810-92fosk3c	348	5	combined	combine	VBN
cord-324810-92fosk3c	348	6	in	in	IN
cord-324810-92fosk3c	348	7	a	a	DT
cord-324810-92fosk3c	348	8	ratio	ratio	NN
cord-324810-92fosk3c	348	9	of	of	IN
cord-324810-92fosk3c	348	10	1	1	CD
cord-324810-92fosk3c	348	11	:	:	SYM
cord-324810-92fosk3c	348	12	20	20	CD
cord-324810-92fosk3c	348	13	,	,	,
cord-324810-92fosk3c	348	14	is	be	VBZ
cord-324810-92fosk3c	348	15	a	a	DT
cord-324810-92fosk3c	348	16	bactericidal	bactericidal	JJ
cord-324810-92fosk3c	348	17	combination	combination	NN
cord-324810-92fosk3c	348	18	which	which	WDT
cord-324810-92fosk3c	348	19	works	work	VBZ
cord-324810-92fosk3c	348	20	synergistically	synergistically	RB
cord-324810-92fosk3c	348	21	against	against	IN
cord-324810-92fosk3c	348	22	bacterial	bacterial	JJ
cord-324810-92fosk3c	348	23	organisms	organism	NNS
cord-324810-92fosk3c	348	24	.	.	.
cord-324810-92fosk3c	349	1	Both	both	DT
cord-324810-92fosk3c	349	2	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	349	3	inhibit	inhibit	VBP
cord-324810-92fosk3c	349	4	enzyme	enzyme	NN
cord-324810-92fosk3c	349	5	systems	system	NNS
cord-324810-92fosk3c	350	1	In	in	IN
cord-324810-92fosk3c	350	2	1948	1948	CD
cord-324810-92fosk3c	350	3	,	,	,
cord-324810-92fosk3c	350	4	chlortetracycline	chlortetracycline	NNP
cord-324810-92fosk3c	350	5	was	be	VBD
cord-324810-92fosk3c	350	6	the	the	DT
cord-324810-92fosk3c	350	7	first	first	JJ
cord-324810-92fosk3c	350	8	tetracycline	tetracycline	NN
cord-324810-92fosk3c	350	9	discovered	discover	VBD
cord-324810-92fosk3c	350	10	.	.	.
cord-324810-92fosk3c	351	1	involved	involve	VBN
cord-324810-92fosk3c	351	2	in	in	IN
cord-324810-92fosk3c	351	3	the	the	DT
cord-324810-92fosk3c	351	4	bacterial	bacterial	JJ
cord-324810-92fosk3c	351	5	synthesis	synthesis	NN
cord-324810-92fosk3c	351	6	of	of	IN
cord-324810-92fosk3c	351	7	tetrahydrofolic	tetrahydrofolic	JJ
cord-324810-92fosk3c	351	8	acid	acid	NN
cord-324810-92fosk3c	351	9	by	by	IN
cord-324810-92fosk3c	351	10	Since	since	IN
cord-324810-92fosk3c	351	11	then	then	RB
cord-324810-92fosk3c	351	12	,	,	,
cord-324810-92fosk3c	351	13	tetracycline	tetracycline	NN
cord-324810-92fosk3c	351	14	,	,	,
cord-324810-92fosk3c	351	15	demeclocycline	demeclocycline	NN
cord-324810-92fosk3c	351	16	,	,	,
cord-324810-92fosk3c	351	17	doxycycline	doxycycline	NNP
cord-324810-92fosk3c	351	18	,	,	,
cord-324810-92fosk3c	351	19	and	and	CC
cord-324810-92fosk3c	351	20	minodifferent	minodifferent	NN
cord-324810-92fosk3c	351	21	mechanisms	mechanism	NNS
cord-324810-92fosk3c	351	22	.	.	.
cord-324810-92fosk3c	352	1	Resistance	resistance	NN
cord-324810-92fosk3c	352	2	occurs	occur	VBZ
cord-324810-92fosk3c	352	3	with	with	IN
cord-324810-92fosk3c	352	4	development	development	NN
cord-324810-92fosk3c	352	5	of	of	IN
cord-324810-92fosk3c	352	6	a	a	DT
cord-324810-92fosk3c	352	7	cycline	cycline	NN
cord-324810-92fosk3c	352	8	have	have	VBP
cord-324810-92fosk3c	352	9	been	be	VBN
cord-324810-92fosk3c	352	10	synthesized	synthesize	VBN
cord-324810-92fosk3c	352	11	for	for	IN
cord-324810-92fosk3c	352	12	clinical	clinical	JJ
cord-324810-92fosk3c	352	13	use	use	NN
cord-324810-92fosk3c	352	14	,	,	,
cord-324810-92fosk3c	352	15	although	although	IN
cord-324810-92fosk3c	352	16	doxytarget	doxytarget	NNP
cord-324810-92fosk3c	352	17	enzyme	enzyme	NNP
cord-324810-92fosk3c	352	18	with	with	IN
cord-324810-92fosk3c	352	19	decreased	decreased	JJ
cord-324810-92fosk3c	352	20	bacterial	bacterial	JJ
cord-324810-92fosk3c	352	21	affinity	affinity	NN
cord-324810-92fosk3c	352	22	for	for	IN
cord-324810-92fosk3c	352	23	the	the	DT
cord-324810-92fosk3c	352	24	drugs	drug	NNS
cord-324810-92fosk3c	352	25	and	and	CC
cord-324810-92fosk3c	352	26	cycline	cycline	NN
cord-324810-92fosk3c	352	27	and	and	CC
cord-324810-92fosk3c	352	28	minocycline	minocycline	NNP
cord-324810-92fosk3c	352	29	are	be	VBP
cord-324810-92fosk3c	352	30	the	the	DT
cord-324810-92fosk3c	352	31	most	most	RBS
cord-324810-92fosk3c	352	32	frequently	frequently	RB
cord-324810-92fosk3c	352	33	prescribed	prescribe	VBN
cord-324810-92fosk3c	352	34	.	.	.
cord-324810-92fosk3c	353	1	The	the	DT
cord-324810-92fosk3c	353	2	via	via	IN
cord-324810-92fosk3c	353	3	dihydrofolic	dihydrofolic	JJ
cord-324810-92fosk3c	353	4	reductase	reductase	NN
cord-324810-92fosk3c	353	5	gene	gene	NN
cord-324810-92fosk3c	353	6	mutations	mutation	NNS
cord-324810-92fosk3c	353	7	.	.	.
cord-324810-92fosk3c	354	1	Although	although	IN
cord-324810-92fosk3c	354	2	very	very	RB
cord-324810-92fosk3c	354	3	popular	popular	JJ
cord-324810-92fosk3c	354	4	tetracyclines	tetracycline	NNS
cord-324810-92fosk3c	354	5	are	be	VBP
cord-324810-92fosk3c	354	6	broad	broad	JJ
cord-324810-92fosk3c	354	7	-	-	HYPH
cord-324810-92fosk3c	354	8	spectrum	spectrum	NN
cord-324810-92fosk3c	354	9	bacteriostatic	bacteriostatic	JJ
cord-324810-92fosk3c	354	10	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	354	11	.	.	.
cord-324810-92fosk3c	355	1	in	in	IN
cord-324810-92fosk3c	355	2	the	the	DT
cord-324810-92fosk3c	355	3	1970s	1970	NNS
cord-324810-92fosk3c	355	4	and	and	CC
cord-324810-92fosk3c	355	5	1980s	1980	NNS
cord-324810-92fosk3c	355	6	,	,	,
cord-324810-92fosk3c	355	7	the	the	DT
cord-324810-92fosk3c	355	8	potential	potential	NN
cord-324810-92fosk3c	355	9	for	for	IN
cord-324810-92fosk3c	355	10	resistance	resistance	NN
cord-324810-92fosk3c	355	11	and	and	CC
cord-324810-92fosk3c	355	12	increasing	increase	VBG
cord-324810-92fosk3c	355	13	They	-PRON-	PRP
cord-324810-92fosk3c	355	14	either	either	CC
cord-324810-92fosk3c	355	15	passively	passively	RB
cord-324810-92fosk3c	355	16	diffuse	diffuse	VBP
cord-324810-92fosk3c	355	17	or	or	CC
cord-324810-92fosk3c	355	18	are	be	VBP
cord-324810-92fosk3c	355	19	actively	actively	RB
cord-324810-92fosk3c	355	20	transported	transport	VBN
cord-324810-92fosk3c	355	21	into	into	IN
cord-324810-92fosk3c	355	22	the	the	DT
cord-324810-92fosk3c	355	23	availability	availability	NN
cord-324810-92fosk3c	355	24	of	of	IN
cord-324810-92fosk3c	355	25	safer	safe	JJR
cord-324810-92fosk3c	355	26	agents	agent	NNS
cord-324810-92fosk3c	355	27	has	have	VBZ
cord-324810-92fosk3c	355	28	resulted	result	VBN
cord-324810-92fosk3c	355	29	in	in	IN
cord-324810-92fosk3c	355	30	declining	decline	VBG
cord-324810-92fosk3c	355	31	use	use	NN
cord-324810-92fosk3c	355	32	of	of	IN
cord-324810-92fosk3c	355	33	this	this	DT
cord-324810-92fosk3c	355	34	bacterial	bacterial	JJ
cord-324810-92fosk3c	355	35	cell	cell	NN
cord-324810-92fosk3c	355	36	.	.	.
cord-324810-92fosk3c	356	1	They	-PRON-	PRP
cord-324810-92fosk3c	356	2	inhibit	inhibit	VBP
cord-324810-92fosk3c	356	3	ribosomal	ribosomal	JJ
cord-324810-92fosk3c	356	4	bacterial	bacterial	JJ
cord-324810-92fosk3c	356	5	protein	protein	NN
cord-324810-92fosk3c	356	6	synthesis	synthesis	NN
cord-324810-92fosk3c	356	7	.	.	.
cord-324810-92fosk3c	357	1	antimicrobial	antimicrobial	NNP
cord-324810-92fosk3c	357	2	.	.	.
cord-324810-92fosk3c	358	1	In	in	IN
cord-324810-92fosk3c	358	2	older	old	JJR
cord-324810-92fosk3c	358	3	studies	study	NNS
cord-324810-92fosk3c	358	4	,	,	,
cord-324810-92fosk3c	358	5	comparisons	comparison	NNS
cord-324810-92fosk3c	358	6	with	with	IN
cord-324810-92fosk3c	358	7	oral	oral	JJ
cord-324810-92fosk3c	358	8	The	the	DT
cord-324810-92fosk3c	358	9	mechanism	mechanism	NN
cord-324810-92fosk3c	358	10	of	of	IN
cord-324810-92fosk3c	358	11	resistance	resistance	NN
cord-324810-92fosk3c	358	12	to	to	IN
cord-324810-92fosk3c	358	13	tetracycline	tetracycline	NNP
cord-324810-92fosk3c	358	14	is	be	VBZ
cord-324810-92fosk3c	358	15	to	to	TO
cord-324810-92fosk3c	358	16	prevent	prevent	VB
cord-324810-92fosk3c	358	17	accumucephalosporins	accumucephalosporin	NNS
cord-324810-92fosk3c	358	18	have	have	VBP
cord-324810-92fosk3c	358	19	generally	generally	RB
cord-324810-92fosk3c	358	20	shown	show	VBN
cord-324810-92fosk3c	358	21	equivalent	equivalent	JJ
cord-324810-92fosk3c	358	22	efficacy	efficacy	NN
cord-324810-92fosk3c	358	23	.	.	.
cord-324810-92fosk3c	359	1	[	[	-LRB-
cord-324810-92fosk3c	359	2	104	104	CD
cord-324810-92fosk3c	359	3	]	]	-RRB-
cord-324810-92fosk3c	360	1	The	the	DT
cord-324810-92fosk3c	360	2	lation	lation	NN
cord-324810-92fosk3c	360	3	of	of	IN
cord-324810-92fosk3c	360	4	the	the	DT
cord-324810-92fosk3c	360	5	drug	drug	NN
cord-324810-92fosk3c	360	6	inside	inside	IN
cord-324810-92fosk3c	360	7	the	the	DT
cord-324810-92fosk3c	360	8	cell	cell	NN
cord-324810-92fosk3c	360	9	by	by	IN
cord-324810-92fosk3c	360	10	decreasing	decrease	VBG
cord-324810-92fosk3c	360	11	influx	influx	NN
cord-324810-92fosk3c	360	12	or	or	CC
cord-324810-92fosk3c	360	13	increasing	increase	VBG
cord-324810-92fosk3c	360	14	SENTRY	SENTRY	NNP
cord-324810-92fosk3c	360	15	Antimicrobial	Antimicrobial	NNP
cord-324810-92fosk3c	360	16	Surveillance	Surveillance	NNP
cord-324810-92fosk3c	360	17	Program	Program	NNP
cord-324810-92fosk3c	360	18	reported	report	VBD
cord-324810-92fosk3c	360	19	15	15	CD
cord-324810-92fosk3c	360	20	-	-	SYM
cord-324810-92fosk3c	360	21	20	20	CD
cord-324810-92fosk3c	360	22	%	%	NN
cord-324810-92fosk3c	360	23	efflux	efflux	NN
cord-324810-92fosk3c	360	24	.	.	.
cord-324810-92fosk3c	361	1	Many	many	JJ
cord-324810-92fosk3c	361	2	of	of	IN
cord-324810-92fosk3c	361	3	the	the	DT
cord-324810-92fosk3c	361	4	original	original	JJ
cord-324810-92fosk3c	361	5	trials	trial	NNS
cord-324810-92fosk3c	361	6	of	of	IN
cord-324810-92fosk3c	361	7	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	361	8	therapy	therapy	NN
cord-324810-92fosk3c	361	9	demontrimethoprim	demontrimethoprim	NNP
cord-324810-92fosk3c	361	10	/	/	SYM
cord-324810-92fosk3c	361	11	sulfamethoxazole	sulfamethoxazole	NN
cord-324810-92fosk3c	361	12	resistance	resistance	NN
cord-324810-92fosk3c	361	13	to	to	IN
cord-324810-92fosk3c	361	14	common	common	JJ
cord-324810-92fosk3c	361	15	respiratory	respiratory	JJ
cord-324810-92fosk3c	361	16	strated	strate	VBD
cord-324810-92fosk3c	361	17	that	that	IN
cord-324810-92fosk3c	361	18	tetracycline	tetracycline	NNP
cord-324810-92fosk3c	361	19	therapy	therapy	NN
cord-324810-92fosk3c	361	20	was	be	VBD
cord-324810-92fosk3c	361	21	more	more	RBR
cord-324810-92fosk3c	361	22	effective	effective	JJ
cord-324810-92fosk3c	361	23	than	than	IN
cord-324810-92fosk3c	361	24	placebo	placebo	NN
cord-324810-92fosk3c	361	25	in	in	IN
cord-324810-92fosk3c	361	26	pathogens	pathogen	NNS
cord-324810-92fosk3c	361	27	in	in	IN
cord-324810-92fosk3c	361	28	Europe	Europe	NNP
cord-324810-92fosk3c	361	29	and	and	CC
cord-324810-92fosk3c	361	30	the	the	DT
cord-324810-92fosk3c	361	31	US	US	NNP
cord-324810-92fosk3c	361	32	,	,	,
cord-324810-92fosk3c	361	33	and	and	CC
cord-324810-92fosk3c	361	34	higher	high	JJR
cord-324810-92fosk3c	361	35	in	in	IN
cord-324810-92fosk3c	361	36	Latin	Latin	NNP
cord-324810-92fosk3c	361	37	America	America	NNP
cord-324810-92fosk3c	361	38	and	and	CC
cord-324810-92fosk3c	361	39	milder	mild	JJR
cord-324810-92fosk3c	361	40	infections	infection	NNS
cord-324810-92fosk3c	361	41	.	.	.
cord-324810-92fosk3c	362	1	Tetracyclines	Tetracyclines	NNP
cord-324810-92fosk3c	362	2	can	can	MD
cord-324810-92fosk3c	362	3	be	be	VB
cord-324810-92fosk3c	362	4	used	use	VBN
cord-324810-92fosk3c	362	5	in	in	IN
cord-324810-92fosk3c	362	6	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	362	7	because	because	IN
cord-324810-92fosk3c	362	8	Asia	Asia	NNP
cord-324810-92fosk3c	362	9	-	-	HYPH
cord-324810-92fosk3c	362	10	Pacific	Pacific	NNP
cord-324810-92fosk3c	362	11	regions	region	NNS
cord-324810-92fosk3c	362	12	.	.	.
cord-324810-92fosk3c	363	1	[	[	-LRB-
cord-324810-92fosk3c	363	2	105	105	CD
cord-324810-92fosk3c	363	3	]	]	-RRB-
cord-324810-92fosk3c	363	4	Penicillin	Penicillin	NNP
cord-324810-92fosk3c	363	5	-	-	HYPH
cord-324810-92fosk3c	363	6	resistant	resistant	JJ
cord-324810-92fosk3c	363	7	pneumococci	pneumococcus	NNS
cord-324810-92fosk3c	363	8	have	have	VBP
cord-324810-92fosk3c	363	9	they	-PRON-	PRP
cord-324810-92fosk3c	363	10	are	be	VBP
cord-324810-92fosk3c	363	11	active	active	JJ
cord-324810-92fosk3c	363	12	against	against	IN
cord-324810-92fosk3c	363	13	H.	h.	NN
cord-324810-92fosk3c	363	14	influenzae	influenzae	NN
cord-324810-92fosk3c	363	15	and	and	CC
cord-324810-92fosk3c	363	16	atypical	atypical	JJ
cord-324810-92fosk3c	363	17	pathogens	pathogen	NNS
cord-324810-92fosk3c	363	18	,	,	,
cord-324810-92fosk3c	363	19	but	but	CC
cord-324810-92fosk3c	363	20	80	80	CD
cord-324810-92fosk3c	363	21	-	-	SYM
cord-324810-92fosk3c	363	22	90	90	CD
cord-324810-92fosk3c	363	23	%	%	NN
cord-324810-92fosk3c	363	24	likelihood	likelihood	NN
cord-324810-92fosk3c	363	25	of	of	IN
cord-324810-92fosk3c	363	26	cross	cross	NN
cord-324810-92fosk3c	363	27	-	-	NN
cord-324810-92fosk3c	363	28	resistance	resistance	NN
cord-324810-92fosk3c	363	29	to	to	IN
cord-324810-92fosk3c	363	30	trimethoprim/	trimethoprim/	CD
cord-324810-92fosk3c	363	31	there	there	EX
cord-324810-92fosk3c	363	32	have	have	VBP
cord-324810-92fosk3c	363	33	been	be	VBN
cord-324810-92fosk3c	363	34	reports	report	NNS
cord-324810-92fosk3c	363	35	of	of	IN
cord-324810-92fosk3c	363	36	increasing	increase	VBG
cord-324810-92fosk3c	363	37	resistance	resistance	NN
cord-324810-92fosk3c	363	38	against	against	IN
cord-324810-92fosk3c	363	39	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	363	40	.	.	.
cord-324810-92fosk3c	364	1	[	[	-LRB-
cord-324810-92fosk3c	364	2	106	106	CD
cord-324810-92fosk3c	364	3	]	]	-RRB-
cord-324810-92fosk3c	365	1	Consequently	consequently	RB
cord-324810-92fosk3c	365	2	,	,	,
cord-324810-92fosk3c	365	3	local	local	JJ
cord-324810-92fosk3c	365	4	resistance	resistance	NN
cord-324810-92fosk3c	365	5	patterns	pattern	NNS
cord-324810-92fosk3c	365	6	and	and	CC
cord-324810-92fosk3c	365	7	pneumococci	pneumococcus	NNS
cord-324810-92fosk3c	365	8	.	.	.
cord-324810-92fosk3c	366	1	[	[	-LRB-
cord-324810-92fosk3c	366	2	88	88	CD
cord-324810-92fosk3c	366	3	]	]	-RRB-
cord-324810-92fosk3c	366	4	[	[	-LRB-
cord-324810-92fosk3c	366	5	89	89	CD
cord-324810-92fosk3c	366	6	]	]	-RRB-
cord-324810-92fosk3c	367	1	[	[	-LRB-
cord-324810-92fosk3c	367	2	90	90	CD
cord-324810-92fosk3c	367	3	]	]	-RRB-
cord-324810-92fosk3c	367	4	99	99	CD
cord-324810-92fosk3c	367	5	]	]	-RRB-
cord-324810-92fosk3c	367	6	severity	severity	NN
cord-324810-92fosk3c	367	7	of	of	IN
cord-324810-92fosk3c	367	8	disease	disease	NN
cord-324810-92fosk3c	367	9	should	should	MD
cord-324810-92fosk3c	367	10	be	be	VB
cord-324810-92fosk3c	367	11	taken	take	VBN
cord-324810-92fosk3c	367	12	into	into	IN
cord-324810-92fosk3c	367	13	account	account	NN
cord-324810-92fosk3c	367	14	for	for	IN
cord-324810-92fosk3c	367	15	appropriate	appropriate	JJ
cord-324810-92fosk3c	367	16	use	use	NN
cord-324810-92fosk3c	367	17	β	β	NNP
cord-324810-92fosk3c	367	18	-	-	HYPH
cord-324810-92fosk3c	367	19	Lactam	Lactam	NNP
cord-324810-92fosk3c	367	20	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	367	21	are	be	VBP
cord-324810-92fosk3c	367	22	generally	generally	RB
cord-324810-92fosk3c	367	23	bactericidal	bactericidal	JJ
cord-324810-92fosk3c	367	24	by	by	IN
cord-324810-92fosk3c	367	25	virtue	virtue	NN
cord-324810-92fosk3c	367	26	of	of	IN
cord-324810-92fosk3c	367	27	of	of	IN
cord-324810-92fosk3c	367	28	trimethoprim	trimethoprim	NNP
cord-324810-92fosk3c	367	29	/	/	SYM
cord-324810-92fosk3c	367	30	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	367	31	in	in	IN
cord-324810-92fosk3c	367	32	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	367	33	.	.	.
cord-324810-92fosk3c	368	1	inhibition	inhibition	NN
cord-324810-92fosk3c	368	2	of	of	IN
cord-324810-92fosk3c	368	3	bacterial	bacterial	JJ
cord-324810-92fosk3c	368	4	cell	cell	NN
cord-324810-92fosk3c	368	5	wall	wall	NN
cord-324810-92fosk3c	368	6	synthesis	synthesis	NN
cord-324810-92fosk3c	368	7	.	.	.
cord-324810-92fosk3c	369	1	Bacterial	bacterial	JJ
cord-324810-92fosk3c	369	2	resistance	resistance	NN
cord-324810-92fosk3c	369	3	to	to	IN
cord-324810-92fosk3c	369	4	β	β	NN
cord-324810-92fosk3c	369	5	-	-	HYPH
cord-324810-92fosk3c	369	6	lactams	lactam	NNS
cord-324810-92fosk3c	369	7	may	may	MD
cord-324810-92fosk3c	369	8	occur	occur	VB
cord-324810-92fosk3c	369	9	by	by	IN
cord-324810-92fosk3c	369	10	any	any	DT
cord-324810-92fosk3c	369	11	of	of	IN
cord-324810-92fosk3c	369	12	three	three	CD
cord-324810-92fosk3c	369	13	general	general	JJ
cord-324810-92fosk3c	369	14	mechanisms	mechanism	NNS
cord-324810-92fosk3c	369	15	:	:	:
cord-324810-92fosk3c	370	1	(	(	-LRB-
cord-324810-92fosk3c	370	2	i	i	NN
cord-324810-92fosk3c	370	3	)	)	-RRB-
cord-324810-92fosk3c	370	4	10	10	CD
cord-324810-92fosk3c	370	5	.	.	.
cord-324810-92fosk3c	371	1	Second	second	JJ
cord-324810-92fosk3c	371	2	-	-	HYPH
cord-324810-92fosk3c	371	3	Line	line	NN
cord-324810-92fosk3c	371	4	Antimicrobials	Antimicrobials	NNP
cord-324810-92fosk3c	371	5	decreased	decrease	VBD
cord-324810-92fosk3c	371	6	penetration	penetration	NN
cord-324810-92fosk3c	371	7	of	of	IN
cord-324810-92fosk3c	371	8	antimicrobial	antimicrobial	NN
cord-324810-92fosk3c	371	9	to	to	IN
cord-324810-92fosk3c	371	10	the	the	DT
cord-324810-92fosk3c	371	11	target	target	NN
cord-324810-92fosk3c	371	12	binding	bind	VBG
cord-324810-92fosk3c	371	13	protein	protein	NN
cord-324810-92fosk3c	371	14	in	in	IN
cord-324810-92fosk3c	371	15	the	the	DT
cord-324810-92fosk3c	371	16	bacterial	bacterial	JJ
cord-324810-92fosk3c	371	17	plasma	plasma	NN
cord-324810-92fosk3c	371	18	membrane	membrane	NN
cord-324810-92fosk3c	371	19	;	;	,
cord-324810-92fosk3c	371	20	(	(	-LRB-
cord-324810-92fosk3c	371	21	ii	ii	NN
cord-324810-92fosk3c	371	22	)	)	-RRB-
cord-324810-92fosk3c	371	23	alterations	alteration	NNS
cord-324810-92fosk3c	371	24	in	in	IN
cord-324810-92fosk3c	371	25	penicillin-	penicillin-	NN
cord-324810-92fosk3c	372	1	The	the	DT
cord-324810-92fosk3c	372	2	mechanism	mechanism	NN
cord-324810-92fosk3c	372	3	of	of	IN
cord-324810-92fosk3c	372	4	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	372	5	action	action	NN
cord-324810-92fosk3c	372	6	of	of	IN
cord-324810-92fosk3c	372	7	newer	new	JJR
cord-324810-92fosk3c	372	8	macrolides	macrolide	NNS
cord-324810-92fosk3c	372	9	is	be	VBZ
cord-324810-92fosk3c	372	10	binding	bind	VBG
cord-324810-92fosk3c	372	11	proteins	protein	NNS
cord-324810-92fosk3c	372	12	;	;	:
cord-324810-92fosk3c	372	13	and	and	CC
cord-324810-92fosk3c	372	14	(	(	-LRB-
cord-324810-92fosk3c	372	15	iii	iii	NN
cord-324810-92fosk3c	372	16	)	)	-RRB-
cord-324810-92fosk3c	372	17	production	production	NN
cord-324810-92fosk3c	372	18	of	of	IN
cord-324810-92fosk3c	372	19	β	β	NN
cord-324810-92fosk3c	372	20	-	-	HYPH
cord-324810-92fosk3c	372	21	lactamase	lactamase	NNP
cord-324810-92fosk3c	372	22	,	,	,
cord-324810-92fosk3c	372	23	which	which	WDT
cord-324810-92fosk3c	372	24	may	may	MD
cord-324810-92fosk3c	372	25	similar	similar	JJ
cord-324810-92fosk3c	372	26	to	to	IN
cord-324810-92fosk3c	372	27	that	that	DT
cord-324810-92fosk3c	372	28	of	of	IN
cord-324810-92fosk3c	372	29	erythromycin	erythromycin	NN
cord-324810-92fosk3c	372	30	.	.	.
cord-324810-92fosk3c	373	1	These	these	DT
cord-324810-92fosk3c	373	2	agents	agent	NNS
cord-324810-92fosk3c	373	3	bind	bind	VBP
cord-324810-92fosk3c	373	4	to	to	IN
cord-324810-92fosk3c	373	5	the	the	DT
cord-324810-92fosk3c	373	6	50S	50	NNS
cord-324810-92fosk3c	373	7	cleave	cleave	VBP
cord-324810-92fosk3c	373	8	the	the	DT
cord-324810-92fosk3c	373	9	penicillins	penicillin	NNS
cord-324810-92fosk3c	373	10	or	or	CC
cord-324810-92fosk3c	373	11	cephalosporins	cephalosporin	NNS
cord-324810-92fosk3c	373	12	.	.	.
cord-324810-92fosk3c	374	1	Production	production	NN
cord-324810-92fosk3c	374	2	of	of	IN
cord-324810-92fosk3c	374	3	βsubunit	βsubunit	NNS
cord-324810-92fosk3c	374	4	of	of	IN
cord-324810-92fosk3c	374	5	bacterial	bacterial	JJ
cord-324810-92fosk3c	374	6	ribosome	ribosome	NN
cord-324810-92fosk3c	374	7	and	and	CC
cord-324810-92fosk3c	374	8	inhibit	inhibit	VB
cord-324810-92fosk3c	374	9	bacterial	bacterial	JJ
cord-324810-92fosk3c	374	10	protein	protein	NN
cord-324810-92fosk3c	374	11	synthelactamase	synthelactamase	NN
cord-324810-92fosk3c	374	12	is	be	VBZ
cord-324810-92fosk3c	374	13	the	the	DT
cord-324810-92fosk3c	374	14	most	most	RBS
cord-324810-92fosk3c	374	15	important	important	JJ
cord-324810-92fosk3c	374	16	mechanism	mechanism	NN
cord-324810-92fosk3c	374	17	.	.	.
cord-324810-92fosk3c	375	1	The	the	DT
cord-324810-92fosk3c	375	2	bacteria	bacteria	NNS
cord-324810-92fosk3c	375	3	may	may	MD
cord-324810-92fosk3c	375	4	sis	sis	NN
cord-324810-92fosk3c	375	5	.	.	.
cord-324810-92fosk3c	376	1	Compared	compare	VBN
cord-324810-92fosk3c	376	2	with	with	IN
cord-324810-92fosk3c	376	3	erythromycin	erythromycin	NNS
cord-324810-92fosk3c	376	4	,	,	,
cord-324810-92fosk3c	376	5	these	these	DT
cord-324810-92fosk3c	376	6	agents	agent	NNS
cord-324810-92fosk3c	376	7	are	be	VBP
cord-324810-92fosk3c	376	8	more	more	RBR
cord-324810-92fosk3c	376	9	acid	acid	JJ
cord-324810-92fosk3c	376	10	either	either	CC
cord-324810-92fosk3c	376	11	synthesize	synthesize	VBP
cord-324810-92fosk3c	376	12	β	β	NN
cord-324810-92fosk3c	376	13	-	-	HYPH
cord-324810-92fosk3c	376	14	lactamase	lactamase	NN
cord-324810-92fosk3c	376	15	constitutively	constitutively	RB
cord-324810-92fosk3c	376	16	or	or	CC
cord-324810-92fosk3c	376	17	initiate	initiate	VB
cord-324810-92fosk3c	376	18	synthesis	synthesis	NN
cord-324810-92fosk3c	376	19	in	in	IN
cord-324810-92fosk3c	376	20	stable	stable	JJ
cord-324810-92fosk3c	376	21	,	,	,
cord-324810-92fosk3c	376	22	have	have	VBP
cord-324810-92fosk3c	376	23	improved	improve	VBN
cord-324810-92fosk3c	376	24	oral	oral	JJ
cord-324810-92fosk3c	376	25	absorption	absorption	NN
cord-324810-92fosk3c	376	26	and	and	CC
cord-324810-92fosk3c	376	27	tolerance	tolerance	NN
cord-324810-92fosk3c	376	28	,	,	,
cord-324810-92fosk3c	376	29	and	and	CC
cord-324810-92fosk3c	376	30	have	have	VB
cord-324810-92fosk3c	376	31	a	a	DT
cord-324810-92fosk3c	376	32	the	the	DT
cord-324810-92fosk3c	376	33	presence	presence	NN
cord-324810-92fosk3c	376	34	of	of	IN
cord-324810-92fosk3c	376	35	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	376	36	;	;	:
cord-324810-92fosk3c	376	37	the	the	DT
cord-324810-92fosk3c	376	38	β	β	NN
cord-324810-92fosk3c	376	39	-	-	HYPH
cord-324810-92fosk3c	376	40	lactamase	lactamase	NN
cord-324810-92fosk3c	376	41	positivity	positivity	NN
cord-324810-92fosk3c	376	42	varies	vary	VBZ
cord-324810-92fosk3c	376	43	broader	broad	JJR
cord-324810-92fosk3c	376	44	spectrum	spectrum	NN
cord-324810-92fosk3c	376	45	of	of	IN
cord-324810-92fosk3c	376	46	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	376	47	activity	activity	NN
cord-324810-92fosk3c	376	48	.	.	.
cord-324810-92fosk3c	377	1	Macrolides	macrolide	NNS
cord-324810-92fosk3c	377	2	and	and	CC
cord-324810-92fosk3c	377	3	fluorobetween	fluorobetween	NN
cord-324810-92fosk3c	377	4	centers	center	NNS
cord-324810-92fosk3c	377	5	and	and	CC
cord-324810-92fosk3c	377	6	countries	country	NNS
cord-324810-92fosk3c	377	7	.	.	.
cord-324810-92fosk3c	378	1	Amoxicillin	Amoxicillin	NNP
cord-324810-92fosk3c	378	2	has	have	VBZ
cord-324810-92fosk3c	378	3	been	be	VBN
cord-324810-92fosk3c	378	4	widely	widely	RB
cord-324810-92fosk3c	378	5	used	use	VBN
cord-324810-92fosk3c	378	6	quinolones	quinolone	NNS
cord-324810-92fosk3c	378	7	are	be	VBP
cord-324810-92fosk3c	378	8	active	active	JJ
cord-324810-92fosk3c	378	9	against	against	IN
cord-324810-92fosk3c	378	10	C.	C.	NNP
cord-324810-92fosk3c	378	11	pneumoniae	pneumoniae	NNS
cord-324810-92fosk3c	378	12	.	.	.
cord-324810-92fosk3c	379	1	There	there	EX
cord-324810-92fosk3c	379	2	has	have	VBZ
cord-324810-92fosk3c	379	3	been	be	VBN
cord-324810-92fosk3c	379	4	for	for	IN
cord-324810-92fosk3c	379	5	the	the	DT
cord-324810-92fosk3c	379	6	management	management	NN
cord-324810-92fosk3c	379	7	of	of	IN
cord-324810-92fosk3c	379	8	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	379	9	.	.	.
cord-324810-92fosk3c	380	1	[	[	-LRB-
cord-324810-92fosk3c	380	2	74	74	CD
cord-324810-92fosk3c	380	3	]	]	-RRB-
cord-324810-92fosk3c	381	1	In	in	IN
cord-324810-92fosk3c	381	2	countries	country	NNS
cord-324810-92fosk3c	381	3	and	and	CC
cord-324810-92fosk3c	381	4	centers	center	NNS
cord-324810-92fosk3c	381	5	increasing	increase	VBG
cord-324810-92fosk3c	381	6	resistance	resistance	NN
cord-324810-92fosk3c	381	7	to	to	IN
cord-324810-92fosk3c	381	8	macrolides	macrolide	NNS
cord-324810-92fosk3c	381	9	among	among	IN
cord-324810-92fosk3c	381	10	Gram	gram	NN
cord-324810-92fosk3c	381	11	-	-	HYPH
cord-324810-92fosk3c	381	12	positive	positive	JJ
cord-324810-92fosk3c	381	13	orgawhere	orgawhere	JJ
cord-324810-92fosk3c	381	14	resistance	resistance	NN
cord-324810-92fosk3c	381	15	among	among	IN
cord-324810-92fosk3c	381	16	H.	H.	NNP
cord-324810-92fosk3c	381	17	influenzae	influenzae	NN
cord-324810-92fosk3c	381	18	and	and	CC
cord-324810-92fosk3c	381	19	pneumococci	pneumococcus	NNS
cord-324810-92fosk3c	381	20	remain	remain	VBP
cord-324810-92fosk3c	381	21	at	at	IN
cord-324810-92fosk3c	381	22	nisms	nisms	NNP
cord-324810-92fosk3c	381	23	.	.	.
cord-324810-92fosk3c	382	1	Up	up	IN
cord-324810-92fosk3c	382	2	to	to	TO
cord-324810-92fosk3c	382	3	15	15	CD
cord-324810-92fosk3c	382	4	%	%	NN
cord-324810-92fosk3c	382	5	of	of	IN
cord-324810-92fosk3c	382	6	S.	S.	NNP
cord-324810-92fosk3c	382	7	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	382	8	may	may	MD
cord-324810-92fosk3c	382	9	have	have	VB
cord-324810-92fosk3c	382	10	resistance	resistance	NN
cord-324810-92fosk3c	382	11	to	to	IN
cord-324810-92fosk3c	382	12	low	low	JJ
cord-324810-92fosk3c	382	13	levels	level	NNS
cord-324810-92fosk3c	382	14	,	,	,
cord-324810-92fosk3c	382	15	β	β	NN
cord-324810-92fosk3c	382	16	-	-	HYPH
cord-324810-92fosk3c	382	17	lactam	lactam	NN
cord-324810-92fosk3c	382	18	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	382	19	are	be	VBP
cord-324810-92fosk3c	382	20	drugs	drug	NNS
cord-324810-92fosk3c	382	21	of	of	IN
cord-324810-92fosk3c	382	22	choice	choice	NN
cord-324810-92fosk3c	382	23	in	in	IN
cord-324810-92fosk3c	382	24	patients	patient	NNS
cord-324810-92fosk3c	382	25	erythromycin	erythromycin	JJ
cord-324810-92fosk3c	382	26	and	and	CC
cord-324810-92fosk3c	382	27	cross	cross	NN
cord-324810-92fosk3c	382	28	-	-	NN
cord-324810-92fosk3c	382	29	resistance	resistance	NN
cord-324810-92fosk3c	382	30	to	to	IN
cord-324810-92fosk3c	382	31	other	other	JJ
cord-324810-92fosk3c	382	32	macrolides	macrolide	NNS
cord-324810-92fosk3c	382	33	.	.	.
cord-324810-92fosk3c	383	1	Azithrowith	Azithrowith	NNP
cord-324810-92fosk3c	383	2	purulent	purulent	JJ
cord-324810-92fosk3c	383	3	or	or	CC
cord-324810-92fosk3c	383	4	type	type	NN
cord-324810-92fosk3c	383	5	I	-PRON-	PRP
cord-324810-92fosk3c	383	6	and	and	CC
cord-324810-92fosk3c	383	7	II	II	NNP
cord-324810-92fosk3c	383	8	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	383	9	.	.	.
cord-324810-92fosk3c	384	1	Despite	despite	IN
cord-324810-92fosk3c	384	2	their	-PRON-	PRP$
cord-324810-92fosk3c	384	3	relativemycin	relativemycin	NNS
cord-324810-92fosk3c	384	4	and	and	CC
cord-324810-92fosk3c	384	5	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	384	6	have	have	VBP
cord-324810-92fosk3c	384	7	improved	improve	VBN
cord-324810-92fosk3c	384	8	pharmacokinetics	pharmacokinetic	NNS
cord-324810-92fosk3c	384	9	and	and	CC
cord-324810-92fosk3c	384	10	ly	ly	VBD
cord-324810-92fosk3c	384	11	poor	poor	JJ
cord-324810-92fosk3c	384	12	activity	activity	NN
cord-324810-92fosk3c	384	13	and	and	CC
cord-324810-92fosk3c	384	14	suboptimal	suboptimal	JJ
cord-324810-92fosk3c	384	15	respiratory	respiratory	JJ
cord-324810-92fosk3c	384	16	pharmacokinetics	pharmacokinetic	NNS
cord-324810-92fosk3c	384	17	,	,	,
cord-324810-92fosk3c	384	18	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	384	19	activity	activity	NN
cord-324810-92fosk3c	384	20	against	against	IN
cord-324810-92fosk3c	384	21	H.	H.	NNP
cord-324810-92fosk3c	384	22	influenzae	influenzae	NN
cord-324810-92fosk3c	384	23	compared	compare	VBN
cord-324810-92fosk3c	384	24	with	with	IN
cord-324810-92fosk3c	384	25	erythcephalexin	erythcephalexin	NNP
cord-324810-92fosk3c	384	26	and	and	CC
cord-324810-92fosk3c	384	27	cefaclor	cefaclor	NNP
cord-324810-92fosk3c	384	28	have	have	VBP
cord-324810-92fosk3c	384	29	been	be	VBN
cord-324810-92fosk3c	384	30	extensively	extensively	RB
cord-324810-92fosk3c	384	31	used	use	VBN
cord-324810-92fosk3c	384	32	for	for	IN
cord-324810-92fosk3c	384	33	the	the	DT
cord-324810-92fosk3c	384	34	manromycin	manromycin	NNS
cord-324810-92fosk3c	384	35	.	.	.
cord-324810-92fosk3c	385	1	[	[	-LRB-
cord-324810-92fosk3c	385	2	84	84	CD
cord-324810-92fosk3c	385	3	]	]	-RRB-
cord-324810-92fosk3c	386	1	The	the	DT
cord-324810-92fosk3c	386	2	significant	significant	JJ
cord-324810-92fosk3c	386	3	advantages	advantage	NNS
cord-324810-92fosk3c	386	4	of	of	IN
cord-324810-92fosk3c	386	5	azithromycin	azithromycin	NNS
cord-324810-92fosk3c	386	6	are	be	VBP
cord-324810-92fosk3c	386	7	enagement	enagement	JJ
cord-324810-92fosk3c	386	8	of	of	IN
cord-324810-92fosk3c	386	9	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	386	10	.	.	.
cord-324810-92fosk3c	387	1	The	the	DT
cord-324810-92fosk3c	387	2	newer	new	JJR
cord-324810-92fosk3c	387	3	cephalosporins	cephalosporin	NNS
cord-324810-92fosk3c	387	4	,	,	,
cord-324810-92fosk3c	387	5	cefprozil	cefprozil	NNP
cord-324810-92fosk3c	387	6	and	and	CC
cord-324810-92fosk3c	387	7	hanced	hanced	NNP
cord-324810-92fosk3c	387	8	potency	potency	NN
cord-324810-92fosk3c	387	9	against	against	IN
cord-324810-92fosk3c	387	10	H.	H.	NNP
cord-324810-92fosk3c	387	11	influenzae	influenzae	NN
cord-324810-92fosk3c	387	12	,	,	,
cord-324810-92fosk3c	387	13	once	once	RB
cord-324810-92fosk3c	387	14	-	-	HYPH
cord-324810-92fosk3c	387	15	daily	daily	JJ
cord-324810-92fosk3c	387	16	administration	administration	NN
cord-324810-92fosk3c	387	17	,	,	,
cord-324810-92fosk3c	387	18	cefixime	cefixime	NNP
cord-324810-92fosk3c	387	19	,	,	,
cord-324810-92fosk3c	387	20	may	may	MD
cord-324810-92fosk3c	387	21	have	have	VB
cord-324810-92fosk3c	387	22	some	some	DT
cord-324810-92fosk3c	387	23	advantages	advantage	NNS
cord-324810-92fosk3c	387	24	such	such	JJ
cord-324810-92fosk3c	387	25	as	as	IN
cord-324810-92fosk3c	387	26	activity	activity	NN
cord-324810-92fosk3c	387	27	against	against	IN
cord-324810-92fosk3c	387	28	reduced	reduced	JJ
cord-324810-92fosk3c	387	29	rates	rate	NNS
cord-324810-92fosk3c	387	30	of	of	IN
cord-324810-92fosk3c	387	31	adverse	adverse	JJ
cord-324810-92fosk3c	387	32	effects	effect	NNS
cord-324810-92fosk3c	387	33	(	(	-LRB-
cord-324810-92fosk3c	387	34	specifically	specifically	RB
cord-324810-92fosk3c	387	35	gastrointestinal	gastrointestinal	JJ
cord-324810-92fosk3c	387	36	efresistant	efresistant	JJ
cord-324810-92fosk3c	387	37	pneumococci	pneumococcus	NNS
cord-324810-92fosk3c	387	38	,	,	,
cord-324810-92fosk3c	387	39	but	but	CC
cord-324810-92fosk3c	387	40	have	have	VBP
cord-324810-92fosk3c	387	41	not	not	RB
cord-324810-92fosk3c	387	42	been	be	VBN
cord-324810-92fosk3c	387	43	proven	prove	VBN
cord-324810-92fosk3c	387	44	to	to	TO
cord-324810-92fosk3c	387	45	be	be	VB
cord-324810-92fosk3c	387	46	superior	superior	JJ
cord-324810-92fosk3c	387	47	to	to	IN
cord-324810-92fosk3c	387	48	fects	fects	NNP
cord-324810-92fosk3c	387	49	)	)	-RRB-
cord-324810-92fosk3c	387	50	,	,	,
cord-324810-92fosk3c	387	51	an	an	DT
cord-324810-92fosk3c	387	52	abbreviated	abbreviate	VBN
cord-324810-92fosk3c	387	53	3-to	3-to	CD
cord-324810-92fosk3c	387	54	5-day	5-day	JJ
cord-324810-92fosk3c	387	55	treatment	treatment	NN
cord-324810-92fosk3c	387	56	course	course	NN
cord-324810-92fosk3c	387	57	,	,	,
cord-324810-92fosk3c	387	58	and	and	CC
cord-324810-92fosk3c	387	59	perhaps	perhaps	RB
cord-324810-92fosk3c	387	60	a	a	DT
cord-324810-92fosk3c	387	61	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	387	62	[	[	-LRB-
cord-324810-92fosk3c	387	63	100	100	CD
cord-324810-92fosk3c	387	64	,	,	,
cord-324810-92fosk3c	387	65	101	101	CD
cord-324810-92fosk3c	387	66	]	]	-RRB-
cord-324810-92fosk3c	388	1	when	when	WRB
cord-324810-92fosk3c	388	2	organisms	organism	NNS
cord-324810-92fosk3c	388	3	are	be	VBP
cord-324810-92fosk3c	388	4	fully	fully	RB
cord-324810-92fosk3c	388	5	sensitive	sensitive	JJ
cord-324810-92fosk3c	388	6	to	to	IN
cord-324810-92fosk3c	388	7	both	both	CC
cord-324810-92fosk3c	388	8	reduced	reduce	VBN
cord-324810-92fosk3c	388	9	frequency	frequency	NN
cord-324810-92fosk3c	388	10	of	of	IN
cord-324810-92fosk3c	388	11	relapse	relapse	NN
cord-324810-92fosk3c	388	12	during	during	IN
cord-324810-92fosk3c	388	13	extended	extended	JJ
cord-324810-92fosk3c	388	14	follow	follow	NN
cord-324810-92fosk3c	388	15	-	-	HYPH
cord-324810-92fosk3c	388	16	up	up	NN
cord-324810-92fosk3c	388	17	.	.	.
cord-324810-92fosk3c	389	1	[	[	-LRB-
cord-324810-92fosk3c	389	2	107	107	CD
cord-324810-92fosk3c	389	3	]	]	-RRB-
cord-324810-92fosk3c	389	4	[	[	-LRB-
cord-324810-92fosk3c	389	5	108	108	CD
cord-324810-92fosk3c	389	6	]	]	-RRB-
cord-324810-92fosk3c	389	7	[	[	-LRB-
cord-324810-92fosk3c	389	8	109	109	CD
cord-324810-92fosk3c	389	9	]	]	-RRB-
cord-324810-92fosk3c	389	10	[	[	-LRB-
cord-324810-92fosk3c	389	11	110	110	CD
cord-324810-92fosk3c	389	12	]	]	-RRB-
cord-324810-92fosk3c	389	13	agents	agent	NNS
cord-324810-92fosk3c	389	14	.	.	.
cord-324810-92fosk3c	390	1	The	the	DT
cord-324810-92fosk3c	390	2	efficacy	efficacy	NN
cord-324810-92fosk3c	390	3	and	and	CC
cord-324810-92fosk3c	390	4	safety	safety	NN
cord-324810-92fosk3c	390	5	of	of	IN
cord-324810-92fosk3c	390	6	a	a	DT
cord-324810-92fosk3c	390	7	3-day	3-day	JJ
cord-324810-92fosk3c	390	8	regimen	regimen	NN
cord-324810-92fosk3c	390	9	of	of	IN
cord-324810-92fosk3c	390	10	azithromycin	azithromycin	NN
cord-324810-92fosk3c	390	11	and	and	CC
cord-324810-92fosk3c	390	12	of	of	IN
cord-324810-92fosk3c	390	13	The	the	DT
cord-324810-92fosk3c	390	14	combination	combination	NN
cord-324810-92fosk3c	390	15	of	of	IN
cord-324810-92fosk3c	390	16	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	390	17	/	/	SYM
cord-324810-92fosk3c	390	18	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	390	19	acid	acid	NN
cord-324810-92fosk3c	390	20	is	be	VBZ
cord-324810-92fosk3c	390	21	an	an	DT
cord-324810-92fosk3c	390	22	improve-	improve-	NN
cord-324810-92fosk3c	391	1	a	a	DT
cord-324810-92fosk3c	391	2	10-day	10-day	CD
cord-324810-92fosk3c	391	3	regimen	regimen	NN
cord-324810-92fosk3c	391	4	of	of	IN
cord-324810-92fosk3c	391	5	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	391	6	/	/	SYM
cord-324810-92fosk3c	391	7	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	391	8	acid	acid	NN
cord-324810-92fosk3c	391	9	were	be	VBD
cord-324810-92fosk3c	391	10	compared	compare	VBN
cord-324810-92fosk3c	391	11	in	in	IN
cord-324810-92fosk3c	391	12	ment	ment	NNP
cord-324810-92fosk3c	391	13	over	over	IN
cord-324810-92fosk3c	391	14	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	391	15	alone	alone	RB
cord-324810-92fosk3c	391	16	when	when	WRB
cord-324810-92fosk3c	391	17	prescribed	prescribe	VBN
cord-324810-92fosk3c	391	18	for	for	IN
cord-324810-92fosk3c	391	19	β	β	NN
cord-324810-92fosk3c	391	20	-	-	HYPH
cord-324810-92fosk3c	391	21	lactamasepatients	lactamasepatient	NNS
cord-324810-92fosk3c	391	22	with	with	IN
cord-324810-92fosk3c	391	23	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	391	24	.	.	.
cord-324810-92fosk3c	392	1	Major	major	JJ
cord-324810-92fosk3c	392	2	improvement	improvement	NN
cord-324810-92fosk3c	392	3	or	or	CC
cord-324810-92fosk3c	392	4	cure	cure	NN
cord-324810-92fosk3c	392	5	on	on	IN
cord-324810-92fosk3c	392	6	day	day	NN
cord-324810-92fosk3c	392	7	14	14	CD
cord-324810-92fosk3c	392	8	producing	produce	VBG
cord-324810-92fosk3c	392	9	organisms	organism	NNS
cord-324810-92fosk3c	392	10	.	.	.
cord-324810-92fosk3c	393	1	Addition	addition	NN
cord-324810-92fosk3c	393	2	of	of	IN
cord-324810-92fosk3c	393	3	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	393	4	acid	acid	NN
cord-324810-92fosk3c	393	5	makes	make	VBZ
cord-324810-92fosk3c	393	6	the	the	DT
cord-324810-92fosk3c	393	7	com	com	NN
cord-324810-92fosk3c	393	8	-	-	:
cord-324810-92fosk3c	393	9	occurred	occur	VBN
cord-324810-92fosk3c	393	10	in	in	IN
cord-324810-92fosk3c	393	11	95	95	CD
cord-324810-92fosk3c	393	12	%	%	NN
cord-324810-92fosk3c	393	13	of	of	IN
cord-324810-92fosk3c	393	14	patients	patient	NNS
cord-324810-92fosk3c	393	15	in	in	IN
cord-324810-92fosk3c	393	16	the	the	DT
cord-324810-92fosk3c	393	17	azithromycin	azithromycin	NNP
cord-324810-92fosk3c	393	18	group	group	NN
cord-324810-92fosk3c	393	19	compared	compare	VBD
cord-324810-92fosk3c	393	20	bination	bination	NN
cord-324810-92fosk3c	393	21	therapy	therapy	NN
cord-324810-92fosk3c	393	22	resistant	resistant	JJ
cord-324810-92fosk3c	393	23	to	to	IN
cord-324810-92fosk3c	393	24	most	most	JJS
cord-324810-92fosk3c	393	25	but	but	CC
cord-324810-92fosk3c	393	26	not	not	RB
cord-324810-92fosk3c	393	27	all	all	DT
cord-324810-92fosk3c	393	28	bacterial	bacterial	JJ
cord-324810-92fosk3c	393	29	βwith	βwith	XX
cord-324810-92fosk3c	393	30	90	90	CD
cord-324810-92fosk3c	393	31	%	%	NN
cord-324810-92fosk3c	393	32	on	on	IN
cord-324810-92fosk3c	393	33	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	393	34	/	/	SYM
cord-324810-92fosk3c	393	35	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	393	36	acid	acid	NN
cord-324810-92fosk3c	393	37	.	.	.
cord-324810-92fosk3c	394	1	At	at	IN
cord-324810-92fosk3c	394	2	30	30	CD
cord-324810-92fosk3c	394	3	days	day	NNS
cord-324810-92fosk3c	394	4	,	,	,
cord-324810-92fosk3c	394	5	the	the	DT
cord-324810-92fosk3c	394	6	success	success	NN
cord-324810-92fosk3c	394	7	lactamases	lactamase	NNS
cord-324810-92fosk3c	394	8	.	.	.
cord-324810-92fosk3c	395	1	Most	Most	JJS
cord-324810-92fosk3c	395	2	studies	study	NNS
cord-324810-92fosk3c	395	3	of	of	IN
cord-324810-92fosk3c	395	4	patients	patient	NNS
cord-324810-92fosk3c	395	5	with	with	IN
cord-324810-92fosk3c	395	6	lower	low	JJR
cord-324810-92fosk3c	395	7	respiratory	respiratory	JJ
cord-324810-92fosk3c	395	8	tract	tract	NN
cord-324810-92fosk3c	395	9	was	be	VBD
cord-324810-92fosk3c	395	10	77	77	CD
cord-324810-92fosk3c	395	11	%	%	NN
cord-324810-92fosk3c	395	12	and	and	CC
cord-324810-92fosk3c	395	13	66	66	CD
cord-324810-92fosk3c	395	14	%	%	NN
cord-324810-92fosk3c	395	15	in	in	IN
cord-324810-92fosk3c	395	16	azithromycin	azithromycin	NNP
cord-324810-92fosk3c	395	17	-	-	HYPH
cord-324810-92fosk3c	395	18	and	and	CC
cord-324810-92fosk3c	395	19	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	395	20	/	/	SYM
cord-324810-92fosk3c	395	21	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	395	22	infection	infection	NN
cord-324810-92fosk3c	395	23	have	have	VBP
cord-324810-92fosk3c	395	24	shown	show	VBN
cord-324810-92fosk3c	395	25	this	this	DT
cord-324810-92fosk3c	395	26	agent	agent	NN
cord-324810-92fosk3c	395	27	to	to	TO
cord-324810-92fosk3c	395	28	be	be	VB
cord-324810-92fosk3c	395	29	equivalent	equivalent	JJ
cord-324810-92fosk3c	395	30	to	to	IN
cord-324810-92fosk3c	395	31	standard	standard	JJ
cord-324810-92fosk3c	395	32	acid	acid	NN
cord-324810-92fosk3c	395	33	-	-	HYPH
cord-324810-92fosk3c	395	34	treated	treat	VBN
cord-324810-92fosk3c	395	35	patients	patient	NNS
cord-324810-92fosk3c	395	36	,	,	,
cord-324810-92fosk3c	395	37	respectively	respectively	RB
cord-324810-92fosk3c	395	38	.	.	.
cord-324810-92fosk3c	396	1	[	[	-LRB-
cord-324810-92fosk3c	396	2	108	108	CD
cord-324810-92fosk3c	396	3	]	]	-RRB-
cord-324810-92fosk3c	396	4	Another	another	DT
cord-324810-92fosk3c	396	5	recent	recent	JJ
cord-324810-92fosk3c	396	6	randomized	randomized	JJ
cord-324810-92fosk3c	396	7	,	,	,
cord-324810-92fosk3c	396	8	comparators	comparator	NNS
cord-324810-92fosk3c	396	9	.	.	.
cord-324810-92fosk3c	397	1	[	[	-LRB-
cord-324810-92fosk3c	397	2	102	102	CD
cord-324810-92fosk3c	397	3	]	]	-RRB-
cord-324810-92fosk3c	397	4	Comparison	comparison	NN
cord-324810-92fosk3c	397	5	with	with	IN
cord-324810-92fosk3c	397	6	cefixime	cefixime	NN
cord-324810-92fosk3c	397	7	and	and	CC
cord-324810-92fosk3c	397	8	ciprofloxacin	ciprofloxacin	NN
cord-324810-92fosk3c	397	9	double	double	RB
cord-324810-92fosk3c	397	10	-	-	HYPH
cord-324810-92fosk3c	397	11	blind	blind	JJ
cord-324810-92fosk3c	397	12	,	,	,
cord-324810-92fosk3c	397	13	multicenter	multicenter	JJ
cord-324810-92fosk3c	397	14	trial	trial	NN
cord-324810-92fosk3c	397	15	compared	compare	VBD
cord-324810-92fosk3c	397	16	the	the	DT
cord-324810-92fosk3c	397	17	safety	safety	NN
cord-324810-92fosk3c	397	18	and	and	CC
cord-324810-92fosk3c	397	19	efficacy	efficacy	NN
cord-324810-92fosk3c	397	20	of	of	IN
cord-324810-92fosk3c	397	21	showed	show	VBN
cord-324810-92fosk3c	397	22	better	well	JJR
cord-324810-92fosk3c	397	23	clinical	clinical	JJ
cord-324810-92fosk3c	397	24	success	success	NN
cord-324810-92fosk3c	397	25	in	in	IN
cord-324810-92fosk3c	397	26	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	398	1	but	but	CC
cord-324810-92fosk3c	398	2	no	no	DT
cord-324810-92fosk3c	398	3	significant	significant	JJ
cord-324810-92fosk3c	398	4	oral	oral	JJ
cord-324810-92fosk3c	398	5	azithromycin	azithromycin	NN
cord-324810-92fosk3c	398	6	and	and	CC
cord-324810-92fosk3c	398	7	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	398	8	in	in	IN
cord-324810-92fosk3c	398	9	outpatients	outpatient	NNS
cord-324810-92fosk3c	398	10	with	with	IN
cord-324810-92fosk3c	398	11	difference	difference	NN
cord-324810-92fosk3c	398	12	in	in	IN
cord-324810-92fosk3c	398	13	bacterial	bacterial	JJ
cord-324810-92fosk3c	398	14	eradication	eradication	NN
cord-324810-92fosk3c	398	15	rates	rate	NNS
cord-324810-92fosk3c	398	16	.	.	.
cord-324810-92fosk3c	399	1	[	[	-LRB-
cord-324810-92fosk3c	399	2	103	103	CD
cord-324810-92fosk3c	399	3	]	]	-RRB-
cord-324810-92fosk3c	399	4	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	399	5	.	.	.
cord-324810-92fosk3c	400	1	[	[	-LRB-
cord-324810-92fosk3c	400	2	110	110	CD
cord-324810-92fosk3c	400	3	]	]	-RRB-
cord-324810-92fosk3c	401	1	Both	both	DT
cord-324810-92fosk3c	401	2	treatments	treatment	NNS
cord-324810-92fosk3c	401	3	were	be	VBD
cord-324810-92fosk3c	401	4	well	well	RB
cord-324810-92fosk3c	401	5	tolerated	tolerate	VBN
cord-324810-92fosk3c	401	6	,	,	,
cord-324810-92fosk3c	401	7	and	and	CC
cord-324810-92fosk3c	401	8	favorable	favorable	JJ
cord-324810-92fosk3c	401	9	clinical	clinical	JJ
cord-324810-92fosk3c	401	10	outcomes	outcome	NNS
cord-324810-92fosk3c	401	11	were	be	VBD
cord-324810-92fosk3c	401	12	demonstrated	demonstrate	VBN
cord-324810-92fosk3c	401	13	in	in	IN
cord-324810-92fosk3c	401	14	89	89	CD
cord-324810-92fosk3c	401	15	%	%	NN
cord-324810-92fosk3c	401	16	of	of	IN
cord-324810-92fosk3c	401	17	patients	patient	NNS
cord-324810-92fosk3c	401	18	receiving	receive	VBG
cord-324810-92fosk3c	401	19	than	than	IN
cord-324810-92fosk3c	401	20	300	300	CD
cord-324810-92fosk3c	401	21	primary	primary	JJ
cord-324810-92fosk3c	401	22	care	care	NN
cord-324810-92fosk3c	401	23	physicians	physician	NNS
cord-324810-92fosk3c	401	24	compared	compare	VBD
cord-324810-92fosk3c	401	25	the	the	DT
cord-324810-92fosk3c	401	26	efficacy	efficacy	NN
cord-324810-92fosk3c	401	27	of	of	IN
cord-324810-92fosk3c	401	28	azithromycin	azithromycin	NN
cord-324810-92fosk3c	401	29	and	and	CC
cord-324810-92fosk3c	401	30	92	92	CD
cord-324810-92fosk3c	401	31	%	%	NN
cord-324810-92fosk3c	401	32	of	of	IN
cord-324810-92fosk3c	401	33	patients	patient	NNS
cord-324810-92fosk3c	401	34	receiving	receive	VBG
cord-324810-92fosk3c	401	35	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	401	36	by	by	IN
cord-324810-92fosk3c	401	37	day	day	NN
cord-324810-92fosk3c	401	38	4	4	CD
cord-324810-92fosk3c	401	39	ciprofloxacin	ciprofloxacin	NNS
cord-324810-92fosk3c	401	40	and	and	CC
cord-324810-92fosk3c	401	41	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	401	42	.	.	.
cord-324810-92fosk3c	402	1	Equivalent	equivalent	JJ
cord-324810-92fosk3c	402	2	clinical	clinical	JJ
cord-324810-92fosk3c	402	3	success	success	NN
cord-324810-92fosk3c	402	4	of	of	IN
cord-324810-92fosk3c	402	5	therapy	therapy	NN
cord-324810-92fosk3c	402	6	.	.	.
cord-324810-92fosk3c	403	1	At	at	IN
cord-324810-92fosk3c	403	2	day	day	NN
cord-324810-92fosk3c	403	3	24	24	CD
cord-324810-92fosk3c	403	4	,	,	,
cord-324810-92fosk3c	403	5	favorable	favorable	JJ
cord-324810-92fosk3c	403	6	responses	response	NNS
cord-324810-92fosk3c	403	7	were	be	VBD
cord-324810-92fosk3c	403	8	approximately	approximately	RB
cord-324810-92fosk3c	403	9	(	(	-LRB-
cord-324810-92fosk3c	403	10	93	93	CD
cord-324810-92fosk3c	403	11	%	%	NN
cord-324810-92fosk3c	403	12	vs	vs	IN
cord-324810-92fosk3c	403	13	90	90	CD
cord-324810-92fosk3c	403	14	%	%	NN
cord-324810-92fosk3c	403	15	)	)	-RRB-
cord-324810-92fosk3c	403	16	and	and	CC
cord-324810-92fosk3c	403	17	bacteriologic	bacteriologic	JJ
cord-324810-92fosk3c	403	18	eradication	eradication	NN
cord-324810-92fosk3c	403	19	(	(	-LRB-
cord-324810-92fosk3c	403	20	98	98	CD
cord-324810-92fosk3c	403	21	%	%	NN
cord-324810-92fosk3c	403	22	vs	vs	IN
cord-324810-92fosk3c	403	23	95	95	CD
cord-324810-92fosk3c	403	24	%	%	NN
cord-324810-92fosk3c	403	25	)	)	-RRB-
cord-324810-92fosk3c	403	26	were	be	VBD
cord-324810-92fosk3c	403	27	82	82	CD
cord-324810-92fosk3c	403	28	%	%	NN
cord-324810-92fosk3c	403	29	and	and	CC
cord-324810-92fosk3c	403	30	86	86	CD
cord-324810-92fosk3c	403	31	%	%	NN
cord-324810-92fosk3c	403	32	and	and	CC
cord-324810-92fosk3c	403	33	bacterial	bacterial	JJ
cord-324810-92fosk3c	403	34	eradication	eradication	NN
cord-324810-92fosk3c	403	35	rates	rate	NNS
cord-324810-92fosk3c	403	36	were	be	VBD
cord-324810-92fosk3c	403	37	96	96	CD
cord-324810-92fosk3c	403	38	%	%	NN
cord-324810-92fosk3c	403	39	and	and	CC
cord-324810-92fosk3c	403	40	85	85	CD
cord-324810-92fosk3c	403	41	%	%	NN
cord-324810-92fosk3c	403	42	,	,	,
cord-324810-92fosk3c	403	43	reported	report	VBN
cord-324810-92fosk3c	403	44	with	with	IN
cord-324810-92fosk3c	403	45	ciprofloxacin	ciprofloxacin	NNS
cord-324810-92fosk3c	403	46	compared	compare	VBN
cord-324810-92fosk3c	403	47	with	with	IN
cord-324810-92fosk3c	403	48	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	403	49	.	.	.
cord-324810-92fosk3c	404	1	Derespectively	derespectively	RB
cord-324810-92fosk3c	404	2	,	,	,
cord-324810-92fosk3c	404	3	for	for	IN
cord-324810-92fosk3c	404	4	patients	patient	NNS
cord-324810-92fosk3c	404	5	in	in	IN
cord-324810-92fosk3c	404	6	the	the	DT
cord-324810-92fosk3c	404	7	two	two	CD
cord-324810-92fosk3c	404	8	treatment	treatment	NN
cord-324810-92fosk3c	404	9	groups	group	NNS
cord-324810-92fosk3c	404	10	.	.	.
cord-324810-92fosk3c	405	1	Another	another	DT
cord-324810-92fosk3c	405	2	spite	spite	NN
cord-324810-92fosk3c	405	3	a	a	DT
cord-324810-92fosk3c	405	4	relatively	relatively	RB
cord-324810-92fosk3c	405	5	high	high	JJ
cord-324810-92fosk3c	405	6	inhibitory	inhibitory	JJ
cord-324810-92fosk3c	405	7	concentration	concentration	NN
cord-324810-92fosk3c	405	8	against	against	IN
cord-324810-92fosk3c	405	9	S.	S.	NNP
cord-324810-92fosk3c	405	10	study	study	NN
cord-324810-92fosk3c	405	11	compared	compare	VBD
cord-324810-92fosk3c	405	12	the	the	DT
cord-324810-92fosk3c	405	13	clinical	clinical	JJ
cord-324810-92fosk3c	405	14	efficacy	efficacy	NN
cord-324810-92fosk3c	405	15	and	and	CC
cord-324810-92fosk3c	405	16	tolerability	tolerability	NN
cord-324810-92fosk3c	405	17	of	of	IN
cord-324810-92fosk3c	405	18	5-day	5-day	JJ
cord-324810-92fosk3c	405	19	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	406	1	,	,	,
cord-324810-92fosk3c	406	2	ciprofloxacin	ciprofloxacin	NNP
cord-324810-92fosk3c	406	3	has	have	VBZ
cord-324810-92fosk3c	406	4	demonstrated	demonstrate	VBN
cord-324810-92fosk3c	406	5	clinical	clinical	JJ
cord-324810-92fosk3c	406	6	efficacy	efficacy	NN
cord-324810-92fosk3c	406	7	simcourses	simcourse	NNS
cord-324810-92fosk3c	406	8	of	of	IN
cord-324810-92fosk3c	406	9	dirithromycin	dirithromycin	NNS
cord-324810-92fosk3c	406	10	and	and	CC
cord-324810-92fosk3c	406	11	azithromycin	azithromycin	NNP
cord-324810-92fosk3c	406	12	given	give	VBN
cord-324810-92fosk3c	406	13	once	once	RB
cord-324810-92fosk3c	406	14	daily	daily	RB
cord-324810-92fosk3c	406	15	for	for	IN
cord-324810-92fosk3c	406	16	the	the	DT
cord-324810-92fosk3c	406	17	ilar	ilar	NNP
cord-324810-92fosk3c	406	18	to	to	IN
cord-324810-92fosk3c	406	19	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	406	20	,	,	,
cord-324810-92fosk3c	406	21	clarithromycin	clarithromycin	NNP
cord-324810-92fosk3c	406	22	and	and	CC
cord-324810-92fosk3c	406	23	cefuroxime	cefuroxime	NNP
cord-324810-92fosk3c	406	24	.	.	.
cord-324810-92fosk3c	407	1	[	[	-LRB-
cord-324810-92fosk3c	407	2	119	119	CD
cord-324810-92fosk3c	407	3	]	]	-RRB-
cord-324810-92fosk3c	407	4	Oral	oral	JJ
cord-324810-92fosk3c	407	5	treatment	treatment	NN
cord-324810-92fosk3c	407	6	of	of	IN
cord-324810-92fosk3c	407	7	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	407	8	.	.	.
cord-324810-92fosk3c	408	1	Comparable	comparable	JJ
cord-324810-92fosk3c	408	2	clinical	clinical	JJ
cord-324810-92fosk3c	408	3	efficacy	efficacy	NN
cord-324810-92fosk3c	408	4	was	be	VBD
cord-324810-92fosk3c	408	5	revealed	reveal	VBN
cord-324810-92fosk3c	408	6	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	409	1	250	250	CD
cord-324810-92fosk3c	409	2	or	or	CC
cord-324810-92fosk3c	409	3	500	500	CD
cord-324810-92fosk3c	409	4	mg	mg	NNP
cord-324810-92fosk3c	409	5	daily	daily	RB
cord-324810-92fosk3c	409	6	was	be	VBD
cord-324810-92fosk3c	409	7	compared	compare	VBN
cord-324810-92fosk3c	409	8	with	with	IN
cord-324810-92fosk3c	409	9	oral	oral	JJ
cord-324810-92fosk3c	409	10	cefuroxbetween	cefuroxbetween	NNP
cord-324810-92fosk3c	409	11	5-day	5-day	JJ
cord-324810-92fosk3c	409	12	courses	course	NNS
cord-324810-92fosk3c	409	13	of	of	IN
cord-324810-92fosk3c	409	14	once	once	RB
cord-324810-92fosk3c	409	15	-	-	HYPH
cord-324810-92fosk3c	409	16	daily	daily	JJ
cord-324810-92fosk3c	409	17	dirithromycin	dirithromycin	NNS
cord-324810-92fosk3c	409	18	and	and	CC
cord-324810-92fosk3c	409	19	azithroime	azithroime	NNP
cord-324810-92fosk3c	409	20	axetil	axetil	NNP
cord-324810-92fosk3c	409	21	(	(	-LRB-
cord-324810-92fosk3c	409	22	250	250	CD
cord-324810-92fosk3c	409	23	mg	mg	NNS
cord-324810-92fosk3c	409	24	twice	twice	RB
cord-324810-92fosk3c	409	25	daily	daily	RB
cord-324810-92fosk3c	409	26	)	)	-RRB-
cord-324810-92fosk3c	409	27	in	in	IN
cord-324810-92fosk3c	409	28	a	a	DT
cord-324810-92fosk3c	409	29	randomized	randomized	JJ
cord-324810-92fosk3c	409	30	,	,	,
cord-324810-92fosk3c	409	31	double	double	JJ
cord-324810-92fosk3c	409	32	-	-	HYPH
cord-324810-92fosk3c	409	33	blind	blind	JJ
cord-324810-92fosk3c	409	34	,	,	,
cord-324810-92fosk3c	409	35	mycin	mycin	NNS
cord-324810-92fosk3c	409	36	in	in	IN
cord-324810-92fosk3c	409	37	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	409	38	.	.	.
cord-324810-92fosk3c	410	1	[	[	-LRB-
cord-324810-92fosk3c	410	2	111	111	CD
cord-324810-92fosk3c	410	3	]	]	-RRB-
cord-324810-92fosk3c	410	4	multicenter	multicenter	JJ
cord-324810-92fosk3c	410	5	study	study	NN
cord-324810-92fosk3c	410	6	.	.	.
cord-324810-92fosk3c	411	1	[	[	-LRB-
cord-324810-92fosk3c	411	2	120	120	CD
cord-324810-92fosk3c	411	3	]	]	-RRB-
cord-324810-92fosk3c	412	1	The	the	DT
cord-324810-92fosk3c	412	2	cure	cure	NN
cord-324810-92fosk3c	412	3	rates	rate	NNS
cord-324810-92fosk3c	412	4	in	in	IN
cord-324810-92fosk3c	412	5	the	the	DT
cord-324810-92fosk3c	412	6	intention	intention	NN
cord-324810-92fosk3c	412	7	-	-	HYPH
cord-324810-92fosk3c	412	8	to	to	IN
cord-324810-92fosk3c	412	9	-	-	HYPH
cord-324810-92fosk3c	412	10	treat	treat	VB
cord-324810-92fosk3c	412	11	population	population	NN
cord-324810-92fosk3c	412	12	were	be	VBD
cord-324810-92fosk3c	412	13	70	70	CD
cord-324810-92fosk3c	412	14	%	%	NN
cord-324810-92fosk3c	412	15	for	for	IN
cord-324810-92fosk3c	412	16	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	412	17	250	250	CD
cord-324810-92fosk3c	412	18	mg	mg	NNP
cord-324810-92fosk3c	412	19	,	,	,
cord-324810-92fosk3c	412	20	70	70	CD
cord-324810-92fosk3c	412	21	%	%	NN
cord-324810-92fosk3c	412	22	for	for	IN
cord-324810-92fosk3c	412	23	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	412	24	Clarithromycin	Clarithromycin	NNP
cord-324810-92fosk3c	412	25	per	per	FW
cord-324810-92fosk3c	412	26	se	se	FW
cord-324810-92fosk3c	412	27	has	have	VBZ
cord-324810-92fosk3c	412	28	only	only	RB
cord-324810-92fosk3c	412	29	intermediate	intermediate	JJ
cord-324810-92fosk3c	412	30	activity	activity	NN
cord-324810-92fosk3c	412	31	against	against	IN
cord-324810-92fosk3c	412	32	500	500	CD
cord-324810-92fosk3c	412	33	mg	mg	NN
cord-324810-92fosk3c	412	34	and	and	CC
cord-324810-92fosk3c	412	35	61	61	CD
cord-324810-92fosk3c	412	36	%	%	NN
cord-324810-92fosk3c	412	37	for	for	IN
cord-324810-92fosk3c	412	38	cefuroxime	cefuroxime	NNP
cord-324810-92fosk3c	412	39	axetil	axetil	NNP
cord-324810-92fosk3c	412	40	.	.	.
cord-324810-92fosk3c	413	1	Another	another	DT
cord-324810-92fosk3c	413	2	randomized	randomized	JJ
cord-324810-92fosk3c	413	3	,	,	,
cord-324810-92fosk3c	413	4	H.	h.	NN
cord-324810-92fosk3c	413	5	influenzae	influenzae	NN
cord-324810-92fosk3c	413	6	but	but	CC
cord-324810-92fosk3c	413	7	synergy	synergy	NN
cord-324810-92fosk3c	413	8	with	with	IN
cord-324810-92fosk3c	413	9	one	one	CD
cord-324810-92fosk3c	413	10	of	of	IN
cord-324810-92fosk3c	413	11	its	-PRON-	PRP$
cord-324810-92fosk3c	413	12	metabolites	metabolite	NNS
cord-324810-92fosk3c	413	13	increases	increase	VBZ
cord-324810-92fosk3c	413	14	its	-PRON-	PRP$
cord-324810-92fosk3c	413	15	double	double	JJ
cord-324810-92fosk3c	413	16	-	-	HYPH
cord-324810-92fosk3c	413	17	blind	blind	JJ
cord-324810-92fosk3c	413	18	study	study	NN
cord-324810-92fosk3c	413	19	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	413	20	equivalent	equivalent	JJ
cord-324810-92fosk3c	413	21	clinical	clinical	JJ
cord-324810-92fosk3c	413	22	and	and	CC
cord-324810-92fosk3c	413	23	bacterioactivity	bacterioactivity	NN
cord-324810-92fosk3c	413	24	to	to	IN
cord-324810-92fosk3c	413	25	satisfactory	satisfactory	JJ
cord-324810-92fosk3c	413	26	levels	level	NNS
cord-324810-92fosk3c	413	27	.	.	.
cord-324810-92fosk3c	414	1	[	[	-LRB-
cord-324810-92fosk3c	414	2	109	109	CD
cord-324810-92fosk3c	414	3	,	,	,
cord-324810-92fosk3c	414	4	112	112	CD
cord-324810-92fosk3c	414	5	]	]	-RRB-
cord-324810-92fosk3c	414	6	Clinical	clinical	JJ
cord-324810-92fosk3c	414	7	studies	study	NNS
cord-324810-92fosk3c	414	8	of	of	IN
cord-324810-92fosk3c	414	9	clarithrologic	clarithrologic	JJ
cord-324810-92fosk3c	414	10	success	success	NN
cord-324810-92fosk3c	414	11	with	with	IN
cord-324810-92fosk3c	414	12	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	414	13	500	500	CD
cord-324810-92fosk3c	414	14	mg	mg	NNS
cord-324810-92fosk3c	414	15	once	once	RB
cord-324810-92fosk3c	414	16	daily	daily	RB
cord-324810-92fosk3c	414	17	for	for	IN
cord-324810-92fosk3c	414	18	a	a	DT
cord-324810-92fosk3c	414	19	5-or	5-or	CD
cord-324810-92fosk3c	414	20	7-day	7-day	JJ
cord-324810-92fosk3c	414	21	mycin	mycin	NNS
cord-324810-92fosk3c	414	22	involving	involve	VBG
cord-324810-92fosk3c	414	23	7-to	7-to	CD
cord-324810-92fosk3c	414	24	14-day	14-day	CD
cord-324810-92fosk3c	414	25	regimens	regimen	NNS
cord-324810-92fosk3c	414	26	in	in	IN
cord-324810-92fosk3c	414	27	patients	patient	NNS
cord-324810-92fosk3c	414	28	with	with	IN
cord-324810-92fosk3c	414	29	mild	mild	JJ
cord-324810-92fosk3c	414	30	-	-	HYPH
cord-324810-92fosk3c	414	31	tocourse	tocourse	NN
cord-324810-92fosk3c	414	32	.	.	.
cord-324810-92fosk3c	415	1	[	[	-LRB-
cord-324810-92fosk3c	415	2	121	121	CD
cord-324810-92fosk3c	415	3	]	]	-RRB-
cord-324810-92fosk3c	416	1	A	a	DT
cord-324810-92fosk3c	416	2	shorter	short	JJR
cord-324810-92fosk3c	416	3	course	course	NN
cord-324810-92fosk3c	416	4	of	of	IN
cord-324810-92fosk3c	416	5	gatifloxacin	gatifloxacin	NNS
cord-324810-92fosk3c	416	6	for	for	IN
cord-324810-92fosk3c	416	7	5	5	CD
cord-324810-92fosk3c	416	8	days	day	NNS
cord-324810-92fosk3c	416	9	was	be	VBD
cord-324810-92fosk3c	416	10	commoderate	commoderate	NN
cord-324810-92fosk3c	416	11	infections	infection	NNS
cord-324810-92fosk3c	416	12	have	have	VBP
cord-324810-92fosk3c	416	13	shown	show	VBN
cord-324810-92fosk3c	416	14	equivalence	equivalence	NN
cord-324810-92fosk3c	416	15	to	to	IN
cord-324810-92fosk3c	416	16	ampicillin	ampicillin	NN
cord-324810-92fosk3c	416	17	.	.	.
cord-324810-92fosk3c	417	1	[	[	-LRB-
cord-324810-92fosk3c	417	2	113	113	CD
cord-324810-92fosk3c	417	3	]	]	-RRB-
cord-324810-92fosk3c	418	1	A	a	DT
cord-324810-92fosk3c	418	2	phase	phase	NN
cord-324810-92fosk3c	418	3	III	iii	CD
cord-324810-92fosk3c	418	4	randomized	randomized	JJ
cord-324810-92fosk3c	418	5	,	,	,
cord-324810-92fosk3c	418	6	double	double	JJ
cord-324810-92fosk3c	418	7	-	-	HYPH
cord-324810-92fosk3c	418	8	blind	blind	JJ
cord-324810-92fosk3c	418	9	study	study	NN
cord-324810-92fosk3c	418	10	in	in	IN
cord-324810-92fosk3c	418	11	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	418	12	patients	patient	NNS
cord-324810-92fosk3c	418	13	pared	pare	VBN
cord-324810-92fosk3c	418	14	with	with	IN
cord-324810-92fosk3c	418	15	7-day	7-day	JJ
cord-324810-92fosk3c	418	16	gatifloxacin	gatifloxacin	NNS
cord-324810-92fosk3c	418	17	therapy	therapy	NN
cord-324810-92fosk3c	418	18	and	and	CC
cord-324810-92fosk3c	418	19	10-day	10-day	CD
cord-324810-92fosk3c	418	20	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	418	21	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	418	22	that	that	IN
cord-324810-92fosk3c	418	23	extended	extended	JJ
cord-324810-92fosk3c	418	24	release	release	NN
cord-324810-92fosk3c	418	25	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	418	26	at	at	IN
cord-324810-92fosk3c	418	27	500	500	CD
cord-324810-92fosk3c	418	28	mg	mg	NN
cord-324810-92fosk3c	418	29	once	once	IN
cord-324810-92fosk3c	418	30	therapy	therapy	NN
cord-324810-92fosk3c	418	31	for	for	IN
cord-324810-92fosk3c	418	32	acute	acute	JJ
cord-324810-92fosk3c	418	33	exacerbation	exacerbation	NN
cord-324810-92fosk3c	418	34	of	of	IN
cord-324810-92fosk3c	418	35	chronic	chronic	JJ
cord-324810-92fosk3c	418	36	bronchitis	bronchitis	NN
cord-324810-92fosk3c	418	37	.	.	.
cord-324810-92fosk3c	419	1	[	[	-LRB-
cord-324810-92fosk3c	419	2	122	122	CD
cord-324810-92fosk3c	419	3	]	]	-RRB-
cord-324810-92fosk3c	419	4	Similar	similar	JJ
cord-324810-92fosk3c	419	5	daily	daily	RB
cord-324810-92fosk3c	419	6	compared	compare	VBD
cord-324810-92fosk3c	419	7	favorably	favorably	RB
cord-324810-92fosk3c	419	8	with	with	IN
cord-324810-92fosk3c	419	9	immediate	immediate	JJ
cord-324810-92fosk3c	419	10	release	release	NN
cord-324810-92fosk3c	419	11	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	419	12	clinical	clinical	JJ
cord-324810-92fosk3c	419	13	success	success	NN
cord-324810-92fosk3c	419	14	rates	rate	NNS
cord-324810-92fosk3c	419	15	of	of	IN
cord-324810-92fosk3c	419	16	>	>	$
cord-324810-92fosk3c	419	17	88	88	CD
cord-324810-92fosk3c	419	18	%	%	NN
cord-324810-92fosk3c	419	19	were	be	VBD
cord-324810-92fosk3c	419	20	reported	report	VBN
cord-324810-92fosk3c	419	21	compared	compare	VBN
cord-324810-92fosk3c	419	22	with	with	IN
cord-324810-92fosk3c	419	23	500	500	CD
cord-324810-92fosk3c	419	24	mg	mg	NNS
cord-324810-92fosk3c	419	25	twice	twice	RB
cord-324810-92fosk3c	419	26	daily	daily	RB
cord-324810-92fosk3c	419	27	:	:	:
cord-324810-92fosk3c	419	28	the	the	DT
cord-324810-92fosk3c	419	29	clinical	clinical	JJ
cord-324810-92fosk3c	419	30	cure	cure	NN
cord-324810-92fosk3c	419	31	rates	rate	NNS
cord-324810-92fosk3c	419	32	were	be	VBD
cord-324810-92fosk3c	419	33	86	86	CD
cord-324810-92fosk3c	419	34	%	%	NN
cord-324810-92fosk3c	419	35	and	and	CC
cord-324810-92fosk3c	419	36	85	85	CD
cord-324810-92fosk3c	419	37	%	%	NN
cord-324810-92fosk3c	419	38	,	,	,
cord-324810-92fosk3c	419	39	comparator	comparator	NN
cord-324810-92fosk3c	419	40	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	419	41	.	.	.
cord-324810-92fosk3c	420	1	Another	another	DT
cord-324810-92fosk3c	420	2	open	open	JJ
cord-324810-92fosk3c	420	3	-	-	HYPH
cord-324810-92fosk3c	420	4	label	label	NN
cord-324810-92fosk3c	420	5	noncomparative	noncomparative	NN
cord-324810-92fosk3c	420	6	respectively	respectively	RB
cord-324810-92fosk3c	420	7	.	.	.
cord-324810-92fosk3c	421	1	[	[	-LRB-
cord-324810-92fosk3c	421	2	114	114	CD
cord-324810-92fosk3c	421	3	]	]	-RRB-
cord-324810-92fosk3c	422	1	A	a	DT
cord-324810-92fosk3c	422	2	recent	recent	JJ
cord-324810-92fosk3c	422	3	study	study	NN
cord-324810-92fosk3c	422	4	compared	compare	VBN
cord-324810-92fosk3c	422	5	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	422	6	with	with	IN
cord-324810-92fosk3c	422	7	post	post	JJ
cord-324810-92fosk3c	422	8	-	-	JJ
cord-324810-92fosk3c	422	9	marketing	marketing	JJ
cord-324810-92fosk3c	422	10	trial	trial	NN
cord-324810-92fosk3c	422	11	of	of	IN
cord-324810-92fosk3c	422	12	gatifloxacin	gatifloxacin	NNS
cord-324810-92fosk3c	422	13	in	in	IN
cord-324810-92fosk3c	422	14	the	the	DT
cord-324810-92fosk3c	422	15	treatment	treatment	NN
cord-324810-92fosk3c	422	16	of	of	IN
cord-324810-92fosk3c	422	17	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	422	18	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	422	19	/	/	SYM
cord-324810-92fosk3c	422	20	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	422	21	acid	acid	NN
cord-324810-92fosk3c	422	22	in	in	IN
cord-324810-92fosk3c	422	23	the	the	DT
cord-324810-92fosk3c	422	24	treatment	treatment	NN
cord-324810-92fosk3c	422	25	of	of	IN
cord-324810-92fosk3c	422	26	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	422	27	.	.	.
cord-324810-92fosk3c	423	1	Clinical	clinical	JJ
cord-324810-92fosk3c	423	2	in	in	IN
cord-324810-92fosk3c	423	3	community	community	NN
cord-324810-92fosk3c	423	4	-	-	HYPH
cord-324810-92fosk3c	423	5	based	base	VBN
cord-324810-92fosk3c	423	6	practice	practice	NN
cord-324810-92fosk3c	423	7	settings	setting	NNS
cord-324810-92fosk3c	423	8	was	be	VBD
cord-324810-92fosk3c	423	9	reported	report	VBN
cord-324810-92fosk3c	423	10	recently	recently	RB
cord-324810-92fosk3c	423	11	.	.	.
cord-324810-92fosk3c	424	1	[	[	-LRB-
cord-324810-92fosk3c	424	2	123	123	CD
cord-324810-92fosk3c	424	3	]	]	-RRB-
cord-324810-92fosk3c	424	4	success	success	NN
cord-324810-92fosk3c	424	5	was	be	VBD
cord-324810-92fosk3c	424	6	documented	document	VBN
cord-324810-92fosk3c	424	7	in	in	IN
cord-324810-92fosk3c	424	8	85	85	CD
cord-324810-92fosk3c	424	9	%	%	NN
cord-324810-92fosk3c	424	10	of	of	IN
cord-324810-92fosk3c	424	11	patients	patient	NNS
cord-324810-92fosk3c	424	12	receiving	receive	VBG
cord-324810-92fosk3c	424	13	erythromy	erythromy	NN
cord-324810-92fosk3c	424	14	-	-	:
cord-324810-92fosk3c	424	15	Overall	overall	JJ
cord-324810-92fosk3c	424	16	cure	cure	NN
cord-324810-92fosk3c	424	17	rates	rate	NNS
cord-324810-92fosk3c	424	18	were	be	VBD
cord-324810-92fosk3c	424	19	95.8	95.8	CD
cord-324810-92fosk3c	424	20	%	%	NN
cord-324810-92fosk3c	424	21	for	for	IN
cord-324810-92fosk3c	424	22	H.	h.	NN
cord-324810-92fosk3c	424	23	influenzae	influenzae	NN
cord-324810-92fosk3c	424	24	,	,	,
cord-324810-92fosk3c	424	25	98.6	98.6	CD
cord-324810-92fosk3c	424	26	%	%	NN
cord-324810-92fosk3c	424	27	for	for	IN
cord-324810-92fosk3c	424	28	S.	S.	NNP
cord-324810-92fosk3c	424	29	cin	cin	NNP
cord-324810-92fosk3c	424	30	and	and	CC
cord-324810-92fosk3c	424	31	was	be	VBD
cord-324810-92fosk3c	424	32	equivalent	equivalent	JJ
cord-324810-92fosk3c	424	33	to	to	IN
cord-324810-92fosk3c	424	34	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	424	35	/	/	SYM
cord-324810-92fosk3c	424	36	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	424	37	acid	acid	NN
cord-324810-92fosk3c	424	38	,	,	,
cord-324810-92fosk3c	424	39	and	and	CC
cord-324810-92fosk3c	424	40	the	the	DT
cord-324810-92fosk3c	424	41	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	424	42	and	and	CC
cord-324810-92fosk3c	424	43	89.2	89.2	CD
cord-324810-92fosk3c	424	44	%	%	NN
cord-324810-92fosk3c	424	45	for	for	IN
cord-324810-92fosk3c	424	46	M.	M.	NNP
cord-324810-92fosk3c	424	47	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	424	48	;	;	:
cord-324810-92fosk3c	424	49	the	the	DT
cord-324810-92fosk3c	424	50	most	most	RBS
cord-324810-92fosk3c	424	51	serious	serious	JJ
cord-324810-92fosk3c	424	52	adinidence	adinidence	NN
cord-324810-92fosk3c	424	53	of	of	IN
cord-324810-92fosk3c	424	54	adverse	adverse	JJ
cord-324810-92fosk3c	424	55	events	event	NNS
cord-324810-92fosk3c	424	56	was	be	VBD
cord-324810-92fosk3c	424	57	similar	similar	JJ
cord-324810-92fosk3c	424	58	in	in	IN
cord-324810-92fosk3c	424	59	the	the	DT
cord-324810-92fosk3c	424	60	two	two	CD
cord-324810-92fosk3c	424	61	treatment	treatment	NN
cord-324810-92fosk3c	424	62	verse	verse	NN
cord-324810-92fosk3c	424	63	effects	effect	NNS
cord-324810-92fosk3c	425	1	were	be	VBD
cord-324810-92fosk3c	425	2	nausea	nausea	NN
cord-324810-92fosk3c	425	3	(	(	-LRB-
cord-324810-92fosk3c	425	4	1.5	1.5	CD
cord-324810-92fosk3c	425	5	%	%	NN
cord-324810-92fosk3c	425	6	)	)	-RRB-
cord-324810-92fosk3c	425	7	,	,	,
cord-324810-92fosk3c	425	8	dizziness	dizziness	NN
cord-324810-92fosk3c	425	9	(	(	-LRB-
cord-324810-92fosk3c	425	10	1.5	1.5	CD
cord-324810-92fosk3c	425	11	%	%	NN
cord-324810-92fosk3c	425	12	)	)	-RRB-
cord-324810-92fosk3c	425	13	,	,	,
cord-324810-92fosk3c	425	14	diarrhea	diarrhea	NN
cord-324810-92fosk3c	425	15	groups	group	NNS
cord-324810-92fosk3c	425	16	.	.	.
cord-324810-92fosk3c	426	1	[	[	-LRB-
cord-324810-92fosk3c	426	2	115	115	CD
cord-324810-92fosk3c	426	3	]	]	-RRB-
cord-324810-92fosk3c	426	4	(	(	-LRB-
cord-324810-92fosk3c	426	5	1.2	1.2	CD
cord-324810-92fosk3c	426	6	%	%	NN
cord-324810-92fosk3c	426	7	)	)	-RRB-
cord-324810-92fosk3c	426	8	,	,	,
cord-324810-92fosk3c	426	9	and	and	CC
cord-324810-92fosk3c	426	10	vomiting	vomit	VBG
cord-324810-92fosk3c	426	11	(	(	-LRB-
cord-324810-92fosk3c	426	12	0.9	0.9	CD
cord-324810-92fosk3c	426	13	%	%	NN
cord-324810-92fosk3c	426	14	)	)	-RRB-
cord-324810-92fosk3c	426	15	.	.	.
cord-324810-92fosk3c	427	1	[	[	-LRB-
cord-324810-92fosk3c	427	2	123	123	CD
cord-324810-92fosk3c	427	3	]	]	-RRB-
cord-324810-92fosk3c	428	1	Another	another	DT
cord-324810-92fosk3c	428	2	respiratory	respiratory	JJ
cord-324810-92fosk3c	428	3	fluoroquinolone	fluoroquinolone	NN
cord-324810-92fosk3c	428	4	,	,	,
cord-324810-92fosk3c	428	5	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	428	6	,	,	,
cord-324810-92fosk3c	428	7	has	have	VBZ
cord-324810-92fosk3c	428	8	been	be	VBN
cord-324810-92fosk3c	428	9	reported	report	VBN
cord-324810-92fosk3c	428	10	to	to	TO
cord-324810-92fosk3c	428	11	be	be	VB
cord-324810-92fosk3c	428	12	efficacious	efficacious	JJ
cord-324810-92fosk3c	428	13	in	in	IN
cord-324810-92fosk3c	428	14	pa	pa	NNP
cord-324810-92fosk3c	428	15	-	-	HYPH
cord-324810-92fosk3c	428	16	Fluoroquinolones	Fluoroquinolones	NNP
cord-324810-92fosk3c	428	17	,	,	,
cord-324810-92fosk3c	428	18	synthetic	synthetic	JJ
cord-324810-92fosk3c	428	19	analogs	analog	NNS
cord-324810-92fosk3c	428	20	of	of	IN
cord-324810-92fosk3c	428	21	the	the	DT
cord-324810-92fosk3c	428	22	original	original	JJ
cord-324810-92fosk3c	428	23	molecule	molecule	NN
cord-324810-92fosk3c	428	24	tients	tient	NNS
cord-324810-92fosk3c	428	25	with	with	IN
cord-324810-92fosk3c	428	26	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	428	27	.	.	.
cord-324810-92fosk3c	429	1	[	[	-LRB-
cord-324810-92fosk3c	429	2	124	124	CD
cord-324810-92fosk3c	429	3	]	]	-RRB-
cord-324810-92fosk3c	430	1	[	[	-LRB-
cord-324810-92fosk3c	430	2	125	125	CD
cord-324810-92fosk3c	430	3	]	]	-RRB-
cord-324810-92fosk3c	431	1	[	[	-LRB-
cord-324810-92fosk3c	431	2	126	126	CD
cord-324810-92fosk3c	431	3	]	]	-RRB-
cord-324810-92fosk3c	432	1	These	these	DT
cord-324810-92fosk3c	432	2	multicenter	multicenter	JJ
cord-324810-92fosk3c	432	3	trials	trial	NNS
cord-324810-92fosk3c	432	4	compared	compare	VBN
cord-324810-92fosk3c	432	5	(	(	-LRB-
cord-324810-92fosk3c	432	6	nalidixic	nalidixic	NNP
cord-324810-92fosk3c	432	7	acid	acid	NNP
cord-324810-92fosk3c	432	8	)	)	-RRB-
cord-324810-92fosk3c	432	9	,	,	,
cord-324810-92fosk3c	432	10	exert	exert	VB
cord-324810-92fosk3c	432	11	their	-PRON-	PRP$
cord-324810-92fosk3c	432	12	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	432	13	effect	effect	NN
cord-324810-92fosk3c	432	14	by	by	IN
cord-324810-92fosk3c	432	15	direct	direct	JJ
cord-324810-92fosk3c	432	16	inhibition	inhibition	NN
cord-324810-92fosk3c	432	17	oral	oral	JJ
cord-324810-92fosk3c	432	18	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	432	19	400	400	CD
cord-324810-92fosk3c	432	20	mg	mg	NNP
cord-324810-92fosk3c	432	21	/	/	SYM
cord-324810-92fosk3c	432	22	day	day	NN
cord-324810-92fosk3c	432	23	for	for	IN
cord-324810-92fosk3c	432	24	5	5	CD
cord-324810-92fosk3c	432	25	days	day	NNS
cord-324810-92fosk3c	432	26	with	with	IN
cord-324810-92fosk3c	432	27	oral	oral	JJ
cord-324810-92fosk3c	432	28	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	432	29	of	of	IN
cord-324810-92fosk3c	432	30	bacterial	bacterial	JJ
cord-324810-92fosk3c	432	31	DNA	dna	NN
cord-324810-92fosk3c	432	32	synthesis	synthesis	NN
cord-324810-92fosk3c	432	33	.	.	.
cord-324810-92fosk3c	433	1	[	[	-LRB-
cord-324810-92fosk3c	433	2	116	116	CD
cord-324810-92fosk3c	433	3	]	]	-RRB-
cord-324810-92fosk3c	433	4	[	[	-LRB-
cord-324810-92fosk3c	433	5	117	117	CD
cord-324810-92fosk3c	433	6	]	]	-RRB-
cord-324810-92fosk3c	433	7	[	[	-LRB-
cord-324810-92fosk3c	433	8	118	118	CD
cord-324810-92fosk3c	433	9	]	]	-RRB-
cord-324810-92fosk3c	434	1	Two	two	CD
cord-324810-92fosk3c	434	2	bacterial	bacterial	JJ
cord-324810-92fosk3c	434	3	enzymes	enzyme	NNS
cord-324810-92fosk3c	434	4	-DNA	-DNA	.
cord-324810-92fosk3c	435	1	500	500	CD
cord-324810-92fosk3c	435	2	mg	mg	NN
cord-324810-92fosk3c	435	3	/	/	SYM
cord-324810-92fosk3c	435	4	day	day	NN
cord-324810-92fosk3c	435	5	for	for	IN
cord-324810-92fosk3c	435	6	10	10	CD
cord-324810-92fosk3c	435	7	days	day	NNS
cord-324810-92fosk3c	435	8	or	or	CC
cord-324810-92fosk3c	435	9	intramuscular	intramuscular	JJ
cord-324810-92fosk3c	435	10	ceftriaxone	ceftriaxone	NN
cord-324810-92fosk3c	436	1	2	2	LS
cord-324810-92fosk3c	436	2	g	g	NN
cord-324810-92fosk3c	437	1	once	once	IN
cord-324810-92fosk3c	437	2	daily	daily	JJ
cord-324810-92fosk3c	437	3	gyrase	gyrase	NN
cord-324810-92fosk3c	437	4	and	and	CC
cord-324810-92fosk3c	437	5	topoisomerase	topoisomerase	NN
cord-324810-92fosk3c	437	6	IV	IV	NNP
cord-324810-92fosk3c	437	7	-have	-have	HYPH
cord-324810-92fosk3c	437	8	essential	essential	JJ
cord-324810-92fosk3c	437	9	roles	role	NNS
cord-324810-92fosk3c	437	10	in	in	IN
cord-324810-92fosk3c	437	11	DNA	DNA	NNP
cord-324810-92fosk3c	437	12	for	for	IN
cord-324810-92fosk3c	437	13	7	7	CD
cord-324810-92fosk3c	437	14	days	day	NNS
cord-324810-92fosk3c	437	15	or	or	CC
cord-324810-92fosk3c	437	16	oral	oral	JJ
cord-324810-92fosk3c	437	17	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	437	18	/	/	SYM
cord-324810-92fosk3c	437	19	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	437	20	acid	acid	NNP
cord-324810-92fosk3c	437	21	(	(	-LRB-
cord-324810-92fosk3c	437	22	three	three	CD
cord-324810-92fosk3c	437	23	625	625	CD
cord-324810-92fosk3c	437	24	mg	mg	NN
cord-324810-92fosk3c	437	25	tablets	tablet	NNS
cord-324810-92fosk3c	437	26	replication	replication	NN
cord-324810-92fosk3c	437	27	.	.	.
cord-324810-92fosk3c	438	1	Fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	438	2	bind	bind	VBP
cord-324810-92fosk3c	438	3	to	to	IN
cord-324810-92fosk3c	438	4	each	each	DT
cord-324810-92fosk3c	438	5	of	of	IN
cord-324810-92fosk3c	438	6	these	these	DT
cord-324810-92fosk3c	438	7	enzymes	enzyme	NNS
cord-324810-92fosk3c	438	8	,	,	,
cord-324810-92fosk3c	438	9	thus	thus	RB
cord-324810-92fosk3c	438	10	interfering	interfere	VBG
cord-324810-92fosk3c	438	11	with	with	IN
cord-324810-92fosk3c	438	12	DNA	dna	NN
cord-324810-92fosk3c	438	13	replication	replication	NN
cord-324810-92fosk3c	438	14	,	,	,
cord-324810-92fosk3c	438	15	leading	lead	VBG
cord-324810-92fosk3c	438	16	to	to	IN
cord-324810-92fosk3c	438	17	bacterial	bacterial	JJ
cord-324810-92fosk3c	438	18	cell	cell	NN
cord-324810-92fosk3c	438	19	death	death	NN
cord-324810-92fosk3c	438	20	.	.	.
cord-324810-92fosk3c	439	1	daily	daily	RB
cord-324810-92fosk3c	439	2	for	for	IN
cord-324810-92fosk3c	439	3	7	7	CD
cord-324810-92fosk3c	439	4	days	day	NNS
cord-324810-92fosk3c	439	5	)	)	-RRB-
cord-324810-92fosk3c	439	6	.	.	.
cord-324810-92fosk3c	440	1	Similar	similar	JJ
cord-324810-92fosk3c	440	2	clinical	clinical	JJ
cord-324810-92fosk3c	440	3	success	success	NN
cord-324810-92fosk3c	440	4	rates	rate	NNS
cord-324810-92fosk3c	440	5	,	,	,
cord-324810-92fosk3c	440	6	classified	classify	VBN
cord-324810-92fosk3c	440	7	as	as	IN
cord-324810-92fosk3c	440	8	Resistance	resistance	NN
cord-324810-92fosk3c	440	9	to	to	IN
cord-324810-92fosk3c	440	10	fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	440	11	occurs	occur	VBZ
cord-324810-92fosk3c	440	12	via	via	IN
cord-324810-92fosk3c	440	13	mutations	mutation	NNS
cord-324810-92fosk3c	440	14	in	in	IN
cord-324810-92fosk3c	440	15	the	the	DT
cord-324810-92fosk3c	440	16	genes	gene	NNS
cord-324810-92fosk3c	440	17	resolution	resolution	NN
cord-324810-92fosk3c	440	18	or	or	CC
cord-324810-92fosk3c	440	19	improvement	improvement	NN
cord-324810-92fosk3c	440	20	of	of	IN
cord-324810-92fosk3c	440	21	symptoms	symptom	NNS
cord-324810-92fosk3c	440	22	,	,	,
cord-324810-92fosk3c	440	23	occurred	occur	VBD
cord-324810-92fosk3c	440	24	with	with	IN
cord-324810-92fosk3c	440	25	moxifloxby	moxifloxby	JJ
cord-324810-92fosk3c	440	26	encoding	encode	VBG
cord-324810-92fosk3c	440	27	the	the	DT
cord-324810-92fosk3c	440	28	subunits	subunit	NNS
cord-324810-92fosk3c	440	29	of	of	IN
cord-324810-92fosk3c	440	30	DNA	dna	NN
cord-324810-92fosk3c	440	31	gyrase	gyrase	NN
cord-324810-92fosk3c	440	32	and	and	CC
cord-324810-92fosk3c	440	33	topoisomerase	topoisomerase	NN
cord-324810-92fosk3c	440	34	IV	IV	NNP
cord-324810-92fosk3c	440	35	.	.	.
cord-324810-92fosk3c	441	1	acin	acin	NNP
cord-324810-92fosk3c	441	2	.	.	.
cord-324810-92fosk3c	442	1	A	a	DT
cord-324810-92fosk3c	442	2	multinational	multinational	JJ
cord-324810-92fosk3c	442	3	,	,	,
cord-324810-92fosk3c	442	4	double	double	JJ
cord-324810-92fosk3c	442	5	-	-	HYPH
cord-324810-92fosk3c	442	6	blind	blind	JJ
cord-324810-92fosk3c	442	7	study	study	NN
cord-324810-92fosk3c	442	8	,	,	,
cord-324810-92fosk3c	442	9	MOSAIC	MOSAIC	NNP
cord-324810-92fosk3c	442	10	(	(	-LRB-
cord-324810-92fosk3c	442	11	Moxiflox	Moxiflox	NNP
cord-324810-92fosk3c	442	12	-	-	HYPH
cord-324810-92fosk3c	442	13	Altered	alter	VBN
cord-324810-92fosk3c	442	14	permeation	permeation	NN
cord-324810-92fosk3c	442	15	mechanisms	mechanism	NNS
cord-324810-92fosk3c	442	16	may	may	MD
cord-324810-92fosk3c	442	17	contribute	contribute	VB
cord-324810-92fosk3c	442	18	to	to	IN
cord-324810-92fosk3c	442	19	resistance	resistance	NN
cord-324810-92fosk3c	442	20	by	by	IN
cord-324810-92fosk3c	442	21	acin	acin	NNS
cord-324810-92fosk3c	442	22	Oral	oral	JJ
cord-324810-92fosk3c	442	23	tablets	tablet	NNS
cord-324810-92fosk3c	442	24	to	to	IN
cord-324810-92fosk3c	442	25	Standard	standard	JJ
cord-324810-92fosk3c	442	26	oral	oral	JJ
cord-324810-92fosk3c	442	27	antibiotic	antibiotic	JJ
cord-324810-92fosk3c	442	28	regimen	regimen	NN
cord-324810-92fosk3c	442	29	given	give	VBN
cord-324810-92fosk3c	442	30	as	as	IN
cord-324810-92fosk3c	442	31	firstenhancing	firstenhance	VBG
cord-324810-92fosk3c	442	32	cytoplasmic	cytoplasmic	JJ
cord-324810-92fosk3c	442	33	membrane	membrane	NN
cord-324810-92fosk3c	442	34	efflux	efflux	NN
cord-324810-92fosk3c	442	35	pumps	pump	NNS
cord-324810-92fosk3c	442	36	.	.	.
cord-324810-92fosk3c	443	1	These	these	DT
cord-324810-92fosk3c	443	2	agents	agent	NNS
cord-324810-92fosk3c	443	3	line	line	VBP
cord-324810-92fosk3c	443	4	therapy	therapy	NN
cord-324810-92fosk3c	443	5	in	in	IN
cord-324810-92fosk3c	443	6	out	out	NN
cord-324810-92fosk3c	443	7	-	-	HYPH
cord-324810-92fosk3c	443	8	patients	patient	NNS
cord-324810-92fosk3c	443	9	with	with	IN
cord-324810-92fosk3c	443	10	Acute	Acute	NNP
cord-324810-92fosk3c	443	11	Infective	Infective	NNP
cord-324810-92fosk3c	443	12	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	443	13	of	of	IN
cord-324810-92fosk3c	443	14	penetrate	penetrate	VBP
cord-324810-92fosk3c	443	15	well	well	RB
cord-324810-92fosk3c	443	16	into	into	IN
cord-324810-92fosk3c	443	17	the	the	DT
cord-324810-92fosk3c	443	18	respiratory	respiratory	JJ
cord-324810-92fosk3c	443	19	secretions	secretion	NNS
cord-324810-92fosk3c	443	20	and	and	CC
cord-324810-92fosk3c	443	21	bronchial	bronchial	JJ
cord-324810-92fosk3c	443	22	muco	muco	NNS
cord-324810-92fosk3c	443	23	-	-	HYPH
cord-324810-92fosk3c	443	24	Chronic	Chronic	NNP
cord-324810-92fosk3c	443	25	Bronchitis	Bronchitis	NNP
cord-324810-92fosk3c	443	26	)	)	-RRB-
cord-324810-92fosk3c	443	27	,	,	,
cord-324810-92fosk3c	443	28	compared	compare	VBN
cord-324810-92fosk3c	443	29	effectiveness	effectiveness	NN
cord-324810-92fosk3c	443	30	of	of	IN
cord-324810-92fosk3c	443	31	moxifloxacin	moxifloxacin	NNP
cord-324810-92fosk3c	443	32	sa	sa	NNP
cord-324810-92fosk3c	443	33	,	,	,
cord-324810-92fosk3c	443	34	but	but	CC
cord-324810-92fosk3c	443	35	the	the	DT
cord-324810-92fosk3c	443	36	clinical	clinical	JJ
cord-324810-92fosk3c	443	37	relevance	relevance	NN
cord-324810-92fosk3c	443	38	of	of	IN
cord-324810-92fosk3c	443	39	this	this	DT
cord-324810-92fosk3c	443	40	is	be	VBZ
cord-324810-92fosk3c	443	41	uncertain	uncertain	JJ
cord-324810-92fosk3c	443	42	.	.	.
cord-324810-92fosk3c	444	1	The	the	DT
cord-324810-92fosk3c	444	2	respiratory	respiratory	NN
cord-324810-92fosk3c	444	3	(	(	-LRB-
cord-324810-92fosk3c	444	4	400	400	CD
cord-324810-92fosk3c	444	5	mg	mg	PRP
cord-324810-92fosk3c	444	6	once	once	RB
cord-324810-92fosk3c	444	7	daily	daily	RB
cord-324810-92fosk3c	444	8	for	for	IN
cord-324810-92fosk3c	444	9	5	5	CD
cord-324810-92fosk3c	444	10	days	day	NNS
cord-324810-92fosk3c	444	11	)	)	-RRB-
cord-324810-92fosk3c	444	12	and	and	CC
cord-324810-92fosk3c	444	13	standard	standard	JJ
cord-324810-92fosk3c	444	14	therapy	therapy	NN
cord-324810-92fosk3c	444	15	(	(	-LRB-
cord-324810-92fosk3c	444	16	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	444	17	fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	444	18	are	be	VBP
cord-324810-92fosk3c	444	19	active	active	JJ
cord-324810-92fosk3c	444	20	against	against	IN
cord-324810-92fosk3c	444	21	both	both	CC
cord-324810-92fosk3c	444	22	typical	typical	JJ
cord-324810-92fosk3c	444	23	and	and	CC
cord-324810-92fosk3c	444	24	atypical	atypical	JJ
cord-324810-92fosk3c	444	25	bac-[500	bac-[500	CC
cord-324810-92fosk3c	444	26	mg	mg	NNP
cord-324810-92fosk3c	444	27	three	three	CD
cord-324810-92fosk3c	444	28	times	time	NNS
cord-324810-92fosk3c	444	29	daily	daily	RB
cord-324810-92fosk3c	444	30	for	for	IN
cord-324810-92fosk3c	444	31	7	7	CD
cord-324810-92fosk3c	444	32	days	day	NNS
cord-324810-92fosk3c	444	33	]	]	-RRB-
cord-324810-92fosk3c	444	34	,	,	,
cord-324810-92fosk3c	444	35	clarithromycin	clarithromycin	NNPS
cord-324810-92fosk3c	444	36	[	[	-LRB-
cord-324810-92fosk3c	444	37	500	500	CD
cord-324810-92fosk3c	444	38	mg	mg	NN
cord-324810-92fosk3c	444	39	twice	twice	JJ
cord-324810-92fosk3c	444	40	terial	terial	JJ
cord-324810-92fosk3c	444	41	pathogens	pathogen	NNS
cord-324810-92fosk3c	444	42	.	.	.
cord-324810-92fosk3c	445	1	The	the	DT
cord-324810-92fosk3c	445	2	fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	445	3	are	be	VBP
cord-324810-92fosk3c	445	4	highly	highly	RB
cord-324810-92fosk3c	445	5	active	active	JJ
cord-324810-92fosk3c	445	6	against	against	IN
cord-324810-92fosk3c	445	7	βdaily	βdaily	NNP
cord-324810-92fosk3c	445	8	for	for	IN
cord-324810-92fosk3c	445	9	7	7	CD
cord-324810-92fosk3c	445	10	days	day	NNS
cord-324810-92fosk3c	445	11	]	]	-RRB-
cord-324810-92fosk3c	445	12	,	,	,
cord-324810-92fosk3c	445	13	or	or	CC
cord-324810-92fosk3c	445	14	cefuroxime	cefuroxime	NN
cord-324810-92fosk3c	445	15	-	-	HYPH
cord-324810-92fosk3c	445	16	axetil	axetil	NNP
cord-324810-92fosk3c	445	17	[	[	-LRB-
cord-324810-92fosk3c	445	18	25	25	CD
cord-324810-92fosk3c	445	19	mg	mg	NNS
cord-324810-92fosk3c	445	20	twice	twice	RB
cord-324810-92fosk3c	445	21	daily	daily	RB
cord-324810-92fosk3c	445	22	for	for	IN
cord-324810-92fosk3c	445	23	7	7	CD
cord-324810-92fosk3c	445	24	lactamase	lactamase	NN
cord-324810-92fosk3c	445	25	producing	produce	VBG
cord-324810-92fosk3c	445	26	H.	h.	NN
cord-324810-92fosk3c	445	27	influenzae	influenzae	NN
cord-324810-92fosk3c	445	28	and	and	CC
cord-324810-92fosk3c	445	29	M.	M.	NNP
cord-324810-92fosk3c	445	30	catarrhalis	catarrhalis	NNP
cord-324810-92fosk3c	445	31	.	.	.
cord-324810-92fosk3c	446	1	These	these	DT
cord-324810-92fosk3c	446	2	days	day	NNS
cord-324810-92fosk3c	446	3	]	]	-RRB-
cord-324810-92fosk3c	446	4	)	)	-RRB-
cord-324810-92fosk3c	446	5	.	.	.
cord-324810-92fosk3c	447	1	Patients	patient	NNS
cord-324810-92fosk3c	447	2	were	be	VBD
cord-324810-92fosk3c	447	3	stratified	stratify	VBN
cord-324810-92fosk3c	447	4	according	accord	VBG
cord-324810-92fosk3c	447	5	to	to	IN
cord-324810-92fosk3c	447	6	oral	oral	JJ
cord-324810-92fosk3c	447	7	and	and	CC
cord-324810-92fosk3c	447	8	inhaled	inhale	VBN
cord-324810-92fosk3c	447	9	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	447	10	agents	agent	NNS
cord-324810-92fosk3c	447	11	have	have	VBP
cord-324810-92fosk3c	447	12	70	70	CD
cord-324810-92fosk3c	447	13	-	-	SYM
cord-324810-92fosk3c	447	14	95	95	CD
cord-324810-92fosk3c	447	15	%	%	NN
cord-324810-92fosk3c	447	16	bioavailability	bioavailability	NN
cord-324810-92fosk3c	447	17	after	after	IN
cord-324810-92fosk3c	447	18	oral	oral	JJ
cord-324810-92fosk3c	447	19	adcorticosteroid	adcorticosteroid	NNP
cord-324810-92fosk3c	447	20	usage	usage	NN
cord-324810-92fosk3c	447	21	.	.	.
cord-324810-92fosk3c	448	1	The	the	DT
cord-324810-92fosk3c	448	2	primary	primary	JJ
cord-324810-92fosk3c	448	3	endpoint	endpoint	NN
cord-324810-92fosk3c	448	4	was	be	VBD
cord-324810-92fosk3c	448	5	clinical	clinical	JJ
cord-324810-92fosk3c	448	6	success	success	NN
cord-324810-92fosk3c	448	7	ministration	ministration	NN
cord-324810-92fosk3c	448	8	,	,	,
cord-324810-92fosk3c	448	9	a	a	DT
cord-324810-92fosk3c	448	10	prolonged	prolonged	JJ
cord-324810-92fosk3c	448	11	half	half	JJ
cord-324810-92fosk3c	448	12	-	-	HYPH
cord-324810-92fosk3c	448	13	life	life	NN
cord-324810-92fosk3c	448	14	(	(	-LRB-
cord-324810-92fosk3c	448	15	>	>	NFP
cord-324810-92fosk3c	448	16	8	8	CD
cord-324810-92fosk3c	448	17	-	-	SYM
cord-324810-92fosk3c	448	18	12	12	CD
cord-324810-92fosk3c	448	19	hours	hour	NNS
cord-324810-92fosk3c	448	20	)	)	-RRB-
cord-324810-92fosk3c	448	21	,	,	,
cord-324810-92fosk3c	448	22	low	low	JJ
cord-324810-92fosk3c	448	23	protein	protein	NN
cord-324810-92fosk3c	448	24	(	(	-LRB-
cord-324810-92fosk3c	448	25	sufficient	sufficient	JJ
cord-324810-92fosk3c	448	26	improvement	improvement	NN
cord-324810-92fosk3c	448	27	,	,	,
cord-324810-92fosk3c	448	28	no	no	DT
cord-324810-92fosk3c	448	29	alternative	alternative	JJ
cord-324810-92fosk3c	448	30	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	448	31	therapy	therapy	NN
cord-324810-92fosk3c	448	32	rebinding	rebinding	NN
cord-324810-92fosk3c	448	33	and	and	CC
cord-324810-92fosk3c	448	34	renal	renal	JJ
cord-324810-92fosk3c	448	35	clearance	clearance	NN
cord-324810-92fosk3c	448	36	.	.	.
cord-324810-92fosk3c	449	1	Fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	449	2	are	be	VBP
cord-324810-92fosk3c	449	3	well	well	RB
cord-324810-92fosk3c	449	4	tolerated	tolerate	VBN
cord-324810-92fosk3c	449	5	,	,	,
cord-324810-92fosk3c	450	1	quired	quired	NNP
cord-324810-92fosk3c	450	2	)	)	-RRB-
cord-324810-92fosk3c	450	3	7	7	CD
cord-324810-92fosk3c	450	4	-	-	SYM
cord-324810-92fosk3c	450	5	10	10	CD
cord-324810-92fosk3c	450	6	days	day	NNS
cord-324810-92fosk3c	450	7	after	after	IN
cord-324810-92fosk3c	450	8	therapy	therapy	NN
cord-324810-92fosk3c	450	9	.	.	.
cord-324810-92fosk3c	451	1	Secondary	secondary	JJ
cord-324810-92fosk3c	451	2	predefined	predefined	JJ
cord-324810-92fosk3c	451	3	endpoints	endpoint	NNS
cord-324810-92fosk3c	451	4	and	and	CC
cord-324810-92fosk3c	451	5	adverse	adverse	JJ
cord-324810-92fosk3c	451	6	effects	effect	NNS
cord-324810-92fosk3c	451	7	are	be	VBP
cord-324810-92fosk3c	451	8	mild	mild	JJ
cord-324810-92fosk3c	451	9	and	and	CC
cord-324810-92fosk3c	451	10	transient	transient	JJ
cord-324810-92fosk3c	451	11	,	,	,
cord-324810-92fosk3c	451	12	including	include	VBG
cord-324810-92fosk3c	451	13	rash	rash	JJ
cord-324810-92fosk3c	451	14	,	,	,
cord-324810-92fosk3c	451	15	dizziwere	dizziwere	VBZ
cord-324810-92fosk3c	451	16	clinical	clinical	JJ
cord-324810-92fosk3c	451	17	cure	cure	NN
cord-324810-92fosk3c	451	18	(	(	-LRB-
cord-324810-92fosk3c	451	19	return	return	NN
cord-324810-92fosk3c	451	20	to	to	IN
cord-324810-92fosk3c	451	21	pre	pre	JJ
cord-324810-92fosk3c	451	22	-	-	JJ
cord-324810-92fosk3c	451	23	exacerbation	exacerbation	JJ
cord-324810-92fosk3c	451	24	status	status	NN
cord-324810-92fosk3c	451	25	)	)	-RRB-
cord-324810-92fosk3c	451	26	,	,	,
cord-324810-92fosk3c	451	27	further	further	JJ
cord-324810-92fosk3c	451	28	antiness	antiness	NN
cord-324810-92fosk3c	451	29	,	,	,
cord-324810-92fosk3c	451	30	headache	headache	NN
cord-324810-92fosk3c	451	31	,	,	,
cord-324810-92fosk3c	451	32	gastrointestinal	gastrointestinal	JJ
cord-324810-92fosk3c	451	33	disturbance	disturbance	NN
cord-324810-92fosk3c	451	34	(	(	-LRB-
cord-324810-92fosk3c	451	35	nausea	nausea	NN
cord-324810-92fosk3c	451	36	,	,	,
cord-324810-92fosk3c	451	37	vomiting	vomiting	NN
cord-324810-92fosk3c	451	38	,	,	,
cord-324810-92fosk3c	451	39	microbial	microbial	JJ
cord-324810-92fosk3c	451	40	use	use	NN
cord-324810-92fosk3c	451	41	,	,	,
cord-324810-92fosk3c	451	42	time	time	NN
cord-324810-92fosk3c	451	43	to	to	IN
cord-324810-92fosk3c	451	44	next	next	JJ
cord-324810-92fosk3c	451	45	exacerbation	exacerbation	NN
cord-324810-92fosk3c	451	46	and	and	CC
cord-324810-92fosk3c	451	47	bacteriologic	bacteriologic	JJ
cord-324810-92fosk3c	451	48	success	success	NN
cord-324810-92fosk3c	451	49	.	.	.
cord-324810-92fosk3c	452	1	diarrhea	diarrhea	JJ
cord-324810-92fosk3c	452	2	,	,	,
cord-324810-92fosk3c	452	3	abdominal	abdominal	JJ
cord-324810-92fosk3c	452	4	pain	pain	NN
cord-324810-92fosk3c	452	5	)	)	-RRB-
cord-324810-92fosk3c	452	6	and	and	CC
cord-324810-92fosk3c	452	7	minor	minor	JJ
cord-324810-92fosk3c	452	8	hematologic	hematologic	JJ
cord-324810-92fosk3c	452	9	abnormalities	abnormality	NNS
cord-324810-92fosk3c	452	10	.	.	.
cord-324810-92fosk3c	453	1	In	in	IN
cord-324810-92fosk3c	453	2	this	this	DT
cord-324810-92fosk3c	453	3	parallel	parallel	JJ
cord-324810-92fosk3c	453	4	study	study	NN
cord-324810-92fosk3c	453	5	,	,	,
cord-324810-92fosk3c	453	6	354	354	CD
cord-324810-92fosk3c	453	7	patients	patient	NNS
cord-324810-92fosk3c	453	8	received	receive	VBD
cord-324810-92fosk3c	453	9	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	453	10	and	and	CC
cord-324810-92fosk3c	453	11	376	376	CD
cord-324810-92fosk3c	454	1	The	the	DT
cord-324810-92fosk3c	454	2	efficacy	efficacy	NN
cord-324810-92fosk3c	454	3	of	of	IN
cord-324810-92fosk3c	454	4	fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	454	5	has	have	VBZ
cord-324810-92fosk3c	454	6	been	be	VBN
cord-324810-92fosk3c	454	7	established	establish	VBN
cord-324810-92fosk3c	454	8	in	in	IN
cord-324810-92fosk3c	454	9	sever	sever	NN
cord-324810-92fosk3c	454	10	-	-	HYPH
cord-324810-92fosk3c	454	11	patients	patient	NNS
cord-324810-92fosk3c	454	12	received	receive	VBD
cord-324810-92fosk3c	454	13	standard	standard	JJ
cord-324810-92fosk3c	454	14	therapy	therapy	NN
cord-324810-92fosk3c	454	15	.	.	.
cord-324810-92fosk3c	455	1	In	in	IN
cord-324810-92fosk3c	455	2	an	an	DT
cord-324810-92fosk3c	455	3	intention	intention	NN
cord-324810-92fosk3c	455	4	-	-	HYPH
cord-324810-92fosk3c	455	5	to	to	IN
cord-324810-92fosk3c	455	6	-	-	HYPH
cord-324810-92fosk3c	455	7	treat	treat	VB
cord-324810-92fosk3c	455	8	(	(	-LRB-
cord-324810-92fosk3c	455	9	ITT	ITT	NNP
cord-324810-92fosk3c	455	10	)	)	-RRB-
cord-324810-92fosk3c	455	11	al	al	NNP
cord-324810-92fosk3c	455	12	randomized	randomize	VBD
cord-324810-92fosk3c	455	13	trials	trial	NNS
cord-324810-92fosk3c	455	14	.	.	.
cord-324810-92fosk3c	456	1	A	a	DT
cord-324810-92fosk3c	456	2	community	community	NN
cord-324810-92fosk3c	456	3	-	-	HYPH
cord-324810-92fosk3c	456	4	based	base	VBN
cord-324810-92fosk3c	456	5	study	study	NN
cord-324810-92fosk3c	456	6	involving	involve	VBG
cord-324810-92fosk3c	456	7	more	more	JJR
cord-324810-92fosk3c	456	8	population	population	NN
cord-324810-92fosk3c	456	9	,	,	,
cord-324810-92fosk3c	456	10	clinical	clinical	JJ
cord-324810-92fosk3c	456	11	success	success	NN
cord-324810-92fosk3c	456	12	rates	rate	NNS
cord-324810-92fosk3c	456	13	were	be	VBD
cord-324810-92fosk3c	456	14	similar	similar	JJ
cord-324810-92fosk3c	456	15	(	(	-LRB-
cord-324810-92fosk3c	456	16	87.6	87.6	CD
cord-324810-92fosk3c	456	17	%	%	NN
cord-324810-92fosk3c	456	18	for	for	IN
cord-324810-92fosk3c	456	19	mox	mox	NNP
cord-324810-92fosk3c	456	20	-	-	HYPH
cord-324810-92fosk3c	456	21	ifloxacin	ifloxacin	NNP
cord-324810-92fosk3c	456	22	,	,	,
cord-324810-92fosk3c	456	23	83	83	CD
cord-324810-92fosk3c	456	24	%	%	NN
cord-324810-92fosk3c	456	25	for	for	IN
cord-324810-92fosk3c	456	26	standard	standard	JJ
cord-324810-92fosk3c	456	27	therapy	therapy	NN
cord-324810-92fosk3c	456	28	,	,	,
cord-324810-92fosk3c	456	29	p	p	NN
cord-324810-92fosk3c	456	30	=	=	SYM
cord-324810-92fosk3c	456	31	0.02	0.02	CD
cord-324810-92fosk3c	456	32	)	)	-RRB-
cord-324810-92fosk3c	456	33	at	at	IN
cord-324810-92fosk3c	456	34	7	7	CD
cord-324810-92fosk3c	456	35	-	-	SYM
cord-324810-92fosk3c	456	36	10	10	CD
cord-324810-92fosk3c	456	37	days	day	NNS
cord-324810-92fosk3c	456	38	after	after	IN
cord-324810-92fosk3c	456	39	creased	creased	JJ
cord-324810-92fosk3c	456	40	sputum	sputum	NN
cord-324810-92fosk3c	456	41	volume	volume	NN
cord-324810-92fosk3c	456	42	,	,	,
cord-324810-92fosk3c	456	43	and	and	CC
cord-324810-92fosk3c	456	44	increased	increase	VBN
cord-324810-92fosk3c	456	45	sputum	sputum	NN
cord-324810-92fosk3c	456	46	purulence	purulence	NN
cord-324810-92fosk3c	456	47	)	)	-RRB-
cord-324810-92fosk3c	456	48	,	,	,
cord-324810-92fosk3c	456	49	should	should	MD
cord-324810-92fosk3c	456	50	therapy	therapy	NN
cord-324810-92fosk3c	456	51	.	.	.
cord-324810-92fosk3c	457	1	Moxifloxacin	Moxifloxacin	NNS
cord-324810-92fosk3c	457	2	showed	show	VBD
cord-324810-92fosk3c	457	3	superior	superior	JJ
cord-324810-92fosk3c	457	4	clinical	clinical	JJ
cord-324810-92fosk3c	457	5	cure	cure	NN
cord-324810-92fosk3c	457	6	rates	rate	NNS
cord-324810-92fosk3c	457	7	over	over	IN
cord-324810-92fosk3c	457	8	be	be	VB
cord-324810-92fosk3c	457	9	treated	treat	VBN
cord-324810-92fosk3c	457	10	.	.	.
cord-324810-92fosk3c	458	1	The	the	DT
cord-324810-92fosk3c	458	2	traditional	traditional	JJ
cord-324810-92fosk3c	458	3	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	458	4	termed	term	VBN
cord-324810-92fosk3c	458	5	as	as	IN
cord-324810-92fosk3c	458	6	first	first	JJ
cord-324810-92fosk3c	458	7	-	-	HYPH
cord-324810-92fosk3c	458	8	line	line	NN
cord-324810-92fosk3c	458	9	therstandard	therstandard	NN
cord-324810-92fosk3c	458	10	therapy	therapy	NN
cord-324810-92fosk3c	458	11	in	in	IN
cord-324810-92fosk3c	458	12	both	both	CC
cord-324810-92fosk3c	458	13	ITT	ITT	NNP
cord-324810-92fosk3c	458	14	patients	patient	NNS
cord-324810-92fosk3c	458	15	(	(	-LRB-
cord-324810-92fosk3c	458	16	95	95	CD
cord-324810-92fosk3c	458	17	%	%	NN
cord-324810-92fosk3c	458	18	CI	CI	NNP
cord-324810-92fosk3c	458	19	1.4	1.4	CD
cord-324810-92fosk3c	458	20	,	,	,
cord-324810-92fosk3c	458	21	14.9	14.9	CD
cord-324810-92fosk3c	458	22	)	)	-RRB-
cord-324810-92fosk3c	458	23	and	and	CC
cord-324810-92fosk3c	458	24	per	per	IN
cord-324810-92fosk3c	458	25	apy	apy	NNP
cord-324810-92fosk3c	458	26	are	be	VBP
cord-324810-92fosk3c	458	27	appropriate	appropriate	JJ
cord-324810-92fosk3c	458	28	;	;	:
cord-324810-92fosk3c	458	29	these	these	DT
cord-324810-92fosk3c	458	30	include	include	VBP
cord-324810-92fosk3c	458	31	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	458	32	,	,	,
cord-324810-92fosk3c	458	33	tetracycline	tetracycline	NNP
cord-324810-92fosk3c	458	34	,	,	,
cord-324810-92fosk3c	458	35	doxyprotocol	doxyprotocol	NN
cord-324810-92fosk3c	458	36	patients	patient	NNS
cord-324810-92fosk3c	458	37	(	(	-LRB-
cord-324810-92fosk3c	458	38	95	95	CD
cord-324810-92fosk3c	458	39	%	%	NN
cord-324810-92fosk3c	458	40	CI	CI	NNP
cord-324810-92fosk3c	458	41	0.3	0.3	CD
cord-324810-92fosk3c	458	42	,	,	,
cord-324810-92fosk3c	458	43	15.6	15.6	CD
cord-324810-92fosk3c	458	44	)	)	-RRB-
cord-324810-92fosk3c	458	45	,	,	,
cord-324810-92fosk3c	458	46	and	and	CC
cord-324810-92fosk3c	458	47	higher	high	JJR
cord-324810-92fosk3c	458	48	bacteriologic	bacteriologic	NN
cord-324810-92fosk3c	458	49	cycline	cycline	NN
cord-324810-92fosk3c	458	50	and	and	CC
cord-324810-92fosk3c	458	51	trimethoprim	trimethoprim	NNP
cord-324810-92fosk3c	458	52	/	/	SYM
cord-324810-92fosk3c	458	53	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	458	54	.	.	.
cord-324810-92fosk3c	459	1	Cure	cure	NN
cord-324810-92fosk3c	459	2	rates	rate	NNS
cord-324810-92fosk3c	459	3	with	with	IN
cord-324810-92fosk3c	459	4	these	these	DT
cord-324810-92fosk3c	459	5	success	success	NN
cord-324810-92fosk3c	459	6	in	in	IN
cord-324810-92fosk3c	459	7	microbiologically	microbiologically	RB
cord-324810-92fosk3c	459	8	valid	valid	JJ
cord-324810-92fosk3c	459	9	patients	patient	NNS
cord-324810-92fosk3c	459	10	(	(	-LRB-
cord-324810-92fosk3c	459	11	95	95	CD
cord-324810-92fosk3c	459	12	%	%	NN
cord-324810-92fosk3c	459	13	CI	CI	NNP
cord-324810-92fosk3c	459	14	0.4	0.4	CD
cord-324810-92fosk3c	459	15	,	,	,
cord-324810-92fosk3c	459	16	22.1	22.1	CD
cord-324810-92fosk3c	459	17	)	)	-RRB-
cord-324810-92fosk3c	459	18	.	.	.
cord-324810-92fosk3c	460	1	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	460	2	approach	approach	VBP
cord-324810-92fosk3c	460	3	80	80	CD
cord-324810-92fosk3c	460	4	-	-	SYM
cord-324810-92fosk3c	460	5	90	90	CD
cord-324810-92fosk3c	460	6	%	%	NN
cord-324810-92fosk3c	460	7	in	in	IN
cord-324810-92fosk3c	460	8	mild	mild	NN
cord-324810-92fosk3c	460	9	-	-	HYPH
cord-324810-92fosk3c	460	10	to	to	IN
cord-324810-92fosk3c	460	11	-	-	HYPH
cord-324810-92fosk3c	460	12	moderate	moderate	JJ
cord-324810-92fosk3c	460	13	exacerba	exacerba	NN
cord-324810-92fosk3c	460	14	-	-	HYPH
cord-324810-92fosk3c	460	15	Time	time	NN
cord-324810-92fosk3c	460	16	to	to	IN
cord-324810-92fosk3c	460	17	next	next	JJ
cord-324810-92fosk3c	460	18	exacerbation	exacerbation	NN
cord-324810-92fosk3c	460	19	was	be	VBD
cord-324810-92fosk3c	460	20	longer	long	JJR
cord-324810-92fosk3c	460	21	with	with	IN
cord-324810-92fosk3c	460	22	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	460	23	;	;	:
cord-324810-92fosk3c	460	24	median	median	JJ
cord-324810-92fosk3c	460	25	tions	tion	NNS
cord-324810-92fosk3c	460	26	.	.	.
cord-324810-92fosk3c	461	1	In	in	IN
cord-324810-92fosk3c	461	2	patients	patient	NNS
cord-324810-92fosk3c	461	3	who	who	WP
cord-324810-92fosk3c	461	4	have	have	VBP
cord-324810-92fosk3c	461	5	more	more	RBR
cord-324810-92fosk3c	461	6	severe	severe	JJ
cord-324810-92fosk3c	461	7	underlying	underlying	JJ
cord-324810-92fosk3c	461	8	lung	lung	NN
cord-324810-92fosk3c	461	9	disease	disease	NN
cord-324810-92fosk3c	461	10	,	,	,
cord-324810-92fosk3c	461	11	time	time	NN
cord-324810-92fosk3c	461	12	to	to	IN
cord-324810-92fosk3c	461	13	new	new	JJ
cord-324810-92fosk3c	461	14	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	461	15	was	be	VBD
cord-324810-92fosk3c	461	16	132.8	132.8	CD
cord-324810-92fosk3c	461	17	days	day	NNS
cord-324810-92fosk3c	461	18	in	in	IN
cord-324810-92fosk3c	461	19	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	461	20	,	,	,
cord-324810-92fosk3c	461	21	and	and	CC
cord-324810-92fosk3c	461	22	118.0	118.0	CD
cord-324810-92fosk3c	461	23	frequent	frequent	JJ
cord-324810-92fosk3c	461	24	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	461	25	,	,	,
cord-324810-92fosk3c	461	26	and	and	CC
cord-324810-92fosk3c	461	27	comorbid	comorbid	NN
cord-324810-92fosk3c	461	28	conditions	condition	NNS
cord-324810-92fosk3c	461	29	,	,	,
cord-324810-92fosk3c	461	30	failure	failure	NN
cord-324810-92fosk3c	461	31	of	of	IN
cord-324810-92fosk3c	461	32	initial	initial	JJ
cord-324810-92fosk3c	461	33	days	day	NNS
cord-324810-92fosk3c	461	34	in	in	IN
cord-324810-92fosk3c	461	35	standard	standard	JJ
cord-324810-92fosk3c	461	36	therapy	therapy	NN
cord-324810-92fosk3c	461	37	,	,	,
cord-324810-92fosk3c	461	38	respectively	respectively	RB
cord-324810-92fosk3c	461	39	(	(	-LRB-
cord-324810-92fosk3c	461	40	p	p	NN
cord-324810-92fosk3c	461	41	=	=	SYM
cord-324810-92fosk3c	461	42	0.03	0.03	CD
cord-324810-92fosk3c	461	43	)	)	-RRB-
cord-324810-92fosk3c	461	44	.	.	.
cord-324810-92fosk3c	462	1	The	the	DT
cord-324810-92fosk3c	462	2	occurrence	occurrence	NN
cord-324810-92fosk3c	462	3	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	462	4	therapy	therapy	NN
cord-324810-92fosk3c	462	5	may	may	MD
cord-324810-92fosk3c	462	6	result	result	VB
cord-324810-92fosk3c	462	7	in	in	IN
cord-324810-92fosk3c	462	8	repeat	repeat	NN
cord-324810-92fosk3c	462	9	visits	visit	NNS
cord-324810-92fosk3c	462	10	,	,	,
cord-324810-92fosk3c	462	11	hospitalization	hospitalization	NN
cord-324810-92fosk3c	462	12	,	,	,
cord-324810-92fosk3c	462	13	of	of	IN
cord-324810-92fosk3c	462	14	failure	failure	NN
cord-324810-92fosk3c	462	15	,	,	,
cord-324810-92fosk3c	462	16	new	new	JJ
cord-324810-92fosk3c	462	17	exacerbation	exacerbation	NN
cord-324810-92fosk3c	462	18	,	,	,
cord-324810-92fosk3c	462	19	or	or	CC
cord-324810-92fosk3c	462	20	any	any	DT
cord-324810-92fosk3c	462	21	further	further	JJ
cord-324810-92fosk3c	462	22	antibiotic	antibiotic	JJ
cord-324810-92fosk3c	462	23	use	use	NN
cord-324810-92fosk3c	462	24	was	be	VBD
cord-324810-92fosk3c	462	25	less	less	JJR
cord-324810-92fosk3c	462	26	and	and	CC
cord-324810-92fosk3c	462	27	increased	increase	VBN
cord-324810-92fosk3c	462	28	morbidity	morbidity	NN
cord-324810-92fosk3c	462	29	and	and	CC
cord-324810-92fosk3c	462	30	mortality	mortality	NN
cord-324810-92fosk3c	462	31	.	.	.
cord-324810-92fosk3c	463	1	In	in	IN
cord-324810-92fosk3c	463	2	these	these	DT
cord-324810-92fosk3c	463	3	patients	patient	NNS
cord-324810-92fosk3c	463	4	(	(	-LRB-
cord-324810-92fosk3c	463	5	complifrequent	complifrequent	NN
cord-324810-92fosk3c	463	6	in	in	IN
cord-324810-92fosk3c	463	7	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	463	8	-	-	HYPH
cord-324810-92fosk3c	463	9	treated	treat	VBN
cord-324810-92fosk3c	463	10	patients	patient	NNS
cord-324810-92fosk3c	463	11	for	for	IN
cord-324810-92fosk3c	463	12	up	up	IN
cord-324810-92fosk3c	463	13	to	to	TO
cord-324810-92fosk3c	463	14	5	5	CD
cord-324810-92fosk3c	463	15	months	month	NNS
cord-324810-92fosk3c	463	16	of	of	IN
cord-324810-92fosk3c	463	17	cated	cat	VBN
cord-324810-92fosk3c	463	18	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	463	19	)	)	-RRB-
cord-324810-92fosk3c	463	20	,	,	,
cord-324810-92fosk3c	463	21	second	second	JJ
cord-324810-92fosk3c	463	22	-	-	HYPH
cord-324810-92fosk3c	463	23	line	line	NN
cord-324810-92fosk3c	463	24	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	463	25	including	include	VBG
cord-324810-92fosk3c	463	26	macrolides	macrolide	NNS
cord-324810-92fosk3c	463	27	follow	follow	NN
cord-324810-92fosk3c	463	28	-	-	HYPH
cord-324810-92fosk3c	463	29	up	up	NN
cord-324810-92fosk3c	463	30	(	(	-LRB-
cord-324810-92fosk3c	463	31	p	p	NN
cord-324810-92fosk3c	463	32	=	=	SYM
cord-324810-92fosk3c	463	33	0.03	0.03	CD
cord-324810-92fosk3c	463	34	)	)	-RRB-
cord-324810-92fosk3c	463	35	.	.	.
cord-324810-92fosk3c	464	1	[	[	-LRB-
cord-324810-92fosk3c	464	2	127	127	CD
cord-324810-92fosk3c	464	3	]	]	-RRB-
cord-324810-92fosk3c	465	1	A	a	DT
cord-324810-92fosk3c	465	2	recent	recent	JJ
cord-324810-92fosk3c	465	3	randomized	randomized	JJ
cord-324810-92fosk3c	465	4	,	,	,
cord-324810-92fosk3c	465	5	double	double	JJ
cord-324810-92fosk3c	465	6	-	-	HYPH
cord-324810-92fosk3c	465	7	blind	blind	JJ
cord-324810-92fosk3c	465	8	trial	trial	NN
cord-324810-92fosk3c	465	9	and	and	CC
cord-324810-92fosk3c	465	10	fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	465	11	,	,	,
cord-324810-92fosk3c	465	12	and	and	CC
cord-324810-92fosk3c	465	13	second	second	JJ
cord-324810-92fosk3c	465	14	-	-	HYPH
cord-324810-92fosk3c	465	15	or	or	CC
cord-324810-92fosk3c	465	16	third	third	JJ
cord-324810-92fosk3c	465	17	-	-	HYPH
cord-324810-92fosk3c	465	18	generation	generation	NN
cord-324810-92fosk3c	465	19	macrolides	macrolide	NNS
cord-324810-92fosk3c	465	20	of	of	IN
cord-324810-92fosk3c	465	21	gemifloxacin	gemifloxacin	NNS
cord-324810-92fosk3c	465	22	320	320	CD
cord-324810-92fosk3c	465	23	mg	mg	NN
cord-324810-92fosk3c	466	1	once	once	RB
cord-324810-92fosk3c	466	2	daily	daily	JJ
cord-324810-92fosk3c	466	3	antibiotic	antibiotic	JJ
cord-324810-92fosk3c	466	4	therapy	therapy	NN
cord-324810-92fosk3c	466	5	was	be	VBD
cord-324810-92fosk3c	466	6	used	use	VBN
cord-324810-92fosk3c	466	7	to	to	TO
cord-324810-92fosk3c	466	8	should	should	MD
cord-324810-92fosk3c	466	9	be	be	VB
cord-324810-92fosk3c	466	10	considered	consider	VBN
cord-324810-92fosk3c	466	11	.	.	.
cord-324810-92fosk3c	467	1	investigate	investigate	VB
cord-324810-92fosk3c	467	2	its	-PRON-	PRP$
cord-324810-92fosk3c	467	3	efficacy	efficacy	NN
cord-324810-92fosk3c	467	4	and	and	CC
cord-324810-92fosk3c	467	5	the	the	DT
cord-324810-92fosk3c	467	6	magnitude	magnitude	NN
cord-324810-92fosk3c	467	7	and	and	CC
cord-324810-92fosk3c	467	8	time	time	NN
cord-324810-92fosk3c	467	9	course	course	NN
cord-324810-92fosk3c	467	10	of	of	IN
cord-324810-92fosk3c	467	11	effect	effect	NN
cord-324810-92fosk3c	468	1	Clinical	clinical	JJ
cord-324810-92fosk3c	468	2	trials	trial	NNS
cord-324810-92fosk3c	468	3	utilizing	utilize	VBG
cord-324810-92fosk3c	468	4	newer	new	JJR
cord-324810-92fosk3c	468	5	antimicrobials	antimicrobial	NNS
cord-324810-92fosk3c	468	6	showed	show	VBD
cord-324810-92fosk3c	468	7	equivaof	equivaof	NNP
cord-324810-92fosk3c	468	8	an	an	DT
cord-324810-92fosk3c	468	9	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	468	10	on	on	IN
cord-324810-92fosk3c	468	11	health	health	NN
cord-324810-92fosk3c	468	12	status	status	NN
cord-324810-92fosk3c	468	13	.	.	.
cord-324810-92fosk3c	469	1	Clarithromycin	Clarithromycin	NNP
cord-324810-92fosk3c	469	2	500	500	CD
cord-324810-92fosk3c	469	3	mg	mg	NN
cord-324810-92fosk3c	469	4	twice	twice	RB
cord-324810-92fosk3c	469	5	lence	lence	NNP
cord-324810-92fosk3c	469	6	but	but	CC
cord-324810-92fosk3c	469	7	not	not	RB
cord-324810-92fosk3c	469	8	superiority	superiority	NN
cord-324810-92fosk3c	469	9	compared	compare	VBN
cord-324810-92fosk3c	469	10	with	with	IN
cord-324810-92fosk3c	469	11	the	the	DT
cord-324810-92fosk3c	469	12	regimens	regimen	NNS
cord-324810-92fosk3c	469	13	already	already	RB
cord-324810-92fosk3c	469	14	in	in	IN
cord-324810-92fosk3c	469	15	daily	daily	NN
cord-324810-92fosk3c	469	16	for	for	IN
cord-324810-92fosk3c	469	17	7	7	CD
cord-324810-92fosk3c	469	18	days	day	NNS
cord-324810-92fosk3c	469	19	was	be	VBD
cord-324810-92fosk3c	469	20	used	use	VBN
cord-324810-92fosk3c	469	21	as	as	IN
cord-324810-92fosk3c	469	22	comparator	comparator	NN
cord-324810-92fosk3c	469	23	drug	drug	NN
cord-324810-92fosk3c	469	24	,	,	,
cord-324810-92fosk3c	469	25	patients	patient	NNS
cord-324810-92fosk3c	469	26	were	be	VBD
cord-324810-92fosk3c	469	27	use	use	NN
cord-324810-92fosk3c	469	28	.	.	.
cord-324810-92fosk3c	470	1	Future	future	JJ
cord-324810-92fosk3c	470	2	studies	study	NNS
cord-324810-92fosk3c	470	3	should	should	MD
cord-324810-92fosk3c	470	4	attempt	attempt	VB
cord-324810-92fosk3c	470	5	to	to	TO
cord-324810-92fosk3c	470	6	identify	identify	VB
cord-324810-92fosk3c	470	7	patients	patient	NNS
cord-324810-92fosk3c	470	8	with	with	IN
cord-324810-92fosk3c	470	9	followed	follow	VBN
cord-324810-92fosk3c	470	10	up	up	RP
cord-324810-92fosk3c	470	11	for	for	IN
cord-324810-92fosk3c	470	12	26	26	CD
cord-324810-92fosk3c	470	13	weeks	week	NNS
cord-324810-92fosk3c	470	14	.	.	.
cord-324810-92fosk3c	471	1	Clinical	clinical	JJ
cord-324810-92fosk3c	471	2	success	success	NN
cord-324810-92fosk3c	471	3	rates	rate	NNS
cord-324810-92fosk3c	471	4	at	at	IN
cord-324810-92fosk3c	471	5	the	the	DT
cord-324810-92fosk3c	471	6	2	2	CD
cord-324810-92fosk3c	471	7	-	-	SYM
cord-324810-92fosk3c	471	8	3	3	CD
cord-324810-92fosk3c	471	9	week	week	NN
cord-324810-92fosk3c	471	10	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	471	11	most	most	RBS
cord-324810-92fosk3c	471	12	likely	likely	JJ
cord-324810-92fosk3c	471	13	to	to	TO
cord-324810-92fosk3c	471	14	benefit	benefit	VB
cord-324810-92fosk3c	471	15	from	from	IN
cord-324810-92fosk3c	471	16	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	471	17	therapy	therapy	NN
cord-324810-92fosk3c	471	18	.	.	.
cord-324810-92fosk3c	472	1	Well	well	UH
cord-324810-92fosk3c	472	2	follow	follow	VB
cord-324810-92fosk3c	472	3	-	-	HYPH
cord-324810-92fosk3c	472	4	up	up	RP
cord-324810-92fosk3c	472	5	visit	visit	NN
cord-324810-92fosk3c	472	6	were	be	VBD
cord-324810-92fosk3c	472	7	85.4	85.4	CD
cord-324810-92fosk3c	472	8	%	%	NN
cord-324810-92fosk3c	472	9	for	for	IN
cord-324810-92fosk3c	472	10	gemifloxacin	gemifloxacin	NNS
cord-324810-92fosk3c	472	11	and	and	CC
cord-324810-92fosk3c	472	12	84.6	84.6	CD
cord-324810-92fosk3c	472	13	%	%	NN
cord-324810-92fosk3c	472	14	for	for	IN
cord-324810-92fosk3c	472	15	defined	define	VBN
cord-324810-92fosk3c	472	16	prospective	prospective	JJ
cord-324810-92fosk3c	472	17	analyses	analysis	NNS
cord-324810-92fosk3c	472	18	of	of	IN
cord-324810-92fosk3c	472	19	cost	cost	NN
cord-324810-92fosk3c	472	20	,	,	,
cord-324810-92fosk3c	472	21	DFI	DFI	NNP
cord-324810-92fosk3c	472	22	,	,	,
cord-324810-92fosk3c	472	23	quality	quality	NN
cord-324810-92fosk3c	472	24	-	-	HYPH
cord-324810-92fosk3c	472	25	of	of	IN
cord-324810-92fosk3c	472	26	-	-	HYPH
cord-324810-92fosk3c	472	27	life	life	NN
cord-324810-92fosk3c	472	28	improveclarithromycin	improveclarithromycin	NNS
cord-324810-92fosk3c	472	29	.	.	.
cord-324810-92fosk3c	473	1	Bacteriologic	Bacteriologic	NNP
cord-324810-92fosk3c	473	2	success	success	NN
cord-324810-92fosk3c	473	3	rates	rate	NNS
cord-324810-92fosk3c	473	4	were	be	VBD
cord-324810-92fosk3c	473	5	86.7	86.7	CD
cord-324810-92fosk3c	473	6	%	%	NN
cord-324810-92fosk3c	473	7	for	for	IN
cord-324810-92fosk3c	473	8	ment	ment	NN
cord-324810-92fosk3c	473	9	and	and	CC
cord-324810-92fosk3c	473	10	recovery	recovery	NN
cord-324810-92fosk3c	473	11	of	of	IN
cord-324810-92fosk3c	473	12	lung	lung	NN
cord-324810-92fosk3c	473	13	function	function	NN
cord-324810-92fosk3c	473	14	should	should	MD
cord-324810-92fosk3c	473	15	be	be	VB
cord-324810-92fosk3c	473	16	addressed	address	VBN
cord-324810-92fosk3c	473	17	in	in	IN
cord-324810-92fosk3c	473	18	these	these	DT
cord-324810-92fosk3c	473	19	gemifloxacin	gemifloxacin	NNS
cord-324810-92fosk3c	473	20	and	and	CC
cord-324810-92fosk3c	473	21	73.1	73.1	CD
cord-324810-92fosk3c	473	22	%	%	NN
cord-324810-92fosk3c	473	23	for	for	IN
cord-324810-92fosk3c	473	24	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	473	25	.	.	.
cord-324810-92fosk3c	474	1	Significantly	significantly	RB
cord-324810-92fosk3c	474	2	more	more	JJR
cord-324810-92fosk3c	474	3	studies	study	NNS
cord-324810-92fosk3c	474	4	to	to	TO
cord-324810-92fosk3c	474	5	ascertain	ascertain	VB
cord-324810-92fosk3c	474	6	the	the	DT
cord-324810-92fosk3c	474	7	utility	utility	NN
cord-324810-92fosk3c	474	8	of	of	IN
cord-324810-92fosk3c	474	9	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	474	10	therapy	therapy	NN
cord-324810-92fosk3c	474	11	in	in	IN
cord-324810-92fosk3c	474	12	patients	patient	NNS
cord-324810-92fosk3c	474	13	receiving	receive	VBG
cord-324810-92fosk3c	474	14	gemifloxacin	gemifloxacin	NNS
cord-324810-92fosk3c	474	15	than	than	IN
cord-324810-92fosk3c	474	16	clarithromycin	clarithromycin	NNP
cord-324810-92fosk3c	474	17	remained	remain	VBD
cord-324810-92fosk3c	474	18	free	free	JJ
cord-324810-92fosk3c	474	19	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	474	20	.	.	.
cord-324810-92fosk3c	475	1	of	of	IN
cord-324810-92fosk3c	475	2	AECB	AECB	NNP
cord-324810-92fosk3c	475	3	recurrences	recurrence	NNS
cord-324810-92fosk3c	475	4	(	(	-LRB-
cord-324810-92fosk3c	475	5	71.0	71.0	CD
cord-324810-92fosk3c	475	6	%	%	NN
cord-324810-92fosk3c	475	7	vs	vs	IN
cord-324810-92fosk3c	475	8	58.5	58.5	CD
cord-324810-92fosk3c	475	9	%	%	NN
cord-324810-92fosk3c	475	10	,	,	,
cord-324810-92fosk3c	475	11	respectively	respectively	RB
cord-324810-92fosk3c	475	12	;	;	:
cord-324810-92fosk3c	475	13	p	p	NN
cord-324810-92fosk3c	475	14	=	=	SYM
cord-324810-92fosk3c	475	15	0.016	0.016	CD
cord-324810-92fosk3c	475	16	)	)	-RRB-
cord-324810-92fosk3c	475	17	.	.	.
cord-324810-92fosk3c	476	1	[	[	-LRB-
cord-324810-92fosk3c	476	2	128	128	CD
cord-324810-92fosk3c	476	3	]	]	-RRB-
cord-324810-92fosk3c	477	1	The	the	DT
cord-324810-92fosk3c	477	2	greatest	great	JJS
cord-324810-92fosk3c	477	3	improvement	improvement	NN
cord-324810-92fosk3c	477	4	in	in	IN
cord-324810-92fosk3c	477	5	St	St	NNP
cord-324810-92fosk3c	477	6	George	George	NNP
cord-324810-92fosk3c	477	7	's	's	POS
cord-324810-92fosk3c	477	8	Respiratory	Respiratory	NNP
cord-324810-92fosk3c	477	9	A	a	DT
cord-324810-92fosk3c	477	10	study	study	NN
cord-324810-92fosk3c	477	11	of	of	IN
cord-324810-92fosk3c	477	12	infective	infective	JJ
cord-324810-92fosk3c	477	13	and	and	CC
cord-324810-92fosk3c	477	14	other	other	JJ
cord-324810-92fosk3c	477	15	factors	factor	NNS
cord-324810-92fosk3c	477	16	in	in	IN
cord-324810-92fosk3c	477	17	flora	flora	NNS
cord-324810-92fosk3c	477	18	in	in	IN
cord-324810-92fosk3c	477	19	sputum	sputum	NN
cord-324810-92fosk3c	477	20	and	and	CC
cord-324810-92fosk3c	477	21	functional	functional	JJ
cord-324810-92fosk3c	477	22	impairment	impairment	NN
cord-324810-92fosk3c	477	23	in	in	IN
cord-324810-92fosk3c	477	24	patients	patient	NNS
cord-324810-92fosk3c	477	25	with	with	IN
cord-324810-92fosk3c	477	26	acute	acute	JJ
cord-324810-92fosk3c	477	27	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	477	28	of	of	IN
cord-324810-92fosk3c	477	29	COPD	COPD	NNP
cord-324810-92fosk3c	477	30	Airway	Airway	NNP
cord-324810-92fosk3c	477	31	bacterial	bacterial	JJ
cord-324810-92fosk3c	477	32	load	load	NN
cord-324810-92fosk3c	477	33	and	and	CC
cord-324810-92fosk3c	477	34	FEV1	FEV1	NNP
cord-324810-92fosk3c	477	35	decline	decline	NN
cord-324810-92fosk3c	477	36	tions	tion	NNS
cord-324810-92fosk3c	477	37	of	of	IN
cord-324810-92fosk3c	477	38	chronic	chronic	JJ
cord-324810-92fosk3c	477	39	obstructive	obstructive	JJ
cord-324810-92fosk3c	477	40	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	477	41	disease	disease	NN
cord-324810-92fosk3c	477	42	(	(	-LRB-
cord-324810-92fosk3c	477	43	COPD	COPD	NNP
cord-324810-92fosk3c	477	44	)	)	-RRB-
cord-324810-92fosk3c	477	45	requiring	require	VBG
cord-324810-92fosk3c	477	46	mechanical	mechanical	JJ
cord-324810-92fosk3c	477	47	in	in	IN
cord-324810-92fosk3c	477	48	patients	patient	NNS
cord-324810-92fosk3c	477	49	with	with	IN
cord-324810-92fosk3c	477	50	chronic	chronic	JJ
cord-324810-92fosk3c	477	51	obstructive	obstructive	JJ
cord-324810-92fosk3c	477	52	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	477	53	disease	disease	NN
cord-324810-92fosk3c	477	54	.	.	.
cord-324810-92fosk3c	478	1	Am	be	VBP
cord-324810-92fosk3c	478	2	J	J	NNP
cord-324810-92fosk3c	478	3	Respir	Respir	NNP
cord-324810-92fosk3c	478	4	Crit	Crit	NNP
cord-324810-92fosk3c	478	5	Care	Care	NNP
cord-324810-92fosk3c	478	6	ventilation	ventilation	NN
cord-324810-92fosk3c	478	7	colour	colour	NN
cord-324810-92fosk3c	478	8	:	:	:
cord-324810-92fosk3c	478	9	correlation	correlation	NN
cord-324810-92fosk3c	478	10	with	with	IN
cord-324810-92fosk3c	478	11	airways	airway	NNS
cord-324810-92fosk3c	478	12	inflammation	inflammation	NN
cord-324810-92fosk3c	478	13	Bacterial	bacterial	JJ
cord-324810-92fosk3c	478	14	infection	infection	NN
cord-324810-92fosk3c	478	15	in	in	IN
cord-324810-92fosk3c	478	16	chronic	chronic	JJ
cord-324810-92fosk3c	478	17	obstructive	obstructive	JJ
cord-324810-92fosk3c	478	18	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	478	19	disease	disease	NN
cord-324810-92fosk3c	478	20	40	40	CD
cord-324810-92fosk3c	478	21	.	.	.
cord-324810-92fosk3c	479	1	Wedzicha	Wedzicha	NNP
cord-324810-92fosk3c	479	2	JA	JA	NNP
cord-324810-92fosk3c	479	3	.	.	.
cord-324810-92fosk3c	480	1	Airway	airway	JJ
cord-324810-92fosk3c	480	2	infection	infection	NN
cord-324810-92fosk3c	480	3	accelerates	accelerate	VBZ
cord-324810-92fosk3c	480	4	decline	decline	NN
cord-324810-92fosk3c	480	5	of	of	IN
cord-324810-92fosk3c	480	6	lung	lung	NN
cord-324810-92fosk3c	480	7	function	function	NN
cord-324810-92fosk3c	480	8	in	in	IN
cord-324810-92fosk3c	480	9	chronic	chronic	NN
cord-324810-92fosk3c	480	10	in	in	IN
cord-324810-92fosk3c	480	11	200	200	CD
cord-324810-92fosk3c	480	12	:	:	:
cord-324810-92fosk3c	480	13	a	a	DT
cord-324810-92fosk3c	480	14	state	state	NN
cord-324810-92fosk3c	480	15	-	-	HYPH
cord-324810-92fosk3c	480	16	of	of	IN
cord-324810-92fosk3c	480	17	-	-	HYPH
cord-324810-92fosk3c	480	18	the	the	DT
cord-324810-92fosk3c	480	19	-	-	HYPH
cord-324810-92fosk3c	480	20	art	art	NN
cord-324810-92fosk3c	480	21	review	review	NN
cord-324810-92fosk3c	480	22	Viral	viral	JJ
cord-324810-92fosk3c	480	23	infections	infection	NNS
cord-324810-92fosk3c	480	24	in	in	IN
cord-324810-92fosk3c	480	25	obstructive	obstructive	JJ
cord-324810-92fosk3c	480	26	airway	airway	NN
cord-324810-92fosk3c	480	27	diseases	disease	NNS
cord-324810-92fosk3c	480	28	Host	host	NN
cord-324810-92fosk3c	480	29	-	-	HYPH
cord-324810-92fosk3c	480	30	microbial	microbial	JJ
cord-324810-92fosk3c	480	31	interrelationships	interrelationship	NNS
cord-324810-92fosk3c	480	32	in	in	IN
cord-324810-92fosk3c	480	33	respiratory	respiratory	JJ
cord-324810-92fosk3c	480	34	infection	infection	NN
cord-324810-92fosk3c	480	35	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	480	36	infections	infection	NNS
cord-324810-92fosk3c	480	37	with	with	IN
cord-324810-92fosk3c	480	38	acute	acute	JJ
cord-324810-92fosk3c	480	39	respiratory	respiratory	JJ
cord-324810-92fosk3c	480	40	illness	illness	NN
cord-324810-92fosk3c	480	41	in	in	IN
cord-324810-92fosk3c	480	42	patients	patient	NNS
cord-324810-92fosk3c	480	43	with	with	IN
cord-324810-92fosk3c	480	44	chronic	chronic	JJ
cord-324810-92fosk3c	480	45	42	42	CD
cord-324810-92fosk3c	480	46	.	.	.
cord-324810-92fosk3c	481	1	Wilson	Wilson	NNP
cord-324810-92fosk3c	481	2	R.	R.	NNP
cord-324810-92fosk3c	481	3	Outcome	Outcome	NNP
cord-324810-92fosk3c	481	4	predictors	predictor	NNS
cord-324810-92fosk3c	481	5	in	in	IN
cord-324810-92fosk3c	481	6	bronchitis	bronchitis	NN
cord-324810-92fosk3c	481	7	Chronic	Chronic	NNP
cord-324810-92fosk3c	481	8	bronchitis	bronchitis	NN
cord-324810-92fosk3c	481	9	Characterization	characterization	NN
cord-324810-92fosk3c	481	10	of	of	IN
cord-324810-92fosk3c	481	11	distal	distal	JJ
cord-324810-92fosk3c	481	12	bronchial	bronchial	JJ
cord-324810-92fosk3c	481	13	44	44	CD
cord-324810-92fosk3c	481	14	.	.	.
cord-324810-92fosk3c	482	1	Howard	Howard	NNP
cord-324810-92fosk3c	482	2	P.	P.	NNP
cord-324810-92fosk3c	483	1	A	a	DT
cord-324810-92fosk3c	483	2	long	long	JJ
cord-324810-92fosk3c	483	3	-	-	HYPH
cord-324810-92fosk3c	483	4	term	term	NN
cord-324810-92fosk3c	483	5	follow	follow	NN
cord-324810-92fosk3c	483	6	-	-	HYPH
cord-324810-92fosk3c	483	7	up	up	NN
cord-324810-92fosk3c	483	8	of	of	IN
cord-324810-92fosk3c	483	9	respiratory	respiratory	JJ
cord-324810-92fosk3c	483	10	symptoms	symptom	NNS
cord-324810-92fosk3c	483	11	and	and	CC
cord-324810-92fosk3c	483	12	ventilatory	ventilatory	JJ
cord-324810-92fosk3c	483	13	funcmicroflora	funcmicroflora	NN
cord-324810-92fosk3c	483	14	during	during	IN
cord-324810-92fosk3c	483	15	acute	acute	JJ
cord-324810-92fosk3c	483	16	exacerbation	exacerbation	NN
cord-324810-92fosk3c	483	17	of	of	IN
cord-324810-92fosk3c	483	18	chronic	chronic	JJ
cord-324810-92fosk3c	483	19	bronchitis	bronchitis	NN
cord-324810-92fosk3c	483	20	.	.	.
cord-324810-92fosk3c	484	1	Am	be	VBP
cord-324810-92fosk3c	484	2	Rev	Rev	NNP
cord-324810-92fosk3c	484	3	Respir	Respir	NNP
cord-324810-92fosk3c	484	4	Dis	Dis	NNP
cord-324810-92fosk3c	484	5	tion	tion	NN
cord-324810-92fosk3c	484	6	in	in	IN
cord-324810-92fosk3c	484	7	a	a	DT
cord-324810-92fosk3c	484	8	group	group	NN
cord-324810-92fosk3c	484	9	of	of	IN
cord-324810-92fosk3c	484	10	working	work	VBG
cord-324810-92fosk3c	484	11	men	man	NNS
cord-324810-92fosk3c	485	1	The	the	DT
cord-324810-92fosk3c	485	2	fate	fate	NN
cord-324810-92fosk3c	485	3	of	of	IN
cord-324810-92fosk3c	485	4	the	the	DT
cord-324810-92fosk3c	485	5	chronic	chronic	JJ
cord-324810-92fosk3c	485	6	bronchitis	bronchitis	NN
cord-324810-92fosk3c	485	7	:	:	:
cord-324810-92fosk3c	485	8	a	a	DT
cord-324810-92fosk3c	485	9	report	report	NN
cord-324810-92fosk3c	485	10	of	of	IN
cord-324810-92fosk3c	485	11	the	the	DT
cord-324810-92fosk3c	485	12	10-year	10-year	CD
cord-324810-92fosk3c	485	13	follow	follow	NN
cord-324810-92fosk3c	485	14	-	-	HYPH
cord-324810-92fosk3c	485	15	up	up	NN
cord-324810-92fosk3c	485	16	in	in	IN
cord-324810-92fosk3c	485	17	Bacterial	bacterial	JJ
cord-324810-92fosk3c	485	18	infection	infection	NN
cord-324810-92fosk3c	485	19	in	in	IN
cord-324810-92fosk3c	485	20	chronic	chronic	JJ
cord-324810-92fosk3c	485	21	obstructive	obstructive	JJ
cord-324810-92fosk3c	485	22	the	the	DT
cord-324810-92fosk3c	485	23	Canadian	Canadian	NNP
cord-324810-92fosk3c	485	24	Department	Department	NNP
cord-324810-92fosk3c	485	25	of	of	IN
cord-324810-92fosk3c	485	26	Veterans	Veterans	NNP
cord-324810-92fosk3c	485	27	Affairs	Affairs	NNP
cord-324810-92fosk3c	485	28	coordinated	coordinate	VBD
cord-324810-92fosk3c	485	29	study	study	NN
cord-324810-92fosk3c	485	30	of	of	IN
cord-324810-92fosk3c	485	31	chronic	chronic	JJ
cord-324810-92fosk3c	485	32	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	485	33	disease	disease	NN
cord-324810-92fosk3c	485	34	:	:	:
cord-324810-92fosk3c	485	35	a	a	DT
cord-324810-92fosk3c	485	36	study	study	NN
cord-324810-92fosk3c	485	37	of	of	IN
cord-324810-92fosk3c	485	38	stable	stable	JJ
cord-324810-92fosk3c	485	39	and	and	CC
cord-324810-92fosk3c	485	40	exacerbated	exacerbated	JJ
cord-324810-92fosk3c	485	41	outpatients	outpatient	NNS
cord-324810-92fosk3c	485	42	using	use	VBG
cord-324810-92fosk3c	485	43	the	the	DT
cord-324810-92fosk3c	485	44	bronchitis	bronchitis	NN
cord-324810-92fosk3c	485	45	Effects	effect	NNS
cord-324810-92fosk3c	485	46	of	of	IN
cord-324810-92fosk3c	485	47	smoking	smoking	NN
cord-324810-92fosk3c	485	48	intervention	intervention	NN
cord-324810-92fosk3c	485	49	and	and	CC
cord-324810-92fosk3c	485	50	the	the	DT
cord-324810-92fosk3c	485	51	Infective	Infective	NNP
cord-324810-92fosk3c	485	52	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	485	53	of	of	IN
cord-324810-92fosk3c	485	54	chronic	chronic	JJ
cord-324810-92fosk3c	485	55	bronchitis	bronchitis	NN
cord-324810-92fosk3c	485	56	:	:	:
cord-324810-92fosk3c	485	57	use	use	NN
cord-324810-92fosk3c	485	58	of	of	IN
cord-324810-92fosk3c	485	59	an	an	DT
cord-324810-92fosk3c	485	60	inhaled	inhale	VBN
cord-324810-92fosk3c	485	61	anticholinergic	anticholinergic	JJ
cord-324810-92fosk3c	485	62	bronchodilator	bronchodilator	NN
cord-324810-92fosk3c	485	63	on	on	IN
cord-324810-92fosk3c	485	64	the	the	DT
cord-324810-92fosk3c	485	65	rate	rate	NN
cord-324810-92fosk3c	485	66	of	of	IN
cord-324810-92fosk3c	485	67	decline	decline	NN
cord-324810-92fosk3c	485	68	of	of	IN
cord-324810-92fosk3c	485	69	FEV1	FEV1	NNP
cord-324810-92fosk3c	485	70	.	.	.
cord-324810-92fosk3c	486	1	relation	relation	NN
cord-324810-92fosk3c	486	2	between	between	IN
cord-324810-92fosk3c	486	3	bacteriologic	bacteriologic	NNP
cord-324810-92fosk3c	486	4	etiology	etiology	NN
cord-324810-92fosk3c	486	5	and	and	CC
cord-324810-92fosk3c	486	6	lung	lung	NN
cord-324810-92fosk3c	486	7	function	function	NN
cord-324810-92fosk3c	486	8	Lower	low	JJR
cord-324810-92fosk3c	486	9	respiratory	respiratory	JJ
cord-324810-92fosk3c	486	10	illnesses	illness	NNS
cord-324810-92fosk3c	486	11	promote	promote	VBP
cord-324810-92fosk3c	486	12	FEV1	FEV1	NNP
cord-324810-92fosk3c	486	13	decline	decline	NN
cord-324810-92fosk3c	486	14	in	in	IN
cord-324810-92fosk3c	486	15	current	current	JJ
cord-324810-92fosk3c	486	16	smokers	smoker	NNS
cord-324810-92fosk3c	486	17	but	but	CC
cord-324810-92fosk3c	486	18	not	not	RB
cord-324810-92fosk3c	486	19	in	in	IN
cord-324810-92fosk3c	486	20	ex	ex	NNS
cord-324810-92fosk3c	486	21	-	-	NNS
cord-324810-92fosk3c	486	22	smokers	smoker	NNS
cord-324810-92fosk3c	486	23	with	with	IN
cord-324810-92fosk3c	486	24	mild	mild	JJ
cord-324810-92fosk3c	486	25	chronic	chronic	JJ
cord-324810-92fosk3c	486	26	and	and	CC
cord-324810-92fosk3c	486	27	inflammatory	inflammatory	JJ
cord-324810-92fosk3c	486	28	markers	marker	NNS
cord-324810-92fosk3c	486	29	in	in	IN
cord-324810-92fosk3c	486	30	acute	acute	JJ
cord-324810-92fosk3c	486	31	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	486	32	and	and	CC
cord-324810-92fosk3c	486	33	stable	stable	JJ
cord-324810-92fosk3c	486	34	chronic	chronic	JJ
cord-324810-92fosk3c	486	35	obstructive	obstructive	JJ
cord-324810-92fosk3c	486	36	48	48	CD
cord-324810-92fosk3c	486	37	Respiratory	respiratory	JJ
cord-324810-92fosk3c	486	38	viruses	virus	NNS
cord-324810-92fosk3c	486	39	in	in	IN
cord-324810-92fosk3c	486	40	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	486	41	of	of	IN
cord-324810-92fosk3c	486	42	chronic	chronic	JJ
cord-324810-92fosk3c	486	43	status	status	NN
cord-324810-92fosk3c	486	44	following	follow	VBG
cord-324810-92fosk3c	486	45	an	an	DT
cord-324810-92fosk3c	486	46	ineffective	ineffective	JJ
cord-324810-92fosk3c	486	47	exacerbation	exacerbation	NN
cord-324810-92fosk3c	486	48	of	of	IN
cord-324810-92fosk3c	486	49	chronic	chronic	JJ
cord-324810-92fosk3c	486	50	bronchitis	bronchitis	NN
cord-324810-92fosk3c	487	1	Do	do	VBP
cord-324810-92fosk3c	487	2	bacteria	bacteria	NNS
cord-324810-92fosk3c	487	3	cause	cause	VB
cord-324810-92fosk3c	487	4	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	487	5	of	of	IN
cord-324810-92fosk3c	487	6	COPD	COPD	NNP
cord-324810-92fosk3c	487	7	?	?	.
cord-324810-92fosk3c	488	1	Survival	survival	NN
cord-324810-92fosk3c	488	2	of	of	IN
cord-324810-92fosk3c	488	3	acute	acute	JJ
cord-324810-92fosk3c	488	4	respiratory	respiratory	JJ
cord-324810-92fosk3c	488	5	failure	failure	NN
cord-324810-92fosk3c	488	6	:	:	:
cord-324810-92fosk3c	488	7	a	a	DT
cord-324810-92fosk3c	488	8	study	study	NN
cord-324810-92fosk3c	488	9	of	of	IN
cord-324810-92fosk3c	488	10	239	239	CD
cord-324810-92fosk3c	488	11	Role	role	NN
cord-324810-92fosk3c	488	12	of	of	IN
cord-324810-92fosk3c	488	13	infection	infection	NN
cord-324810-92fosk3c	488	14	in	in	IN
cord-324810-92fosk3c	488	15	chronic	chronic	JJ
cord-324810-92fosk3c	488	16	bronchitis	bronchitis	NN
cord-324810-92fosk3c	488	17	Outcomes	outcome	NNS
cord-324810-92fosk3c	488	18	following	follow	VBG
cord-324810-92fosk3c	488	19	acute	acute	JJ
cord-324810-92fosk3c	488	20	exacerba	exacerba	NN
cord-324810-92fosk3c	488	21	State	State	NNP
cord-324810-92fosk3c	488	22	of	of	IN
cord-324810-92fosk3c	488	23	the	the	DT
cord-324810-92fosk3c	488	24	art	art	NN
cord-324810-92fosk3c	488	25	;	;	,
cord-324810-92fosk3c	488	26	bacterial	bacterial	JJ
cord-324810-92fosk3c	488	27	infection	infection	NN
cord-324810-92fosk3c	488	28	in	in	IN
cord-324810-92fosk3c	488	29	chronic	chronic	JJ
cord-324810-92fosk3c	488	30	obstructive	obstructive	JJ
cord-324810-92fosk3c	488	31	lung	lung	NN
cord-324810-92fosk3c	488	32	tion	tion	NN
cord-324810-92fosk3c	488	33	of	of	IN
cord-324810-92fosk3c	488	34	severe	severe	JJ
cord-324810-92fosk3c	488	35	chronic	chronic	JJ
cord-324810-92fosk3c	488	36	obstructive	obstructive	JJ
cord-324810-92fosk3c	488	37	lung	lung	NN
cord-324810-92fosk3c	488	38	disease	disease	NN
cord-324810-92fosk3c	488	39	.	.	.
cord-324810-92fosk3c	489	1	Am	be	VBP
cord-324810-92fosk3c	489	2	J	J	NNP
cord-324810-92fosk3c	489	3	Respir	Respir	NNP
cord-324810-92fosk3c	489	4	Crit	Crit	NNP
cord-324810-92fosk3c	489	5	Care	Care	NNP
cord-324810-92fosk3c	489	6	Med	Med	NNP
cord-324810-92fosk3c	489	7	disease	disease	NN
cord-324810-92fosk3c	489	8	Acute	acute	JJ
cord-324810-92fosk3c	489	9	infective	infective	JJ
cord-324810-92fosk3c	489	10	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	489	11	of	of	IN
cord-324810-92fosk3c	489	12	chronic	chronic	JJ
cord-324810-92fosk3c	489	13	tion	tion	NN
cord-324810-92fosk3c	489	14	and	and	CC
cord-324810-92fosk3c	489	15	the	the	DT
cord-324810-92fosk3c	489	16	frequency	frequency	NN
cord-324810-92fosk3c	489	17	,	,	,
cord-324810-92fosk3c	489	18	character	character	NN
cord-324810-92fosk3c	489	19	,	,	,
cord-324810-92fosk3c	489	20	and	and	CC
cord-324810-92fosk3c	489	21	severity	severity	NN
cord-324810-92fosk3c	489	22	of	of	IN
cord-324810-92fosk3c	489	23	COPD	COPD	NNP
cord-324810-92fosk3c	489	24	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	489	25	.	.	.
cord-324810-92fosk3c	490	1	Thorax	Thorax	NNP
cord-324810-92fosk3c	490	2	bronchitis	bronchitis	NN
cord-324810-92fosk3c	491	1	Acute	acute	JJ
cord-324810-92fosk3c	491	2	exacerbation	exacerbation	NN
cord-324810-92fosk3c	491	3	of	of	IN
cord-324810-92fosk3c	491	4	COPD	COPD	NNP
cord-324810-92fosk3c	491	5	:	:	:
cord-324810-92fosk3c	492	1	factors	factor	NNS
cord-324810-92fosk3c	492	2	Clinical	clinical	JJ
cord-324810-92fosk3c	492	3	audit	audit	NN
cord-324810-92fosk3c	492	4	indicators	indicator	NNS
cord-324810-92fosk3c	492	5	of	of	IN
cord-324810-92fosk3c	492	6	outcome	outcome	NN
cord-324810-92fosk3c	493	1	238	238	CD
cord-324810-92fosk3c	493	2	-	-	SYM
cord-324810-92fosk3c	493	3	44	44	CD
cord-324810-92fosk3c	494	1	following	follow	VBG
cord-324810-92fosk3c	494	2	admission	admission	NN
cord-324810-92fosk3c	494	3	to	to	IN
cord-324810-92fosk3c	494	4	hospital	hospital	NN
cord-324810-92fosk3c	494	5	with	with	IN
cord-324810-92fosk3c	494	6	acute	acute	JJ
cord-324810-92fosk3c	494	7	exacerbation	exacerbation	NN
cord-324810-92fosk3c	494	8	of	of	IN
cord-324810-92fosk3c	494	9	chronic	chronic	JJ
cord-324810-92fosk3c	494	10	obstructive	obstructive	JJ
cord-324810-92fosk3c	494	11	Strain	strain	NN
cord-324810-92fosk3c	494	12	-	-	HYPH
cord-324810-92fosk3c	494	13	specific	specific	JJ
cord-324810-92fosk3c	494	14	and	and	CC
cord-324810-92fosk3c	494	15	immunodominant	immunodominant	JJ
cord-324810-92fosk3c	494	16	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	494	17	disease	disease	NN
cord-324810-92fosk3c	494	18	Survival	Survival	NNP
cord-324810-92fosk3c	494	19	of	of	IN
cord-324810-92fosk3c	494	20	patients	patient	NNS
cord-324810-92fosk3c	494	21	with	with	IN
cord-324810-92fosk3c	494	22	chronic	chronic	JJ
cord-324810-92fosk3c	494	23	obstructive	obstructive	JJ
cord-324810-92fosk3c	494	24	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	494	25	disease	disease	NN
cord-324810-92fosk3c	494	26	receiving	receive	VBG
cord-324810-92fosk3c	494	27	fluenzae	fluenzae	NN
cord-324810-92fosk3c	494	28	Acute	acute	JJ
cord-324810-92fosk3c	494	29	respiratory	respiratory	JJ
cord-324810-92fosk3c	494	30	failure	failure	NN
cord-324810-92fosk3c	494	31	of	of	IN
cord-324810-92fosk3c	494	32	chronic	chronic	JJ
cord-324810-92fosk3c	494	33	obstructive	obstructive	JJ
cord-324810-92fosk3c	494	34	Rev	Rev	NNP
cord-324810-92fosk3c	494	35	Respir	Respir	NNP
cord-324810-92fosk3c	494	36	Dis	Dis	NNP
cord-324810-92fosk3c	494	37	Costs	Costs	NNPS
cord-324810-92fosk3c	494	38	of	of	IN
cord-324810-92fosk3c	494	39	COPD	COPD	NNP
cord-324810-92fosk3c	494	40	in	in	IN
cord-324810-92fosk3c	494	41	Sweden	Sweden	NNP
cord-324810-92fosk3c	494	42	according	accord	VBG
cord-324810-92fosk3c	494	43	to	to	IN
cord-324810-92fosk3c	494	44	markers	marker	NNS
cord-324810-92fosk3c	494	45	of	of	IN
cord-324810-92fosk3c	494	46	airway	airway	JJ
cord-324810-92fosk3c	494	47	inflammation	inflammation	NN
cord-324810-92fosk3c	494	48	in	in	IN
cord-324810-92fosk3c	494	49	patients	patient	NNS
cord-324810-92fosk3c	494	50	with	with	IN
cord-324810-92fosk3c	494	51	stable	stable	JJ
cord-324810-92fosk3c	494	52	chronic	chronic	JJ
cord-324810-92fosk3c	494	53	bronchitis	bronchitis	NN
cord-324810-92fosk3c	494	54	Pharmacoeconomic	Pharmacoeconomic	NNP
cord-324810-92fosk3c	494	55	evaluation	evaluation	NN
cord-324810-92fosk3c	494	56	of	of	IN
cord-324810-92fosk3c	494	57	Role	role	NN
cord-324810-92fosk3c	494	58	of	of	IN
cord-324810-92fosk3c	494	59	bacteria	bacteria	NNS
cord-324810-92fosk3c	494	60	in	in	IN
cord-324810-92fosk3c	494	61	the	the	DT
cord-324810-92fosk3c	494	62	pathogenesis	pathogenesis	NN
cord-324810-92fosk3c	494	63	and	and	CC
cord-324810-92fosk3c	494	64	progression	progression	NN
cord-324810-92fosk3c	494	65	of	of	IN
cord-324810-92fosk3c	494	66	acute	acute	JJ
cord-324810-92fosk3c	494	67	and	and	CC
cord-324810-92fosk3c	494	68	COPD	COPD	NNP
cord-324810-92fosk3c	494	69	Severe	severe	JJ
cord-324810-92fosk3c	494	70	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	494	71	of	of	IN
cord-324810-92fosk3c	494	72	chronic	chronic	JJ
cord-324810-92fosk3c	494	73	Relationship	relationship	NN
cord-324810-92fosk3c	494	74	of	of	IN
cord-324810-92fosk3c	494	75	sputum	sputum	NN
cord-324810-92fosk3c	494	76	color	color	NN
cord-324810-92fosk3c	494	77	to	to	IN
cord-324810-92fosk3c	494	78	nature	nature	NN
cord-324810-92fosk3c	494	79	and	and	CC
cord-324810-92fosk3c	494	80	obstructive	obstructive	JJ
cord-324810-92fosk3c	494	81	airways	airways	NNP
cord-324810-92fosk3c	494	82	disease	disease	NN
cord-324810-92fosk3c	494	83	:	:	:
cord-324810-92fosk3c	494	84	health	health	NN
cord-324810-92fosk3c	494	85	resource	resource	NN
cord-324810-92fosk3c	494	86	use	use	NN
cord-324810-92fosk3c	494	87	in	in	IN
cord-324810-92fosk3c	494	88	general	general	JJ
cord-324810-92fosk3c	494	89	practice	practice	NN
cord-324810-92fosk3c	494	90	and	and	CC
cord-324810-92fosk3c	494	91	hospioutpatient	hospioutpatient	NN
cord-324810-92fosk3c	494	92	management	management	NN
cord-324810-92fosk3c	494	93	of	of	IN
cord-324810-92fosk3c	494	94	acute	acute	JJ
cord-324810-92fosk3c	494	95	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	494	96	of	of	IN
cord-324810-92fosk3c	494	97	COPD	COPD	NNP
cord-324810-92fosk3c	494	98	Pharmacoeconomic	Pharmacoeconomic	NNP
cord-324810-92fosk3c	494	99	evaluation	evaluation	NN
cord-324810-92fosk3c	494	100	of	of	IN
cord-324810-92fosk3c	494	101	acute	acute	JJ
cord-324810-92fosk3c	494	102	New	new	JJ
cord-324810-92fosk3c	494	103	strains	strain	NNS
cord-324810-92fosk3c	494	104	of	of	IN
cord-324810-92fosk3c	494	105	bacteria	bacteria	NNS
cord-324810-92fosk3c	494	106	and	and	CC
cord-324810-92fosk3c	494	107	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	494	108	of	of	IN
cord-324810-92fosk3c	494	109	exacerbation	exacerbation	NN
cord-324810-92fosk3c	494	110	of	of	IN
cord-324810-92fosk3c	494	111	chronic	chronic	JJ
cord-324810-92fosk3c	494	112	bronchitis	bronchitis	NN
cord-324810-92fosk3c	495	1	The	the	DT
cord-324810-92fosk3c	495	2	economic	economic	JJ
cord-324810-92fosk3c	495	3	burden	burden	NN
cord-324810-92fosk3c	495	4	of	of	IN
cord-324810-92fosk3c	495	5	COPD	COPD	NNP
cord-324810-92fosk3c	495	6	Infectious	infectious	JJ
cord-324810-92fosk3c	495	7	etiology	etiology	NN
cord-324810-92fosk3c	495	8	of	of	IN
cord-324810-92fosk3c	495	9	acute	acute	JJ
cord-324810-92fosk3c	495	10	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	495	11	of	of	IN
cord-324810-92fosk3c	495	12	chronic	chronic	JJ
cord-324810-92fosk3c	495	13	bronchitis	bronchitis	NN
cord-324810-92fosk3c	495	14	Antibiotics	antibiotic	NNS
cord-324810-92fosk3c	495	15	in	in	IN
cord-324810-92fosk3c	495	16	chronic	chronic	JJ
cord-324810-92fosk3c	495	17	obstructive	obstructive	JJ
cord-324810-92fosk3c	495	18	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	495	19	medical	medical	JJ
cord-324810-92fosk3c	495	20	costs	cost	NNS
cord-324810-92fosk3c	495	21	of	of	IN
cord-324810-92fosk3c	495	22	asthma	asthma	NN
cord-324810-92fosk3c	495	23	and	and	CC
cord-324810-92fosk3c	495	24	chronic	chronic	JJ
cord-324810-92fosk3c	495	25	obstructive	obstructive	JJ
cord-324810-92fosk3c	495	26	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	495	27	disease	disease	NN
cord-324810-92fosk3c	495	28	in	in	IN
cord-324810-92fosk3c	495	29	the	the	DT
cord-324810-92fosk3c	495	30	disease	disease	NN
cord-324810-92fosk3c	495	31	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	495	32	:	:	:
cord-324810-92fosk3c	495	33	a	a	DT
cord-324810-92fosk3c	495	34	meta	meta	JJ
cord-324810-92fosk3c	495	35	-	-	HYPH
cord-324810-92fosk3c	495	36	analysis	analysis	NN
cord-324810-92fosk3c	496	1	The	the	DT
cord-324810-92fosk3c	496	2	excess	excess	NN
cord-324810-92fosk3c	496	3	of	of	IN
cord-324810-92fosk3c	496	4	acute	acute	JJ
cord-324810-92fosk3c	496	5	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	496	6	of	of	IN
cord-324810-92fosk3c	496	7	chronic	chronic	JJ
cord-324810-92fosk3c	496	8	chronic	chronic	JJ
cord-324810-92fosk3c	496	9	bronchitis	bronchitis	NN
cord-324810-92fosk3c	496	10	Infections	Infections	NNPS
cord-324810-92fosk3c	496	11	respiratories	respiratorie	NNS
cord-324810-92fosk3c	496	12	récidivantes	récidivante	NNS
cord-324810-92fosk3c	496	13	du	du	NNP
cord-324810-92fosk3c	496	14	sujet	sujet	NNP
cord-324810-92fosk3c	497	1	1190	1190	CD
cord-324810-92fosk3c	497	2	-	-	SYM
cord-324810-92fosk3c	497	3	209	209	CD
cord-324810-92fosk3c	497	4	atteint	atteint	NNP
cord-324810-92fosk3c	497	5	de	de	NNP
cord-324810-92fosk3c	497	6	bronchite	bronchite	NNP
cord-324810-92fosk3c	497	7	chronique	chronique	NNP
cord-324810-92fosk3c	497	8	obstructive	obstructive	NNP
cord-324810-92fosk3c	498	1	:	:	:
cord-324810-92fosk3c	498	2	prise	prise	NNP
cord-324810-92fosk3c	498	3	en	en	NNP
cord-324810-92fosk3c	498	4	charge	charge	NNP
cord-324810-92fosk3c	498	5	médicale	médicale	NNP
cord-324810-92fosk3c	498	6	et	et	NNP
cord-324810-92fosk3c	498	7	coüts	coüts	NNP
cord-324810-92fosk3c	499	1	(	(	-LRB-
cord-324810-92fosk3c	499	2	Recurrent	recurrent	JJ
cord-324810-92fosk3c	499	3	respiratory	respiratory	JJ
cord-324810-92fosk3c	499	4	infections	infection	NNS
cord-324810-92fosk3c	499	5	in	in	IN
cord-324810-92fosk3c	499	6	patients	patient	NNS
cord-324810-92fosk3c	499	7	with	with	IN
cord-324810-92fosk3c	499	8	chronic	chronic	JJ
cord-324810-92fosk3c	499	9	obstructive	obstructive	JJ
cord-324810-92fosk3c	499	10	bronchitis	bronchitis	NN
cord-324810-92fosk3c	499	11	:	:	:
cord-324810-92fosk3c	499	12	86	86	CD
cord-324810-92fosk3c	499	13	Streptococcus	streptococcus	NN
cord-324810-92fosk3c	499	14	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	499	15	in	in	IN
cord-324810-92fosk3c	499	16	the	the	DT
cord-324810-92fosk3c	499	17	United	United	NNP
cord-324810-92fosk3c	499	18	States	States	NNP
cord-324810-92fosk3c	499	19	,	,	,
cord-324810-92fosk3c	499	20	1997	1997	CD
cord-324810-92fosk3c	499	21	-	-	SYM
cord-324810-92fosk3c	499	22	8	8	CD
cord-324810-92fosk3c	500	1	The	the	DT
cord-324810-92fosk3c	500	2	costs	cost	NNS
cord-324810-92fosk3c	500	3	of	of	IN
cord-324810-92fosk3c	500	4	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	500	5	in	in	IN
cord-324810-92fosk3c	500	6	chronic	chronic	JJ
cord-324810-92fosk3c	500	7	Prevalence	prevalence	NN
cord-324810-92fosk3c	500	8	of	of	IN
cord-324810-92fosk3c	500	9	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	500	10	resistance	resistance	NN
cord-324810-92fosk3c	500	11	obstructive	obstructive	JJ
cord-324810-92fosk3c	500	12	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	500	13	disease	disease	NN
cord-324810-92fosk3c	500	14	(	(	-LRB-
cord-324810-92fosk3c	500	15	COPD	COPD	NNP
cord-324810-92fosk3c	500	16	)	)	-RRB-
cord-324810-92fosk3c	500	17	Clinical	clinical	JJ
cord-324810-92fosk3c	500	18	and	and	CC
cord-324810-92fosk3c	500	19	economic	economic	JJ
cord-324810-92fosk3c	500	20	considera	considera	NNP
cord-324810-92fosk3c	500	21	-	-	NNP
cord-324810-92fosk3c	500	22	America	America	NNP
cord-324810-92fosk3c	500	23	:	:	:
cord-324810-92fosk3c	501	1	1997	1997	CD
cord-324810-92fosk3c	501	2	results	result	NNS
cord-324810-92fosk3c	501	3	from	from	IN
cord-324810-92fosk3c	501	4	SENTRY	SENTRY	NNP
cord-324810-92fosk3c	501	5	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	501	6	surveillance	surveillance	NN
cord-324810-92fosk3c	501	7	program	program	NN
cord-324810-92fosk3c	501	8	.	.	.
cord-324810-92fosk3c	502	1	Clin	Clin	NNP
cord-324810-92fosk3c	502	2	tions	tion	NNS
cord-324810-92fosk3c	502	3	in	in	IN
cord-324810-92fosk3c	502	4	acute	acute	JJ
cord-324810-92fosk3c	502	5	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	502	6	of	of	IN
cord-324810-92fosk3c	502	7	chronic	chronic	JJ
cord-324810-92fosk3c	502	8	bronchitis	bronchitis	NN
cord-324810-92fosk3c	502	9	Antimicrobial	Antimicrobial	NNP
cord-324810-92fosk3c	502	10	resistance	resistance	NN
cord-324810-92fosk3c	502	11	among	among	IN
cord-324810-92fosk3c	502	12	Economic	economic	JJ
cord-324810-92fosk3c	502	13	evaluation	evaluation	NN
cord-324810-92fosk3c	502	14	of	of	IN
cord-324810-92fosk3c	502	15	ciprofloxacin	ciprofloxacin	NN
cord-324810-92fosk3c	502	16	clinical	clinical	JJ
cord-324810-92fosk3c	502	17	isolates	isolate	NNS
cord-324810-92fosk3c	502	18	of	of	IN
cord-324810-92fosk3c	502	19	Streptococcus	streptococcus	NN
cord-324810-92fosk3c	502	20	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	502	21	in	in	IN
cord-324810-92fosk3c	502	22	the	the	DT
cord-324810-92fosk3c	502	23	United	United	NNP
cord-324810-92fosk3c	502	24	States	States	NNP
cord-324810-92fosk3c	502	25	during	during	IN
cord-324810-92fosk3c	502	26	compared	compare	VBN
cord-324810-92fosk3c	502	27	with	with	IN
cord-324810-92fosk3c	502	28	usual	usual	JJ
cord-324810-92fosk3c	502	29	antibacterial	antibacterial	JJ
cord-324810-92fosk3c	502	30	care	care	NN
cord-324810-92fosk3c	502	31	for	for	IN
cord-324810-92fosk3c	502	32	the	the	DT
cord-324810-92fosk3c	502	33	treatment	treatment	NN
cord-324810-92fosk3c	502	34	of	of	IN
cord-324810-92fosk3c	502	35	acute	acute	JJ
cord-324810-92fosk3c	502	36	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	502	37	1999	1999	CD
cord-324810-92fosk3c	502	38	-	-	SYM
cord-324810-92fosk3c	502	39	2000	2000	CD
cord-324810-92fosk3c	502	40	,	,	,
cord-324810-92fosk3c	502	41	including	include	VBG
cord-324810-92fosk3c	502	42	a	a	DT
cord-324810-92fosk3c	502	43	comparison	comparison	NN
cord-324810-92fosk3c	502	44	of	of	IN
cord-324810-92fosk3c	502	45	resistance	resistance	NN
cord-324810-92fosk3c	502	46	rates	rate	NNS
cord-324810-92fosk3c	502	47	since	since	IN
cord-324810-92fosk3c	502	48	1994	1994	CD
cord-324810-92fosk3c	502	49	-	-	SYM
cord-324810-92fosk3c	502	50	1995	1995	CD
cord-324810-92fosk3c	502	51	.	.	.
cord-324810-92fosk3c	503	1	Anof	anof	JJ
cord-324810-92fosk3c	503	2	chronic	chronic	JJ
cord-324810-92fosk3c	503	3	bronchitis	bronchitis	NN
cord-324810-92fosk3c	503	4	in	in	IN
cord-324810-92fosk3c	503	5	patients	patient	NNS
cord-324810-92fosk3c	503	6	followed	follow	VBD
cord-324810-92fosk3c	503	7	for	for	IN
cord-324810-92fosk3c	503	8	1	1	CD
cord-324810-92fosk3c	503	9	year	year	NN
cord-324810-92fosk3c	503	10	Comparison	comparison	NN
cord-324810-92fosk3c	503	11	of	of	IN
cord-324810-92fosk3c	503	12	Streptococcus	Streptococcus	NNP
cord-324810-92fosk3c	503	13	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	503	14	Pharmacoeconomic	Pharmacoeconomic	NNP
cord-324810-92fosk3c	503	15	analysis	analysis	NN
cord-324810-92fosk3c	503	16	of	of	IN
cord-324810-92fosk3c	503	17	selected	select	VBN
cord-324810-92fosk3c	503	18	and	and	CC
cord-324810-92fosk3c	503	19	Haemophilus	haemophilus	JJ
cord-324810-92fosk3c	503	20	influenzae	influenzae	NN
cord-324810-92fosk3c	503	21	susceptibilities	susceptibility	NNS
cord-324810-92fosk3c	503	22	from	from	IN
cord-324810-92fosk3c	503	23	community	community	NN
cord-324810-92fosk3c	503	24	-	-	HYPH
cord-324810-92fosk3c	503	25	acquired	acquire	VBN
cord-324810-92fosk3c	503	26	respiraantibiotics	respiraantibiotic	NNS
cord-324810-92fosk3c	503	27	in	in	IN
cord-324810-92fosk3c	503	28	lower	low	JJR
cord-324810-92fosk3c	503	29	respiratory	respiratory	JJ
cord-324810-92fosk3c	503	30	tract	tract	NN
cord-324810-92fosk3c	503	31	infection	infection	NN
cord-324810-92fosk3c	503	32	Economic	economic	JJ
cord-324810-92fosk3c	503	33	evaluation	evaluation	NN
cord-324810-92fosk3c	503	34	of	of	IN
cord-324810-92fosk3c	503	35	alternative	alternative	JJ
cord-324810-92fosk3c	503	36	antibi	antibi	NNP
cord-324810-92fosk3c	503	37	-	-	HYPH
cord-324810-92fosk3c	503	38	Dis	Dis	NNP
cord-324810-92fosk3c	503	39	otic	otic	JJ
cord-324810-92fosk3c	503	40	regimens	regimen	NNS
cord-324810-92fosk3c	503	41	in	in	IN
cord-324810-92fosk3c	503	42	the	the	DT
cord-324810-92fosk3c	503	43	management	management	NN
cord-324810-92fosk3c	503	44	of	of	IN
cord-324810-92fosk3c	503	45	acute	acute	JJ
cord-324810-92fosk3c	503	46	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	503	47	of	of	IN
cord-324810-92fosk3c	503	48	chronic	chronic	JJ
cord-324810-92fosk3c	503	49	bronchitis	bronchitis	NN
cord-324810-92fosk3c	503	50	Streptococcus	streptococcus	NN
cord-324810-92fosk3c	503	51	pneumoniae	pneumoniae	NN
cord-324810-92fosk3c	503	52	,	,	,
cord-324810-92fosk3c	503	53	Haemophilus	haemophilus	JJ
cord-324810-92fosk3c	503	54	influenzae	influenzae	NN
cord-324810-92fosk3c	503	55	and	and	CC
cord-324810-92fosk3c	503	56	Moraxella	Moraxella	NNP
cord-324810-92fosk3c	503	57	catarrhal	catarrhal	NN
cord-324810-92fosk3c	503	58	Acute	acute	JJ
cord-324810-92fosk3c	503	59	exacerbation	exacerbation	NN
cord-324810-92fosk3c	503	60	of	of	IN
cord-324810-92fosk3c	503	61	chronic	chronic	JJ
cord-324810-92fosk3c	503	62	bronchitis	bronchitis	NN
cord-324810-92fosk3c	503	63	:	:	:
cord-324810-92fosk3c	503	64	is	be	VBZ
cord-324810-92fosk3c	503	65	:	:	:
cord-324810-92fosk3c	503	66	a	a	DT
cord-324810-92fosk3c	503	67	European	european	JJ
cord-324810-92fosk3c	503	68	multicenter	multicenter	JJ
cord-324810-92fosk3c	503	69	study	study	NN
cord-324810-92fosk3c	503	70	during	during	IN
cord-324810-92fosk3c	503	71	Antibacterial	antibacterial	JJ
cord-324810-92fosk3c	503	72	resistance	resistance	NN
cord-324810-92fosk3c	503	73	in	in	IN
cord-324810-92fosk3c	503	74	Streptococcus	Streptococcus	NNP
cord-324810-92fosk3c	503	75	Model	Model	NNP
cord-324810-92fosk3c	503	76	to	to	TO
cord-324810-92fosk3c	503	77	evaluate	evaluate	VB
cord-324810-92fosk3c	503	78	the	the	DT
cord-324810-92fosk3c	503	79	costpneumoniae	costpneumoniae	NN
cord-324810-92fosk3c	503	80	and	and	CC
cord-324810-92fosk3c	503	81	Haemophilus	haemophilus	JJ
cord-324810-92fosk3c	503	82	influenzae	influenzae	NN
cord-324810-92fosk3c	503	83	from	from	IN
cord-324810-92fosk3c	503	84	Italy	Italy	NNP
cord-324810-92fosk3c	503	85	and	and	CC
cord-324810-92fosk3c	503	86	Spain	Spain	NNP
cord-324810-92fosk3c	503	87	:	:	:
cord-324810-92fosk3c	504	1	data	datum	NNS
cord-324810-92fosk3c	504	2	from	from	IN
cord-324810-92fosk3c	504	3	the	the	DT
cord-324810-92fosk3c	504	4	effectiveness	effectiveness	NN
cord-324810-92fosk3c	504	5	of	of	IN
cord-324810-92fosk3c	504	6	different	different	JJ
cord-324810-92fosk3c	504	7	antibiotics	antibiotic	NNS
cord-324810-92fosk3c	504	8	in	in	IN
cord-324810-92fosk3c	504	9	the	the	DT
cord-324810-92fosk3c	504	10	management	management	NN
cord-324810-92fosk3c	504	11	of	of	IN
cord-324810-92fosk3c	504	12	acute	acute	JJ
cord-324810-92fosk3c	504	13	bacterial	bacterial	JJ
cord-324810-92fosk3c	504	14	PROTEKT	PROTEKT	NNP
cord-324810-92fosk3c	504	15	surveillance	surveillance	NN
cord-324810-92fosk3c	504	16	study	study	NN
cord-324810-92fosk3c	504	17	Antimicrobial	Antimicrobial	NNP
cord-324810-92fosk3c	504	18	resistance	resistance	NN
cord-324810-92fosk3c	504	19	in	in	IN
cord-324810-92fosk3c	504	20	isolates	isolate	NNS
cord-324810-92fosk3c	504	21	from	from	IN
cord-324810-92fosk3c	504	22	evaluating	evaluate	VBG
cord-324810-92fosk3c	504	23	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	504	24	treatment	treatment	NN
cord-324810-92fosk3c	504	25	of	of	IN
cord-324810-92fosk3c	504	26	acute	acute	JJ
cord-324810-92fosk3c	504	27	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	504	28	of	of	IN
cord-324810-92fosk3c	504	29	chronic	chronic	JJ
cord-324810-92fosk3c	504	30	bronchitis	bronchitis	NN
cord-324810-92fosk3c	504	31	.	.	.
cord-324810-92fosk3c	505	1	inpatients	inpatient	NNS
cord-324810-92fosk3c	505	2	and	and	CC
cord-324810-92fosk3c	505	3	outpatients	outpatient	NNS
cord-324810-92fosk3c	505	4	in	in	IN
cord-324810-92fosk3c	505	5	the	the	DT
cord-324810-92fosk3c	505	6	United	United	NNP
cord-324810-92fosk3c	505	7	States	States	NNP
cord-324810-92fosk3c	505	8	:	:	:
cord-324810-92fosk3c	505	9	increasing	increase	VBG
cord-324810-92fosk3c	505	10	importance	importance	NN
cord-324810-92fosk3c	505	11	of	of	IN
cord-324810-92fosk3c	505	12	the	the	DT
cord-324810-92fosk3c	505	13	87S-92S	87s-92s	CD
cord-324810-92fosk3c	505	14	intensive	intensive	JJ
cord-324810-92fosk3c	505	15	care	care	NN
cord-324810-92fosk3c	505	16	unit	unit	NN
cord-324810-92fosk3c	505	17	Five	five	CD
cord-324810-92fosk3c	505	18	day	day	NN
cord-324810-92fosk3c	505	19	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	505	20	therapy	therapy	NN
cord-324810-92fosk3c	505	21	compared	compare	VBN
cord-324810-92fosk3c	505	22	with	with	IN
cord-324810-92fosk3c	505	23	7	7	CD
cord-324810-92fosk3c	505	24	antibiotics	antibiotic	NNS
cord-324810-92fosk3c	505	25	in	in	IN
cord-324810-92fosk3c	505	26	the	the	DT
cord-324810-92fosk3c	505	27	treatment	treatment	NN
cord-324810-92fosk3c	505	28	of	of	IN
cord-324810-92fosk3c	505	29	acute	acute	JJ
cord-324810-92fosk3c	505	30	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	505	31	of	of	IN
cord-324810-92fosk3c	505	32	chronic	chronic	JJ
cord-324810-92fosk3c	505	33	obstructive	obstructive	JJ
cord-324810-92fosk3c	505	34	day	day	NN
cord-324810-92fosk3c	505	35	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	505	36	therapy	therapy	NN
cord-324810-92fosk3c	505	37	for	for	IN
cord-324810-92fosk3c	505	38	the	the	DT
cord-324810-92fosk3c	505	39	treatment	treatment	NN
cord-324810-92fosk3c	505	40	of	of	IN
cord-324810-92fosk3c	505	41	acute	acute	JJ
cord-324810-92fosk3c	505	42	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	505	43	of	of	IN
cord-324810-92fosk3c	505	44	chronic	chronic	JJ
cord-324810-92fosk3c	505	45	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	505	46	disease	disease	NN
cord-324810-92fosk3c	505	47	Comparison	comparison	NN
cord-324810-92fosk3c	505	48	of	of	IN
cord-324810-92fosk3c	505	49	5-day	5-day	JJ
cord-324810-92fosk3c	505	50	,	,	,
cord-324810-92fosk3c	505	51	short	short	JJ
cord-324810-92fosk3c	505	52	-	-	HYPH
cord-324810-92fosk3c	505	53	course	course	NN
cord-324810-92fosk3c	505	54	outcome	outcome	NN
cord-324810-92fosk3c	505	55	of	of	IN
cord-324810-92fosk3c	505	56	adult	adult	NN
cord-324810-92fosk3c	505	57	lower	low	JJR
cord-324810-92fosk3c	505	58	respiratory	respiratory	JJ
cord-324810-92fosk3c	505	59	tract	tract	NN
cord-324810-92fosk3c	505	60	infections	infection	NNS
cord-324810-92fosk3c	505	61	in	in	IN
cord-324810-92fosk3c	505	62	the	the	DT
cord-324810-92fosk3c	505	63	community	community	NN
cord-324810-92fosk3c	505	64	.	.	.
cord-324810-92fosk3c	506	1	Lancet	Lancet	NNP
cord-324810-92fosk3c	506	2	gatifloxacin	gatifloxacin	NNS
cord-324810-92fosk3c	506	3	therapy	therapy	NN
cord-324810-92fosk3c	506	4	with	with	IN
cord-324810-92fosk3c	506	5	7-day	7-day	JJ
cord-324810-92fosk3c	506	6	gatifloxacin	gatifloxacin	NNS
cord-324810-92fosk3c	506	7	therapy	therapy	NN
cord-324810-92fosk3c	506	8	and	and	CC
cord-324810-92fosk3c	506	9	10-day	10-day	CD
cord-324810-92fosk3c	506	10	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	506	11	Respiratory	respiratory	JJ
cord-324810-92fosk3c	506	12	tract	tract	NN
cord-324810-92fosk3c	506	13	infections	infection	NNS
cord-324810-92fosk3c	506	14	:	:	:
cord-324810-92fosk3c	506	15	when	when	WRB
cord-324810-92fosk3c	506	16	is	be	VBZ
cord-324810-92fosk3c	506	17	antibiotic	antibiotic	JJ
cord-324810-92fosk3c	506	18	therapy	therapy	NN
cord-324810-92fosk3c	506	19	indicated	indicate	VBN
cord-324810-92fosk3c	506	20	?	?	.
cord-324810-92fosk3c	507	1	Clin	Clin	NNP
cord-324810-92fosk3c	507	2	97	97	CD
cord-324810-92fosk3c	507	3	-	-	SYM
cord-324810-92fosk3c	507	4	107	107	CD
cord-324810-92fosk3c	508	1	The	the	DT
cord-324810-92fosk3c	508	2	safety	safety	NN
cord-324810-92fosk3c	508	3	and	and	CC
cord-324810-92fosk3c	508	4	efficacy	efficacy	NN
cord-324810-92fosk3c	508	5	Predictive	predictive	JJ
cord-324810-92fosk3c	508	6	factors	factor	NNS
cord-324810-92fosk3c	508	7	of	of	IN
cord-324810-92fosk3c	508	8	hospitalization	hospitalization	NN
cord-324810-92fosk3c	508	9	for	for	IN
cord-324810-92fosk3c	508	10	of	of	IN
cord-324810-92fosk3c	508	11	short	short	JJ
cord-324810-92fosk3c	508	12	course	course	NN
cord-324810-92fosk3c	508	13	moxifloxacin	moxifloxacin	NNS
cord-324810-92fosk3c	508	14	vs	vs	IN
cord-324810-92fosk3c	508	15	azithromycin	azithromycin	NNP
cord-324810-92fosk3c	508	16	in	in	IN
cord-324810-92fosk3c	508	17	the	the	DT
cord-324810-92fosk3c	508	18	treatment	treatment	NN
cord-324810-92fosk3c	508	19	of	of	IN
cord-324810-92fosk3c	508	20	patients	patient	NNS
cord-324810-92fosk3c	508	21	with	with	IN
cord-324810-92fosk3c	508	22	acute	acute	JJ
cord-324810-92fosk3c	508	23	exacerbation	exacerbation	NN
cord-324810-92fosk3c	508	24	in	in	IN
cord-324810-92fosk3c	508	25	a	a	DT
cord-324810-92fosk3c	508	26	series	series	NN
cord-324810-92fosk3c	508	27	of	of	IN
cord-324810-92fosk3c	508	28	64	64	CD
cord-324810-92fosk3c	508	29	patients	patient	NNS
cord-324810-92fosk3c	508	30	with	with	IN
cord-324810-92fosk3c	508	31	chronic	chronic	JJ
cord-324810-92fosk3c	508	32	obstructive	obstructive	JJ
cord-324810-92fosk3c	508	33	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	508	34	acute	acute	JJ
cord-324810-92fosk3c	508	35	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	508	36	of	of	IN
cord-324810-92fosk3c	508	37	chronic	chronic	JJ
cord-324810-92fosk3c	508	38	bronchitis	bronchitis	NN
cord-324810-92fosk3c	508	39	A	a	DT
cord-324810-92fosk3c	508	40	one	one	CD
cord-324810-92fosk3c	508	41	year	year	NN
cord-324810-92fosk3c	508	42	community	community	NN
cord-324810-92fosk3c	508	43	-	-	HYPH
cord-324810-92fosk3c	508	44	based	base	VBN
cord-324810-92fosk3c	508	45	health	health	NN
cord-324810-92fosk3c	508	46	Factors	factor	NNS
cord-324810-92fosk3c	508	47	associated	associate	VBN
cord-324810-92fosk3c	508	48	with	with	IN
cord-324810-92fosk3c	508	49	increased	increase	VBN
cord-324810-92fosk3c	508	50	economic	economic	JJ
cord-324810-92fosk3c	508	51	study	study	NN
cord-324810-92fosk3c	508	52	of	of	IN
cord-324810-92fosk3c	508	53	ciprofloxacin	ciprofloxacin	NNP
cord-324810-92fosk3c	508	54	vs	vs	IN
cord-324810-92fosk3c	508	55	usual	usual	JJ
cord-324810-92fosk3c	508	56	antibiotic	antibiotic	JJ
cord-324810-92fosk3c	508	57	treatment	treatment	NN
cord-324810-92fosk3c	508	58	in	in	IN
cord-324810-92fosk3c	508	59	acute	acute	JJ
cord-324810-92fosk3c	508	60	exacerbarisk	exacerbarisk	NN
cord-324810-92fosk3c	508	61	of	of	IN
cord-324810-92fosk3c	508	62	exacerbation	exacerbation	NN
cord-324810-92fosk3c	508	63	and	and	CC
cord-324810-92fosk3c	508	64	hospital	hospital	NN
cord-324810-92fosk3c	508	65	admission	admission	NN
cord-324810-92fosk3c	508	66	in	in	IN
cord-324810-92fosk3c	508	67	a	a	DT
cord-324810-92fosk3c	508	68	cohort	cohort	NN
cord-324810-92fosk3c	508	69	of	of	IN
cord-324810-92fosk3c	508	70	ambulatory	ambulatory	JJ
cord-324810-92fosk3c	508	71	COPD	COPD	NNP
cord-324810-92fosk3c	508	72	tions	tion	NNS
cord-324810-92fosk3c	508	73	of	of	IN
cord-324810-92fosk3c	508	74	chronic	chronic	JJ
cord-324810-92fosk3c	508	75	bronchitis	bronchitis	NN
cord-324810-92fosk3c	508	76	.	.	.
cord-324810-92fosk3c	509	1	The	the	DT
cord-324810-92fosk3c	509	2	Canadian	Canadian	NNP
cord-324810-92fosk3c	509	3	Ciprofloxacin	Ciprofloxacin	NNP
cord-324810-92fosk3c	509	4	Health	Health	NNP
cord-324810-92fosk3c	509	5	Economic	Economic	NNP
cord-324810-92fosk3c	509	6	patients	patient	NNS
cord-324810-92fosk3c	509	7	:	:	:
cord-324810-92fosk3c	509	8	a	a	DT
cord-324810-92fosk3c	509	9	multiple	multiple	JJ
cord-324810-92fosk3c	509	10	logistic	logistic	JJ
cord-324810-92fosk3c	509	11	regression	regression	NN
cord-324810-92fosk3c	509	12	analysis	analysis	NN
cord-324810-92fosk3c	509	13	.	.	.
cord-324810-92fosk3c	510	1	The	the	DT
cord-324810-92fosk3c	510	2	EOLO	EOLO	NNP
cord-324810-92fosk3c	510	3	Study	Study	NNP
cord-324810-92fosk3c	510	4	Group	Group	NNP
cord-324810-92fosk3c	510	5	.	.	.
cord-324810-92fosk3c	511	1	Study	Study	NNP
cord-324810-92fosk3c	511	2	Group	Group	NNP
cord-324810-92fosk3c	511	3	Clinical	clinical	JJ
cord-324810-92fosk3c	511	4	outcomes	outcome	NNS
cord-324810-92fosk3c	511	5	of	of	IN
cord-324810-92fosk3c	511	6	ambula	ambula	NN
cord-324810-92fosk3c	511	7	Factors	factor	NNS
cord-324810-92fosk3c	511	8	associated	associate	VBN
cord-324810-92fosk3c	511	9	with	with	IN
cord-324810-92fosk3c	511	10	relapse	relapse	NN
cord-324810-92fosk3c	511	11	after	after	IN
cord-324810-92fosk3c	511	12	tory	tory	NNP
cord-324810-92fosk3c	511	13	acute	acute	JJ
cord-324810-92fosk3c	511	14	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	511	15	of	of	IN
cord-324810-92fosk3c	511	16	chronic	chronic	JJ
cord-324810-92fosk3c	511	17	bronchitis	bronchitis	NN
cord-324810-92fosk3c	511	18	with	with	IN
cord-324810-92fosk3c	511	19	older	old	JJR
cord-324810-92fosk3c	511	20	versus	versus	IN
cord-324810-92fosk3c	511	21	newer	new	JJR
cord-324810-92fosk3c	511	22	anambulatory	anambulatory	JJ
cord-324810-92fosk3c	511	23	treatment	treatment	NN
cord-324810-92fosk3c	511	24	of	of	IN
cord-324810-92fosk3c	511	25	acute	acute	JJ
cord-324810-92fosk3c	511	26	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	511	27	of	of	IN
cord-324810-92fosk3c	511	28	chronic	chronic	JJ
cord-324810-92fosk3c	511	29	bronchitis	bronchitis	NN
cord-324810-92fosk3c	511	30	Treatment	treatment	NN
cord-324810-92fosk3c	511	31	of	of	IN
cord-324810-92fosk3c	511	32	acute	acute	JJ
cord-324810-92fosk3c	511	33	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	511	34	of	of	IN
cord-324810-92fosk3c	511	35	chronic	chronic	JJ
cord-324810-92fosk3c	511	36	bronchitis	bronchitis	NN
cord-324810-92fosk3c	511	37	:	:	:
cord-324810-92fosk3c	511	38	antibiotic	antibiotic	JJ
cord-324810-92fosk3c	511	39	therapy	therapy	NN
cord-324810-92fosk3c	511	40	Recommendations	recommendation	NNS
cord-324810-92fosk3c	511	41	on	on	IN
cord-324810-92fosk3c	511	42	the	the	DT
cord-324810-92fosk3c	511	43	management	management	NN
cord-324810-92fosk3c	511	44	of	of	IN
cord-324810-92fosk3c	511	45	chronic	chronic	JJ
cord-324810-92fosk3c	511	46	bronchitis	bronchitis	NN
cord-324810-92fosk3c	511	47	Surveillance	surveillance	NN
cord-324810-92fosk3c	511	48	of	of	IN
cord-324810-92fosk3c	511	49	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	511	50	resistance	resistance	NN
cord-324810-92fosk3c	511	51	in	in	IN
cord-324810-92fosk3c	511	52	S	S	NNP
cord-324810-92fosk3c	511	53	pneumonia	pneumonia	NN
cord-324810-92fosk3c	511	54	,	,	,
cord-324810-92fosk3c	511	55	H	h	NN
cord-324810-92fosk3c	511	56	influenzae	influenzae	NN
cord-324810-92fosk3c	511	57	and	and	CC
cord-324810-92fosk3c	511	58	M	M	NNP
cord-324810-92fosk3c	511	59	Catarrhalis	Catarrhalis	NNP
cord-324810-92fosk3c	511	60	in	in	IN
cord-324810-92fosk3c	511	61	the	the	DT
cord-324810-92fosk3c	511	62	United	United	NNP
cord-324810-92fosk3c	511	63	States	States	NNP
cord-324810-92fosk3c	511	64	Canadian	canadian	JJ
cord-324810-92fosk3c	511	65	guideline	guideline	NN
cord-324810-92fosk3c	511	66	for	for	IN
cord-324810-92fosk3c	511	67	the	the	DT
cord-324810-92fosk3c	511	68	management	management	NN
cord-324810-92fosk3c	511	69	of	of	IN
cord-324810-92fosk3c	511	70	acute	acute	JJ
cord-324810-92fosk3c	511	71	exacerbation	exacerbation	NN
cord-324810-92fosk3c	511	72	of	of	IN
cord-324810-92fosk3c	511	73	chronic	chronic	JJ
cord-324810-92fosk3c	511	74	bronchitis	bronchitis	NN
cord-324810-92fosk3c	511	75	:	:	:
cord-324810-92fosk3c	511	76	executive	executive	NN
cord-324810-92fosk3c	511	77	summary	summary	NN
cord-324810-92fosk3c	511	78	Cefaclor	Cefaclor	NNP
cord-324810-92fosk3c	511	79	in	in	IN
cord-324810-92fosk3c	511	80	the	the	DT
cord-324810-92fosk3c	511	81	treatment	treatment	NN
cord-324810-92fosk3c	511	82	of	of	IN
cord-324810-92fosk3c	511	83	chronic	chronic	JJ
cord-324810-92fosk3c	511	84	bronchitis	bronchitis	NN
cord-324810-92fosk3c	511	85	Guidelines	guideline	NNS
cord-324810-92fosk3c	511	86	for	for	IN
cord-324810-92fosk3c	511	87	the	the	DT
cord-324810-92fosk3c	511	88	treatment	treatment	NN
cord-324810-92fosk3c	511	89	of	of	IN
cord-324810-92fosk3c	511	90	acute	acute	JJ
cord-324810-92fosk3c	511	91	exacerbation	exacerbation	NN
cord-324810-92fosk3c	511	92	of	of	IN
cord-324810-92fosk3c	511	93	chronic	chronic	JJ
cord-324810-92fosk3c	511	94	bronchitis	bronchitis	NN
cord-324810-92fosk3c	511	95	Efficacy	Efficacy	NNP
cord-324810-92fosk3c	511	96	of	of	IN
cord-324810-92fosk3c	511	97	cefixime	cefixime	NN
cord-324810-92fosk3c	511	98	in	in	IN
cord-324810-92fosk3c	511	99	respiratory	respiratory	JJ
cord-324810-92fosk3c	511	100	tract	tract	NN
cord-324810-92fosk3c	511	101	infections	infection	NNS
cord-324810-92fosk3c	511	102	Augmentin	Augmentin	NNP
cord-324810-92fosk3c	511	103	(	(	-LRB-
cord-324810-92fosk3c	511	104	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	511	105	/	/	SYM
cord-324810-92fosk3c	511	106	clavulanate	clavulanate	NNP
cord-324810-92fosk3c	511	107	)	)	-RRB-
cord-324810-92fosk3c	511	108	in	in	IN
cord-324810-92fosk3c	511	109	the	the	DT
cord-324810-92fosk3c	511	110	editors	editor	NNS
cord-324810-92fosk3c	511	111	.	.	.
cord-324810-92fosk3c	512	1	Asthma	Asthma	NNP
cord-324810-92fosk3c	512	2	and	and	CC
cord-324810-92fosk3c	512	3	COPD	COPD	NNP
cord-324810-92fosk3c	512	4	:	:	:
cord-324810-92fosk3c	512	5	basic	basic	JJ
cord-324810-92fosk3c	512	6	mechanisms	mechanism	NNS
cord-324810-92fosk3c	512	7	and	and	CC
cord-324810-92fosk3c	512	8	clinical	clinical	JJ
cord-324810-92fosk3c	512	9	management	management	NN
cord-324810-92fosk3c	512	10	.	.	.
cord-324810-92fosk3c	513	1	treatment	treatment	NN
cord-324810-92fosk3c	513	2	of	of	IN
cord-324810-92fosk3c	513	3	community	community	NN
cord-324810-92fosk3c	513	4	-	-	HYPH
cord-324810-92fosk3c	513	5	acquired	acquire	VBN
cord-324810-92fosk3c	513	6	respiratory	respiratory	JJ
cord-324810-92fosk3c	513	7	tract	tract	NN
cord-324810-92fosk3c	513	8	infection	infection	NN
cord-324810-92fosk3c	513	9	:	:	:
cord-324810-92fosk3c	513	10	a	a	DT
cord-324810-92fosk3c	513	11	review	review	NN
cord-324810-92fosk3c	513	12	of	of	IN
cord-324810-92fosk3c	513	13	the	the	DT
cord-324810-92fosk3c	513	14	London	London	NNP
cord-324810-92fosk3c	513	15	Amoxicillin	Amoxicillin	NNP
cord-324810-92fosk3c	513	16	/	/	SYM
cord-324810-92fosk3c	513	17	clavulanic	clavulanic	NNP
cord-324810-92fosk3c	513	18	:	:	:
cord-324810-92fosk3c	513	19	an	an	DT
cord-324810-92fosk3c	513	20	update	update	NN
cord-324810-92fosk3c	513	21	of	of	IN
cord-324810-92fosk3c	513	22	its	-PRON-	PRP$
cord-324810-92fosk3c	513	23	antibacterial	antibacterial	JJ
cord-324810-92fosk3c	513	24	activi	activi	NNP
cord-324810-92fosk3c	513	25	-	-	HYPH
cord-324810-92fosk3c	513	26	Inc	Inc	NNP
cord-324810-92fosk3c	513	27	.	.	NNP
cord-324810-92fosk3c	513	28	,	,	,
cord-324810-92fosk3c	513	29	editor	editor	NN
cord-324810-92fosk3c	514	1	A	a	DT
cord-324810-92fosk3c	514	2	comparison	comparison	NN
cord-324810-92fosk3c	514	3	of	of	IN
cord-324810-92fosk3c	514	4	cefuroxime	cefuroxime	NN
cord-324810-92fosk3c	514	5	and	and	CC
cord-324810-92fosk3c	514	6	co	co	JJ
cord-324810-92fosk3c	514	7	-	-	JJ
cord-324810-92fosk3c	514	8	trimoxazole	trimoxazole	JJ
cord-324810-92fosk3c	514	9	relapse	relapse	NN
cord-324810-92fosk3c	514	10	rate	rate	NN
cord-324810-92fosk3c	514	11	in	in	IN
cord-324810-92fosk3c	514	12	outpatients	outpatient	NNS
cord-324810-92fosk3c	514	13	with	with	IN
cord-324810-92fosk3c	514	14	acute	acute	JJ
cord-324810-92fosk3c	514	15	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	514	16	iof	iof	NNP
cord-324810-92fosk3c	514	17	COPD	COPD	NNP
cord-324810-92fosk3c	514	18	Resistance	Resistance	NNP
cord-324810-92fosk3c	514	19	to	to	IN
cord-324810-92fosk3c	514	20	trimethoprim	trimethoprim	NNP
cord-324810-92fosk3c	514	21	-	-	HYPH
cord-324810-92fosk3c	514	22	sulfamethoxazole	sulfamethoxazole	NNP
cord-324810-92fosk3c	514	23	Multivariate	Multivariate	NNP
cord-324810-92fosk3c	514	24	analyresults	analyresult	NNS
cord-324810-92fosk3c	514	25	of	of	IN
cord-324810-92fosk3c	514	26	a	a	DT
cord-324810-92fosk3c	514	27	national	national	JJ
cord-324810-92fosk3c	514	28	multicenter	multicenter	JJ
cord-324810-92fosk3c	514	29	surveillance	surveillance	NN
cord-324810-92fosk3c	514	30	study	study	NN
cord-324810-92fosk3c	514	31	.	.	.
cord-324810-92fosk3c	515	1	Antimicrob	Antimicrob	NNP
cord-324810-92fosk3c	515	2	Agents	Agents	NNPS
cord-324810-92fosk3c	515	3	sis	sis	NN
cord-324810-92fosk3c	515	4	of	of	IN
cord-324810-92fosk3c	515	5	risk	risk	NN
cord-324810-92fosk3c	515	6	factors	factor	NNS
cord-324810-92fosk3c	515	7	for	for	IN
cord-324810-92fosk3c	515	8	infection	infection	NN
cord-324810-92fosk3c	515	9	due	due	IN
cord-324810-92fosk3c	515	10	to	to	IN
cord-324810-92fosk3c	515	11	penicillin	penicillin	NN
cord-324810-92fosk3c	515	12	resistant	resistant	JJ
cord-324810-92fosk3c	515	13	and	and	CC
cord-324810-92fosk3c	515	14	multidrug	multidrug	NN
cord-324810-92fosk3c	515	15	resistant	resistant	JJ
cord-324810-92fosk3c	515	16	Chemother	Chemother	NNP
cord-324810-92fosk3c	516	1	the	the	DT
cord-324810-92fosk3c	516	2	treatment	treatment	NN
cord-324810-92fosk3c	516	3	of	of	IN
cord-324810-92fosk3c	516	4	acute	acute	JJ
cord-324810-92fosk3c	516	5	exacerbation	exacerbation	NN
cord-324810-92fosk3c	516	6	of	of	IN
cord-324810-92fosk3c	516	7	chronic	chronic	JJ
cord-324810-92fosk3c	516	8	bronchitis	bronchitis	NN
cord-324810-92fosk3c	516	9	:	:	:
cord-324810-92fosk3c	516	10	results	result	NNS
cord-324810-92fosk3c	516	11	of	of	IN
cord-324810-92fosk3c	516	12	a	a	DT
cord-324810-92fosk3c	516	13	randomized	randomized	JJ
cord-324810-92fosk3c	516	14	,	,	,
cord-324810-92fosk3c	516	15	double	double	JJ
cord-324810-92fosk3c	516	16	-	-	HYPH
cord-324810-92fosk3c	516	17	blind	blind	JJ
cord-324810-92fosk3c	516	18	study	study	NN
cord-324810-92fosk3c	516	19	Randomized	randomized	JJ
cord-324810-92fosk3c	516	20	,	,	,
cord-324810-92fosk3c	516	21	double	double	JJ
cord-324810-92fosk3c	516	22	-	-	HYPH
cord-324810-92fosk3c	516	23	blind	blind	JJ
cord-324810-92fosk3c	516	24	study	study	NN
cord-324810-92fosk3c	516	25	comparing	compare	VBG
cord-324810-92fosk3c	516	26	5-and	5-and	CD
cord-324810-92fosk3c	516	27	7-treatment	7-treatment	CD
cord-324810-92fosk3c	516	28	of	of	IN
cord-324810-92fosk3c	516	29	adults	adult	NNS
cord-324810-92fosk3c	516	30	with	with	IN
cord-324810-92fosk3c	516	31	lower	low	JJR
cord-324810-92fosk3c	516	32	respiratory	respiratory	JJ
cord-324810-92fosk3c	516	33	tract	tract	NN
cord-324810-92fosk3c	516	34	infections	infection	NNS
cord-324810-92fosk3c	516	35	and	and	CC
cord-324810-92fosk3c	516	36	effects	effect	NNS
cord-324810-92fosk3c	516	37	on	on	IN
cord-324810-92fosk3c	516	38	long	long	JJ
cord-324810-92fosk3c	516	39	day	day	NN
cord-324810-92fosk3c	516	40	regimens	regimen	NNS
cord-324810-92fosk3c	516	41	of	of	IN
cord-324810-92fosk3c	516	42	oral	oral	JJ
cord-324810-92fosk3c	516	43	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	516	44	in	in	IN
cord-324810-92fosk3c	516	45	patients	patient	NNS
cord-324810-92fosk3c	516	46	with	with	IN
cord-324810-92fosk3c	516	47	acute	acute	JJ
cord-324810-92fosk3c	516	48	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	516	49	of	of	IN
cord-324810-92fosk3c	516	50	term	term	NN
cord-324810-92fosk3c	516	51	outcome	outcome	NN
cord-324810-92fosk3c	516	52	Comparison	comparison	NN
cord-324810-92fosk3c	516	53	of	of	IN
cord-324810-92fosk3c	516	54	5-day	5-day	NN
cord-324810-92fosk3c	516	55	,	,	,
cord-324810-92fosk3c	517	1	short	short	JJ
cord-324810-92fosk3c	517	2	cause	cause	NN
cord-324810-92fosk3c	518	1	azithromycin	azithromycin	NNP
cord-324810-92fosk3c	518	2	levofloxacin	levofloxacin	NNS
cord-324810-92fosk3c	518	3	in	in	IN
cord-324810-92fosk3c	518	4	the	the	DT
cord-324810-92fosk3c	518	5	outpatient	outpatient	NN
cord-324810-92fosk3c	518	6	treatment	treatment	NN
cord-324810-92fosk3c	518	7	of	of	IN
cord-324810-92fosk3c	518	8	acute	acute	JJ
cord-324810-92fosk3c	518	9	bacterial	bacterial	JJ
cord-324810-92fosk3c	518	10	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	518	11	of	of	IN
cord-324810-92fosk3c	518	12	97	97	CD
cord-324810-92fosk3c	518	13	-	-	SYM
cord-324810-92fosk3c	518	14	107	107	CD
cord-324810-92fosk3c	518	15	chronic	chronic	JJ
cord-324810-92fosk3c	518	16	bronchitis	bronchitis	NN
cord-324810-92fosk3c	518	17	Efficacy	efficacy	NN
cord-324810-92fosk3c	518	18	and	and	CC
cord-324810-92fosk3c	518	19	tolerability	tolerability	NN
cord-324810-92fosk3c	518	20	of	of	IN
cord-324810-92fosk3c	518	21	gatifloxacin	gatifloxacin	NNS
cord-324810-92fosk3c	519	1	A	a	DT
cord-324810-92fosk3c	519	2	comparison	comparison	NN
cord-324810-92fosk3c	519	3	of	of	IN
cord-324810-92fosk3c	519	4	5-day	5-day	JJ
cord-324810-92fosk3c	519	5	courses	course	NNS
cord-324810-92fosk3c	519	6	of	of	IN
cord-324810-92fosk3c	519	7	in	in	IN
cord-324810-92fosk3c	519	8	community	community	NN
cord-324810-92fosk3c	519	9	treatment	treatment	NN
cord-324810-92fosk3c	519	10	of	of	IN
cord-324810-92fosk3c	519	11	acute	acute	JJ
cord-324810-92fosk3c	519	12	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	519	13	of	of	IN
cord-324810-92fosk3c	519	14	chronic	chronic	JJ
cord-324810-92fosk3c	519	15	bronchitis	bronchitis	NN
cord-324810-92fosk3c	519	16	.	.	.
cord-324810-92fosk3c	520	1	Clin	Clin	NNP
cord-324810-92fosk3c	520	2	Ther	Ther	NNP
cord-324810-92fosk3c	520	3	dirithromycin	dirithromycin	NNS
cord-324810-92fosk3c	520	4	and	and	CC
cord-324810-92fosk3c	520	5	azithromycin	azithromycin	NN
cord-324810-92fosk3c	520	6	in	in	IN
cord-324810-92fosk3c	520	7	the	the	DT
cord-324810-92fosk3c	520	8	treatment	treatment	NN
cord-324810-92fosk3c	520	9	of	of	IN
cord-324810-92fosk3c	520	10	acute	acute	JJ
cord-324810-92fosk3c	520	11	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	520	12	of	of	IN
cord-324810-92fosk3c	520	13	chronic	chronic	JJ
cord-324810-92fosk3c	520	14	obstructive	obstructive	JJ
cord-324810-92fosk3c	520	15	pulmonary	pulmonary	JJ
cord-324810-92fosk3c	520	16	disease	disease	NN
cord-324810-92fosk3c	520	17	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	520	18	immediate	immediate	JJ
cord-324810-92fosk3c	520	19	-	-	HYPH
cord-324810-92fosk3c	520	20	release	release	NN
cord-324810-92fosk3c	520	21	tablets	tablet	NNS
cord-324810-92fosk3c	520	22	for	for	IN
cord-324810-92fosk3c	520	23	the	the	DT
cord-324810-92fosk3c	520	24	treatment	treatment	NN
cord-324810-92fosk3c	520	25	of	of	IN
cord-324810-92fosk3c	520	26	patients	patient	NNS
cord-324810-92fosk3c	520	27	with	with	IN
cord-324810-92fosk3c	520	28	125	125	CD
cord-324810-92fosk3c	520	29	.	.	.
cord-324810-92fosk3c	521	1	Schaberg	Schaberg	NNP
cord-324810-92fosk3c	521	2	T	T	NNP
cord-324810-92fosk3c	521	3	,	,	,
cord-324810-92fosk3c	521	4	Ballin	Ballin	NNP
cord-324810-92fosk3c	521	5	I	I	NNP
cord-324810-92fosk3c	521	6	,	,	,
cord-324810-92fosk3c	521	7	Huchon	Huchon	NNP
cord-324810-92fosk3c	521	8	G	G	NNP
cord-324810-92fosk3c	521	9	,	,	,
cord-324810-92fosk3c	521	10	et	et	NNP
cord-324810-92fosk3c	521	11	al	al	NNP
cord-324810-92fosk3c	521	12	.	.	.
cord-324810-92fosk3c	522	1	A	a	DT
cord-324810-92fosk3c	522	2	Multinational	Multinational	NNP
cord-324810-92fosk3c	522	3	,	,	,
cord-324810-92fosk3c	522	4	multicentre	multicentre	NNP
cord-324810-92fosk3c	522	5	,	,	,
cord-324810-92fosk3c	522	6	non	non	JJ
cord-324810-92fosk3c	522	7	-	-	JJ
cord-324810-92fosk3c	522	8	blinded	blinded	JJ
cord-324810-92fosk3c	522	9	,	,	,
cord-324810-92fosk3c	522	10	acute	acute	JJ
cord-324810-92fosk3c	522	11	bacterial	bacterial	JJ
cord-324810-92fosk3c	522	12	exacerbation	exacerbation	NN
cord-324810-92fosk3c	522	13	of	of	IN
cord-324810-92fosk3c	522	14	chronic	chronic	JJ
cord-324810-92fosk3c	522	15	bronchitis	bronchitis	NN
cord-324810-92fosk3c	523	1	A	a	DT
cord-324810-92fosk3c	523	2	comparative	comparative	JJ
cord-324810-92fosk3c	523	3	study	study	NN
cord-324810-92fosk3c	523	4	of	of	IN
cord-324810-92fosk3c	523	5	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	523	6	and	and	CC
cord-324810-92fosk3c	523	7	ampicillin	ampicillin	NN
cord-324810-92fosk3c	523	8	in	in	IN
cord-324810-92fosk3c	523	9	the	the	DT
cord-324810-92fosk3c	523	10	treatoral	treatoral	JJ
cord-324810-92fosk3c	523	11	tablets	tablet	NNS
cord-324810-92fosk3c	523	12	in	in	IN
cord-324810-92fosk3c	523	13	the	the	DT
cord-324810-92fosk3c	523	14	treatment	treatment	NN
cord-324810-92fosk3c	523	15	of	of	IN
cord-324810-92fosk3c	523	16	acute	acute	JJ
cord-324810-92fosk3c	523	17	exacerbation	exacerbation	NN
cord-324810-92fosk3c	523	18	of	of	IN
cord-324810-92fosk3c	523	19	chronic	chronic	JJ
cord-324810-92fosk3c	523	20	bronchitis	bronchitis	NN
cord-324810-92fosk3c	523	21	.	.	.
cord-324810-92fosk3c	524	1	J	J	NNP
cord-324810-92fosk3c	524	2	Int	Int	NNP
cord-324810-92fosk3c	524	3	ment	ment	NN
cord-324810-92fosk3c	524	4	of	of	IN
cord-324810-92fosk3c	524	5	patients	patient	NNS
cord-324810-92fosk3c	524	6	with	with	IN
cord-324810-92fosk3c	524	7	acute	acute	JJ
cord-324810-92fosk3c	524	8	bacterial	bacterial	JJ
cord-324810-92fosk3c	524	9	exacerbation	exacerbation	NN
cord-324810-92fosk3c	524	10	of	of	IN
cord-324810-92fosk3c	524	11	chronic	chronic	JJ
cord-324810-92fosk3c	524	12	bronchitis	bronchitis	NN
cord-324810-92fosk3c	524	13	Studio	Studio	NNP
cord-324810-92fosk3c	524	14	Multicentrico	Multicentrico	NNP
cord-324810-92fosk3c	524	15	con	con	NN
cord-324810-92fosk3c	524	16	Moxifloxacina	Moxifloxacina	NNP
cord-324810-92fosk3c	524	17	nel	nel	NN
cord-324810-92fosk3c	524	18	release	release	NN
cord-324810-92fosk3c	524	19	clarithromycin	clarithromycin	NNS
cord-324810-92fosk3c	524	20	tablets	tablet	NNS
cord-324810-92fosk3c	524	21	and	and	CC
cord-324810-92fosk3c	524	22	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	524	23	/	/	SYM
cord-324810-92fosk3c	524	24	clavulanate	clavulanate	NNP
cord-324810-92fosk3c	524	25	tablets	tablet	NNS
cord-324810-92fosk3c	524	26	in	in	IN
cord-324810-92fosk3c	524	27	the	the	DT
cord-324810-92fosk3c	524	28	treat	treat	NN
cord-324810-92fosk3c	524	29	-	-	HYPH
cord-324810-92fosk3c	524	30	Trattamento	Trattamento	NNP
cord-324810-92fosk3c	524	31	delle	delle	NN
cord-324810-92fosk3c	524	32	Riacutizzazioni	Riacutizzazioni	NNP
cord-324810-92fosk3c	524	33	de	de	NNP
cord-324810-92fosk3c	524	34	Bronchite	Bronchite	NNP
cord-324810-92fosk3c	524	35	Cronica	Cronica	NNP
cord-324810-92fosk3c	524	36	Short	Short	NNP
cord-324810-92fosk3c	524	37	-	-	HYPH
cord-324810-92fosk3c	524	38	term	term	NN
cord-324810-92fosk3c	524	39	and	and	CC
cord-324810-92fosk3c	524	40	long	long	JJ
cord-324810-92fosk3c	524	41	-	-	HYPH
cord-324810-92fosk3c	524	42	term	term	NN
cord-324810-92fosk3c	524	43	outcomes	outcome	NNS
cord-324810-92fosk3c	524	44	of	of	IN
cord-324810-92fosk3c	524	45	comparative	comparative	JJ
cord-324810-92fosk3c	524	46	study	study	NN
cord-324810-92fosk3c	524	47	of	of	IN
cord-324810-92fosk3c	524	48	clarithromycin	clarithromycin	NNP
cord-324810-92fosk3c	524	49	modified	modify	VBN
cord-324810-92fosk3c	524	50	release	release	NN
cord-324810-92fosk3c	524	51	and	and	CC
cord-324810-92fosk3c	524	52	amoxicillin	amoxicillin	NNP
cord-324810-92fosk3c	524	53	/	/	SYM
cord-324810-92fosk3c	524	54	clavumoxifloxacin	clavumoxifloxacin	NNS
cord-324810-92fosk3c	524	55	compared	compare	VBN
cord-324810-92fosk3c	524	56	to	to	IN
cord-324810-92fosk3c	524	57	standard	standard	JJ
cord-324810-92fosk3c	524	58	antibiotic	antibiotic	JJ
cord-324810-92fosk3c	524	59	treatment	treatment	NN
cord-324810-92fosk3c	524	60	in	in	IN
cord-324810-92fosk3c	524	61	acute	acute	JJ
cord-324810-92fosk3c	524	62	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	524	63	lanic	lanic	JJ
cord-324810-92fosk3c	524	64	acid	acid	NN
cord-324810-92fosk3c	524	65	in	in	IN
cord-324810-92fosk3c	524	66	the	the	DT
cord-324810-92fosk3c	524	67	treatment	treatment	NN
cord-324810-92fosk3c	524	68	of	of	IN
cord-324810-92fosk3c	524	69	acute	acute	JJ
cord-324810-92fosk3c	524	70	exacerbation	exacerbation	NN
cord-324810-92fosk3c	524	71	of	of	IN
cord-324810-92fosk3c	524	72	chronic	chronic	JJ
cord-324810-92fosk3c	524	73	bronchitis	bronchitis	NN
cord-324810-92fosk3c	525	1	A	a	DT
cord-324810-92fosk3c	525	2	review	review	NN
cord-324810-92fosk3c	525	3	of	of	IN
cord-324810-92fosk3c	525	4	the	the	DT
cord-324810-92fosk3c	525	5	comparative	comparative	JJ
cord-324810-92fosk3c	525	6	in	in	FW
cord-324810-92fosk3c	525	7	vitro	vitro	FW
cord-324810-92fosk3c	525	8	activities	activity	NNS
cord-324810-92fosk3c	525	9	of	of	IN
cord-324810-92fosk3c	525	10	12	12	CD
cord-324810-92fosk3c	525	11	antimicrobial	antimicrobial	JJ
cord-324810-92fosk3c	525	12	agents	agent	NNS
cord-324810-92fosk3c	525	13	,	,	,
cord-324810-92fosk3c	525	14	with	with	IN
cord-324810-92fosk3c	525	15	a	a	DT
cord-324810-92fosk3c	525	16	focus	focus	NN
cord-324810-92fosk3c	525	17	on	on	IN
cord-324810-92fosk3c	525	18	five	five	CD
cord-324810-92fosk3c	525	19	new	new	JJ
cord-324810-92fosk3c	525	20	"	"	``
cord-324810-92fosk3c	525	21	respiratory	respiratory	JJ
cord-324810-92fosk3c	525	22	quinolones	quinolone	NNS
cord-324810-92fosk3c	525	23	"	"	''
cord-324810-92fosk3c	525	24	.	.	.
cord-324810-92fosk3c	526	1	J	J	NNP
cord-324810-92fosk3c	526	2	Antimicrob	Antimicrob	NNP
cord-324810-92fosk3c	526	3	mycin	mycin	NNS
cord-324810-92fosk3c	526	4	in	in	IN
cord-324810-92fosk3c	526	5	acute	acute	JJ
cord-324810-92fosk3c	526	6	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	526	7	of	of	IN
cord-324810-92fosk3c	526	8	chronic	chronic	JJ
cord-324810-92fosk3c	526	9	bronchitis	bronchitis	NN
cord-324810-92fosk3c	526	10	and	and	CC
cord-324810-92fosk3c	527	1	long	long	JJ
cord-324810-92fosk3c	527	2	-	-	HYPH
cord-324810-92fosk3c	527	3	term	term	NN
cord-324810-92fosk3c	527	4	clinical	clinical	JJ
cord-324810-92fosk3c	527	5	Time	time	NN
cord-324810-92fosk3c	527	6	course	course	NN
cord-324810-92fosk3c	527	7	of	of	IN
cord-324810-92fosk3c	527	8	recovery	recovery	NN
cord-324810-92fosk3c	527	9	of	of	IN
cord-324810-92fosk3c	527	10	health	health	NN
cord-324810-92fosk3c	527	11	status	status	NN
cord-324810-92fosk3c	527	12	following	follow	VBG
cord-324810-92fosk3c	527	13	an	an	DT
cord-324810-92fosk3c	527	14	infections	infection	NNS
cord-324810-92fosk3c	527	15	Current	current	JJ
cord-324810-92fosk3c	527	16	issues	issue	NNS
cord-324810-92fosk3c	527	17	on	on	IN
cord-324810-92fosk3c	527	18	resistance	resistance	NN
cord-324810-92fosk3c	527	19	,	,	,
cord-324810-92fosk3c	527	20	treatment	treatment	NN
cord-324810-92fosk3c	527	21	guidelines	guideline	NNS
cord-324810-92fosk3c	527	22	,	,	,
cord-324810-92fosk3c	527	23	and	and	CC
cord-324810-92fosk3c	527	24	the	the	DT
cord-324810-92fosk3c	527	25	appropriate	appropriate	JJ
cord-324810-92fosk3c	527	26	use	use	NN
cord-324810-92fosk3c	527	27	of	of	IN
cord-324810-92fosk3c	527	28	fluoroquinolones	fluoroquinolone	NNS
cord-324810-92fosk3c	527	29	for	for	IN
cord-324810-92fosk3c	527	30	respiratory	respiratory	JJ
cord-324810-92fosk3c	527	31	tract	tract	NN
cord-324810-92fosk3c	527	32	infections	infection	NNS
cord-324810-92fosk3c	527	33	Etiology	etiology	NN
cord-324810-92fosk3c	527	34	,	,	,
cord-324810-92fosk3c	527	35	susceptibility	susceptibility	NN
cord-324810-92fosk3c	527	36	,	,	,
cord-324810-92fosk3c	527	37	and	and	CC
cord-324810-92fosk3c	527	38	treatment	treatment	NN
cord-324810-92fosk3c	527	39	BG034	BG034	NNP
cord-324810-92fosk3c	527	40	,	,	,
cord-324810-92fosk3c	527	41	St	St	NNP
cord-324810-92fosk3c	527	42	Boniface	Boniface	NNP
cord-324810-92fosk3c	527	43	General	General	NNP
cord-324810-92fosk3c	527	44	Hospital	Hospital	NNP
cord-324810-92fosk3c	527	45	,	,	,
cord-324810-92fosk3c	527	46	409	409	CD
cord-324810-92fosk3c	527	47	Tache	Tache	NNP
cord-324810-92fosk3c	527	48	Avenue	Avenue	NNP
cord-324810-92fosk3c	527	49	of	of	IN
cord-324810-92fosk3c	527	50	acute	acute	JJ
cord-324810-92fosk3c	527	51	bacterial	bacterial	JJ
cord-324810-92fosk3c	527	52	exacerbations	exacerbation	NNS
cord-324810-92fosk3c	527	53	of	of	IN
cord-324810-92fosk3c	527	54	complicated	complicated	JJ
cord-324810-92fosk3c	527	55	chronic	chronic	JJ
cord-324810-92fosk3c	527	56	bronchitis	bronchitis	NN
cord-324810-92fosk3c	527	57	in	in	IN
cord-324810-92fosk3c	527	58	the	the	DT
cord-324810-92fosk3c	527	59	prima-2A6	prima-2A6	NNP
cord-324810-92fosk3c	527	60	,	,	,
cord-324810-92fosk3c	527	61	Canada	Canada	NNP
cord-324810-92fosk3c	527	62	.	.	.
cord-324810-92fosk3c	528	1	ry	ry	NNP
cord-324810-92fosk3c	528	2	care	care	NNP
cord-324810-92fosk3c	528	3	setting	setting	NN
cord-324810-92fosk3c	528	4	:	:	:
cord-324810-92fosk3c	528	5	ciprofloxacin	ciprofloxacin	NNP
cord-324810-92fosk3c	528	6	750	750	CD
cord-324810-92fosk3c	528	7	mg	mg	NNP
cord-324810-92fosk3c	528	8	b.i.d	b.i.d	NN
cord-324810-92fosk3c	528	9	.	.	.
cord-324810-92fosk3c	528	10	versus	versus	IN
cord-324810-92fosk3c	528	11	clarithromycin	clarithromycin	NNP
cord-324810-92fosk3c	528	12	500	500	CD
cord-324810-92fosk3c	528	13	mg	mg	NN
cord-324810-92fosk3c	529	1	b.i.d	b.i.d	NNP
cord-324810-92fosk3c	529	2	.	.	.
cord-324810-92fosk3c	530	1	E	e	NN
cord-324810-92fosk3c	530	2	-	-	NN
cord-324810-92fosk3c	530	3	mail	mail	NN
cord-324810-92fosk3c	530	4	:	:	:
cord-324810-92fosk3c	530	5	ssharma@sbgh	ssharma@sbgh	NNS
cord-324810-92fosk3c	530	6	Questionnaire	Questionnaire	NNP
cord-324810-92fosk3c	530	7	score	score	NN
cord-324810-92fosk3c	530	8	occurred	occur	VBD
cord-324810-92fosk3c	530	9	within	within	IN
cord-324810-92fosk3c	530	10	the	the	DT
cord-324810-92fosk3c	530	11	first	first	JJ
cord-324810-92fosk3c	530	12	4	4	CD
cord-324810-92fosk3c	530	13	weeks	week	NNS
cord-324810-92fosk3c	530	14	(	(	-LRB-
cord-324810-92fosk3c	530	15	mean	mean	VBP
cord-324810-92fosk3c	530	16	8.9	8.9	CD
cord-324810-92fosk3c	530	17	units	unit	NNS
cord-324810-92fosk3c	530	18	,	,	,
cord-324810-92fosk3c	530	19	95	95	CD
cord-324810-92fosk3c	530	20	%	%	NN
cord-324810-92fosk3c	530	21	CI	CI	NNP
cord-324810-92fosk3c	530	22	6.5	6.5	CD
cord-324810-92fosk3c	530	23	,	,	,
cord-324810-92fosk3c	530	24	11.5	11.5	CD
cord-324810-92fosk3c	530	25	;	;	:
cord-324810-92fosk3c	530	26	p	p	NN
cord-324810-92fosk3c	530	27	<	<	XX
cord-324810-92fosk3c	530	28	0.0001	0.0001	CD
cord-324810-92fosk3c	530	29	)	)	-RRB-
cord-324810-92fosk3c	530	30	.	.	.
cord-324810-92fosk3c	531	1	[	[	-LRB-
cord-324810-92fosk3c	531	2	128	128	CD
cord-324810-92fosk3c	531	3	]	]	-RRB-
cord-324810-92fosk3c	532	1	Subsequently	subsequently	RB
cord-324810-92fosk3c	532	2	,	,	,
cord-324810-92fosk3c	532	3	scores	score	NNS
cord-324810-92fosk3c	532	4	This	this	DT
cord-324810-92fosk3c	532	5	study	study	NN
cord-324810-92fosk3c	532	6	demonstrated	demonstrate	VBD
cord-324810-92fosk3c	532	7	sustained	sustained	JJ
cord-324810-92fosk3c	532	8	effect	effect	NN
cord-324810-92fosk3c	532	9	on	on	IN
cord-324810-92fosk3c	532	10	health	health	NN
cord-324810-92fosk3c	532	11	status	status	NN
cord-324810-92fosk3c	532	12	even	even	RB
cord-324810-92fosk3c	532	13	after	after	IN
cord-324810-92fosk3c	532	14	a	a	DT
cord-324810-92fosk3c	532	15	single	single	JJ
cord-324810-92fosk3c	532	16	episode	episode	NN
cord-324810-92fosk3c	532	17	of	of	IN
cord-324810-92fosk3c	532	18	AECOPD	AECOPD	NNP
cord-324810-92fosk3c	532	19	;	;	:
cord-324810-92fosk3c	532	20	recurrences	recurrence	NNS
cord-324810-92fosk3c	532	21	unfavorably	unfavorably	RB
cord-324810-92fosk3c	532	22	affect	affect	VBP
cord-324810-92fosk3c	532	23	quality	quality	NN
cord-324810-92fosk3c	532	24	of	of	IN
cord-324810-92fosk3c	532	25	life	life	NN
cord-324810-92fosk3c	532	26	.	.	.
cord-324810-92fosk3c	533	1	Treatments	treatment	NNS
cord-324810-92fosk3c	533	2	that	that	WDT
cord-324810-92fosk3c	533	3	reduce	reduce	VBP
cord-324810-92fosk3c	533	4	exacerbation	exacerbation	NN
cord-324810-92fosk3c	533	5	frequency	frequency	NN
cord-324810-92fosk3c	534	1	References	reference	NNS
cord-324810-92fosk3c	534	2	could	could	MD
cord-324810-92fosk3c	534	3	have	have	VB
cord-324810-92fosk3c	534	4	a	a	DT
cord-324810-92fosk3c	534	5	significant	significant	JJ
cord-324810-92fosk3c	534	6	impact	impact	NN
cord-324810-92fosk3c	534	7	on	on	IN
cord-324810-92fosk3c	534	8	health	health	NN
cord-324810-92fosk3c	534	9	status	status	NN
cord-324810-92fosk3c	534	10	.	.	.
cord-324810-92fosk3c	535	1	Despite	despite	IN
cord-324810-92fosk3c	535	2	consider-	consider-	JJ